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ABSTRACT 
Introduction: Human rhinovirus (HRV) is the most prevalent virus detected in children with 
respiratory symptoms; however, its aetiological role during disease episodes remains unclear as 
detection of HRV is also ubiquitous among asymptomatic children. We evaluated the clinical 
epidemiology of HRV-associated disease among children hospitalised with severe and very 
severe pneumonia together with community control children living in Africa and Southeast Asia. 
In addition, we explored the associations between the molecular subtyping and nasopharyngeal 
viral loads of the HRV species and their ability to cause viraemia as potential markers for HRV 
disease.  
 
Methods: Using a case-control study conducted in seven countries, we compared the clinical 
characteristics of children (1-59 months of age) hospitalised with HRV-associated pneumonia 
between August 2011 - January 2014 and age-frequency matched controls. Nasopharyngeal 
swabs from the cases and controls were tested for HRV, together with 27 other respiratory 
pathogens, with quantitative real-time PCR assays. The 5’ NCR region of the HRV positive 
samples were sequenced to determine the species/strains of HRV and phylogenetic analysis was 
performed. Additionally, the blood samples from a limited number of cases (n=210) and controls 
(n=212) were tested for the presence of HRV viraemia and the 5’ NCR sequence of positive 
blood samples were further characterised. 
 
Results: Overall, HRV detection was 1.45-fold (aOR 95% CI: 1.29-1.62) higher among children 
hospitalised with pneumonia (24%) compared to controls (21%, P<0.005); including being 2.08-
fold (28% vs 18%, aOR 95% CI: 1.75-2.47) more associated with case status among children 12-
59 months of age. The HRV-associated cases were younger (13.1 months) than controls with 
HRV infection (15.4 months, P=0.001) and more likely to be malnourished (30% vs. 12%, 
P<0.001) and HIV-1 exposed (10% vs. 8%, P=0.046). HRV nasopharyngeal viral load was 
significantly higher among cases compared to controls (3.7 vs. 3.5 log10 copies/mL, P<0.001). 
Also, HRV viraemia was 7.02-fold (aOR 95% CI 1.70-28.94) more prevalent among cases (7%) 
compared to controls (2%, P=0.007). Moreover, HRV nasopharyngeal viral loads ≥4 log10 
copies/mL differentiated between viraemia positive and negative cases. There was, however, no 
difference in the molecular subtyping of the HRV species prevalence among cases (HRV-
A:48%; HRV-B:7%; HRV-C:45%) and controls (HRV-A:45%; HRV-B:10%; HRV-C:45%, 
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P=0.496); as well as no evidence of seasonal or temporal clustering of the HRV species over 
time.  
 
Among cases, HRV detection was less likely to be associated with presence of radiographically 
confirmed pneumonia (40% vs 46%, P=0.001) or hospital stay >3 days (52% vs 61%, P=0.001). 
It was, however, positively associated with older age (13.1 months vs. 11.3 months, P<0.001) 
and presence of wheeze (46% vs. 31%, P<0.001) compared to the HRV uninfected cases. HRV 
was the sole virus detected in the 53% of cases and generally there were no differences in 
severity or clinical presentation among cases with HRV mono-infections compared to those with 
HRV-mixed infections. The HRV mono-infections, however, were associated with a 2.83-fold 
(aOR 95% CI: 1.44-5.53) higher case fatality ratio than cases with HRV and other viral mixed 
infections (10% vs. 5%, P=0.002). The HRV-associated case fatalities were more likely to have 
markers of bacterial co-infections compared to the HRV-associated cases that survived.  
 
Among the HRV species, HRV-C compared to HRV-A cases were older (12.1 vs. 9.4 months, 
P=0.033), more likely to present with wheeze (35% vs. 25%, P=0.031) and 2.59-fold (aOR 95% 
CI: 1.23-5.95) more likely to be associated with viraemia (12% vs. 2%, P=0.025). Conversely, 
the HRV-A infected cases were more likely to have radiographically confirmed pneumonia 
(46%) compared to HRV-C infected cases (36%, P=0.040) and HRV-A mono-infected cases 
were more likely to have hospital stay of >3 days (72%) than HRV-C mono-infected cases (54%, 
P=0.039).  
 
Conclusion: HRV detection, especially among children 1-5 years of age, was associated with 
severe lower respiratory tract infection; however, HRV detection was ubiquitous with a high 
degree of genetic diversity among both cases and controls. Thus the true etiologic role of HRV 
during childhood disease, especially among infants, remains uncertain. Nonetheless, HRV 
nasopharyngeal viral loads ≥4log10 copies/mL in conjunction with HRV viraemia are potential 
markers for HRV-associated severe respiratory disease. Among cases, HRV-A was associated 
with radiographically confirmed pneumonia and generally more severe disease than HRV-C 
which was more associated with viraemia and wheezing disease.  
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nurses and doctors at the respective sites. 
 
Laboratory component: All processing of South African samples was performed or 
overseen by VB and all the South African laboratory assays - including the RT-PCR testing of 
the respiratory samples, blood samples and all the antibiotic activity assays as well as 
sequencing assays - were conducted by VB. The culturing of the sterile site samples, 
including the blood and CSF samples, were conducted by the National Health Laboratory 
Service. All South African laboratory related data were entered onto the PERCH database by 
VB. The laboratory component for the other site were conducted by the individual sites local 
laboratory staff; however, the rhinovirus positive samples from the Zambian and Mali sites 
were shipped to South Africa for molecular typing of the strain. 
 
Statistical analysis: All statistical and phylogenetic analyses were conducted by VB
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1.0 Introduction 
 
1.1 Epidemiology of Childhood pneumonia 
Pneumonia is the leading cause of childhood morbidity and mortality globally, including 
approximately 120 million cases annually [1]. In 2013, approximately 6.6 million children 
under 5 years of age died with 3.257 million deaths due to infectious causes, with 
pneumonia causing 0.935 million deaths. Approximately 60% of all under-5 childhood 
deaths occurred in sub-Saharan Africa [2]. Based on reporting to the Department of Home 
Affairs, in 2013, diseases of the respiratory system accounted for 10.4% of all deaths in 
South Africa. Influenza and pneumonia overall were the second leading natural cause of 
death, accounting for 23 727 deaths in 2013, down from 33 847 deaths in 2011 [3]. 
Furthermore, in 2013, there were 25 993 deaths in infants, 9 101 deaths in the 1-4 year old 
age group, 3 382 in children 5-9 years old and 3 261 in children 10-14 years old. In infants, 
influenza and pneumonia accounted for 2 343 (9%) of the deaths, making it the third most 
common cause of death in South African infants, following respiratory and cardiovascular 
disorders specific to the perinatal period (3 727 deaths, 14.3%) and intestinal infectious 
diseases (3 591, 13.8%) [3].  
 
The burden and epidemiology of pneumonia in children has been significantly impacted by 
the Human Immunodeficiency Virus (HIV) epidemic, as HIV-infected children are at an 
increased risk for severe pneumonia, bacteraemia and recurrent infections, with respiratory 
diseases being the leading cause of hospitalisation and death. In South Africa, the number of 
pneumonia hospitalisations had increased in the 1990s, largely due to an increase in the 
number of pneumonia admissions in HIV-infected children [4]. Of all children admitted to 
hospital in South Africa with severe pneumonia, approximately 45% are HIV positive, and 
whom had a 3-6 times greater case fatality ratio [5, 6].  
 
1.2 Community-acquired pneumonia 
Community-acquired pneumonia (CAP) is defined as an inflammatory lung infection which 
can be caused by a number of pathogens including viruses, bacteria and parasites [7, 8]. 
Determining the aetiology of pneumonia is difficult and traditionally no causative pathogens 
were identified in 20-60% of pneumonia cases [8-10]. This is due to the limited sensitivity 
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and specificity of previous methods for identifying specifically bacterial pathogens [11], 
further aggravated by many commensal organisms commonly colonising the airways, which 
limits the utility of sampling of the nasopharynx for identifying the causative agent of CAP.  
 
Nevertheless, respiratory viruses are associated with 14-80% of childhood CAP episode in 
younger children [8]. In a study conducted in Finland between January 1993 and November 
1995, 80% of 254 children hospitalised for CAP under the age of 2 years had evidence of 
respiratory viral infections, compared to only 49% in older children. Of these respiratory 
viral infections, Human rhinovirus (HRV) was the second most common infection (24%) 
after Respiratory Syncytial Virus (RSV; 29%) [12]. In Oakland, CA in 2007, HRV was 
found to be the most prevalent virus (21%) followed by Parainfluenza viruses (PIVs) (17%) 
and RSV (15%) [13].  
 
HRV was also found to be present in 50% of the children admitted to the intensive care unit 
in California with a lower respiratory tract infection (LRTI) in children of 1.4 years’ median 
age [14]. In this study, it was also established that children with HRV infection more 
frequently required mechanical ventilation and had longer hospital stay compared to those 
whose LTRIs were associated with other viral pathogens, suggesting that HRV infection was 
associated with severe LRTI [14]. More recently in a study conducted in Italy over four 
consecutive winter and early spring periods (November to end April) starting in 2007 and 
ending in 2011, a total of 592 children (1 month to 14 years) were enrolled with signs and 
symptoms of CAP [15]. A total of 435 of the children were positive for a respiratory viral 
infection, RSV was found to be most prevalent (31.7%) followed by HRV (24.3%) [16].  
 
1.3 Human rhinovirus (HRV) 
HRV was first identified in 1956 [17] in patients presenting with mild upper respiratory tract 
infection (URTI), and has since been reported to be the most widespread cause of the 
common cold in both children and adults. HRV fall into the Picornaviridae family in the 
Enterovirus genus. They are single stranded positive-sense non-enveloped ribonucleic acid 
(RNA) viruses with a 7.2kb genome. The viral genome is composed of three main sections – 
a 5’ untranslated region, an open reading frame of the polyprotein and a 3’ untranslated 
region. The polyprotein open reading frame codes for the four capsid protein (VP1-4) and 
the non-structural genes [18]. Presently more than 100 serotypes have been classified into 3 
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species - species A (HRV-A: 74 known serotypes), species B (HRV-B: 25 serotypes) and 
most recently classified species C (HRV-C) [19-22]. HRV-C was only classified as a novel 
species in 2007, following studies which identified novel HRV genotypes [10, 23-26]. The 
HRV serotypes are classified according to their nucleotide sequence homologies; HRV-C 
shares a 53-57% amino acid homology with HRV-A and HRV-B and the different HRV 
species use different host surface protein receptors for viral entry, namely ICAM-1 and low 
density lipoprotein for HRV-A and HRV-B [27, 28] whereas HRV-C uses the human 
cadherin-related family member 3 receptors (CDHR-3) [29]. These differences in receptors 
could potentially indicate differences in mechanisms of infection and replication for HRV-C, 
which could indicate differences in pathogenicity between the three HRV species. Figure 1.1 
is the phylogenetic tree showing the relationship between all HRV serotypes known to date 
based on full genome sequences.  
 
Previously, HRV were detected using standard virus culture in susceptible cell lines of either 
HeLa or human embryo lung fibroblasts cultured in tubes that rotated slowly at 33
o
C. Acid 
lability tests were then used to differentiate between HRV and enteroviruses (a closely 
related member of the Picornaviridae family). This process was very time consuming and 
laborious, sometimes taking up to 10 days to get a positive result, and was relatively 
insensitive which most likely lead to the underestimation of HRV as an important pathogen 
[30], especially as current HRV culture techniques cannot culture the HRV-C serotypes 
[19]. The inability to culture HRV-C using traditional methods is linked to the different host 
receptor proteins required for HRV-C binding and replication [29]. However, since the 
introduction of diagnostic polymerase chain reaction (PCR) assays, which has been shown 
to be at least three times more sensitive at detecting HRV infections [31], HRV’s importance 
and role in severe illness has been re-evaluated. Furthermore, it is feasible that additional 
new serotypes of HRV may yet be discovered, with a newly diverging fourth HRV species 
(HRV-D) having been proposed recently [32].  
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Figure 1.1: Phylogenetic tree of known HRV-A, HRV-B and HRV-C serotypes. The tree was 
generated with neighbour-joining methods from full length RNA genome sequences obtained 
from GenBank. The numbers at the branch nodes are bootstrapping values (percentages of 
2 000 replicates) indicating the confidence of the branching. 
 
HRV has been widely associated with URTI; however, they are now also considered as an 
important pathogen contributing to the pathogenesis of severe LRTIs in children requiring 
hospitalisation [10, 14, 15, 22, 33-35]. HRV has also been associated with otitis media, 
sinusitis, exacerbation of asthma, cystic fibrosis and bronchitis and is the leading cause of 
wheeze and chronic obstructive pulmonary disease [35-39]. HRV has also been shown to be 
one of the most significant viral pathogens in elderly people [40, 41], occasionally resulting 
in high mortality rate – for example, in one case series 12 (21.4%) of 56 patients died due to 
acute infection which was linked to the HRV serotype A82 [40]. It has also been 
hypothesised that HRV may be one of the most important LRTI pathogens in children 
during non-influenza and non-RSV seasons [14].  
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Studies from Africa, Asia, Europe, America and Australia suggest that HRV-C may cause 
more severe illness [26, 37, 42, 43], be more associated with acute asthma [44] and be more 
prevalent in LRTIs,  in influenza-like-illnesses (ILI) [10] and that they may have different 
seasonal circulation patterns compared to the other HRV species [45]. However, more 
recently in a prospective household-based study conducted in Peru in children younger than 
3 years of age in which weekly active surveillance was conducted, in comparison to HRV-A 
and -C, HRV-B species was more commonly associated with fever, reduced appetite and 
malaise in children with acute respiratory infections (ARI); although HRV-B species only 
represented 10% of the HRV population. Furthermore, children repeatedly positive for HRV 
infections were due to new HRV strain acquisitions, rather than prolonged HRV infection 
with a single strain [46].  
 
Attributing causality of illness to HRV is complicated by the high prevalence of detection of 
HRV in asymptomatic individuals [47] and the fact that virus shedding can occur for 
between 10-14 days in some people [48]. The vast diversity of HRV serotypes (>100) may 
account for the differences in clinical phenotypes between sick and asymptomatic 
individuals as different serotypes may favour viral replication at different temperatures in 
the different regions of the respiratory tract, with certain serotypes favouring replication at 
the lower temperatures found in the upper respiratory tract and others favouring replication 
at the higher temperatures found in the lower respiratory tract [49].  
 
In order to determine the clinical significance of HRV detection in both diseased and healthy 
individuals, several studies have examined HRV prevalence in both hospitalised children 
and healthy controls. In the majority of these studies, the cases had significantly higher 
prevalence of HRV detected than the controls [50-54]; however, these studies often did not 
investigate the HRV molecular epidemiology further [51, 54] or were not designed to 
specifically address clinical epidemiology of specific HRV species in relation to disease 
severity [50, 52]. 
 
1.3.1 HRV as a pathogen or an innocent coloniser? 
The aetiological role of HRV during disease remains difficult to determine. Understanding 
the importance of HRV infection is critical when it comes to determining future strategies 
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for disease treatment and prevention. RSV is known to be one of the most important 
childhood respiratory pathogens and similar to HRV it also has a large variability in disease 
severity; however, during infection it has been shown that RSV nasopharyngeal viral load is 
closely correlated with disease severity in children [55-57]. Thus, studies have tried to 
determine whether HRV nasopharyngeal viral loads are also correlated to disease severity, 
with conflicting results between studies. In a study conducted in The Netherlands [58] on 
asthmatic children with LRTI, no association was observed between HRV nasopharyngeal 
viral load and disease severity. In a study from Japan, HRV nasopharyngeal viral load was 
not associated with disease severity in children less than 11 months age, but was associated 
with disease severity in older children, although overall there was no association [59]. 
Conversely, in a study conducted in Italian immunocompromised and immunocompetent 
children and adults, HRV nasopharyngeal viral load was correlated with disease severity for 
all age groups [60].  
 
Alternative to using nasopharyngeal viral loads, some respiratory viruses - such as RSV, 
Influenza virus and Cytomegalovirus (CMV) - have also been shown to spread and cause 
more severe disease by causing a viraemic state [61-63]. Studies have now confirmed that 
HRV can also cause viraemia, [64-67] i.e. where viruses enter the bloodstream of an 
individual thus allowing it to have access to other areas of the body resulting in a systemic 
infection. The presence of a systemic infection caused by HRV, in particular HRV-C, was 
highlighted in a case report of a 14 month old child presenting with complicated acute 
pericardial disease following an acute LRTI [67]. In this patient HRV-C was detected in the 
child’s bronchoalveolar lavage, pericardial fluid, plasma and stool samples. They reported 
the virological findings together with the childs’ medical history which suggested that the 
acute respiratory tract infection resulted in a HRV-C blood viraemia, which then allowed the 
virus to extend to the pericardial space, which then contributed to the acute pericarditis [67]. 
Other case studies have identified HRV viraemia between 11.4% to 12.3% of children 
presenting with positive HRV respiratory samples [64-66]. In studies which looked at the 
HRV molecular epidemiology of viraemia positive patients, HRV-C was significantly more 
likely to cause viraemia than both HRV-A and -B, [64, 66] suggesting that HRV-C might 
have a different pathogenesis to HRV-A and -B. Furthermore, the prevalence of HRV 
viraemia differed based on the type of ARI episode, with viraemia rates being higher during 
episodes of asthma exacerbations (25%) compared to 7.7%, 4% and 0% during URTI, 
bronchiolitis and pneumonia respectively [65]. HRV viraemia positivity was also 
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significantly associated with more severe disease, with viraemic children having higher 
respiratory rates, white blood cell counts, C-reactive protein levels (CRP), lower blood 
oxygen saturation levels and thus more often requiring oxygen therapy [64]. In addition, 
viraemia was also associated with higher respiratory sample HRV viral loads, suggesting 
that higher viral loads might be a prerequisite for the development of HRV viraemia [64].  
 
Thus, it has been hypothesised that the detection of HRV viraemia, as well as high viral 
loads could allow for the differentiation between respiratory infections in which HRV is the 
causal agent and respiratory infections in which HRV is merely a bystander [64]. 
Unfortunately, asymptomatic individuals were not enrolled as controls in any of these HRV 
viraemia studies to test this hypothesis. 
 
HRV could also interact with other pathogens resulting in more severe disease. 
Streptococcus pneumoniae is one of the leading causes of bacterial invasive disease and 
respiratory tract infections (RTI) in children worldwide [68] and is estimated to cause 
approximately 18% of all severe pneumonia episodes and 33% of pneumonia related deaths 
in children in Africa and Southeast Asia [1]. Asymptomatic colonisation of the nasopharynx 
by S. pneumoniae is common during childhood and generally resolves without progressing 
to disease; however, it can also develop into invasive pneumococcal disease (IPD) and 
pneumonia. Many risk factors for the progression of S. pneumoniae colonisation to disease 
have been identified, including young age, day care attendance, passive household smoking, 
a history of asthma, a lack of breastfeeding, younger siblings, and underlying illness such as 
a respiratory virus infection [69, 70].  
 
Respiratory viruses, including RSV, PIV and Influenza virus, have been shown to 
predispose individuals to secondary bacterial infections through the upregulation of certain 
receptors on respiratory epithelial cells thus promoting the adhesion of bacteria to the cells 
which could contribute to disease progression [71]. A similar upregulation of S. pneumoniae 
adherence to epithelial cells post HRV infection was observed in cultured human airway 
epithelial cells, suggesting that HRV infection might also predispose individuals to 
pneumococcal disease [72], leading to several studies which have tried to analyse the HRV 
and pneumococcal disease association further. Peltola et al. [73] reported that HRV was 
found in two out of nine children hospitalised with bacteraemic pneumococcal infection, and 
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suggested that the viral infection may have predisposed these patients to the IPD, as 
respiratory symptoms were observed prior to the onset of the more severe disease symptoms 
[73]. In a follow up study, they analysed the mean rates of IPD in young children compared 
to the rates of HRV activity by analysing the data from several surveillance studies and 
hospital databases in Finland, and reported that IPD rates correlated with HRV activity in 
the general community but not with RSV and influenza [74]. Additionally, in a study 
conducted in Peru from 2009-2011 on children with ARI, they found that HRV was 
associated with increased densities of pneumococcus in the nasopharynx [75]. They 
suggested that ARI episodes are most likely driven by complex virus-bacteria-host dynamics 
which require further work to fully elucidate. Subsequent to these studies there has been a 
paucity of data further characterising whether HRV infections are a risk factor for IPD. 
 
1.3.2 Human HRV in low to middle income countries in Africa and Southeast Asia 
 HRV are increasingly attributed to be an important cause of respiratory illness in children 
[36, 38, 49, 76]. In high-income countries, HRV and enteroviruses (both from the 
Picornaviridae family of viruses) have been proposed as the leading cause of respiratory 
infections; however, there is a paucity of similar data from low to middle income countries 
where under-5 childhood respiratory morbidity and mortality is greatest [77]. Thus the 
greatest burden of HRV associated disease likely occurs in low to middle income settings, 
where there are the greatest gaps in knowledge on HRV prevalence, species distribution and 
seasonal patterns.  
 
We undertook a systematic literature review to identify the prevalence and molecular 
epidemiology of HRV in Africa and Southeast Asia up until January 2016, according to the 
Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) guidelines [78]. 
We searched PubMed, Scopus, Cochrane, MEDLINE, Global Health library and the World 
Health Organisation (WHO) regional databases.  
 
Searches for articles published in English, French and Portuguese were included in the 
analysis. The objective of this review was to elucidate the role of HRV associated lower 
respiratory tract infection (LRTI) prevalence and incidence among children living in low to 
middle income countries. Due to the limited sensitivity of culture techniques for HRV [31, 
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79], only studies which employed molecular diagnostic techniques were included. 
Furthermore, we screened the references in the reviewed manuscripts for any additional 
relevant manuscripts reporting on HRV in low to middle income countries in Africa and 
Southeast Asia. Also, Google Scholar searches were undertaken to search for country 
specific publications that reported on HRV associated LRTI from African or Southeast 
Asian countries.  
 
Studies reporting on observational surveillance reports, cross-sectional, retrospective, 
cohort, and prospective data for prevalence rates of HRV were included in the review. 
Review articles were excluded from this review; however, we did assess references in these 
to identify any additional citations that were relevant to this review. We included all 
appropriate studies regardless of gender of study participant or case definition used for the 
study. Only studies which reported on HRV in children were included. Citations which 
detailed studies done outside of Africa and Southeast Asia were excluded. In cases where 
multiple reports were identified from the same authors with overlapping study periods, only 
the most recent or most comprehensive article was included for the review. Information on 
study region and population, study design, period of recruitment, recruitment of cases and 
controls, case definitions, age range of cases and controls, HRV prevalence and incidence 
rates in cases and controls, molecular epidemiology of HRV in cases and controls, the 
prevalence and co-infections with other respiratory viruses and bacteria were extracted from 
all relevant articles and included in the review.  
 
In addition, an exploratory meta-analysis, using exact conditional logistical regression, was 
undertaken to compare the prevalence of HRV detection in the case-control studies in order 
to determine the pooled odds ratios and confidence intervals for cases versus controls. Also, 
meta-analysis was conducted on the case studies which reported HRV prevalence by age-
categories (1-12months, 1-5 years and 5-10 years), so as to determine the odds ratio for 
HRV infection by age group. All data analyses were conducted using STATA version 13.0 
(College Station, TX, USA) and SAS version 9.2 (Cary, NC, USA). Two tailed P-values 
<0.05 were considered to be statistically significant.  
 
The research identified 712 citations from PubMed, Scopus, Cochrane, MEDLINE, Global 
Health library and the WHO regional databases (Figure 1.2). A total of 635 manuscripts 
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were removed through the elimination of duplicate articles and through the screening of the 
titles and abstracts, leaving 77 articles for assessment of the full text. Of these, 55 
manuscripts did not pass the inclusion criteria screening and were eliminated from the 
review - the main reasons being that the studies were conducted in all age groups and HRV 
results were not reported separately for children (n=19) and duplication of study materials 
published by the same authors with overlapping study period and geography (n=11). An 
additional 8 manuscripts were identified through reviewing the references in the included 
manuscripts as well as through Google Scholar searches for country wide reporting on HRV 
prevalence [80-87]. Consequently, 31 articles were included in this review; Figure 1.2. 
 
We identified 23 manuscripts reporting on HRV prevalence data from only 13 of the 54 
African countries, six of which were from South Africa [35, 54, 88-91], four from Kenya 
[92-95], two each from Madagascar [81, 96] and Mozambique [80, 97] and one each from 
Angola [98], Botswana [99], Burkina Faso [100], Burundi [16], Morocco [101], Niger [102], 
Nigeria [103], Senegal [104] and Zambia [105]. From Southeast Asia, we identified 8 
manuscripts reporting on HRV prevalence from 6 of the 11 Southeast Asian/Pacific 
countries, including two each from Vietnam [84, 85] and Thailand [86, 106] and one from 
Cambodia [83], Malaysia [87], Philippines [66], and Singapore [29, 107]. 
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Figure 1.2: Flow diagram of article selection reporting on HRV in Africa and Southeast Asia 
 
Of the 31 manuscripts included in the review, 9 reported on the molecular epidemiology of 
HRV detected within the population [16, 35, 66, 85-87, 92, 99, 107] and only two (Kenya 
and Botswana) of the 9 enrolled controls [92, 99]; Table 1.1.  
 
712 articles identified through database 
searches
-553 from Africa
-159 from Southeast Asia
120 eliminated as duplicates
-39 from Africa
-81 from Southeast Asia/PacificIslands
592 articles after removal of duplicates
-514 from Africa
-78 from South-east Asia/Pacific Islands
341 eliminated after title screening
-316 from Africa
-25 from Southeast Asia/Pacific islands
251 articles after title screening
-198 from Africa
-53 from South-east Asia/Pacific islands
174 eliminated after abstract screening
-142 from Africa
-32 from Southeast Asia/Pacific islands
77 full text articles assessed for eligibility
-56 from Africa
-21 from Southeast Asia/Pacific islands 54 eliminated
-Outside geographic region= 6 
-Duplication of study data= 11
-Study in all ages groups= 20
-HRV prevalence not reported= 12
-Review articles= 1
-study used culture= 2
-Did not discriminate between 
rhinovirus and Enterovirus infections=2
31 articles met inclusion criteria
-23 from Africa
-8 from Southeast Asia/Pacific islands
8 additional 
articles found from 
Google searches 
and through review 
of references of 
included articles
Studies reporting on rhinovirus 
molecular  epidemiology
-9 manuscripts (2 of these 
were case-control studies) 
Studies which reported on only 
HRV prevalence in diseased 
individual
- 17 manuscripts
Studies which included HRV prevalence in 
case and control populations
-8 manuscripts
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In the Kenyan study [92], children less than 12 years of age presenting at the local hospital 
with any severity of LRTI were enrolled (n=1759), as well as children with or without an 
URTI as a control group (n=254). HRV was detected in 22% of the cases (n=380/1759; with 
HRV-A, HRV-B, HRV-C constituting 47%, 5% and 48%, respectively) and 24% (P=0.38) 
of the controls (n=61/254; HRV-A, HRV-B, HRV-C constituting 41%, 15% and 44% 
respectively). None of the HRV species were associated with more severe disease when 
comparing between the cases with LRTI; and similarly the prevalence of HRV detection and 
species distribution was similar between cases with severe disease compared to controls 
with URTI. Nevertheless, the authors cautioned that due to the study design, including 
imbalance between case and control enrolment, they were unable to make definitive 
conclusions on HRV epidemiology and disease severity. The controls were also enrolled 
from a convenient sample of children presenting at the hospital for routine immunisation, 
and might not have been representative of the population. Also, they experienced challenges 
to classify all the HRV positive samples, with 25% (n=109/441) of the samples failing to 
amplify during sequencing, which was significantly higher among samples from controls 
(44%, n=27/61) compared to cases (22%, n=82/280, P<0.001), which further limited the 
robustness of their findings. In addition, due to limited availability of clinical data, they were 
unable to analyse for any association between the HRV types and disease severity; and also 
did not investigate for other respiratory virus co-infections [92].  
 
Similar findings as in Kenya were observed in Botswana [99] which enrolled 310 cases and 
133 matched case-controls. This study too did not identify a difference in prevalence of 
HRV between cases aged 1-23 months hospitalised for pneumonia (31%; n=97/310) and 
controls (30%; n=40/133, P>0.99) who were matched for age and date of enrolment. In this 
study, 75% of cases had at least one respiratory virus detected, including RSV, which in 
contrast to HRV was detected in 35% (n=107/310) of the cases and only 2% (n=2/133) of 
the controls (P<0.001). Co-infections between HRV, RSV, Influenza A and B virus, PIVs 
(type 1-3), human Metapneumovirus (HMPV) and Adenovirus occurred in 8% (n=25/310) 
of the cases overall, of which 64% (n=16/25) were between RSV and HRV. Serotyping was 
conducted in 84 of the cases positive for HRV (HRV-A=44%, HRV-B=8%, HRV-C=48%); 
however, in the case-control matched participants only 34 cases (HRV-A=44%, HRV-
B=15%, HRV-C=41%) and 31 controls (HRV-A=51%, HRV-B=10%, HRV-C=39%, 
P=0.99) were serotyped, with no difference in serotype distribution observed [99]. This 
study did not explore whether there was any association between specific HRV type and 
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disease severity. Both of these studies acknowledged that their sample size were not 
sufficient to fully elucidate the causal role of HRV in the aetiology of pneumonia.  
 
The remaining seven studies which analysed the clinical and molecular epidemiology of 
HRV did not enrol controls. Two of the studies sequenced less than 100 HRV positive 
samples and only provided a descriptive analysis of the molecular characterisation of HRV 
without associating it with disease outcome [35, 107]. The South African [35] study focused 
on wheezing in children younger than 5 years and found that HRV was the most common 
virus detected (58%; n=128/220), with HRV-C being the most commonly detected species 
(HRV-A=37%, HRV-B=11% and HRV-C=52%), although only 55% (n=71/128) of the 
samples were serotyped. Smuts et al. [35] also investigated for RSV, influenza virus, 
adenovirus, PIVs, HMPV, human Coronavirus (HCoV) and human Bocavirus (HBoV); and 
found that co-infection occurred in 16% (n=20/128) of the HRV positive samples. The most 
common co-infecting virus being HMPV (n=8/128, 6.3%), followed by HBoV (n=6/128, 
4.7%) and HCoV (n=1/128, 0.8%). Comparing the HRV positive and negative participants, 
cases with HRV were more likely to have vomiting and less likely to be febrile. In the 
Singaporean study (Tan et al. 2009), HRV was the most commonly detected respiratory 
virus (13%; n=64/500) in children hospitalised with ARI; which included 48% (n=31/64) 
with LRTI, 25% (n=16/64) with URTI and 27% (n=17/64) with undefined symptoms. The 
molecular epidemiology of HRV was determined in 90% (n=58/64) of the samples, with 
HRV-A dominating (HRV-A=73%, HRV-B=14% and HRV-C=3%). HRV co-infections 
were detected in 8% (n=10/128) of the participants, most commonly with HBoV (n=7/10) 
followed by RSV (n=2/10), and 60% of these co-infections were in children hospitalised 
with LRTI, suggesting that HRV associated co-infections may result in more severe disease 
episodes albeit not being statistically significant.  
 
In the remaining five studies which examined the clinical and molecular epidemiology of 
HRV, there were suggestive associations between HRV infection and disease severity. In the 
Burundian study [16] which enrolled children aged 1 month to14 years of age hospitalised 
with LRTI, HRV was identified among 40% of cases, with a dominance of HRV-A 
(A=55%, HRV-B=12 and HRV-C=32%). HRV-A infections were the most frequently 
identified HRV species in children with pneumonia and bronchiolitis diagnosis, whereas 
HRV-C infections were most common in children presenting with wheezing. They did not, 
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however, investigate the association of HRV with any other respiratory pathogens. In the 
Malaysian study [87], 165 children younger than 5 years of age hospitalised with acute 
LRTIs were enrolled, among whom HRV was identified in 33% of cases. Although these 
cases were also investigated for RSV, HMPV, Influenza-A and Influenza-B, PIVs, HCoVs, 
HBoV and adenovirus, the majority (67%) of HRV cases were mono-infections, whilst HRV 
was most likely to form co-infections with RSV (n=11/18; 61%). Children with HRV mono-
infections were significantly older than children with RSV mono-infections (11.8 versus 9 
months), and younger than children with Influenza-A mono-infections (11.8 versus 12.7 
months). They also reported that children with HRV mono-infections were hospitalised 
earlier during the course of disease, 1.9 days’ post symptom onset compared to 4 and 4.8 
days for RSV and Influenza mono-infections respectively, P<0.001. Furthermore, children 
with HRV infections were less likely to be febrile (67%) compared to RSV (92%, P<0.003) 
and Influenza (100%, P=0.044) associated LRTI cases. The molecular distribution of the 
HRV mono-infections were HRV-A=61%, HRV-B=0 and HRV-C=39%; with HRV-C being 
more commonly associated with wheezing, vomiting, rhonchi, higher neutrophil counts and 
generally more severe disease compared to HRV-A infections. Furthermore, HRV-A was 
detected more frequently in younger age groups (6-11 months) and HRV-C in older children 
(12-23 months) [87].  
 
In the Thai study [86], of 289 children hospitalised with acute LRTI, 30% were positive for 
HRV, with HRV-C being most common (HRV-A=33%, HRV-B=9% and HRV-C=58%). 
HRV was a mono-infection in 62% of the positive cases, whilst co-infections in the others 
included RSV (36%), Influenza and adenovirus (18% each). Other viruses investigated for 
included: PIVs, HBoV, Influenza-A and Influenza-B, Adenovirus, RSV, HMPV and 
Polyomaviruses (WU/KI). The authors, however, concluded that the sample size was 
inadequate for statistical analysis between disease outcomes of HRV compared to other 
respiratory viruses, or by HRV species and disease severity. However, 50% and 72% of 
hospitalised participants infected with HRV-C presented with asthma and wheeze, 
respectively.  
 
The Vietnamese [85] study enrolled 1082 children hospitalised with ARI, with HRV 
identified in 30% of cases, including 72% mono-infections. Of the 91 mixed HRV co-
infections which included investigation for Influenza-A and Influenza-B, HMPV, PIVs, 
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HCoVs, adenovirus, HBoV and RSV which accounted for 53% (n=48) of the co-infections. 
Similarly to the Malaysian study [87], children with HRV mono-infections were older than 
children with RSV mono-infections (9 versus 7 months, P=0.02) and younger than children 
with influenza mono-infections (9 versus 22.5 months, P<0.001). Furthermore, similar to 
the South African [35] and Malaysian study [87], children with HRV mono-infections were 
less likely to present with febrile disease compared to the other virus mono-infections 
(P<0.001). HRV mono-infections were also more likely associated with hypoxia (12.4%) 
compared to RSV (3.8%, P=0.002) and PIVs mono-infections (0%, P=0.02); and presented 
more often with wheezing (63.2%) compared to Influenza mono-infections (42.3%, 
P=0.038). Finally, the blood eosinophil count was significantly elevated during HRV mono-
infections in comparison to all the other virus mono-infections (P<0.001). As eosinophil 
levels are a predictor of reactive airway disease, this could been indicative of these children 
having underlying asthma, or that HRV might predispose to subsequent asthma [85]. On 
comparison of mono and mixed HRV infections, generally there were no differences in 
clinical features, except that HRV co-infections were more likely to be associated with chest 
retractions (70.3% versus 57.3%, P=0.032). Of the 18% of the HRV serotyped, HRV-A was 
the most dominant (HRV-A=76%, HRV-B=0, HRV-C=24%) [85].  
 
Finally, in the Philippino study [66], HRV was identified in 33% of the 816 children 
hospitalised with severe pneumonia. The molecular epidemiology of these cases also 
indicated HRV-A as being the most dominant - HRV-A=56%, HRV=10% and HRV-C=34% 
- whilst 1% of samples failed to amplify and 10% were identified as enteroviruses. Viraemia 
for HRV was identified among 12% (n=30/243) of the HRV cases tested, with cases with 
HRV-C being 15.04-fold more likely to be viraemic (31%; n=26/83) compared to HRV-A 
(n=4/135, 3%, P<0.01) and HRV-B (n=0/25, P<0.01). Furthermore, cases with HRV 
viraemia had significantly lower oxygen saturation for both HRV-A and HRV-C compared 
to those without viraemia. Also, HRV-A cases with viraemia were significantly more likely 
to have wheezing (100%) compared to HRV-A cases without viraemia (45%, P<0.05); with 
a similar trend observed for HRV-C (69% vs. 48%, P=0.1). Case fatality ratio, however, did 
not differ by the presence (3%) or absence (9.5%, P=0.37) of viraemia. This study 
concluded that HRV-C is more likely to be associated with viraemia [66], which could 
explain that the association of increased disease severity reported in several studies with 
HRV-C compared to the other HRV species [26, 37, 42, 43]. This study did not investigate 
for any other respiratory virus infections [66]. 
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Table 1.1: HRV prevalence and molecular epidemiology by Region (Africa and Southeast Asia) and Country  
Country Study 
population 
Case definition Median 
age 
Study 
duration 
# Cases enrolled HRV prevalence* Percentage species 
distribution in cases 
Africa        
Botswana [99] <2 years Hospitalised with 
WHO defined 
pneumonia 
6.1 months April 2012-
Aug 2014 
310 31% A=36% 
B=7% 
C=41% 
Burundi [16] <14 years Hospitalised with 
LRTI 
1.94 years Nov 2010 – 
Oct 2011 
462 40.3% A=43.5% 
B=9.7% 
C=25.3% 
Kenya [92] <12 years  Hospitalised with 
LRTI 
Not 
reported 
Jan 2007-
Dec 2009 
1759 21% A=47% 
B=4.4% 
C=48% 
South Africa [35] 2-59 
months 
Presenting with 
acute wheezing 
12.2 
months 
May 2004- 
Nov 2005 
220 58.2% A=37% 
B=11% 
C=52% 
Southeast Asia       
Malaysia [87] <5 years  Hospitalised with 
LRTI 
11.8 
months 
June-Dec 
2009 
165 33% A=61% 
B=0% 
C=39% 
Philippines [66] <15 years Hospitalised with 
severe pneumonia 
9 months May 2008 – 
May 2009 
816 29.8% in nasal 
swabs. 12.3% in 
serum samples 
A=55% (3% in serum) 
B=10% (0% in serum) 
C=34% (32% in serum) 
Singapore [107]  <12 years  Hospitalised with 
RTI 
Not 
reported 
Oct 2005-
Mar 2007 
Retrospective 
study of 500 
samples 
12.8% A=73% 
B=14% 
C=3% 
Thailand [86] Paediatric 
patients 
Hospitalised with 
LRTI 
Not 
reported 
Feb 2006-
Feb 2008 
289 30% A=33% 
B=8% 
C=58% 
Vietnam [85] <15 years Hospitalised with 
RTI 
9 months April 2010-
May 2011 
1082 30% A=75.9% 
B=0% 
C=24.1% 
HRV: Human rhinovirus; ALRTI: Acute lower respiratory tract infection; LRTI: Lower respiratory tract infections; URTI: Upper respiratory tract infections; RTI: 
Respiratory tract infection; WHO: World Health organisation. *All HRV prevalence’s were detected in nasopharyngeal swabs unless stated otherwise
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Seven studies were identified that enrolled both cases with severe respiratory disease and 
asymptomatic controls or controls with mild respiratory disease to determine the attributable 
role of HRV in the aetiology of LRTI [54, 83, 92, 93, 95, 99, 106]; Table 1.2. Of these seven 
studies, there was higher odds for HRV to be prevalent in LRTI cases than controls in only 
the South African study (33% vs. 18.8%, P=0.02); however, the lower bound of 95% 
confidence interval of these estimates approximated 1.0; Figure 1.3 [54]. The study from 
South Africa [54] enrolled children presenting at the hospital and were categorised as acute 
LRTI (ALRTI) presenting at the emergency room but not requiring hospitalisation, children 
hospitalised as well as patients requiring intensive care unit (ICU) treatment. They also 
enrolled a limited number of controls which were children presenting at a vaccine centre. 
They reported that HRV prevalence was higher among cases requiring hospitalisation (36%) 
compared to controls (19%, P=0.047) and there was a trend for all the ALRTI cases 
(regardless of hospitalisation) to have a higher HRV prevalence compared to the controls 
(32.5% versus 19%, P=0.072). HRV was detected as a mono-infection in 50% of all the 
ALRTI cases, and HRV was detected as a mono-infection in 88% of the hospitalised cases 
(n=88/109). A significantly greater proportion of the children with HRV mono-infections 
had to be hospitalised and required ICU treatment compared to children hospitalised with 
HRV co-infections (P<0.001). They also investigated for RSV, Influenza virus (A and B), 
PIV (Type 1-3), HCoV (OC43, NL63, 229E, HKU1), Adenovirus (AdV), HMPV and HBoV 
and found that HRV was the most prevalent virus detected (33%) followed by RSV (30.1%) 
and HBoV (6.1%) [54]. 
 
The Cambodian study [83] was the only other case-control study which analysed the 
detection of HRV further than only its prevalence in the cases and controls. They found that 
HRV (20%) was detected in similar prevalence to RSV (19%). They also investigated for 
Influenza (A and B), PIV (type 1-4), AdV, HMPV, HBoV, HCoV (OC43, NL63, 229E, 
HKU1) and enterovirus. HRV was the second most commonly detected mono-infection 
(n=169/204, 83%) following RSV (n=167/192, 87%); and HRV was most commonly 
detected together with RSV (n=10/35, 29%) and the HBoV (n=8/35, 23%). They found that 
infections with RSV and HRV could not be distinguished clinically for either infants or 
children 1-4 years of age. They also enrolled 50 controls but did not elaborate on the 
inclusion criteria for these controls or how they went about recruiting the controls. HRV was 
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detected in 12% (n=6/50) of the controls and RSV was detected in 8% (n=4/50) [83]. The 
number of controls was too small for any additional analysis. 
 
The remaining five studies found no difference in HRV prevalence between cases (47.5%-
18%) and the controls (19%-50%) [92, 93, 95, 99, 106] and hence, did not undertake any 
further analysis specific to HRV. The only studies which matched community controls to 
cases were from Botswana, with matching including for age, HIV status and period of 
enrolment [99] and Kenya [95] which age frequency matched the cases and controls as well 
as matched for month of the year of enrolment. The controls for the remainder of the studies 
were either a convenience sample of children presenting for routine immunisation or in 
vaccine trials. This could have biased their generalisability to the population. Furthermore, 
the number of cases enrolled greatly outnumbered the number of control participants, 
possibly further compromising statistical comparisons. 
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Table 1.2: HRV prevalence reported in case-control studies 
Study area Ages Case definition # cases 
enrolled 
(n) 
HRV positives 
cases (n, %) 
Control definition # 
controls 
enrolled 
(n) 
HRV 
positive 
controls  
(n, %) 
RSA [54] <5 years for case 
<2 years for 
controls 
ALRTI 610 201 (33%) Community controls without respiratory 
disease 
48 9 (18.8%) 
Botswana [99] 1-23 months Hospitalised with Pneumonia 310 97 (31.3%) Community based controls without ALRTI, 
age and enrolment date matched to cases 
133 40 (30%) 
Kenya [93] <5 years Hospitalised with severe or 
very severe pneumonia 
204 97 (47.5%) Presenting for immunisation or medicine 
refills. Non severe illness 
48 24 (50%) 
Kenya [92] 1 day-12 years Hospitalised with LRTI 1759 380 (21.6%) Presenting for routine immunisation- with or 
without URTI 
254 61 (24%) 
Kenya [95] <5 years Hospitalised with severe or 
very severe pneumonia 
810 184(23%) Convenient sample of children presenting to 
outpatient clinics - with or without URTI 
369 82 (22%) 
Cambodia [83] <5 years Hospitalised with LRTI 1006 204 (20%) Not reported 50 6 (12%) 
Thailand [106] <5 years Hospitalised with LRTI 903 169 (18%) Convenient sample from outpatients without 
fever, cough, sore throat or diarrhoea  
116 14 (12%) 
Abbreviations – n: number; HRV: Human rhinovirus; ALRTI: Acute lower respiratory tract infection; LRTI: Lower respiratory tract infections; URTI: Upper 
respiratory tract infections 
All HRV prevalence in the table are based on nasopharyngeal samples 
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Overall, there was no difference observed in the meta-analysis on prevalence of HRV 
identification between cases of ARI (23.9%; which varied in their severity and clinical 
presentation between studies) and controls (23.7%, P=0.197; which varied in their 
representivity to the general population); Figure 1.3. Also, this meta-analysis needs to be 
interpreted with caution, since in addition to differences in case definitions and control 
selection between the studies, the studies also varied in the age groups included; Table 1.2.  
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Figure 1.3: Studies reporting on the proportion of HRV-associated cases and controls. Using exact conditional logistic regression, odds ratios 
(OR) were used to compare the proportions of children with HRV-associated severe disease (cases) versus children with asymptomatic HRV 
infections (controls). 
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The remaining 17 studies were primarily surveillance studies conducted in children 
presenting with respiratory infections and mainly focused on other more established 
respiratory pathogens such as RSV and Influenza virus [81, 94, 96, 97, 101, 102, 104]; Table 
1.3. HRV prevalence in these studies was reported as part of the general surveillance, and no 
further analyses of the prevalence or clinical presentation of HRV were undertaken in these 
studies. Furthermore, the studies varied in age groups of children enrolled, case definition 
with some focusing only on URTI [91, 94], others only on LRTI [80, 88, 89, 96, 101, 102, 
105], others reported on both URTI and LRTI separately [81, 84] or some which enrolled all 
RTI and did not differentiate between URTI and LRTI cases [90, 97, 98, 100, 103, 104].  
 
The majority of the surveillance studies, however, did focus on LRTI in children, including 
7 which were hospital based [80, 89, 96, 101, 102, 105, 108] and two others which enrolled 
hospitalised children with either LRTI or URTI and reported the results separately [81, 84]; 
Table 1.3. In these studies, the prevalence of HRV ranged from 17%-53%, with the 
Madagascar study [96] reporting the lowest prevalence (17%). In this study, HRV was the 
third most common detected virus following RSV (n=130/295, 44%) and influenza-A virus 
(n=71/295, 24%). HRV was detected as a mono-infection in 14% of cases, and more 
commonly detected as a co-infection with RSV (n=12/49, 24%) and influenza-A virus 
(n=9/49, 18%). The study from Morocco [101] reported the highest HRV prevalence (53%), 
followed by RSV (n=125/684, 18%) and adenovirus (n=16/684, 17%). No further analysis 
was conducted on HRV in this study, as was the case in the majority of the other 
observational studies, with many authors suggesting that the pathogenic role of HRV during 
disease remained uncertain due to the high prevalence reported in asymptomatic individuals 
and prolonged duration of shedding of HRV [81, 84, 88, 102, 105].  
 
Similarly, in the studies which did not distinguish between LRTI or URTI, the prevalence of 
HRV ranged from 10% to 42%. The study conducted in Senegal [104] had the lowest 
prevalence of HRV (10%) and was conducted in children <5 years age with fever and any 
other sign of respiratory infection. The inclusion of fever as a pre-requisite for screening, 
might explain why influenza virus was the most prevalent virus detected in this study 
(n=25/82, 31%), followed by RSV (n=13/82, 16%). Nevertheless, HRV was predominantly 
identified as a mono-infection in this study, with only a single case of HRV-RSV mixed 
infection observed. The prevalence of HRV in the other four studies ranged from 33%-42%. 
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The study in Burkina Faso [100] reported the highest prevalence of HRV (42%), 85% of 
which were mono-infections. In the Mozambican study [80] the overall prevalence of HRV 
in infants with ARI episodes was 26%. This tended to be higher among hospitalised cases 
(36%, n=10/28, P=0.22), making it the most prevalent virus identified among hospitalised 
ARI cases of which 67% were mono-infections, and adenovirus being the most common co-
infection among those with a mixed-infection.  
 
The other studies were conducted in children presenting with URTI, the first included 
children with acute otitis media, among whom HRV was identified on nasopharyngeal 
swabs in 38% of cases [91], and as the most prevalent virus identified irrespective of HIV 
status (33% in HIV-infected and 39% in HIV-uninfected children). In the study from Kenya 
[94] among older children (5-10 years) presenting with malaria like symptoms, HRV was 
detected in 26% of cases, including among 37% of the cases who tested positive for malaria.
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Table 1.3: The prevalence of HRV in paediatric surveillance studies of respiratory disease 
   LRTI URTI  URTI AND LRTI combined 
 Median 
age 
Ages 
included 
# cases 
(n) 
Prevalence  Case definition # cases 
(n) 
HRV 
prevalence 
Case 
definition 
# cases 
(n) 
HRV 
prevalence  
Case definition 
Enrolled patients with both URTI and LRTI.       
Madagascar [81] 2 years 2-59 
months 
178 43 (24%) Physician 
diagnosed LRTI 
117 18 (15%) URTI with or 
without cough 
295 61 (21%) URTI and LRTI 
combined 
Vietnam [84] 1.4 years <15 year 557 153 (28%) Hospitalised with 
LRTI 
391 113 (29%) Hospitalised 
with URTI 
948 266 (28%) Hospitalised 
with ALRTI 
Enrolled only patients with LRTI       
Madagascar [96] 1.1 years <5 years 290 49 (17%) Hospitalised with 
LRTI 
URTI cases not included in this study 
Morocco [101] 21.5 
months 
2-59 
months 
684 360 (53%) Hospitalised with 
Severe pneumonia 
URTI cases not included in this study   
Mozambique [80] not 
reported 
<5 years 807 196 (24%) Hospitalised with 
severe pneumonia 
URTI cases not included in this study    
South Africa [88] not 
reported 
<5 years 8393 3115 (37%) Hospitalised with 
LRTI 
URTI cases not included in this study    
South Africa [89] 10 
months 
<2 years 1460 466 (32%) Hospitalised with 
LRTI 
URTI cases not included in this study   
Zambia [105] 9.6 
months 
<5 years 297 57 (19%) Hospitalised with 
SARI 
URTI cases not included in this study   
Niger [102] 9 months <5 years 160 47 (29%) Hospitalised with 
SARI 
URTI cases not included in this study   
Enrolled only patients with 
URTI 
           
Kenya [94] 7 years 5-10 
years 
LRTI cases not enrolled in this study 197 52 (26%) URTI with 
Malaria like 
symptoms 
LRTI cases not enrolled in this study 
South Africa [91] 14 
months 
<5 years LRTI cases not enrolled in this study 260 98 (38%) Acute Otitis 
Medias 
LRTI cases not enrolled in this study 
Enrolled all RTI and did not differentiate between URTI and LRTI           
Mozambique [97] 6 months <12 
months 
LRTI and URTI not reported separately  333 86 (26%) ARI – inpatients 
and outpatients  
Angola [98] 36 
months 
1 month – 
14 years 
LRTI and URTI not reported separately 102 34 (33%) RTI - 
outpatients 
Burkina Faso [100] Not <3 years LRTI and URTI not reported separately 209 88 (42%) RTI – inpatients 
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reported and outpatients  
Nigeria [103] not 
reported 
<14 years LRTI and URTI not reported separately 246 87 (35%) RTI – inpatients 
and outpatients 
Senegal [104] not 
reported  
<5 years LRTI and URTI not reported separately 82 8 (10%) RTI - 
outpatients 
South Africa [90] 4.7 
months 
2-
13months 
LRTI and URTI not reported separately 195 76 (39%) Admission to 
ICU with 
positive 
respiratory virus 
sample 
Abbreviations - ALRTI: Acute lower respiratory tract infection; LRTI: Lower respiratory tract infections; URTI: Upper respiratory tract infections 
All shaded blocks indicate that these fields were not applicable to these studies 
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The differences in age groups and clinical definitions could account for the variability in 
HRV detection (16%-53%) between the studies; Table 1.3. Of the 17 surveillance studies, 
10 provided the prevalence of HRV among LRTI cases by age groups. The majority of the 
studies stratified for infants and age 1-5 years (9/10). Furthermore, 3 studies included 
prevalence in children >5 years. Nevertheless, the meta-analysis on prevalence of HRV did 
not differ by age groups, including 39% (95% CI: 0.32-0.46) among the 1 to 12-month age 
group (Figure 1.4A) and 36% in the 1 to 5-year group (95% CI: 0.31-0.41) (Figure 1.4B) 
and 5 to 10-year age group (Figure 1.4C).  
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Figure 1.4A: The prevalence of HRV in children <12 months. Using exact conditional logistic regression, odds ratios (OR) were used to 
compare the proportions of children with HRV-associated disease in infants. 
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 Figure 1.4B: The prevalence of HRV in children 1-5 years of age. Using exact conditional logistic regression, odds ratios (OR) were used to 
compare the proportions of children with HRV-associated disease in children 1-5 years of age. 
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Figure 1.4C: The prevalence of HRV in children 5-10 years of age. Using exact conditional logistic regression, odds ratios (OR) were used to 
compare the proportions of children with HRV-associated disease in children 5-10 years of age. 
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Our systematic review on HRV in low to middle income countries in Africa and Southeast 
Asian/Pacific countries confirms the scarcity and limitations of the available clinical and 
molecular epidemiology data. This further emphasises the uncertainty on the role of HRV in 
the pathogenesis of childhood respiratory disease, even though in all of the studies HRV was 
one of the most if not the most prevalent virus detected. In the studies which reported on 
more than just the prevalence of HRV in the study population, it was evident that HRV was 
most commonly detected as the only respiratory virus. None of the studies, however, 
analysed for co-infections with bacteria even though HRV infections have been shown to 
enhance both subsequent infection with Streptococcus pneumoniae and Staphylococcus 
aureus through the upregulation of bacterial adhesion to the respiratory epithelial cells and 
through the modulation of the host immune responses [109, 110]. This is most likely 
because bacterial co-infection relationships are difficult to fully elucidate as the currently 
available diagnostic tools for diagnosing bacterial pneumonia are insensitive, with blood 
culture sensitivity ranging between 15-30%, whilst obtaining samples from the site of 
infection is challenging with direct aspiration of the lungs rarely performed [95, 111].  
 
The need for a large sample size was highlighted by the two studies which investigated the 
HRV molecular epidemiology in both case and controls [92, 99], but failed to analyse the 
epidemiology in terms of clinical outcomes, disease severity or even basic comparison 
between case and control populations due to the limited statistical power of the study, 
particularly the limited number of control subjects. In the studies which did not enrol 
controls [16, 35, 66, 85-87, 107], the analysis of the different HRV species in terms of 
clinical outcomes and disease outcome showed that the HRV species could in fact have 
different clinical presentations; however, without the controls it is uncertain what the 
contribution of different HRV types is in the pathogenesis and aetiology of LRTI. 
Nevertheless, the studies provide some indication that HRV might be an important 
respiratory pathogen, especially in developing countries where HRV is found to be the most 
prevalent virus detected in RTI cases irrespective of age group and clinical syndromes. 
 
A large scale surveillance project is needed which looks at both severe RTI and healthy 
controls to fully elucidate the attributable pathogenic role of the different HRV species in 
severe LRTI among children in low to middle income countries. This will need to include an 
in-depth clinical and socio-economic analysis from cases and healthy cohorts, to fully study 
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the clinical manifestation and risk factors for HRV infection; and also to evaluate the impact 
of HIV infection on HRV associated severe pneumonia hospitalisations.  
 
1.4  The Pneumonia Etiology Research for Child Health (PERCH) project 
The PERCH project is a case-control study aimed at fully characterising the aetiology of 
WHO-defined severe and very severe pneumonia in children aged 28 days to 59 months in 
nine sites across seven countries in Africa and Southeast Asia making it the biggest study 
looking at the aetiology of childhood pneumonia since the Board of Science and Technology 
for International Development studies which were conducted in the late 1980s [112]. In 
order to provide a comprehensive analysis of epidemiological data from a broad 
representation of regions where the highest incidences of pneumonia related morbidity and 
mortality currently occurs [113] the study included five sites from five African countries and 
four sites from two Southeast Asian countries: Basse, The Gambia; Kilifi, Kenya; Bamako, 
Mali; Lusaka, Zambia; Soweto, South Africa; Dhaka and Matlab, Bangladesh and Nakhom 
Phanom and Se Kaeo, Thailand. Table 1.4 provides a summary of the sites and the 
recruitment statistics for the countries involved in the PERCH project. Enrolment into the 
project started at the South African and Kenyan sites in mid-August 2011 and recruitment 
into the project was completed at all sites by February 2014. During the recruitment phase of 
PERCH, a combined total of 3648 Cases (239 HIV positive) and 4541 Controls (229 HIV 
positive) were enrolled in the project. 
 
The main difference between PERCH and other pneumonia aetiology studies is the specially 
designed and highly sensitive molecular detection techniques employed at all the sites for 
determining the cause of pneumonia as well as the case-control study design. This design 
provides vital information on the controls which in turn allows for additional interpretation 
and extrapolation of the finding from the pneumonia cases. This is especially true for 
interpreting the results from the nasopharyngeal samples which are blurred by the presence 
of colonisation organisms and for identifying risk factors which are associated with severe 
and very severe pneumonia. Strict enrolment criteria for both the cases and the controls, 
sampling strategies and laboratory testing algorithms were employed and standardised 
across all the sites to allow for analysis of cross site data [114]. 
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The PERCH cases were children hospitalised with WHO-defined severe and very severe 
pneumonia and the controls were enrolled from the community based on age-frequency 
matches to the cases, additionally the controls were also HIV status matched at the Kenya 
and South African sites where HIV prevalence was high. The controls could have signs and 
symptoms of ARI provided they did not have severe or very severe pneumonia requiring 
hospitalisation. Cases and controls were subjected to blood draws, nasopharyngeal (NP) 
swabs and urine collection. Additional sample collection amongst cases included induced 
sputum, gastric aspirates, tracheal aspirates, lung aspirates, pleural fluid taps and post-
mortem lung biopsy if clinical relevance was indicated. Extensive information on 
participants’ demographic, nutritional, co-morbidities, family environment and socio-
economic status were obtained on enrolment to allow for risk factor analysis. Clinical 
assessments were performed on controls and cases at enrolment (i.e., on admission to the 
hospital for cases) and then again for the cases at 24 and 48 hours after admission, and on 
the day of discharge from hospital. 
 
Standard culture diagnostic techniques were performed on the samples (blood, pleural fluids, 
lung aspirates, tracheal aspirates and induced sputum) collected from the cases; in addition, 
state-of-the-art molecular diagnostic techniques were performed on the respiratory samples 
collected from the cases and the controls in order to better understand the attributable role of 
analysed respiratory pathogens in severe and very severe pneumonia. The primary molecular 
diagnostic panel was designed by Fast Track Diagnostics (FTD) (Luxembourg) and were 
real-time multiplex PCR assays which detected 33 respiratory pathogens including viral, 
bacterial and fungal parasites. The specificity has been validated using positive plasmid 
controls and the sensitivity using a large number of respiratory samples. In all validation 
experiments the primer and probes for the different pathogens showed a 100% specificity 
and sensitivity.  
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Table 1.4. A summary of the countries involved with PERCH together with their recruitment information  
Site Country HIV 
prevalence 
Urban/ 
Rural 
Date 
enrolment 
commenced 
Date 
enrolment 
completed 
# Cases 
enrolled 
# Controls 
enrolled 
Soweto South Africa Very High Urban Aug 2011 Aug 2013 919 962 
Kilifi  Kenya Medium Rural Aug 2011 Nov 2013 579 793 
Basse The Gambia Low Rural Nov 2011 Oct 2013 539 580 
Bamako Mali Low Urban Jan 2012 Jan 2014 557 583 
Lusaka Zambia High Urban Oct 2011 Sep 2013 574 645 
Sa Kaeo and 
Nakhon Phanom 
Thailand Low Mixed Jan 2012 
 
Jan 2014 
 
192 
 
541 
Dhaka and  
Matlab 
Bangladesh Low Mixed Jan 2012 Dec 2013 377 607 
Abbreviations - HIV: Human Immunodeficiency virus
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1.5 Justification and Objectives 
Studies have identified HRV as one of the most common viruses associated with childhood 
CAP; however, many gaps in knowledge still exist in terms of the role of HRV infection in 
severe pneumonia cases and the impact of different HRV species on disease severity. The 
majority of the HRV studies have focused on the prevalence of HRV in hospitalised children 
only, and thus have been unable to attribute the causal role of HRV in disease as they have 
either collected limited clinical background and/or have not enrolled asymptomatic controls 
positive for HRV infection. In the studies which have analysed HRV prevalence and species 
distribution, the studies have lacked power to evaluate the distribution in relation to clinical 
manifestation in diseased children. Another limitation of studies on HRV include it being 
limited in the geographical distribution of the studies, with the majority conducted in single 
geographic locations over a limited time period, thus restricting the generalisability of the 
findings. This has contributed to the conflicting data on the role of HRV in the aetiology of 
childhood severe pneumonia. This is especially true for low to middle income countries 
where the burden of pneumonia disease is greatest.  
 
The case-control PERCH project provides an attractive framework to examine the 
prevalence, as well as the molecular distribution of HRV species in both sick and 
asymptomatic children over a large geographical location over a period of two calendar 
years. In addition, HRV viraemia and viral load as well as pneumococcal disease and HRV 
infection associations and mixed virus co-infection interactions can be studied in a large 
study population with controls to help interpret the results. Thus allowing for an in-depth 
analysis of the causal role that HRV plays during severe respiratory disease in low to middle 
income countries. To our knowledge, a study such as the one proposed which leveraged on 
data and samples from all the PERCH sites, has not been undertaken at such an international 
level to delineate the clinical and molecular epidemiology of HRV associated with severe 
and very severe pneumonia in children. 
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1.6 Aims and Objectives 
i. To determine the clinical epidemiology of HRV in 9 sites, across 7 countries in Africa 
and Southeast Asia in HIV-uninfected children under 5 years of age who are 
hospitalised for WHO-defined severe or very severe pneumonia, including seasonality 
and risk factors associated with severe illness.  
 
ii. To determine the associations between HRV and pneumococcal disease as well as 
other commonly detected respiratory viruses, including Influenza virus (A, B and C), 
RSV (A and B), AdV, HMPV (A and B), HBoV, PIV (Type 1-4) and HCoV (OC43, 
NL63, 229E, HKU1). 
 
iii. To determine the impact of HIV-infection on the clinical epidemiology of HRV 
associated severe pneumonia in two countries with a high prevalence of HIV.  
 
iv. To determine the molecular subtyping of HRV in children younger than 5 years over a 
two-year period from three African PERCH sites, i.e. Bamako in Mali, Lusaka in 
Zambia and Soweto in South Africa. This would include evaluation on whether there is 
any difference in HRV species associated with asymptomatic colonisation, mild upper 
respiratory illness and severe or very severe childhood CAP.  
 
v. To undertake an analysis of the clinical and molecular subtyping of HRV and its ability 
to cause viraemia in South African children hospitalised with WHO-defined severe or 
very severe pneumonia compared with asymptomatic controls. 
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2.0 Materials and Methods 
 
2.1 The Study Sites  
The nine PERCH sites were chosen so as to represent as broad an epidemiological region as 
possible and which would mirror the expected pneumonia epidemiological setting from 2015 
and forwards. The sites were chosen taking vaccine schedules such as Haemophilus influenza 
(HiB) and pneumococcal conjugate vaccine (PCV) as well as HIV and malaria incidences into 
account. Thus the chosen sites had either already implemented or had plans in place to start 
implementing the HiB and PCV vaccine schedules, except for Thailand where the vaccines 
are freely available but too expensive for the majority of the population; in addition, they had 
diverse epidemiological settings including both Africa and Southeast Asia where the majority 
of the severe and deadly pneumonia incidences occurs. Furthermore, they had economic 
backgrounds ranging from low to upper middle income settings; as well as rural and urban 
sites and factors like varying altitudes and cooking materials [113]. 
 
Figure 2.1 shows the geographic locations of the seven countries involved in the PERCH 
study as well as Baltimore where the PERCH executive committee is based at the Johns 
Hopkins Bloomberg School of Public Health (JHSPH) and where the project was co-
ordinated from.  
 
 
 
Figure 2.1: The geographical locations of the seven PERCH countries are marked in blue and 
the PERCH co-ordination centre in Baltimore is marked with a blue asterix  
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2.1.1  Soweto, South Africa  
The South Africa site was based at the Chris Hani Baragwanath Academic Hospital 
(CHBAH) in Soweto, which is the only public hospital available to the surrounding 
population of approximately 1.5 million people living in a low to middle income urban 
setting. In 2014, the estimated HIV-1 prevalence in South Africa was approximately 10.2% of 
the total population with approximately 5.51 million people living with HIV-1. The highest 
prevalence was in the 15-49 age category with an estimated 16.8% of the population having 
HIV-1 and it is estimated that approximately 20% of South African women in their 
reproductive ages are HIV-1 positive [3]. Thus the South Africa site had the highest HIV-1 
prevalence out of all the sites. According to the United Nations Children’s fund, State of the 
World’s children (SOWC) for 2014, South Africa is rated number 58/195 on the under 5 
mortality rating (1 being the worst affected and 195 having the lowest mortality rate) with an 
estimated under 5 mortality rate of 44 deaths per 1000 live births and 65% of children under 5 
years seeking medical care for signs and symptoms of pneumonia [115]. The HiB vaccine 
was introduced into the national vaccine schedule in January 1999 and PCV in November 
2009 and by 2014 it was estimated that the vaccine coverage for HiB was 65% and for PCV 
was 62% [115]. Enrolment into the PERCH project commenced on the 11 August 2011 and 
was completed at the end of August 2013 with a total of 919 cases and 962 controls enrolled 
into the study. 
 
2.1.2  Bamako, Mali site 
The Mali site was located at the Hospital Gabriel Toure’ in Bamako and is responsible for 
treating all severe childhood disease episodes. In 2000 a review of all hospital admissions 
showed that 71% of all children under the age of 16 were admitted for infections, and 
approximately 21% of the children admitted died within 3 days of admission with pneumonia 
accounting for 12% of these deaths [116]. The area is classified as having a very high malaria 
incidence resulting in 11% of paediatric deaths [116]; however, the HIV-1 incidence is low 
with an estimated 0.9% adult HIV-1 prevalence in 2014 [115]. According to the SOWC for 
2014, the under 5 mortality rate for Mali was 123 deaths per 1000 live births making it 
number 7/195 on the Under 5 mortality rating index with a mortality rate of 78 per 1000 live 
births during infancy and 40 per 1000 live births for children; additionally, approximately 
42% of children under 5 years were seeking medical care for signs and symptoms of 
pneumonia [115]. The HiB vaccine was introduced into the national vaccine schedule in 
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January 2008 and PCV in March 2011 prior to the commencement of PERCH and in 2014 it 
was estimated that both vaccines had an immunisation coverage rate of roughly 74% of 
Mali’s children. Enrolment into PERCH commenced in January 2012 and was completed in 
January 2014 with a total of 557 cases and 583 controls enrolled.  
 
2.1.3  Lusaka, Zambia site 
The Zambia site was located at the University Teaching hospital in Lusaka which serves 
approximately 1.3 million people living in a 70km radius of the hospital. Roughly 30% of 
their admissions are children under 5 years and 23% of admissions are due to severe 
respiratory illness with a pneumonia case fatality rate of up to 25.8%. The estimated under 5 
mortality rate in Zambia for 2014 was 87 per 1000 live births, making it number 21/195 on 
the under 5 mortality index rating, the infant mortality rate was 56 per 1000 live births and the 
neonatal mortality rate was 29 per 1000 live births [115]. In Zambia it is estimated that the 
HIV-1 prevalence is approximately 12.5% with 1.1 million living with HIV-1, 150 000 of 
whom are children. The Zambian site was characterised as a poor urban area with a high HIV-
1 infection and malaria prevalence rate [113]. The HiB vaccine is readily available and widely 
utilised since February 2004 and in 2014 it was estimated that 79% of Zambian children had 
received the full dosing schedule [115]; however, the PCV vaccine was only introduced to 
Lusaka in July 2012 approximately 1 year after enrolment into the PERCH project 
commenced. Enrolment into PERCH commenced in October 2011 and was completed in 
September 2013 with 574 cases and 645 controls enrolled.  
 
The HRV molecular subtyping analysis was conducted on case and control samples from the 
sites in South Africa, Mali and Zambia as these three sites combined give a very good 
representation of Sub-Saharan Africa as a whole and allows for a case population of 2050 
children hospitalised with pneumonia and a control population of 2190 asymptomatic or 
healthy controls. Additionally, the molecular subtyping of HRV in Mali and the Zambia has 
not been previous characterised. Furthermore, at the South African site the ability of HRV to 
cause viraemic infection among cases and controls was analysed. 
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2.1.4  Kilifi, Kenya site 
The Kenyan site was conducted in the rural, coastal community in the Kilifi district at the 
Kilifi District hospital. They have approximately 4 500 paediatric admissions per year mainly 
due to pneumonia and neonatal illness. Malaria used to be a problem in the area; however, 
after extensive treatment and prevention strategies were employed the rates have greatly 
decreased. The under 5 mortality rate in 2014 was 99 per 1000 live births making it number 
33/195 on the under 5 mortality rank with an infant mortality rate of 48 per 1000 live births 
and a neonate mortality rate of 26 per 1000 live births [115]. The HiB vaccine was introduced 
in January 2001 and the PCV vaccine in February 2011 and in 2014 the immunisation 
coverage for HiB was estimated to be 83% and 75% for PCV [115]. Large scale routine 
surveillance projects are being conducted at this site looking at the impacts of PCV on 
pneumococcal disease. The HIV-prevalence for 2014 was estimated to be 6% with 
approximately 1,6 million people living with HIV, 190 000 of which are children [115]. 
Enrolment into the PERCH project began in August 2011 and was completed in Nov 2013, a 
total of 579 cases and 793 controls were enrolled.  
 
2.1.5  Basse, The Gambia 
The Gambian site was conducted in the Basse region through the UK Medical Research 
Council. The Gambia was the first African country to introduce both the HiB vaccine 
(January 1997) and PCV (August 2009) into their national immunisation schedules with 
routine surveillance studies on the impact of both vaccines still being conducted. In 2014, the 
immunisation coverage for HiB was 97% and 96% for PCV [115]. HIV infection rates in The 
Gambia remains low [113] with roughly only 1.2% (n=13 000) people living with HIV, 2000 
of which are children [115]. The under 5 mortality rate in 2014 was 74 per 1000 live births 
making it number 31/195 on the under 5 mortality rating index, the infant mortality was 
roughly 49 per 1000 live births and the neonate mortality rate was 28 per 1000 live births 
[115]. Enrolment into the study commenced in November 2011 and was complete in October 
2013 with a total of 539 cases and 580 controls being enrolled. 
 
2.1.6  Sa Kaeo and Nakhon Phanom, The Thailand sites 
The Thailand enrolments were conducted at two rural sites in Thailand; the first was in the Sa 
Kaeo province which is located near to the Cambodian border in the East of Thailand, and the 
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second is in the Nakhon Phanom province in north eastern region bordering Laos. Both sites 
are classified as rural/periurban communities with very low HIV infection rates and no 
malaria. In 2014, it was estimated that approximately 1.1% (n=440 000) of people were living 
with HIV-1, 8 000 of which were children [115]. The HiB vaccine and PCV are not part of 
the national immunisation schedule and thus usage in the general population is very low with 
the vaccines only being available on the private market. The under 5 mortality rate in 2014 
was 37 per 1000 live births making it 122/195 on the under 5 mortality ranking index, with an 
infant mortality rate of 11 per 1000 live births and a neonate mortality rate of 8 per 1000 live 
births [115]. Enrolment into the PERCH study commenced in January 2012 and was 
completed in January 2014 with a total of 192 cases and 541 controls enrolled over the two 
sites. 
 
2.1.7  Matlab and Dhaka, The Bangladesh sites 
Two Bangladesh sites were chosen for the PERCH study, one was a rural site in Chittagong 
serviced by the Matlab hospital and the other an urban site in Dhaka serviced by the Dhaka 
hospital. The HIV prevalence in Bangladesh is extremely low (<0.1%) with approximately 10 
000 people living with HIV, less than 500 of which are children. The under 5 mortality rate in 
Bangladesh was estimated to be 41 per 1000 live births in 2014 making it number 60/195 on 
the under 5 mortality rank index, with a 33 per 1000 live births mortality rate during infancy 
and a neonatal mortality rate of 24 per 1000 live births [115]. The HiB vaccine was 
introduced in July 2009 and by 2014 the immunisation coverage was estimated to be 97% 
[115]. PCV was not in routine use at any point during the PERCH project at either of the 
Bangladesh sites. Enrolment into the project began in January 2012 and was completed in 
December 2013, with a total of 377 cases and 607 controls enrolled over the two sites.  
 
The clinical epidemiology of HRV during severe and very severe pneumonia will be analysed 
in all cases and controls testing positive for HRV infection at all nine PERCH sites. 
 
2.2 Patient enrolment 
 PERCH cases were children aged 28 days to 59 months hospitalised with WHO-defined 
severe or very severe pneumonia. Severe pneumonia was defined as signs and symptoms of 
cough or breathing difficulty and lower chest wall indrawing. Very severe pneumonia was 
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signs and symptoms of cough or difficulty breathing as well as at least one of the following: 
difficulty breastfeeding or drinking, vomiting, convulsions, central cyanosis, lethargy, 
unconsciousness or head nodding. Exclusion criteria for cases were children presenting with 
wheeze which resolved following bronchodilator therapy for lower chest wall indrawing, 
hospital admission within the previous 2 weeks or enrolment as a PERCH case within the 
previous 30 days or residing outside of the study catchment area.  
 
Controls were community recruited children living within the same study catchment area as 
the cases without signs and symptoms of severe or very severe pneumonia. The controls were 
age frequency matched to the cases using the following age groups: 28 days to less than 6 
months, 6 to less than 12 months, 12 to less than 24 months and 24 to 59 months. At the 
Zambia and South African site the controls were also HIV status matched to the cases. On 
enrolment into the study detailed information was obtained relating to patient demographics, 
history and clinical manifestations of the disease. The controls were also broken up into two 
groups: The ARI controls which had signs or symptoms of cough, runny nose, ear discharge, 
wheezing or difficulty breathing together with either a fever (temperature greater or equal to 
38
o
C in the past 48 hours) or a sore throat and the non-ARI controls which appeared healthy 
or asymptomatic at the time of sampling. 
 
Cases and controls were enrolled throughout the year so as to obtain seasonal data as well as 
throughout the week including weekends and nights so as not to introduce any bias in case 
severity. The rationale for the inclusion and exclusion criteria of the cases and controls are 
detailed in Deloria-Knoll et al. [114]. 
 
2.3  Specimen collection and laboratory testing 
Flocked nasopharyngeal (NP) swab (Flexible minitip, Copan ®) and a rayon oropharyngeal 
(OP) swab specimens were collected from all cases and controls on enrolment into the study. 
The swabs were placed in vials containing 3mL of Universal Transport Media (UTM) (Copan 
®). The NP specimens were maintained at 4-8
o
C for a maximum of 24 hours and then 
archived at -70
o
C until testing occurred.  
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4.3.1 Nucleic Acid extraction 
All sample testing was conducted in-country using standardised operating procedures and re-
training was conducted periodically throughout the study period. Total nucleic acids were 
extracted from 400uL of the NP swabs in UTM using the NucleiSens EasyMag extraction 
system as per manufactures instructions (BioMerieux, Marcy l'Etoile, France) and eluted into 
a final volume of 110uL.  
 
2.3.2 Real time PCR detection for HRV and other common respiratory pathogens 
The total nucleic acid specimens from the NP swab were evaluated with the Fast-track 
Diagnostics multiplexed real-time PCR assays which tests for 33 respiratory pathogens 
according to manufactures instructions (FTD Respiratory Pathogens, Fast-Track Diagnostics, 
Sliema, Malta). The FTD-33 respiratory panel detected 19 viruses with 5 different multiplex 
Real Time (RT)-PCR assays – HRV (A, B and C not differentiated), Influenza virus (A, B 
and C separately), PIV (1, 2, 3 and 4 separately), Coronavirus (HKU1, OC43, NL63, 229E 
separately), Bocavirus, Human Metapneumoviruses (A and B not differentiated), RSV (A 
and B not differentiated), Cytomegalovirus (CMV), Adenovirus, Enterovirus and 
Parechovirus. The FTD-33 respiratory panel also detects nine different bacteria species and 
one fungal parasite using three multiplex RT-PCR assays - Streptococcus pneumoniae, 
Staphylococcus aureus, Haemophilus influenzae and Haemophilus influenzae type B, 
Moraxella cattarahalis, Legionella spp., Salmonella spp., Chlamydia pneumoniae, 
Mycoplasma pneumoniae, Klebsiella pneumoniae and Bordetella pertussis and the fungus 
Pneumocystis jiroveci. RT-PCR was performed using the Applied Biosystems 7500® 
instruments (Applied Biosystems, Foster City, CA) using the following cycling conditions: 
50
o
C for 15 minutes, 95
o
C for 10 minutes followed by 40 cycles of 95
o
C for 8 seconds and 
then 60
o
C for 34 seconds.  
 
Pathogen densities (copies/mL) were calculated with standard curves which were generated 
using ten-fold dilutions of plasmid standards provided by Fast Track Diagnostics together 
with the FTD-33 Respiratory panels. The standard curves were run in duplicate every three 
months and the cycle threshold values were used to determine a regression line from which 
the copy numbers present in each clinical sample was derived. The detection limits for the 
assays were from 10
4
 up to 10
8 
copies per mL. The resulting copy numbers were analysed and 
the appropriate dilution factors taken into account in order to provide quantitative viral or 
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bacterial load results for each sample which were expressed as log10 RNA copies per mL for 
viruses or log10 colony forming units per mL for the bacterium and fungus parasites. Each 
assay included template and non-template controls as well as an external internal controls 
supplied with the FTD-33 respiratory panels. In addition, external quality assessment 
programs which were monitored and set up by FTD, were conducted throughout the study 
period and reports and practical feedback were given, allowing sites to identify and resolve 
any potential problems. 
 
2.3.3 Routine standard of care testing of case samples 
Standard diagnostic techniques were also employed; blood cultures were conducted on all 
cases using Bactec bottles and processed through a Bact/Alert microbial system (Organon 
Teknika, Durham, NC). Positive blood cultures were identified via standard culture and 
biochemical tests. Where clinically indicated pleural fluids and gastric aspirates were collected 
and cultured using standard culture and biochemical tests. Additionally, at the South Africa, 
The Gambia, Mali and Bangladesh sites lung aspirates were collected and cultured if 
consolidations were visible on the chest X-rays. The pleural fluids and lung aspirates were 
also tested using the FTD-33 respiratory panels as discussed above as well as tested for 
pneumococcal antigens with the BinaxNow® antigen detection system as per manufacturers’ 
instructions (Alere, Orlando, Florida). Standard diagnostics were also conducted on all case 
blood samples to determine white blood cell and neutrophil counts as well as C-reactive 
protein (CRP) levels, a marker of infection and inflammation. At the South African site, a 
randomly selected group of control participants’ blood samples were also tested for CRP 
levels. 
 
Microbiologically confirmed pneumococcal pneumonia (MCPP) was defined as having 
Streptococcus pneumoniae cultured from a normally sterile fluid – culture positive blood, 
pleural fluid or lung aspirate. In addition, a case was considered to have MCPP if the pleural 
fluid or lung aspirate was FTD33 PCR positive for pneumococcus or pneumococcus antigen 
positive on the BinaxNow® assay. In addition, in other PERCH analyses it has been 
determined that there is a strong association between high pneumococcal densities, in the 
nasopharynx or the whole blood (WB) samples, and the presence of MCPP in the pneumonia 
cases [117]. It was determined that the optimal nasopharynx colonisation density threshold for 
differentiating between MCPP cases and controls was >6.9 log10 copies/mL with a sensitivity 
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of 64% and specificity of 92%. The optimal WB density, measured through the LytA RT-PCR 
assay on all case and control WB samples, for discriminating MCPP cases from controls was 
determined to be >2.2 log10 copies/mL. These high density pneumococcal (HDP) thresholds 
together with MCPP were used as markers for likely MCPP in order to analyse the 
relationship between HRV and pneumococcus disease.  
All the laboratory testing and clinical data up until this point were used for the clinical 
epidemiology chapters (Chapter 3 and 4). 
 
2.4 Determination of HRV molecular subtyping 
The Fast track respiratory 33 panels were used to identify cases and controls testing positive 
for HRV infection as well as to calculate the HRV viral load in the NP swabs. All FTD-33 
testing was conducted in-country; however, once the samples, both case and controls, testing 
positive for HRV infection at the South Africa, Mali and Zambia sites were identified the 
aliquots of archived NP samples were transferred to South Africa for further testing with 
results given in Chapter 5 of this thesis.  
 
The HRV positive samples were re-extracted as described previously and then further 
analysed using single round PCR assays targeting a 390bp area in the 5’ non-coding region 
(NCR) region of the HRV genome [66, 118]. This assay targets 2/3 of the NCR region and 
has been proven to differentiate between all 101 HRV serotypes as well as all currently 
available HRV-C serotypes, in addition it was also able to identify previously unknown HRV-
C strains straight from clinical samples [118]. The primer sequences were DK001 forward 
(5’- CAAGCACTTCTGTTTCC - 3’) and reverse primer DK004 (5’ – 
CACGGACACCCAAAGTAGT – 3’). Amplification was conducted using Promega Access 
RT according to manufacturers’ instructions (Promega, Belgium) using the following cycling 
conditions: denaturation for 95
o
C for 5 minutes, followed by 40 cycles of 95
o
C for 15 
seconds, annealing at 55
o
C for 15 seconds and polymerisation at 72
o
C for 60 seconds. 
Negative and positive controls were included in each run. The presence of a PCR product was 
confirmed and quantified through visualisation of the PCR product on an ethidium bromide 
stained 2% Agarose gel. The GeneRuler 100 base pairs DNA ladder (Thermo Scientific, 
Carlsbad, CA) was used to determine the nucleotide length of the PCR product, 
approximately 400 base pairs, as well as to quantify the DNA concentration prior to 
sequencing as per manufactures instructions. The PCR products were purified using the 
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Nucleofast 96 well plates (Macherey Nagel) and sequenced using the BigDye Terminator 
V3.1 sequencing kit (Applied BioSystem, Foster City, CA) in both the forward and reverse 
orientation using the same primers as used in the PCR (DK001 and DK004). The forward and 
reverse sequences were analysed and aligned using the ClustalW algorithm implemented in 
Geneious 4.7.6 [119], and the resultant consensus sequence was compared with reference 
HRV sequences using the nucleotide-nucleotide BLAST algorithm 
(http://www.ncbi.nlm.nih.gov) from GenBank in order to identify the HRV species (A, B and 
C). The typing of the isolates was confirmed through phylogenetic analysis against reference 
HRV strains (Discussed in detail in section 2.7.2). 
 
2.5 Detection of HRV viraemia  
The HRV viraemia analysis was only conducted on the cases and controls enrolled at the 
South Africa site. The Fast Track respiratory 33 panels were used to identify the cases and 
controls positive for HRV infection and to calculate the HRV viral loads. The testing of the 
respiratory samples was completed prior to the testing of the blood samples in order to 
prevent cross contamination. In addition, HRV viraemia was also tested for in 10% of cases 
and controls testing negative for HRV infection with results given in Chapter 6 of this thesis 
 
Total nucleic acids were extracted from 200uL of archived blood samples using the NucliSens 
EasyMag automated extraction robot (Biomerieux, France) using the blood specific extraction 
protocol and eluted in 60uL. The presence of HRV viraemia was tested for using the same 
primers (DK001 and DK004) and methods as those used for determining the HRV molecular 
subtyping in the respiratory samples. These primers have been used in previous studies 
looking for HRV viraemia and were proven to be highly sensitive in blood samples [66]. 
 
2.6 The PERCH electronic database 
There were over 30 case/control report forms completed per participant - 3 737 cases and 4 
712 controls – with multiple samples collected from each participant. Thus in order to track 
and analyse such a large database an external company, EMMES incorporated (Rockville, 
MD), was contracted to oversee the development and maintenance of the electronic database 
from each site. Regular data management, quality indicators of study performance and reports 
were generated in order to monitor the progression of the project and to ensure the integrity of 
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the data from each site. This database was utilised for the clinical and molecular analysis of 
the HRV subtyping over the full PERCH study period.  
 
2.7 Statistical analysis 
All statistical analysis and reverse cumulative plots were performed using STATA Version 
12.1 (College Station, TX, USA) and a two-sided P-value <0.05 was considered statistically 
significant.  
 
2.7.1 Clinical Epidemiology analysis 
Parametric tests (Student’s t-test) were used on normally distributed continuous variables and 
Wilcoxon and chi-squared tests were used on the distribution of categorical variables where 
applicable. Binary, multinomial logistic regression and odds ratio analysis were used to model 
the prevalence of HRV within the study population. We initially performed univariate analysis 
which introduced site of enrolment, age categories, gender, HIV status, socio-economic status, 
severity of pneumonia diagnosis, presence of fever and hypoxia, chest X-ray findings and case 
fatality ratios as independent variables. Additionally, we also performed univariate analysis 
for markers of potential bacterial co-infection as well as the different respiratory viruses 
detected for by the FTD33 assays. If these independent variables were <0.2 in the univariate 
analysis, then they were introduced into the different multivariate models where applicable in 
order to remove the prospect of mutually co-founding variates.  
 
In the clinical epidemiology chapters (3.0 and 4.0), Chapter 3.0 focused on HIV-uninfected 
children thus in addition to the variables mentioned above, all models were also adjusted for 
HIV-exposure whereby the mothers could have been HIV positive but the children were 
uninfected. Additionally, reverse cumulative dot plots, generated in STATA Version 12.1, 
were used to visually analyse the relationship between HRV NP viral load among cases 
compared to controls as well as to analyse whether HRV viral load is associated with severity 
of disease.  
 
Chapter 4.0 focused on HIV-1-infected children from the sites with high HIV burdens - South 
Africa and Zambia. In this chapter the models were also adjusted for HIV infection and HIV 
exposure status.  
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2.7.2 Molecular epidemiology analysis 
Chapter 5.0 focused on the clinical and molecular subtyping of HRV in Sub Saharan Africa. 
Thus the case-control and clinical analyses of the three HRV species were analysed and 
adjusted as above. The multivariate models were adjusted for HIV-1-infection.  
 
For the phylogenetic analysis, the sequences were aligned with each other as well as with the 
published HRV-A, HRV-B and HRV-C sequences using the nucleotide-nucleotide BLAST 
algorithm available in GenBank (http://www.ncbi.nlm.nih.gov) in order to determine the HRV 
species present in the participants respiratory samples. Subsequent phylogenetic analysis was 
conducted using the ClustalW algorithm implemented in Geneious 4.7.6 [119]. The 
Phylogenetic trees were constructed using the neighbour-joining methods using Kimura’s 2-
parameter technique with bootstrap values estimated with 1000 bootstrap replications [120] 
with evolutionary analysis conducted in MEGA-6 [121]. HRV subtypes with bootstrap values 
>90% will be considered to form monophyletic groups.  
 
Chapter 6.0 focused on the clinical and molecular subtyping of HRV in South Africa and 
focused on the nasopharyngeal HRV viral load using regression analysis adjusted for the 
variables mentioned above as well as HIV infection status. Reverse cumulative plots were 
used to determine thresholds capable of differentiation between viraemia positive and negative 
children.  
 
2.8 Ethical considerations 
The PERCH study was reviewed by 10 different institution review boards (IRB) – the initial 
overall clinical and laboratory testing protocols were reviewed by the JHSPH’s IRB after 
which the protocols were customised for each of the sites and reviewed by their local boards. 
The revised protocols and approvals for each site were then submitted to the JHSPH’s IRB as 
amendments. This allowed for the collective ownership of the project by the PERCH 
executive committee as well across the sites. The ethical approvals for each of the sites are 
listed below: 
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1. Study Site: South Africa conducted by the Respiratory and Meningeal Pathogens 
Research Unit, Wits Health Consortium, based at Chris Hani Baragwanath Academic 
Hospital 
Wits HREC Approval number: M10M101129 
Principal investigator: Prof Shabir A. Madhi 
 
2. Study Site: Kilifi, Kenya conducted by the Kilifi-KEMRI Wellcome Trust Institute  
Approval number from the Kenya Medical Research Institute: KEMRI/RES/7/3/1 
Oxtrec Approval number: 60-09 
Principal investigator: Dr Laura Hammitt 
 
3. Study site: Basse in The Gambia at the MRC insitution 
Approval number from The Gambia Government/MRC joint Ethics Committee: L2010.105 
Principal investigators: Dr Stephen Howie 
 
4. Study Site: Bamako, Mali at the University of Maryland Insitution 
Approval number from FMPOS Ethics committee: 2011/07/FMPOS 
Approval number from The University of Maryland Institutional Review Board (IRB): 
HP00048100 
Principal Investigator: Dr Karen Kotloff 
 
5. Study Site: Lusaka, Zambia at the Boston University Institution 
Approval number from the Blue Panel IRB: HP-29860 
Approval from the ERES Converge IRB: 2010-Dec-001 
Principal Investigator: Dr Donald Thea 
 
6. Study site: Dhaka, Bangladesh at the ICDDR and JHSPH institution  
Approval number from ICDDR,B Ethics Review Committee: PR-11012 
Principal Investigators: Dr Abdullah Brooks 
 
7. Study site: Sa Kaeo and Nakhon Phanom in Thailand at the CDC-Thailand 
Approval number from the Ethical Review Committee for Research in Human Subjects-
Ministry of Public Health, Thailand: 17/2554 
Principal Investigators: Dr Pasakorn Akarasewi 
 
Approval to conduct the clinical and molecular subtyping analysis of HRV in the PERCH 
project was obtained from the PERCH executive committee on the 18
th
 of June 2014 and 
ethical approval was granted by the University of the Witwatersrand Human Rights and 
Ethics Board (HREC number: M140906). The additional HRV viraemia analysis on the South 
African case and control samples was approved by the PERCH executive committee on the 
14
th
 of September 2015 and ethical approval was granted by the Wits HREC board (HREC 
number: M151042). The HREC clearance certificates are available in Appendix 1 and 2. 
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3.0 Clinical epidemiology of the Human rhinovirus (HRV) in African and 
Southeast Asian children: A case-control pneumonia aetiology study 
 
The role of HRV in severe lower respiratory tract infection (LRTI) in children has yet to be 
fully elucidated, since HRV identification is ubiquitous in both diseased and asymptomatic 
children [47]. Additionally, advances in molecular diagnostic tools have enhanced the 
detection of HRV, as well as other viruses, in children with respiratory illness, including in 
the PERCH case-control study on aetiology of severe and very severe pneumonia in children 
among whom two or more viruses were often detected in the nasopharynx. Thus, detection of 
a virus during a disease episode does not necessarily imply causation.  
 
In this chapter, the clinical epidemiology of HRV infections in children under 5 years of age 
hospitalised with WHO-defined severe or very severe pneumonia and community controls 
with mild upper respiratory tract infection or who were asymptomatic was characterised.  
 
3.1 RESULTS 
3.1.1 The study population 
Between August 2011 and January 2014, 3 876 HIV-uninfected children under the age of five 
with WHO-defined severe or very severe pneumonia; and 4 997 community controls 
including asymptomatic children or children with URTI were enrolled into the PERCH study.  
 
3.1.2 Characteristics of community controls by HRV status 
Of the 4 977 control participants, 76% (n=3 796) were asymptomatic and 24% (n=1 181) had 
signs or symptoms of RTI. HRV was detected in 21% (n=1 056) of the controls and after 
multivariate logistic regression, HRV was found to be 1.56-fold (aOR 95% CI: 1.32-1.84) 
more likely to be present in children with URTI (25%, n=300/1 181) than asymptomatic 
controls (20%, n=756/3 796, P<0.001). There were no differences in the HRV viral load 
between the HRV-associated controls with URTI (3.5 log10 copies/mL) compared to the 
asymptomatic children (3.4 log10 copies/mL, P=0.233).  
 
The all-site demographics and clinical characteristics of community controls showed that the 
HRV-associated community controls were younger (mean 13.2 months vs. 16 months, 
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P<0.001) than controls without HRV infections; but did not differ in other common risk 
factors for infections including day care attendance (16% vs. 19%, P=0.234), exposure to a 
smoker in the household (37% vs. 39%, P=0.202) and premature birth (12% vs. 10%, 
P=0.754). Conversely, the HRV-associated controls were 1.72-fold (aOR 95% CI: 1.43-2.07) 
more likely to have symptoms of rhinorrhoea (21% vs. 16%, P<0.001) and 1.62-fold (aOR 
95% CI: 1.28-2.04) more likely to have a cough (11% vs. 8%, P=0<0.001) than controls 
without HRV infection. Furthermore, HRV infected controls were also more likely to have 
higher mean S. pneumoniae (LytA) density in the nasopharynx; including a higher percentage 
with densities >6.9 log10 copies/mL (11% vs. 7%, aOR1.54, 95% CI: 1.21-1.95, P<0.001) 
which in PERCH was associated with pneumonia, including microbiologically confirmed 
pneumococcal pneumonia among pneumonia cases [117]; Table 3.1.  
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Table 3.1: The demographical, clinical and markers for bacterial co-infection of the 
Community controls by HRV infection status for all sites data combined 
 HRV+ 
(n=1056) 
HRV-  
(n= 3921) 
Unadjusted 
P-value   OR (95% CI) 
Adjusted 
P-value
     
aOR (95% CI) 
Age in months, mean (SD) 13.2 (12.9) 16.0 (14.7) P<0.001   P<0.001   
Female, n(%) 515 (49%) 1957 (50%) 0.505 0.95 (0.83-1.09) 0.473  0.95 (0.83-1.09) 
Never breast fed, n(%) 277 (7%) 312 (8%) 0.475 0.91 (0.70-1.28) 0.440 1.12 (0.84-1.51) 
Under weight, n (%)
a
 127 (12%) 471 (12%) 0.990 1.0 (0.81-1.23) 0.890 1.02 (0.82-1.26) 
HEU, n(%)
b
 177 (9%) 625 (9%) 0.714 1.05 (0.81-1.35) 0.817 1.02 (0.84-1.25) 
Day Care attendance, n(%) 163 (16%) 739 (19%) 0.012 0.79 (0.65-0.95) 0.706 0.95 (0.74-1.23) 
Smoker in household, n(%) 392 (37%) 1518 (39%) 0.334 0.94 (0.81-1.08) 0.202 0.91 (0.78-1.05) 
Premature birth, n(%)
c
 130 (12%) 376 (10%) 0.009 1.32 (1.07-1.64) 0.234 1.01 (0.95-1.08) 
Birth weight, mean (SD) 3.0 (0.6) 3.0 (0.5) 0.617   0.886  
Clinical features:      
 
Tachypnea, n(%)
d
 103 (10%) 457 (12%) 0.090 0.82 (0.66-1.03) 0.046 0.79 (0.63-0.99) 
Cough, n(%) 120 (11%) 301 (8%) P<0.001 1.55 (1.23-1.93) P<0.001 1.62 (1.28-2.04) 
Fever, n(%)
e
 56 (5%) 212 (5%) 0.898  0.98 (0.72-1.33) 0.789 0.96 (0.70-1.31) 
Diarrhoea, n(%) 13 (1%) 82 (2%) 0.072 0.58 (0.32-1.05) 0.051 0.55 (0.30-1.00) 
Rhinorrhoea, n(%) 223 (21%) 629 (16%) P<0.001 1.40 (1.28-1.66) P<0.001 1.72 (1.43-2.07) 
Markers for Bacterial co-infection:      
LytA positive, n(%)
f
 60 (6%) 193 (5%) 0.327 1.16 (0.86-1.57) 0.605 1.08 (0.80-1.47) 
S. pneu load, mean (SD)
g
 5.89 (1.17) 5.5 (2.1) P<0.001  P<0.001  
HDP, n(%)
h
       
-Blood 36 (4%) 104 (3%) 0.192 1.29 (0.88-1.90) 0.334 1.21 (0.82-1.79) 
-NP 113 (11%) 266 (7%) P<0.001 1.65 (1.31-2.07) P<0.001 1.54 (1.21-1.95) 
Viral infections in the nasopharynx:      
-RSV, n(%) 24 (2%) 116 (3%) 0.233  0.76 (0.49-1.19) 0.277 0.78 (0.50-1.22) 
-AdV, n(%) 134 (13%) 459 (12%) 0.381 1.09 (0.89-1.35) 0.121 1.23 (0.99-1.82) 
-HMPV, n(%) 59 (6%) 147 (4%) 0.008 1.52 (1.11-2.07) 0.155 1.26 (0.92-1.75) 
-HBoV, n(%) 139 (13%) 521 (13%) 0.916 0.99 (0.81-1.21) 0.727 1.04 (0.85-1.27) 
-InFV A-C, n(%) 9 (1%) 104 (3%) 0.001 0.32 (0.16-0.63) P<0.001 0.29 (0.15-0.58) 
-PIV, n(%) 68 (6%) 246 (6%) 0.844 1.03 (0.78-1.36) 0.621 0.93 (0.70-1.23) 
-HCoV, n(%) 93 (9%) 408 (11%) 0.126 0.83 (0.66-1.05) 0.049 0.79 (0.62-0.99) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: 
Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; HEU: HIV exposed but 
uninfected; HDP: High density pneumococcus; RSV: Respiratory Syncytial Virus, HMPV: Human 
Metapneumovirus; AdV: Adenovirus; PIV: Parainfluenza type 1-4; HBoV: Human Bocavirus; HCoV: Human 
Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, B and C); S. pneu: Streptococcus 
pneumoniae. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU 
defined as HIV-uninfected but HIV-exposed. Undetectable viral load, HIV seronegative in the child with a 
positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative 
children < 7 months of age where documented positive maternal status was required; 
c
 - Premature birth defined 
as gestational age <37 weeks; 
d
 - Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, 
respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
e
 - Fever defined as temperature ≥38oC; f - Blood sample positive for S. pneumoniae colonisation by LytA PCR; g 
- Bacterial load of S. pneu in the nasopharynx, expressed as log10 copies/mL; 
h
 - HDP defined as S. pneumoniae 
density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL. 
 
Individual site control evaluations are available in Table 3.2A and B, with similar trends as 
seen in the all-site data for younger age, more cough, rhinorrhoea and high S. pneumoniae 
colonisation densities of the HRV infected controls compared to the HRV negative controls. 
In addition, prior to adjustment for potentially confounding variates (<0.2 in univariate 
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analysis) in the all-site data the HRV positive controls were associated with premature birth 
(12% vs. 10%, P=0.009 prior to adjustment); Table 3.1, with this association also observed 
specifically in Kenya (20% vs 11%, P=0.002), Mali (4% vs. 1%, P=0.050) and Thailand 
(11% vs. 7%, P=0.023).  
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Table 3.2A: The demographical and clinical characteristics of controls by HRV infection status for each African site individually 
  Kenya (n=855)   Gambia (n=624)   Mali (n=724)   Zambia (n=533)   South Africa (n=823)   
 HRV+ 
(n=162) 
HRV- 
(n=693) 
P-value HRV+ 
(n=177) 
HRV- 
(n=447) 
P-value HRV+ 
(n=143) 
HRV- 
(n=581) 
P-value HRV+ 
(n=93) 
HRV- 
(n=440) 
P-value HRV+ 
(n=194) 
HRV- 
(n=629) 
P-value 
Age in months, mean (SD) 14.8 (14.3) 17.3 (14.7) 0.052 14.1 (13.5) 16.9 (14.7) 0.031 10.0 (9.6) 14.7 (13.5) P<0.001 6.9 (6.2) 10.5 (11.3) 0.004 11.3 (11.3) 12.6 (12.6) 0.207 
Female, n(%) 85 (52%) 319 (46%) 0.158 75 (42%) 220 (49%) 0.118 62 (43%) 304 (52%) 0.052 36 (39%) 226 (51%) 0.028 106 (55%) 317 (50%) 0.261 
Never breast fed, n(%) 1 (1%) 6 (1%) 0.863 1 (1%) 1 (0%) 0.483 0 3 (1%) 0.836 2 (2%) 13 (3%) 0.646 66 (34%) 222 (35%) 0.793 
Under weight, n (%)a 26 (16%) 99 (14%) 0.287 23 (13%) 79 (18%) 0.242 18 (13%) 61 (11%) 0.259 9 (10%) 56 (13%) 0.735 10 (5%) 27 (4%) 0.603 
HEU, n(%)b 0 2 (0%) 0.494 0 0 - 0 2 (0%) 0.482 31 (33%) 119 (27%) 0.221 52 (27%) 172 (27%) 0.882 
Day Care attendance, n(%) 5 (3%) 42 (6%) 0.135 0 11 (2%) 0.053 107 (75%) 445 (77%) 0.657 0 15 (3%) 0.174 28 (14%) 93 (15%) 0.984 
Smoker in household, n(%) 43 (27%) 214 (31%) 0.274 99 (58%) 248 (56%) 0.702 26 (18%) 122 (21%) 0.663 28 (30%) 122 (27%) 0.643 48 (30%) 198 (32%) 0.464 
Premature birth, n(%)c 32 (20%) 75 (11%) 0.002 11 (6%) 22 (5%) 0.648 5 (4%) 7 (1%) 0.050 3 (3%) 28 (6%) 0.230 66 (34%) 184 (29%) 0.171 
Birth weight, mean (SD) 3.1 (0.6) 3.1 (0.6) 0.502 3.1 (0.6) 2.9 (0.5) 0.165 3.3 (0.6) 3.3 (0.7) 0.859 2.9 (0.4) 2.9 (0.5) 0.955 3.0 (0.6) 3.0 (0.5) 0.188 
Clinical Features:                
Tachypnea, n(%)d 31 (19%) 103 (15%) 0.248 23 (13%) 58 (13%) 0.942 20 (14%) 98 (17%) 0.443 6 (6%) 58 (13%) 0.145 11 (6%) 66 (11%) 0.055 
Cough, n(%) 16 (10%) 26 (4%) 0.003 21 (12%) 42 (9%) 0.350 12 (8%) 48 (8%) 0.948 7 (8%) 29 (7%) 0.470 5 (3%) 10 (2%) 0.401 
Fever, n(%)e 8 (5%) 25 (4%) 0.370 25 (14%) 59 (13%) 0.725 2 (1%) 16 (3%) 0.363 0 4 (1%) 0.661 0 5 (1%) 0.407 
Diarrhoea, n(%) 2 (1%) 14 (2%) 0.514 6 (3%) 18 (4%) 0.748 15 (3%) 1 (1%) 0.213 1 (1%) 7 (2%) 0.849 0 2 (0%) 0.566 
Rhinorrhoea, n(%) 39 (24%) 119 (17%) 0.040 25 (14%) 45 (10%) 0.156 52 (36%) 196 (34%) 0.215 3 (3%) 11 (3%) 0.753 2 (1%) 12 (2%) 0.364 
Laboratory markers:                
LytA positive, n(%)f 9 (6%) 39 (6%) 0.930 15 (9%) 32 (8%) 0.563 12 (8%) 26 (5%) 0.068 1 (1%) 23 (6%) 0.109 20 (10%) 65 (10%) 0.930 
HDP, n(%)g 5 (3%) 42 (6%) 0.150 26 (15%) 53 (12%) 0.427 39 (27%) 95 (16%) 0.002 8 (9%) 30 (7%) 0.482 37 (19%) 77 (12%) 0.022 
Abbreviations - SD: Standard deviation; NP: Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; HEU: HIV exposed but uninfected; HDP: 
High density pneumococcus. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable, P-values could not 
be calculated for variables where both values are 0, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU defined as HIV-uninfected but HIV-exposed. Undetectable viral 
load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative children < 7 months of 
age where documented positive maternal status was required; 
c
 - Premature birth defined as gestational age <37 weeks; 
d
 - Tachypnea defined as respiratory rate >60 
breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
e
 - Fever defined as 
temperature ≥38oC;      f - Blood sample positive for S. pneumoniae colonisation by LytA PCR; g - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density 
in whole blood sample >2.2 log10 copies/mL. 
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Table 3.2B: The demographical and clinical characteristics of controls by HRV infection 
status for each Southeast Asian site individually 
  Thailand (n=650)   Bangladesh (n=768)   
 HRV+ 
(n=92) 
HRV- 
(n=558) 
P-value HRV+ 
(n=195) 
HRV- 
(n=573) 
P-value 
Age in months, mean (SD) 20.7 (15.5) 21.1 (15.9) 0.815 14.9 (13.6) 18.5 (16.3) 0.006 
Female, n(%) 49 (53%) 271 (49%) 0.391 102 (53%) 300 (52%) 0.915 
Never breast fed, n(%) 5 (5%) 65 (12%) 0.084 2 (1%) 2 (0%) 0.228 
Under weight, n (%)
a
 4 (4%) 33 (6%) 0.520 37 (19%) 116 (20%) 1.00 
HEU, n(%)
b
 0 0  0 0  
Day Care attendance, n(%) 22 (24%) 132 (24%) 0.957 1 (1%) 1 (0%) 0.613 
Smoker in household, n(%) 57 (62%) 327 (59%) 0.544 81 (42%) 287 (50%) 0.051 
Premature birth, n(%)
c
 10 (11%) 40 (7%) 0.023 3 (2%) 20 (3%) 0.359 
Birth weight, mean (SD) 3.1 (0.4) 3.0 (0.5) 0.463 2.9 (0.6) 2.9 (0.5) 0.956 
Clinical Features:       
Tachypnea, n(%)
d
 2 (2%) 46 (8%) 0.067 10 (5%) 28 (5%) 0.892 
Cough, n(%) 27 (29%) 81 (15%) 0.001 32 (16%) 63 (11%) 0.062 
Fever, n(%)
e
 13 (14%) 73 (13%) 0.827 8 (4%) 30 (5%) 0.497 
Diarrhoea, n(%) 2 (2%) 16 (3%) 0.783 1 (1%) 10 (2%) 0.200 
Rhinorrhoea, n(%) 59 (64%) 175 (31%) P<0.001 43 (22%) 71 (12%) 0.002 
Laboratory markers:       
LytA positive, n(%)
f
 1 (1%) 4 (1%) 0.708 2 (1%) 4 (1%) 0.511 
HDP, n(%)
g
 2 (2%) 9 (2%) 0.700 27 (14%) 55 (10%) 0.094 
Abbreviations - SD: Standard deviation; NP: Nasopharyngeal; HRV: Human rhinovirus; HIV: Human 
immunodeficiency virus; HEU: HIV exposed but uninfected; HDP: High density pneumococcus. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, P-values could not be calculated for variables where both values 
are 0, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU 
defined as HIV-uninfected but HIV-exposed. Undetectable viral load, HIV seronegative in the child with a 
positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative 
children < 7 months of age where documented positive maternal status was required; 
c
 - Premature birth defined 
as gestational age <37 weeks; 
d
 - Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, 
respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
e
 - Fever defined as temperature ≥38oC; f - Blood sample positive for S. pneumoniae colonisation by LytA PCR; g 
- HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 
copies/mL. 
 
In order to evaluate the interactions between HRV and the other respiratory viruses further we 
compared controls with HRV mono-infections (HRV was the only respiratory virus detected 
in the nasopharynx) to controls with viral co-infections; Table 3.3. HRV was most commonly 
detected as co-infecting viruses with HBoV (13%, n=139/400), AdV (13%, n=134/400) and 
then HCoV (9%, n=93/400). Among the HRV infected controls, there was a lower prevalence 
of Influenza virus (1% vs. 3%, P<0.001) than controls without HRV infections, whilst the 
detection of RSV, AdV, HMPV and PIV did not differ in HRV-infected controls compared to 
controls without HRV infections; Table 3.1. 
 
Amongst the HRV controls, those with other co-infecting viruses were clinically 
indistinguishable from children with HRV mono-infection and no differences were observed 
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in HRV viral load between controls with mono- and mixed infections; Table 3.3. Controls 
with HRV mono-infections were, however, associated with premature birth (14%) compared 
to controls with HRV mixed infections (10%, P=0.002) but only trends for the association of 
HRV mono-infections with premature birth were seen in comparison to the individual co-
infecting viruses. For individual co-infecting viruses, those with RSV were more likely to 
have RTI (46% vs. 27%, P=0.031), tachypnea (17% vs. 10%, P=0.044) and whole blood 
LytA positivity (18% vs. 6%, P=0.007) compared to controls with HRV mono-infections. No 
other differences in clinical characteristics were observed between HRV mono- and co-
infections due to any of the other respiratory viruses, including AdV, HMPV (A and B), PIV 
(Type 1-4), HCoV (Types 43, 64, 229 and HKU), Influenza virus (A, B and C) and HBoV; 
Table 3.3. 
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Table 3.3: The demographics, risk factors, clinical and laboratory characteristics of community controls with HRV mono-infections compared to 
HRV mixed infections 
  Mono-
infections 
(n=656) 
Mixed 
infections 
(n=400) 
P-value HRV-
RSV 
(n=24) 
P-value HRV-AdV 
(n=134) 
P-value HRV-
HMPV 
(n=59) 
P-value HRV-PIV 
(n=68) 
P-value HRV-
HBoV 
(n=139) 
P-value HRV-
HCoV 
(n=93) 
P- 
value 
Age in months, mean (SD) 12.4 (12.8) 14.5 (13.0) 0.045 10.0 (8.4) 0.499 18.4 (13.6) P<0.001 12.6 (11.1) 0.450 15.3 (14.5) 0.191 14.9 (12.9) 0.164 12.0 (11.0) 0.740 
Female, n(%) 321 (49%) 194 (49%) 0.900 14 (58%) 0.423 66 (49%) 0.977 30 (51%) 0.243 31 (46%) 0.902 69 (50%) 0.696 45 (48%) 0.847 
Never breast fed, n(%) 52 (8%) 25 (6%) 0.952 3 (13%) 0.409 9 (7%) 0.544 3 (5%) 0.330 2 (3%) 0.691 9 (6%) 0.969 7 (8%) 0.627 
Under weight, n (%)
a
 75 (11%) 52 (13%) 0.926 4 (17%) 0.364 20 (15%) 0.526 6 (10%) 0.328 10 (15%) 0.787 16 (12%) 0.750 11 (12%) 0.785 
HEU, n(%)
b
 58 (9%) 25 (6%) 0.680 1 (4%) 0.330 9 (7%) 0.543 3 (5%) 0.201 0 0.304 8 (6%) 0.702 10 (11%) 0.356 
Day care attendance, n(%) 86 (13%) 816 (19%) 0.089 5 (21%) 0.059 31 (23%) 0.623 1 (2%) 0.554 13 (19%) 0.180 25 (18%) 0.575 21 (23%) 0.132 
Smoker in household, n(%) 243 (37%) 1667 (39%) 0.768 7 (29%) 0.426 53 (40%) 0.602 28 (49%) 0.174 25 (37%) 0.949 5 (38%) 0.908 29 (31%) 0.263 
Premature birth, n(%)
c
 92 (14%) 414 (10%) 0.004 3 (13%) 0.720 13 (10%) 0.388 2 (4%) 0.121 2 (3%) 0.092 14 (10%) 0.464 12 (13%) 0.526 
Birth weight, mean (SD) 3.0 (0.6) 3.0 (0.5) 0.319 2.8 (0.6) 0.081 3.0 (0.6) 0.228 3.0 (0.7) 0.760 3.1 (0.5) 0.286 3.1 (0.5) 0.059 3.0 (0.5) 0.809 
RTI control, n(%)
d
 176 (27%) 124 (31%) 0.720 11 (46%) 0.031 42 (31%) 0.698 18 (31%) 0.710 22 (32%) 0.861 47 (34%) 0.798 30 (32%) 0.250 
Clinical Features:                
Tachypnea, n(%)
e
 62 (10%) 41 (10%) 0.598 4 (17%) 0.044 14 (10%) 0.394 5 (8%) 0.315 9 (13%) 0.655 16 (12%) 0.552 6 (7%) 0.358 
Cough, n(%) 68 (10%) 52 (13%) 0.583 5 (21%) 0.135 17 (12%) 0.649 9 (15%) 0.585 14 (21%) 0.088 20 (14%) 0.622 10 (11%) 0.763 
Fever, n(%)
f
 32 (5%) 24 (6%) 0.872 1 (4%) 0.968 7 (5%) 0.800 8 (14%) 0.823 4 (6%) 0.707 8 (6%) 0.466 4 (4%) 0.903 
Diarrhoea, n(%) 10 (2%) 3 (1%) 0.128 0 0.742 1 (1%) 0.441 1 (2%) 0.363 0 0.397 2 (1%) 0.555 0  
Rhinorrhoea, n(%) 132 (20%) 91 (23%) 0.981 8 (33%) 0.110 34 (25%) 0.657 8 (14%) 0.729 16 (24%) 0.806 34 (25%) 0.712 24 (16%) 0.155 
Laboratory markers:                
CRP ≥40mg/l, n(%)g 2 (0%) 0 0.685 0 0.317 0 0.806 0 0.656 0 0.991 0 0.606 0 0.870 
LytA positive, n(%)
h
 37 (6%) 23 (6%) 0.938 4 (18%) 0.007 6 (5%) 0.760 3 (6%) 0.624 5 (8%) 0.500 5 (4%) 0.278 6 (7%) 0.667 
HDP, n(%)
i
                
-Blood 18 (3%) 18 (3%) 0.206 1 (5%) 0.504 5 (4%) 0.533 3 (6%) 0.237 5 (8%) 0.099 5 (4%) 0.533 5 (3%) 0.210 
-NP 69 (11%) 44 (11%) 0.806 4 (17%) 0.339 17 (13%) 0.463 2 (3%) 0.123 7 (10%) 0.954 13(9%) 0.681 14 (15%) 0.192 
HRV viral load, mean (SD)
j
 3.5 (0.9) 3.4 (0.9) 0.424 3.4 (0.9) 0.383 3.4 (0.9) 0.203 3.5 (0.8) 0.945 3.4 (0.9) 0.472 3.4 (0.9) 0.572 3.5 (1.0) 0.838 
Abbreviations - SD: Standard deviation; NP: Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; HEU: HIV exposed but uninfected; RTI: 
Respiratory tract infection; CRP: C-reactive protein; HDP: High density pneumococcus. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable, P-values could not 
be calculated for variables where both values are 0, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU defined as HIV-uninfected but HIV-exposed. Undetectable viral 
load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative children < 7 months of 
age where documented positive maternal status was required; 
c
 - Premature birth defined as gestational age <37 weeks; 
d
 - RTI were controls showing any signs or symptoms 
of respiratory tract infections including any of the symptoms listed under clinical features; 
e 
- Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, 
respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
f
 - Fever defined as temperature ≥38oC; g - CRP defined as 
levels ≥40mg/mL which are considered to potentially indicate bacterial infection; h - Blood sample positive for S. pneumoniae colonisation by LytA PCR; i - HDP defined as S. 
pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL; 
i
 - HRV viral load in the nasopharynx expressed as log10 copies/mL. 
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3.1.3 Case and control comparison of HRV infection in children 
In multivariate analysis adjusting for multiple confounding variables including co-infecting 
bacteria and viruses, HRV was 1.45-fold (aOR 95% CI: 1.29-1.62, P<0.001) more likely to 
be present among pneumonia cases (n=912, 24% overall; range 17% in Mali to 37% in 
Bangladesh) than controls (n=1 056, 21% overall; range by site 14% in Thailand to 28% in 
The Gambia); Table 3.4. Figure 3.1 details the seasonal distribution of HRV positive cases 
and controls by month of enrolment. HRV were found in both cases and controls throughout 
the study period, with the highest prevalence of HRV among cases in August 2013 (40%) and 
the lowest in October 2011 (13%), and among controls the highest prevalence was in 
November 2013 and January 2014 (both 37%) and the lowest in October 2011 (3%). There 
were no obvious patterns of seasonality in cases or controls as HRV prevalence fluctuated 
month-on-month.  
 
 
Figure 3.1: Distribution of HRV positive cases and controls by month of enrolment 
 
The prevalence of HRV among cases varied by age group, with the lowest prevalence in the 
1-5 month (21%) and 6-12 month age groups (22%) and highest (28%) in the 12-59 month 
age-group. Furthermore, the prevalence of HRV among cases 1-5 month of age was lower 
compared to controls of the same age-group (25%, aOR 0.86, 95% CI: 0.74-0.90, P=0.049); 
which was evident across all sites except Bangladesh and including being significant in The 
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Gambia (20% vs. 32%, aOR 0.51, 95% CI: 0.33-0.79, P=0.002). In contrast, the prevalence 
of HRV positivity was similar between cases (22%) and controls (22%) among the 6 to 12-
month age group (OR 1.0, 95 CI: 0.81-1.24, P=0.96); Table 3.4. Conversely, in children 
between 1-5 years of age, HRV identification was more common among cases (28%) than 
controls (18%, aOR 2.08, 95% CI: 1.75-2.47, P<0.001), which was evident across all sites, 
including being significant in Kenya (26% vs. 21%, aOR 2.09, 95% CI: 1.41-3.11, P<0.001), 
Zambia (25% vs. 12%, aOR 4.22, 95% CI: 1.91-9.38, P<0.001) and Bangladesh (43% vs. 
23%, aOR 3.33, 95% CI: 2.29-4.85, P<0.001); Table 3.4.  
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Table 3.4: Number of study subjects enrolled and tested for HRV, percent positive by age and site 
Age groups     Kenya Gambia Mali Zambia South Africa Thailand Bangladesh Total 
All Enrolled Cases 628 609 650 449 794 221 525 3876 
Controls 855 624 724 533 823 650 768 4977 
HRV positive, n (%) Cases 152 (24%) 139 (23%) 112 (17%) 95 (21%) 182 (23%) 40 (18%) 192 (37%) 912 (24%) 
Controls 162 (19%) 177 (28%) 143 (20%) 93 (17%) 194 (24%) 92 (14%) 195 (25%) 1056 (21%) 
P-value 0.018 0.134 0.093 0.156 0.838 0.140 P<0.001 P<0.001 
1-5 months Enrolled Cases 208 249 299 248 399 37 136 1576 
Controls 231 192 247 253 318 90 221 1552 
HRV positive, n (%) Cases 43 (21%) 49 (20%) 60 (20%) 44 (18%) 80 (20%) 3 (8%) 45 (33%) 324 (21%) 
Controls 57 (25%) 62 (32%) 65 (26%) 53 (21%) 76 (24%) 10 (11%) 68 (31%) 391 (25%) 
P-value 0.391 0.002 0.084 0.363 0.183 0.612 0.647 0.049 
6-11 months Enrolled Cases 130 134 147 108 192 50 121 882 
Controls 190 127 188 135 227 150 167 11843 
HRV positive, n (%) Cases 35 (27%) 22 (16%) 20 (14%) 28 (26%) 48 (25%) 10 (20%) 32 (26%) 195 (22%) 
Controls 33 (17%) 36 (28%) 36 (19%) 23 (17%) 64 (28%) 25 (17%) 39 (23%) 256 (22%) 
 P-value 0.041 0.114 0.177 0.091 0.462 0.591 0.548 0.960 
12-59 months Enrolled Cases 290 226 204 93 203 134 268 1418 
Controls 434 305 289 145 278 410 380 2241 
HRV positive, n (%) Cases 74 (26%) 68 (30%) 32 (16%) 23 (25%) 54 (27%) 27 (20%) 115 (43%) 393 (28%) 
Controls 71 (17%) 79 (26%) 42 (15%) 17 (12%) 54 (19%) 57 (14%) 88 (23%) 409 (18%) 
P-value P<0.001 0.286 0.724 P<0.001 0.062 0.082 P<0.001 P<0.001 
Abbreviations: HRV - Human rhinovirus.  
P-values from chi-square tests with logistic regression models adjusted for confounding variates (<0.2 in univariate analysis). 
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To identify potential risk factors for HRV-associated hospitalisation, we compared the HRV-
associated cases to controls (regardless of HRV status). HRV-associated cases compared to 
controls were younger (mean 13.1 vs. 15.4 months, P=0.001) and less likely to be female 
(41% vs. 50%, aOR 0.70, 95% CI: 0.60-0.81, P<0.001), but 1.33-fold (aOR 95% CI: 1.01-
1.74) more likely to be HIV-exposed (10% vs. 8, P=0.046), 3.21-fold (aOR 95% CI: 2.70-
3.81) more likely to be underweight (30% vs. 12%, P<0.001) and have high nasopharyngeal 
colonisation densities (>6.9 log10 copies/mL) of S. pneumoniae in the nasopharynx (12% vs. 
8%, aOR 1.56, 95% CI: 1.24-1.96, P<0.001); Table 3.5. 
 
Table 3.5: Associations of demographic, clinical and respiratory pathogen co-infections of 
HRV-associated cases and controls regardless of HRV-associations 
 HRV+ cases 
(n=912) 
All controls 
(n=4977) 
Unadjusted 
P-values OR(95%CI) 
Adjusted 
P-value
  
aOR (95%CI) 
Age in months, mean (SD) 13.1 (12.1) 15.4 (14.3) P<0.001  0.001            
Female, n(%) 373 (41%) 2 472 (50%) P<0.001 0.70 (0.61-0.81) P<0.001 0.70 (0.60-0.81) 
Never breast fed, n(%) 80 (9%) 389 (8%) 0.327 1.13 (0.88-1.46) 0.302 1.17 (0.87-1.56) 
Under weight, n (%)
a
 277 (30%) 598 (12%) P<0.001 3.19 (2.71-3.77) P<0.001 3.21 (2.70-3.81) 
HEU, n(%)
b
 94 (10%) 378 (8%) 0.006 1.40 (1.10-1.77) 0.046 1.33 (1.01-1.74) 
Day Care attendance, n(%) 126 (14%) 902 (18%) 0.001 0.72 (0.59-0.88) 0.280 0.86 (0.65-1.13) 
Smoker in household, n(%) 340 (37%) 1910 (38%) 0.523 0.95 (0.82-1.10) 0.568 0.96 (0.82-1.11) 
Premature birth, n(%)
c
 87 (10%) 506 (10%) 0.591 0.94 (0.74-1.19) 0.334 0.88 (0.69-1.14) 
Birth weight, mean (SD) 2.8 (0.7) 3.0 (0.5) P<0.001  P<0.001  
Clinical features:      
 
Tachypnea, n(%)
d
 785 (86% 560 (11%) P<0.001 49.6 (40.2-61.1) P<0.001 53.73 (43.06-67.03) 
Cough, n(%) 647 (71%) 421 (8%) P<0.001 26.6 (22.3-31.6) P<0.001 5.65 (4.80-6.66) 
Fever, n(%)
e
 707 (78%) 268 (5%) P<0.001 60.6 (49.7-73.9) P<0.001 117.2 (90.31-152.1) 
Diarrhoea, n(%) 118 (13%) 95 (2%) P<0.001 7.6 (5.8-10.1) P<0.001 1.31 (1.15-1.50) 
Rhinorrhoea, n(%) 402 (44%) 852 (17%) P<0.001 3.82 (3.28-4.44) P<0.001 2.19 (1.85-2.61) 
Markers for Bacterial co-infection:      
LytA positive, n (%)
f
 52 (6%) 253 (5%) 0.507 1.11 (0.82-1.51) 0.818 1.04 (0.76-1.42) 
S. pneu load, mean (SD)
g
 4.5 (2.4) 4.6 (2.2) 0.210  0.210  
HDP, n(%)
h
       
-Blood 32 (4%) 140 (3%) 0.289 1.24 (0.84-1.83) 0.491 1.17 (0.80-1.75) 
-NP 111 (12%) 379 (8%) P<0.001 1.68 (1.34-2.10) P<0.001 1.56 (1.24-1.96) 
Viral infections in the nasopharynx:      
-RSV, n(%) 121 (13%) 140 (3%) P<0.001 5.29 (4.10-6.82) P<0.001 5.68 (4.34-7.42) 
-AdV, n(%) 108 (12%) 593 (12%) 0.950 0.99 (0.80-1.24) 0.578 1.06 (0.85-1.34) 
-HMPV, n(%) 49 (5%) 206 (4%) 0.093 1.32 (0.96-1.81) 0.341 1.18 (0.84-1.66) 
-HBoV, n(%) 138 (15%) 660 (13%) 0.129 1.17 (0.96-1.42) 0.023 1.27 (1.03-1.56) 
-InFV A-C, n(%) 5 (1%) 113 (3%) 0.002 0.24 (0.10-0.58) P<0.001 0.19 (0.07-0.47) 
-PIV, n(%) 76 (8%) 314 (6%) 0.024 1.35 (1.04-1.75) 0.137 1.23 (0.94-1.61) 
-HCoV, n(%) 56 (6%) 501 (10%) P<0.001 0.58 (0.44-0.78) 0.049 0.55 (0.41-0.75) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: 
Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; HEU: HIV exposed but 
uninfected; HDP: High density pneumococcus; RSV: Respiratory Syncytial Virus, HMPV: human 
metapneumovirus; AdV: adenovirus; PIV: parainfluenza type 1-4; HBoV: Human Bocavirus; HCoV: Human 
Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, B and C); S. pneu: Streptococcus 
pneumoniae. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU 
defined as HIV-uninfected but HIV-exposed. Undetectable viral load, HIV seronegative in the child with a 
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positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative 
children < 7 months of age where documented positive maternal status was required; 
c
 - Premature birth defined 
as gestational age <37 weeks; 
d
 - Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, 
respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
e
 - Fever defined as temperature ≥38oC; f - Blood sample positive for S. pneumoniae colonisation by LytA PCR; g 
- Bacterial load of S. pneu in the nasopharynx, expressed as log10 copies/mL; 
h
 - HDP defined as S. pneumoniae 
density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL. 
 
Additionally, multi logistic regression analyses to ascertain whether HRV viral load and co-
infections were associated with case-control status among the HRV-associated participants 
were conducted; Table 3.6. Among HRV-associated cases and controls, HRV was 1.71-fold 
(aOR 95% CI: 1.40-2.09) more likely to be detected as a co-infection among cases (47% vs. 
38%, P<0.001) and to have higher HRV viral loads in the nasopharynx (3.7 vs. 3.5 log10 
copies/mL, P<0.001) compared to controls with HRV co-infections. This association of 
higher viral loads was irrespective of whether HRV was detected as a mono or mixed 
infection; Table 3.6. No discernible optimal threshold densities for distinguishing HRV-
associated cases from controls based on nasopharyngeal viral loads could be calculated from 
reverse cumulative plots or Youden indices; Figure 3.2.  
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Figure 3.2: Reverse cumulative plot of HRV viral load in the nasopharynx among cases and 
controls. The viral loads of cases are shown in red and the controls in blue. Panel A.) the 
HRV viral load in all cases and controls; Panel B.) the HRV viral load in cases and controls 
with mono-infections; Panel C.) the HRV viral load in cases and controls with HRV co-
infections. 
 
Overall, HRV-RSV co-infections were 9.07-fold (aOR 95% CI: 5.54-14.9) more common 
among cases (13%) than in controls (2%, P<0.001). A similar trend was also observed for 
HRV-PIV co-infections (8% vs. 6%, P=0.052); Table 3.6. For HRV co-detection with 
bacteria in the nasopharynx, HRV co-infections with S. pneumoniae (81% vs. 72%, P<0.001) 
and M. catarrhalis (79% vs. 68%, P<0.001) were more prevalent among controls than cases. 
No HRV co-infections with bacteria were more prevalent among case than controls; Table 
3.6.  
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Table 3.6: Multivariate analysis of HRV viral loads and co-infections among HRV-associated 
cases and controls 
  
Cases 
(n=912) 
Controls 
(n=1056) 
Unadjusted 
P-value OR (95%CI) 
Adjusted   
P-value aOR (95%CI)
 
 
HRV Viral load, Mean (SD)
a
 3.7 (0.94) 3.5 (0.94) P<0.001  P<0.001 
 HRV Mono-infection, n(%) 481 (53%) 656 (62%) P<0.001 0.69 (0.57-0.81) P<0.001 0.58 (0.47-0.71) 
-Viral load of mono-infections
 
 3.8 (0.90) 3.6 (0.93) P<0.001   0.001 
 HRV Co-infections, n(%)
b
 431 (47%) 400 (38%) P<0.001 1.47 (1.23-1.78) P<0.001 1.71 (1.40-2.09) 
-Viral load of mixed infections 3.6 (0.99) 3.4 (0.94) 0.009  0.020 
 HRV Viral Co-infections in nasopharynx with:   
  -HBoV, n(%) 138 (15%) 139 (13%) 0.024 1.35 (1.04-1.76) 0.107 1.24 (0.95-1.61) 
-RSV, n(%) 121 (13%) 24 (2%) P<0.001 6.88 (4.37-10.2) P<0.001 9.07 (5.54-14.9) 
-AdV, n(%) 108 (12%) 134 (13%) 0.507 1.1 (0.83-1.45) 0.663 0.94 (0.70-1.25) 
-HMPV, n(%) 49 (5%) 59 (6%) 0.538 1.13 (0.76-1.68) 0.827 1.05 (0.69-1.59) 
-PIV, n(%) 76 (8%) 68 (6%) 0.017 1.52 (1.06-2.15) 0.052 1.68 (0.99-2.64) 
-InFV A-C , n(%) 5 (1%) 0 0.579  0.088 
 -HCoV, n(%) 56 (6%) 93 (9%) 0.272 0.82 (0.58-1.17) 0.625 0.90 (0.60-1.35) 
Bacterial Co-infections in nasopharynx with:   
  -S. pneu, n(%) 661 (72%) 860 (81%) P<0.001 0.60 (0.49-0.74) P<0.001 0.56 (0.45-0.70) 
-H. inf, n(%) 510 (56%) 603 (57%) 0.598 0.95 (0.80-1.14) 0.415 0.93 (0.77-1.11) 
-HiB, n(%) 23 (3%) 23 (2%) 0.615 1.16 (0.65-2.09) 0.606 1.17 (0.65-2.12) 
-M. cat, n(%) 616 (68%) 836 (79%) P<0.001 0.55 (0.46-0.67) P<0.001 0.49 (0.40-0.61) 
-S. aureus, n(%) 129 (14%) 135 (13%) 0.377 1.12 (0.87-1.46) 0.346 1.14 (0.87-1.49) 
P. jiroveci Co-infections, n(%) 80 (9%) 102 (10%) 0.498 0.90 (0.66-1.22) 0.615 0.92 (0.66-1.28) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: 
Nasopharyngeal; HRV: Human rhinovirus; RSV: Respiratory Syncytial Virus, HMPV: human 
metapneumovirus; AdV: adenovirus; PIV: parainfluenza type 1-4; HBoV: Human Bocavirus; HCoV: Human 
Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, B and C); S. pneu: Streptococcus 
pneumoniae; H.inf: Haemophilus influenza, HiB: Haemophilus influenza Type B, M.cat: Moraxella 
catarrahalis; P. jiroveci: Pneumocytosis jiroveci 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a 
- Rhinovirus viral load in the nasopharynx, expressed as log10 copies/mL; 
b 
- Any viral respiratory coinfection 
with RSV (A and B), HMPV, AdV, InFV (A, B and C), PIV type 1-4, HCoV (OC43, NL63, 229E and HKU1). 
 
3.1.4 Characteristics of cases by HRV status  
Of the 3 876 case participants enrolled, 68% (n=2 630) had severe pneumonia and 32% (n=1 
246) had very severe pneumonia. HRV was detected in 24% (n=912) of the cases and after 
logistic modelling there were no differences in the prevalence of HRV between the severe 
(24%, n=621/2 630) and very severe pneumonia cases (23%, n=291/1 246, P=0.128). The 
HRV-associated very severe pneumonia cases; however, had higher HRV viral loads (3.8 
log10 copies/mL) compared to the HRV-associated severe pneumonia cases (3.6 log10 
copies/mL, P=0.009). No clinically beneficial threshold densities capable of discriminating 
more severe HRV-associated disease could be determined from reverse cumulative plots or 
Youden indices, Figure 3.3. 
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Figure 3.3: Reverse cumulative plot of HRV viral load in the nasopharynx among children 
with severe and very severe pneumonia 
 
In the multivariate logistic regression model, HRV-associated cases were significantly older 
(mean 13.1 months) than those without HRV infection (mean 11.2 months, P<0.001). No 
other associations were seen in risk factors for pneumonia including day care attendance 
(14% vs. 17%, P=0.095), having a smoker in the household (37% vs. 33%, P=0.357) or 
premature birth (10% vs. 11%, P=0.695) between HRV-associated cases compared to HRV 
uninfected cases; Table 3.7.  
 
HRV-associated cases were also 1.73-fold (aOR 95% CI: 1.43-2.0) more likely to have 
wheezing (46% vs. 31%, P<0.001) and 1.36-fold (aOR 95% CI: 1.09-1.70) more likely to 
have tachypnea (86% vs. 81%, P=0.005) than in the absence of HRV infection. Conversely, 
HRV-associated cases were 0.78-fold (aOR 95% CI: 0.67-0.91) less likely to have 
radiographically confirmed pneumonia (chest X-ray with any infiltrate) (40% vs. 46%, 
P=0.001) and 0.70-fold (aOR 95% CI: 0.49-0.99) less likely to present with convulsions (5% 
vs. 7%, P=0.047). There was no other association observed for presence of HRV infection 
and hypoxia (33% vs. 37%, P=0.871), supplementary oxygen therapy (29% vs. 31%, 
P=0.746) or mechanical ventilation (2% vs. 3%, P=0.0752) and very severe pneumonia (32% 
vs. 32%, P=0.128) in HRV-associated cases compared to those without infection. HRV-
associated cases were, however, 0.76-fold (aOR 95% CI: 0.65-0.89) less likely to be 
hospitalised for >3 days duration (52% vs 61, P=0.001) but had similar case fatality ratio (8% 
each, P=0.300) Table 3.7. 
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Table 3.7: The demographical and clinical characteristics of cases by HRV infection status 
for all sites data combined 
  HRV+ 
(n=912) 
HRV-  
(n= 2964) 
Unadjusted  
P-value
  
OR (95% CI) 
Adjusted  
P-value  aOR (95% CI) 
Age in months, mean (SD) 13.1 (12.1) 11.2 (11.3) P<0.001  P<0.001  
Female, n(%) 373 (41%) 1261 (43%) 0.379 0.93 (0.80-1.09) 0.472 0.95 (0.81-1.10) 
Never breast fed, n(%) 80 (9%) 300 (10%) 0.231 0.85 (0.66-1.11) 0.541 1.09 (0.82-1.45) 
Under weight, n (%)
a
 277 (30%) 916 (30%) 0.761 0.98 (0.83-1.15) 0.396 0.93 (0.79-1.10) 
HEU, n(%)
b
 94 (10%) 330 (11%) 0.484 0.92 (0.72-1.17) 0.895 1.02 (0.77-1.35) 
Day care attendance, n(%) 126 (14%) 517 (17%) 0.003 0.77 (0.65-0.91) 0.095 0.87 (0.75-1.02) 
Smoker in household, n(%) 340 (37%) 969 (33%) 0.113 1.10 (0.98-1.24) 0.357  1.06 (0.93-1.21) 
Premature at birth, n(%)
c
 87 (10%) 328 (11%) 0.678 0.99 (0.93-1.05) 0.695 0.99 (0.93-1.05) 
Birth weight, mean (SD) 2.9 (0.6) 2.9 (0.7) 0.998  0.882  
Clinical Features:       
Very severe pneumonia, n(%) 291 (32%) 955 (32%) 0.869 0.98 (0.84-1.16) 0.128  1.14 (0.96-1.35) 
Chest X-ray abnormal, n(%)
d 365 (40%) 1355 (46%) 0.003 0.79 (0.68-0.92) 0.001 0.78 (0.67-0.91) 
Supplementary 02 therapy, n(%) 266 (29%) 928 (31%) 0.278 0.92 (0.80-1.06) 0.746 0.96 (0.76-1.22) 
Mechanical Ventilation, n(%) 15 (2%) 91 (3%) 0.023 0.53 (0.30-0.92) 0.072 0.60 (0.34-1.05) 
Hypoxic, n(%)
e
 297 (33%) 1086 (37%) 0.028 0.84 (0.72-0.98) 0.571 0.98 (0.82-1.19) 
Tachycardia, n(%)
f
 439 (48%) 1514 (51%) 0.108 0.88 (0.76-1.03) 0.834 0.98 (0.84-1.15) 
Tachypnea, n(%)
g
 785 (86%) 2384 (81%) P<0.001 1.47 (1.19-1.82) 0.005 1.36 (1.09-1.70) 
Wheezing, n(%) 421 (46%) 898 (31%) P<0.001 1.96 (1.69-2.29) P<0.001 1.73 (1.43-2.0) 
Cough, n(%) 647 (71%) 2054 (69%) 0.430 1.05 (0.94-1.17) 0.521 0.94 (0.79-1.13) 
Lethargic, n(%) 89 (10%) 311 (11%) 0.520 0.92 (0.72-1.18) 0.777 0.96 (0.74-1.25) 
Convulsions, n(%) 43 (5%) 201 (7%) 0.026 0.68 (0.48-0.96) 0.047 0.70 (0.49-0.99) 
Diarrhoea, n(%) 118 (13%) 451 (15%) 0.060 0.82 (0.66-1.0) 0.580 1.01 (0.81-1.27) 
Head nodding, n(%) 162 (18%) 477 (16%) 0.225 1.13 (0.93-1.37) 0.051 1.31 (0.99-1.62) 
Central cyanosis, n(%) 15 (2%) 65 (2%) 0.310 0.75 (0.42-1.31) 0.958 0.98 (0.55-1.75) 
Unable to Feed, n(%) 58 (6%) 241 (8%) 0.082 0.76 (0.57-1.03) 0.529 0.91 (0.67-1.23) 
Vomiting everything, n(%) 22 (2%) 94 (3%) 0.240 0.75 (0.47-1.21) 0.207 0.73 (0.45-1.19) 
Lower chest wall indrawing, n(%) 846 (93%) 2712 (92%) 0.224 1.19 (0.90-1.58) 0.197 1.21 (0.90-1.63) 
Stridor, n(%) 18 (2%) 77 (3%) 0.277 0.87 (0.68-1.12) 0.459 0.82 (0.48-1.39) 
Grunting, n(%) 225 (13%) 566 (19%) 0.039 0.86 (0.74-0.99) 0.154 0.76 (0.59-0.99) 
Nasal flaring, n (%) 499 (55%) 1757 (59%) 0.004 0.81 (0.71-0.94) 0.229 1.11 (0.93-1.33) 
Hospital stay >3 days, n(%) 477 (52%) 1795 (61%) P<0.001 0.71 (0.62-0.83) 0.001  0.76 (0.65-0.89) 
Case fatality ratio, n(%) 63 (8%) 215 (8%) 0.671 0.94 (0.70-1.26) 0.300 1.18 (0.86-1.60) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: 
Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; HEU: HIV exposed but 
uninfected. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU 
defined as HIV-uninfected but HIV-exposed. Undetectable viral load, HIV seronegative in the child with a 
positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative 
children < 7 months of age where documented positive maternal status was required; 
c
 - Premature birth defined 
as gestational age <37 weeks; 
d
 - Abnormal Chest X-ray defined as radiographically confirmed end point 
pneumonia consolidation or any infiltrates; 
e
 - A child was considered to be hypoxic if 1) a room air pulse-
oximetry reading indicated oxygen saturation <90% at the two sites at elevation (Zambia and South Africa) or 
<92% at all other sites, or 2) a room air oxygen saturation; 
f
 - Tachycardia defined as heart rate >160 beats per 
minute (bpm) if aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 
months; 
g 
- Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 
breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 month. 
 
Among markers of possible bacterial co-infection; Table 3.8, HRV-associated cases were less 
likely associated with fever (78% vs. 83%, P=0.007), alveolar consolidation on CXR (18% vs 
24%, P=0.013) and CRP levels ≥40mg/L (19% vs 24%, P=0.008) compared to cases without 
HRV infection. Children with HRV-associated pneumonia, however, had significantly higher 
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neutrophil percentages (51% vs. 46%, P<0.001) and were 1.39-fold (aOR 95% CI: 1.19-1.63) 
more likely to have leucocytosis (51% vs. 41%, P<0.001); but conversely had significantly 
lower lymphocyte percentages (37.55% vs. 42.8%, P<0.001). There were no other 
associations between the presence of HRV detection and presence of MCPP (1% for both, 
P=0.626), prevalence of concurrent S. pneumoniae (LytA) bacteraemia (6% vs 7%, P=0.837) 
or high colonisation densities of S. pneumoniae in the blood (>2.2 log10 copies/ml; 4% vs. 5%, 
P=0.482) or nasopharynx (>6.9 log10 copies/mL; 12% vs 13%, P=0.858).  
 
Among other commonly detected respiratory viruses; Table 3.8, HRV-associated cases were 
less likely to be infected with RSV (13% vs. 28%, P<0.001), Influenza virus (1% vs. 6%, 
P<0.001), HMPV (5% vs. 10%, P<0.001) and PIV (8% vs. 15%, P<0.001) compared to 
cases without HRV infections; and there was a trend for the HRV-associated cases to be more 
commonly associated with AdV co-infections than cases without HRV infection (12% vs. 
10%, P=0.098). Individual site case-case evaluations are available in Table 3.9A and B, with 
similar trends observed as for the overall site comparisons above. 
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Table 3.8: Markers for possible bacterial co-infections and viral co-infections of cases by 
HRV infection status 
  HRV+  
(n=912) 
HRV-  
(n= 2964) 
Unadjusted 
P-value  OR (95% CI) 
Adjusted  
P-value
  
aOR (95% CI) 
Bacterial co-infection markers:       
Fever, n(%)
a
 707 (78%) 2447 (83%) 0.001 0.73 (0.60-0.87) 0.007 0.76 (0.63-0.93) 
Alveolar consolidation, n(%)
b
 156 (18%) 657 (24%) 0.001  0.72 (0.59-0.87) 0.013 0.78 (0.64-0.95) 
Leucocytosis, n(%)
c
 443 (51%) 1135 (41%) P<0.001 1.54 (1.32-1.80) P<0.001 1.39 (1.19-1.63) 
Neutrophils (%), median (IQR) 51 (35.4-67.9) 46 (31-60.3) P<0.001  P<0.001  
Lymphocytes (%), median (IQR) 37.6 (24-52) 42.8 (29.2-56.9) P<0.001  P<0.001  
Eosinophils (%), median (IQR) 1.3 (0.4-3.5) 0.9 (0.1-2.8) 0.031  0.126  
CRP ≥40mg/l, n(%)d 176 (19%) 718 (24%) 0.002 0.75 (0.62-0.90) 0.008 0.77 (0.64-0.94) 
Blood culture positive, n(%) 29 (3%) 108 (4%) 0.507 0.87 (0.57-1.32) 0.931 0.98 (0.64-1.50) 
LytA positive, n(%)
e
 52 (6%) 192 (7%) 0.355 0.86 (0.63-1.18) 0.837  0.97 (0.70-1.33) 
MCPP, n(%)
f
 8 (1%) 35 (1%) 0.445 0.74 (0.34-2.60) 0.626 0.82 (0.38-1.80) 
HDP, n(%)
g
       
-Blood 32 (4%) 135 (5%) 0.155 0.75 (0.51-1.11) 0.482 0.86 (0.58-1.29) 
-NP 111 (12%) 380 (13%) 0.604 0.94 (0.75-1.18) 0.858 0.98 (0.77-1.23) 
Viral co-infections in the nasopharynx with:     
-RSV, n (%) 121 (13%) 833 (28%) P<0.001 0.39 (0.32-0.48) P<0.001 0.39 (0.31-0.49) 
-AdV, n (%) 108 (12%) 283 (10%) 0.045 1.27 (1.0-1.61) 0.098 1.23 (0.96-1.57) 
-InFV A-C, n (%) 5 (1%) 174 (6%) P<0.001 0.09 (0.04-0.22) P<0.001 0.09 (0.04-0.22) 
-HBoV, n (%) 138 (15%) 365 (12%) 0.027 1.27 (1.02-1.57) 0.116 1.19 (0.96-1.48) 
-HMPV, n (%) 49 (5%) 294 (10%) P<0.001 0.52 (0.38-0.70) P<0.001 0.50 (0.37-0.69) 
-PIV, n (%) 76 (8%) 437 (15%) P<0.001 0.53 (0.41-0.68) P<0.001 0.51 (0.39-0.67) 
-HCoV, n (%) 56 (6%) 232 (8%) 0.090 0.77 (0.57-1.04) 0.145 0.80 (0.59-1.08) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; IQR: Inter quartile range; 
NP: Nasopharyngeal; HRV: Human rhinovirus; HDP: High density pneumococcus; CRP: C-reactive protein; 
RSV: Respiratory Syncytial Virus, HMPV: human metapneumovirus; AdV: adenovirus; PIV: parainfluenza type 
1-4; HBoV: Human Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and HKU1) and InFV: 
Influenza Virus (A, B and C); S. pneu: Streptococcus pneumoniae. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a
 - Fever defined as temperature ≥38oC; b - defined as primary end point pneumonia on the chest X-rays; c - 
Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 
000 cells/uL if age >12 months; 
d
 - CRP defined as levels ≥40mg/mL are considered to potentially indicate 
bacterial infection; 
e 
- Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
f 
- MCPP defined as 
S. pneumoniae was cultured from a normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural 
fluid or lung aspirate was PCR LytA positive; 
g
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 
and/or density in whole blood sample >2.2 log10 copies/mL. 
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Table 3.9A: The demographical and clinical characteristics of cases by HRV infection status for each African site individually 
  Kenya (n=628)   Gambia (n=609) Mali (n=650)   Zambia (n=449)    South Africa (n=794)   
  HRV+ (n=152) HRV- (n=476) P-value HRV+ 
(n=139) 
HRV- 
(n=470) 
P-value HRV+ 
(n=112) 
HRV- 
(n=538) 
P-value HRV+ (n=95) HRV- (n=354) P-value HRV+ (n=182) HRV- (n=794) P-value 
Age in months, mean (SD) 14.5(13.2) 14.2 (13.1) 0.800 14.4 (12.5) 11.3 (11.2) 0.006 9.3 (10.1) 10.0 (10.2) 0.525 9.9 (10.9) 7.6 (8.9) 0.036 9.9 (9.7) 8.5 (9.5) 0.082 
Female, n(%) 60 (39%) 201 (42%) 0.516 55 (40%) 176 (37%) 0.973 50 (45%) 237 (44%) 0.896 47 (49%) 158 (45%) 0.441 80 (44%) 291 (48%) 0.414 
Never breast fed, n(%) 3 (2%) 6 (1%) 0.477 3 (2%) 4 (1%) 0.285 7 (6%) 25 (5%) 0.380 4 (4%) 22 (6%) 0.510 52 (29%) 211 (34%) 0.150 
Under weight, n (%)
a
 60 (39%) 190 (43%) 0.811 41 (30%) 119 (25%) 0.898 37 (33%) 195 (36%) 0.701 34 (36%) 87 (25%) 0.047 37 (20%) 174 (28%) 0.034 
HEU, n(%)
b
 1 (1%) 3 (1%) 0.970 1 (1%) 1 (0%) 0.359 1 (1%) 5 (1%) 0.971 24 (25%) 94 (27%) 0.800 226 (37%) 67 (37%) 0.977 
Day care attendance, n(%) 8 (5%) 29 (6%) 0,570 2 (1%) 11 (2%) 0.507 83 (74%) 350 (65%) 0.170 1 (1%) 5 (1%) 0.842 24 (13%) 92 (15%) 0.380 
Smoker in household, n(%) 1 (1%) 10 (2%) 0.242 79 (57%) 251 (54%) 0.569 33 (30%) 153 (28%) 0.836 27 (28%) 61 (17%) 0.046 73 (40%) 217 (35%) 0.498 
Premature birth, n(%)
c
 28 (18%) 87 (18%) 0.618 5 (4%) 19 (4%) 0.936 3 (3%) 25 (5%) 0.563 2 (2%) 21 (6%) 0.280 33 (18%) 119 (19%) 0.790 
Birth weight, mean (SD) 2. 8 (0.7) 2.8 (0.7) 0.589 3.0 (0.6) 2.9 (0.5) 0.486 3.1 (0.6) 3.0 (0.7) 0.896 2.9 (0.6) 3.0 (0.7) 0.827 2.9 (0.7) 2.9 (0.8) 0.538 
Clinical features:                
Very severe pneumonia, n(%) 80 (53%) 242 (51%) 0.758 25 (18%) 63 (13%) 0.317 65 (58%) 273 (51%) 0.145 32 (34%) 108 (31%) 0.580 65 (36%) 189 (31%) 0.210 
Chest X-ray abnormal, n(%)
d
 65 (43%) 217 (46%) 0.508 58 (42%) 215 (46%) 0.400 34 (30%) 205 (38%) 0.154 32 (34%) 148 (42%) 0.154 85 (47%) 344 (56%) 0.023 
Supplementary 02 therapy, n(%) 32 (21%) 99 (21%) 0.169 3 (2%) 18 (4%) 0.313 3 (3%) 25 (5%) 0.428 46 (48%) 173 (49%) 0.617 167 (92%) 540 (88%) 0.843 
Mechanical ventilation, n(%) 0 0  0 0  1 (1%) 3(1%) 0.680 2 (2%) 6 (2%) 0.788 8 (4%) 57 (9%) 0.050 
Hypoxic, n(%)
e
 48 (32%) 136 (29%) 0.321 7 (5%) 36 (8%) 0.277 57 (51%) 249 (46%) 0.407 29 (31%) 133 (38%) 0.260 135 (75%) 457 (75%) 0.900 
Tachycardia, n(%)
f
 77 (51%) 270 (57%) 0.198 65 (47%) 264 (56%) 0.041 69 (62%) 300 (56%) 0.312 64 (67%) 220 (63%) 0.385 87 (48%) 299 (49%) 0.835 
Tachypnea, n(%)
g
 115 (76%) 322 (68%) 0.060 121 (87%) 409 (87%) 0.808 101 (90%) 450 (84%) 0.059 84 (88%) 302 (86%) 0.736 150 (83%) 459 (77%) 0.100 
Wheezing, n(%) 31 (21%) 52 (11%) 0.002 48 (35%) 142 (30%) 0.135 27 (24%) 87 (16%) 0.066 21 (22%) 35 (10%) 0.005 79 (44%) 188 (32%) 0.008 
Cough, n(%) 76 (50%) 243 (51%) 0.222 77 (55%) 269 (57%) 0.204 65 (58%) 300 (56%) 0.714 60 (63%) 248 (70%) 0.162 161 (88%) 527 (86%) 0.453 
Lethargic, n(%) 37 (24%) 107 (23%) 0.722 14 (10%) 37 (8%) 0.575 16 (14%) 74 (14%) 0.671 13 (14%) 44 (12%) 0.870 7 (4%) 31 (5%) 0.467 
Fever, n(%)
h
 119 (78%) 416 (87%) 0.004 135 (97%) 466 (99%) 0.051 95 (85%) 472 (88%) 0.528 73 (77%) 300 (85%) 0.042 116 (64%) 382 (62%) 0.942 
Convulsions, n(%) 14 (9%) 61 (13%) 0.148 8 (6%) 18 (4%) 0.552 11 (10%) 73 (14%) 0.370 4 (4%) 17 (5%) 0.624 5 (3%) 5 (1%) 0.052 
Diarrhoea, n(%) 25 (16%) 72 (15%) 0.774 13 (9%) 41 (9%) 0.642 25 (22%) 140 (26%) 0.468 22 (23%) 69 (19%) 0.874 30 (16%) 89 (15%) 0.396 
Head nodding, n(%) 25 (17%) 68 (14%) 0.346 8 (6%) 18 (4%) 0.311 40 (36%) 151 (28%) 0.124 12 (13%) 46 (13%) 0.976 58 (32%) 162 (26%) 0.131 
Central cyanosis, n(%) 0 5 (1%) 0.390 2 (1%) 1 (0%) 0.117 7 (6%) 33 (6%) 0.958 5 (5%) 9 (3%) 0.141 0 10 (2%) 0.202 
Unable to Feed, n(%) 19 (13%) 58 (12%) 0.671 2 (1%) 13 (3%) 0.393 26 (23%) 92 (17%) 0.131 7 (7%) 30 (8%) 0.940 2 (1%) 27 (4%) 0.051 
Vomiting everything, n(%) 13 (9%) 54 (11%) 0.225 2 (1%) 6 (1%) 0.980 1 (1%) 11 (2%) 0.484 2 (2%) 1 (0%) 0.114 2 (1%) 13 (2%) 0.321 
Lower chest wall indrawing, n(%) 126 (83%) 364 (76%) 0.040 128 (92%) 442 (94%) 0.825 10 (90%) 496 (92%) 0.340 88 (93%) 342 (97%) 0.147 173 (95%) 588 (96%) 0.574 
Stridor, n(%) 0 8 (2%) 0.241 2 (1%) 5 (1%) 0.392 5 (4%) 13 (2%) 0.299 3 (3%) 4 (1%) 0.228 6 (3%) 37 (6%) 0.733 
Grunting, n(%) 5 (3%) 4 (1%) 0.330 10 (7%) 37 (8%) 0.299 68 (61%) 342 (64%) 0.550 18 (19%) 96 (27%) 0.116 10 (5%) 42 (7%) 0.936 
Nasal flaring, n (%) 80 (53%) 236 (50%) 0.358 74 (53%) 246 (52%) 0.427 89 (79%) 430 (80%) 0.691 55 (58%) 225 (64%) 0.320 161 (88%) 506 (83%) 0.275 
Laboratory markers:                
Leucocytosis, n(%)
i
 77 (52%) 203 (43%) 0.110 50 (48%) 141 (41%) 0.431 28 (25%) 156 (29%) 0.566 43 (46%) 141 (41%) 0.557 93 (51%) 260 (43%) 0.067 
Neutrophils (%), median (IQR) 49.9 (33.3-64) 46.9 (32.8-60) 0.171 53 (37.4-72.2) 48.8 (37-60.5) 0.336 46 (27-64) 42 (28-59) 0.222 48.1 (36.5-64) 45 (30-61.5) 0.109 50.3 (36.6-64.3) 44.1 (28.6-57.7) 0.003 
Lymphocytes (%), median (IQR) 37.9 (24.4-53.8) 39.3 (27.4-53) 0.789 38.4 (20.6-52) 42.2 (31-54.1) 0.338 49 (31-67) 48 (34-62) 0.839 37.9 (24-50.5) 42.5 (26.3-6) 0.179 37.5 (26-49.3) 43.1 (29.7-56.4) 0.009 
CRP >40mg/l, n(%)
j
 29 (19%) 125 (26%) 0.052 25 (18%) 104 (22%) 0.178 30 (27%) 159 (30%) 0.759 31 (33%) 107 (30%) 0.794 38 (21%) 161 (26%) 0.068 
Blood culture positive, n(%)
k
 3 (2%) 9 (2%) 0.798 4 (3%) 23 (5%) 0.214 11 (10%) 28 (5%) 0.059 6 (6%) 22 (6%) 1.0 3 (2%) 16 (3%) 0.519 
LytA positive, n(%)
l
 3 (2%) 28 (7%) 0.059 15 (11%) 43 (10%) 0.550 14 (13%) 54 (10%) 0.349 5 (6%) 22 (7%) 0.610 10 (5%) 42 (7%) 0.443 
MCPP, n(%)
m
 1 (1%) 4 (1%) 0.806 3 (2%) 12 (3%) 0.667 4 (4%) 14 (3%) 0.514 0 2 (1%) 0.839 0 3 (0%) 0.624 
HDP, n(%)
n
 12 (8%) 34 (7%) 0.800 29 (21%) 103 (22%) 0.773 39 (35%) 161 (30%) 0.234 8 (8%) 37 (10%) 0.580 19 (10%) 96 (16%) 0.091 
Hospital stay >3 days, n(%) 25 (16%) 106 (22%) 0.159 10 (7%) 45 (20%) 0.451 47 (42%) 266 (49%) 0.133 38 (40%) 131 (37%) 0.472 77 (42%) 358 (59%) P<0.001 
Case fatality ratio, n(%) 9 (6%) 27 (6%) 0.788 7 (5%) 14 (3%) 0.333 25 (23%) 87 (17%) 0.134 14 (26%) 55 (28%) 0.779 7 (5%) 19 (4%) 0.506 
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Abbreviations - HRV: Human rhinovirus; SD: Standard deviation; IQR: Inter quartile range; CXR: Chest X-ray; HIV: Human immunodeficiency virus; HEU: HIV-uninfected 
but HIV exposed; CRP: C-reactive protein; MCPP: Microbiologically confirmed pneumococcal pneumonia; HDP: High Density pneumococcus; NP: Nasopharyngeal.
 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable. P-values could not 
be calculated for variables where both groups were zero, thus left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU defined as HIV-uninfected but HIV-exposed. Undetectable viral 
load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative children < 7 months of 
age where documented positive maternal status was required; 
c
 - Premature birth defined as gestational age <37 weeks; 
d
 - Abnormal Chest X-ray defined as radiographically 
confirmed end point pneumonia consolidation or any infiltrates; 
e
 - A child was considered to be hypoxic if 1) a room air pulse-oximetry reading indicated oxygen saturation 
<90% at the two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a room air oxygen saturation; 
f
 - Tachycardia defined as heart rate >160 beats per 
minute (bpm) if aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
g 
- Tachypnea defined as respiratory rate >60 
breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 month; 
h 
- Fever defined as 
temperature >38
o
C; 
i
 - Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 000 cells/uL if age >12 months; 
j
 - CRP 
defined as levels ≥40mg/mL which are considered to potentially indicate bacterial infection; k - Blood culture positive for any significant non contaminate bacteria; l - Blood 
sample positive for S. pneumoniae colonisation by LytA PCR; 
m
 - MCPP defined when S. pneumoniae was cultured from a normally sterile body fluid - blood, pleural fluid or 
lung aspirate - or pleural fluid or lung aspirate was PCR LytA positive; 
n
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample 
>2.2 log10 copies/mL.
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Table 3.9B: The demographical and clinical characteristics of cases by HRV infection status 
for each Southeast Asia site individually 
  Thailand (n=221)   Bangladesh (n=525)   
  HRV+ (n=40) HRV- (n=181) P-value HRV+ (n=192) HRV- (n=333) P-P-value 
Age in months, mean (SD) 21.9 (15.1) 17.2 (12.9) 0.046 16.0 (11.7) 13.9 (11.8) 0.041 
Female, n(%) 15 (38%) 73 (40%) 0.713 66 (34%) 125 (38%) 0.417 
Never breast fed, n(%) 9 (23%) 29 (16%) 0.334 2 (1%) 3 (1%) 0.714 
Under weight, n (%)
a
 6 (15%) 47 (26%) 0.181 62 (32%) 114 (34%) 0.315 
HEU, n(%)
b
 0 1 (1%) 0.638 0 0  
Day care attendance, n(%) 7 (18%) 20 (17%) 0.888 1 (1%) 0 0.315 
Smoker in household, n(%) 22 (55%) 105 (58%) 0.830 105 (55%) 172 (52%) 0.502 
Premature birth, n(%)
c
 7 (18%) 37 (20%) 0.500 9 (5%) 21 (6%) 0.474 
Birth weight, mean (SD) 2.9 (0.7) 2.8 (0.7) 0.718 2.8 (0.6) 2.8 (0.6) 0.851 
Clinical Features:       
Very severe pneumonia, n(%) 6 (15%) 45 (25%) 0.235 18 (9%) 35 (11%) 0.774 
Chest X-ray abnormal, n(%)
d
 13 (33%) 85 (47%) 0.109 78 (41%) 141 (42%) 0.599 
Supplementary 02 therapy, n(%) 6 (15%) 58 (32%) 0.051 9 (5%) 15 (5%) 0.915 
Mechanical ventilation, n(%) 6 (15%) 47 (26%) 0.198 15 (8%) 28 (8%) 0.678 
Hypoxic, n(%)
e
 17 (43%) 81 (45%) 0.813 60 (31%) 80 (24%) 0.150 
Tachycardia, n(%)
f
 32 (82%) 135 (78%) 0.553 182 (95%) 307 (92%) 0.415 
Tachypnea, n(%)
g
 30 (75%) 70 (39%) P<0.001 185 (96%) 324 (97%) 0.482 
Wheezing, n(%) 33 (83%) 155 (86%) 0.356 175 (91%) 312 (94%) 0.197 
Cough, n(%) 1 (3%) 8 (4%) 0.675 1 (1%) 10 (3%) 0.099 
Lethargic, n(%) 36 (90%) 169 (93%) 0.235 133 (69%) 242 (73%) 0.494 
Fever, n(%)
h
 0 23 (13%) 0.084 1 (1%) 4 (1%) 0.451 
Convulsions, n(%) 3 (8%) 39 (22%) 0.061 0 1 (0%) 0.736 
Diarrhoea, n(%) 3 (8%) 5 (3%) 0.133 16 (8%) 27 (8%) 0.796 
Head nodding, n(%) 1 (3%) 6 (3%) 0.929 0 1 (0%) 0.736 
Central cyanosis, n(%) 0 8 (4%) 0.347 2 (1%) 13 (4%) 0.083 
Unable to Feed, n(%) 1 (3%) 7 (4%) 0.723 1 (1%) 2 (1%) 0.882 
Vomiting everything, n(%) 39 (98%) 152 (84%) 0.044 191 (99%) 328 (99%) 0.307 
Lower chest wall indrawing, n(%) 1 (3%) 9 (5%) 0.470 1 (1%) 1 (0%) 0.465 
Stridor, n(%) 1 (3%) 5 (3%) 0.970 3 (2%) 10 (3%) 0.326 
Grunting, n(%) 23 (58%) 91 (50%) 0.407 17 (9%) 23 (7%) 0.629 
Nasal flaring, n (%)       
Laboratory Markers:       
Leucocytosis, n(%)
i
 28 (70%) 89 (49%) 0.037 124 (69%) 145 (48%) P<0.001 
Neutrophils (%), median (IQR) 63.7 (46-76.3) 58 (44.5-70) 0.513 52.95 (36.8-68) 42.1 (30.5-58.6) P<0.001 
Lymphocytes (%), median (IQR) 34.3 (22-47.8) 27.1 (17.5-44) 0.436 33.85 (23.6-47) 45.55 (30.3-58) P<0.001 
Eosinophils, median (IQR) 1 (0.2-2.3) 0 (0-1.65) 0.006 3.7 (1.8-6.9) 2.4 (0.9-5.05) 0.002 
CRP >40mg/l, n(%)
j
 6 (15%) 30 (17%) 0.804 17 (9%) 32 (10%) 0.784 
Blood culture positive, n(%)
k
 0 7 (4%) 0.396 2 (1%) 3 (1%) 0.962 
LytA positive, n(%)
l
 1 (3%) 2 (1%) 0.426 4 (2%) 1 (0%) 0.088 
MCPP, n(%)
m
 0 0  0 0  
HDP, n(%)
n
 0 3 (2%) 0.761 26 (14%) 43 (13%) 0.959 
Hospital stay >3 days, n(%) 4 (10%) 76 (42%) 0.001 38 (20%) 70 (21%) 0.927 
Case fatality ratio, n(%) 0 9 (5%) 0.297 1 (1%) 4 (1%) 0.640 
Abbreviations - HRV: Human rhinovirus; SD: Standard deviation; IQR: Inter quartile range; CXR: Chest X-ray; 
HIV: Human immunodeficiency virus; HEU: HIV-uninfected but HIV exposed; CRP: C-reactive protein; 
MCPP: Microbiologically confirmed pneumococcal pneumonia; HDP: High Density pneumococcus; NP: 
Nasopharyngeal.
 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable. P-values could not be calculated for variables where both groups 
were zero, thus left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU 
defined as undetectable viral load, HIV seronegative in the child with a positive maternal history. Positive 
maternal status based on self-report was accepted, except for seronegative children < 7 months of age where 
documented positive maternal status was required; 
c
 - Premature birth defined as gestational age <37 weeks; 
d
 - 
Abnormal Chest X-ray defined as radiographically confirmed end point pneumonia consolidation or any 
infiltrates; 
e
 - A child was considered to be hypoxic if 1) a room air pulse-oximetry reading indicated oxygen 
saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a room 
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air oxygen saturation; 
f
 - Tachycardia defined as heart rate >160 beats per minute (bpm) if aged <11 months, 
heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
g 
- Tachypnea defined as 
respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, 
respiration rate >40 breaths/minute if aged >12 month; 
h 
- Fever defined as temperature >38
o
C; 
i
 - Leucocytosis 
defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 000 cells/uL if 
age >12 months; 
j
 - CRP defined as levels ≥40mg/mL which are considered to potentially indicate bacterial 
infection; 
k
 - Blood culture positive for any significant non contaminate bacteria; 
l
 - Blood sample positive for S. 
pneumoniae colonisation by LytA PCR; 
m
 - MCPP defined when S. pneumoniae was cultured from a normally 
sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or lung aspirate was PCR LytA positive; 
n
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 
copies/mL. 
 
HRV were detected as a mono-infection in 53% of cases (n=481/912). We further evaluated 
the demographic and clinical characteristics amongst HRV mono-infection cases and those 
with other respiratory virus co-infections; Table 3.10. HRV-associated cases with mono-
infections were older (mean 14.1 months) than cases with co-infections (10.3 months, 
P<0.001). Additionally, the HRV mono-infected cases were more likely to have been born 
prematurely (12%) compared to the cases with HRV mixed infections (7%, P=0.026). There 
were no differences in other characteristics between cases with HRV mono-infections than 
those with co-infections, including prevalence of very severe pneumonia (34% vs. 30%, 
P=0.781), hypoxia (33% vs. 33%, P=0.267) or requiring supplementary oxygen therapy 
(32% vs. 26%, P=0.596). Furthermore, cases with HRV mono-infections showed no 
associations with HIV exposure compare to cases with any HRV co-infections (11% vs. 10%, 
P=0.787) or individual co-infecting respiratory virus; Table 3.10. However, after multivariate 
analysis - adjusting for potentially confounding risk factors for death such as age categories, 
HIV exposure, malnutrition, hypoxia, very severe pneumonia diagnosis and markers for 
bacterial co-infections - the HRV mono-infection cases had 2.83-fold (aOR 95% CI: 1.44-
5.53) higher case fatality ratio than cases with HRV mixed infections (10% vs. 5%, P=0.002).  
 
We further evaluated for differences between HRV mono-infections compared to other 
individual co-infecting respiratory viruses; Table 3.10. Comparing HRV mono-infection cases 
to those with RSV co-infections (n=121, 28%), cases with HRV mono-infections were older 
(14.1 months) than the HRV-RSV co-infected cases (14.1 months, P<0.001) and less likely to 
present with cough (68% vs. 81%, P=0.004) than the RSV co-infected cases. Furthermore, 
the HRV mono-infected cases were 2.14-fold (aOR 95% CI: 1.62-2.84) more likely to be 
associated with leucocytosis (55% vs. 28%, P=0.011) and had 4.56-fold (aOR 95% CI: 2.34-
18.70) higher case fatality ratio (10% vs. 6%, P=0.007) compared to the RSV co-infected 
cases.  
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Similarly, the HRV-associated cases with PIV co-infection (n=76/431, 18%) were younger 
(11.0 months) than those with HRV mono-infections (14.1 months, P=0.001). Cases with 
HRV mono-infections were 2.25-fold (aOR 95% CI: 1.45-3.37) more likely to have very 
severe pneumonia (34% vs. 17%, P=0.028) but less likely to present with stridor (2% vs. 8%, 
P=0.006) than those with HRV-PIV co-infections. Nonetheless, there were no other 
differences in clinical characteristics or markers for bacterial co-infections including CRP 
≥40mg/mL (22% vs. 13%, P=0.158), microbiologically confirmed pneumococcal pneumonia 
(1% vs. 1%, P=0.709), or leucocytosis (55% vs. 42%, P=0.109) among cases with HRV 
mono-infections and HRV-PIV co-infections. There was however a trend for case with HRV 
mono-infections to have more prolonged hospital stay (>3 days; 51% vs. 38%, P=0.062) but 
no differences in case fatality ratios (10% vs. 9%, P=0.768) compared to the cases with 
HRV-PIV co-infections.  
 
The HRV mono-infected cases were also older (14.1 months) than the HMPV co-infected 
cases (10.3 months, P<0.001), but there were no other differences in clinical characteristics 
and symptoms including very severe pneumonia (34% vs. 27%, P=0.691) and hypoxic (33% 
vs. 16%, P=0.355) compared to among cases with HRV-HMPV co-infections. The cases with 
HRV mono-infections were, however, associated with less tachycardia (50% vs. 59%, 
P=0.049) but more leucocytosis (55% vs. 40%, P=0.041) compared to cases with HRV 
mono-infections. There were no associations for case fatality ratio (10% vs. 2%, P=0.346) 
and prolonged hospital stays >3 days (51% vs. 47%, P=0.762) between the mono-infections 
and HRV-HMPV co-infections.  
 
Additionally, cases with HRV mono-infections were older (14.1 months) than case with 
HRV-HCoV co-infections (9.3 months, P=0.012) but were clinically indistinguishable for all 
other clinical characteristics and symptoms, markers for bacterial co-infections as well as 
hospital stay >3 days (51% vs. 50%, P=0.641) and case fatality ratio (10% for both, 
P=0.881). Similarly, cases with HRV-AdV co-infections and HRV-HBoV were 
indistinguishable from cases with HRV mono-infections including case fatality ratio (5% vs. 
10%, P=0.124 and 6% vs. 10%, P=0.694 respectively); Table 3.10. 
 
 
 73 
 
Abbreviations - HRV: Human rhinovirus; SD: Standard deviation; IQR: Inter quartile range; CXR: Chest X-ray; HIV: Human immunodeficiency virus; HEU: HIV-uninfected 
but HIV exposed; CRP: C-reactive protein; MCPP: Microbiologically confirmed pneumococcal pneumonia; HDP: High Density pneumococcus; NP: Nasopharyngeal.
 
Table 3.10: The demographics and clinical characteristics of cases with HRV mono-infections compared to cases with HRV mixed infections 
  Mono-
infection 
(n=481) 
Any 
coinfection 
(n=431) 
P-valuea HRV-RSV 
(n=121) 
P-valueb HRV-AdV 
(n=108) 
P-valueb HRV-HMPV 
(n=49) 
P-valueb HRV-PIV 
(n=76) 
P-
valueb 
HRV-HBoV 
(n=138) 
P-valueb HRV-HcoV 
(n=56) 
P-
valueb 
Age in months, mean (SD) 14.1 (12.6) 10.3 (11.3) P<0.001 7.0 (8.7) P<0.001 13.9 (9.5) 0.708 10.3 (10.0) P<0.001 11.0 (10.7) 0.001 14.7 (12.5) 0.590 9.3 (7.1) 0.012 
Female, n(%) 196 (41%) 177 (41%) 0.542  54 (45%) 0.271 59 (55%) 0.754 20 (21%) 0.518 28 (37%) 0.784 61 (42%) 0.212 17 (30%) 0.279 
Never breast fed, n(%) 47 (10%) 33 (8%) 0.274 7 (6%) 0.060 15 (14%) 0.310 3 (6%) 0.843 2 (3%) 0.120 10 (7%) 0.405 9 (16%) 0.216 
Under weight, n (%)c 156 (32%) 121 (28%) 0.451  24 (20%) 0.050 39 (36%) 0.461 14 (19%) 0.870 25 (33%) 0.544 30 (22%) 0.042 15 (27%) 0.632 
HEU, n(%)d 52 (11%)  42 (10%)  0.787  14 (12%)  0.992  12 (11%)  0.437  3 (6%)  0.912  5 (7%)  0.888  3 (9%)  0.787  9 (16%)  0.153  
Day care attendance, n(%) 60 (12%) 66 (15%) 0.300 35 (29%) 0.095 15 (14%) 0.828 1 (2%) 0.087 9 (12%) 0.912 13 (9%) 0.531 7 (13%) 0.943 
Smoker in household, n(%) 163 (34%) 177 (41%) 0.061 46 (38%) 0.636 42 (39%) 0.573 20 (41%) 0.610 34 (45%) 0.183 61 (44%) 0.081 25 (45%) 0.278 
Premature birth, n(%)e 57 (12%) 30 (7%) 0.026 8 (7%) 0.169 6 (6%) 0.140 4 (8%) 0.740 3 (4%) 0.11 11 (8%) 0.057 2 (4%) 0.129 
Birth weight, mean (SD) 2.9 (0.6) 2.9 (0.7) 0.447 2.9 (0.6) 0.539 2.8 (0.7) 0.508 3.0 (0.8) 0.224 2.9 (0.6) 0.513 2.9 (0.7) 0.506 3.0 (0.7) 0.403 
Clinical Features:                
Very severe pneumonia, n(%) 163 (34%) 128 (30%) 0.781 42 (35%) 0.419 40 (37%) 0.087 13 (27%) 0.691 13 (17%) 0.028 37 (27%) 0.759 19 (34%) 0.365 
Chest X-ray abnormal, n(%)f 188 (39%) 177 (41%) 0.430 51 (42%) 0.349 40 (37%) 0.995 22 (45%) 0.556 35 (46%) 0.297 58 (42%) 0.475 25 (45%) 0.388 
Supplementary 02 therapy, n(%) 154 (32%) 112 (26%) 0.596  39 (33%) 0.616 23 (21%) 0.307 9 (18%) 0.820 15 (20%) 0.655 32 (23%) 0.448 20 (36%) 0.399 
Hypoxic , n(%) g 156 (33%) 141 (33%) 0.267  56 (47%) 0.625 32 (30%) 0.539 8 (16%) 0.355 17 (22%) 0.806 36 (26%) 0.734 23 (41%) 0.100 
Tachycardia, n(%)h 240 (50%) 199 (46%) 0.662  56 (46%) 0.333 44 (41%) 0.192 29 (59%) 0.049 44 (58%) 0.131 56 (41%) 0.247 21(38%) 0.202 
Tachypnea, n(%)i 405 (84%) 380 (89%) 0.171 106 (88%) 0.108 93 (86%) 0.590 43 (88%) 0.640 68 (89%) 0.371 122 (89%) 0.669 51 (91%) 0.192 
Wheezing, n(%) 214 (45%) 207 (48%) 0.543  54 (45%) 0.053 60 (56%) 0.803 22 (45%) 0.051 32 (43%) 0.053 76 (55%) 0.496 22 (39%) 0.051 
Cough, n(%) 326 (68%) 321 (74%) 0.041 98 (81%) 0.004 79 (73%) 0.306 32 (65%) 0.406 46 (61%) 0.193 109 (79%) 0.288 40 (71%) 0.819 
Lethargic, n(%) 57 (12%) 32 (7%) 0.336  6 (5%) 0.107 14 (13%) 0.498 4 (8%) 0.854 5 (7%) 0.498 11 (8%) 0.926 7 (13%) 0.348 
Fever, n(%)j 369 (77%) 338 (78%) 0.886 93 (77%) 0.96 82 (76%) 0.675 44 (90%) 0.085 65 (86%) 0.230 106 (77%) 0.813 38 (68%) 0.119 
Convulsions, n(%) 30 (6%) 12 (3%) 0.078 2 (2%) 0.065 5 (5%) 0.512 1 (2%) 0.522 1 (1%) 0.185 7 (5%) 0.802 2 (4%) 0.642 
Diarrhoea, n(%) 67 (14%) 51 (12%) 0.411 15 (12%) 0.109 10 (9%) 0.171 6 (12%) 0.840 13 (17%) 0.207 11 (8%) 0.191 9 (16%) 0.551 
Head nodding, n(%) 81 (17%) 81 (19%) 0.437 32 (27%) 0.309 23 (21%) 0.118 8 (16%) 0.497 7 (9%) 0.221 22 (16%) 0.611 9 (16%) 0.951 
Central cyanosis, n(%) 12 (3%) 4 (1%) 0.065  1 (1%) 0.117 0 0.206 1 (2%) 0.854 0 0.312 1 (1%) 0.355 1 (2%) 0.965 
Unable to Feed, n(%) 35 (7%) 23 (5%) 0.245  11 (9%) 0.414 7 (7%) 0.944 1 (2%) 0.309 2 (3%) 0.107 3 (2%) 0.162 3 (5%) 0.802 
Vomiting everything, n(%) 14 (3%) 8 (2%) 0.844 3 (2%) 0.474 4 (4%) 0.531 1 (2%) 0.968 0 0.416 2 (1%) 0.575 3 (5%) 0.138 
Lower chest wall indrawing, n(%) 436 (91%) 410 (95%) 0.105 120 (99%) 0.068 96 (89%) 0.572 48 (98%) 0.261 74 (97%) 0.180 130 (94%) 0.541 51 (91%) 0.587 
Stridor, n(%) 8 (2%) 10 (2%) 0.363 0 0.187 3 (3%) 0.271 0 0.787 6 (8%) 0.006 1 (1%) 0.315 1 (2%) 0.877 
Grunting, n(%) 51 (11%) 64 (15%) 0.109 29 (24%) 0.136 16 (15%) 0.305 4 (8%) 0.965 6 (8%) 0.160 17 (12%) 0.707 7 (13%) 0.055 
Nasal Flaring, n(%) 268 (56%) 231 (54%) 0.831  75 (62%) 0.597 54 (50%) 0.412 24 (49%) 0.444 39 (51%) 0.374 71 (51%) 0.757 30 (54%) 0.909 
Laboratory markers:                               
Leucocytosis, n(%)k 256 (55%) 187 (27%) 0.099 31 (28%) 0.011 55 (54%) 0.357 17 (40%) 0.041 26 (42%) 0.109 74 (57%) 0.489 30 (59%) 0.562 
Neutrophils (%), median (IQR) 53.2 (36-68.2) 48.7 (34-66.1) 0.507 40 (26-52.5) 0.185 59.8 (41.1-74) 0.535 43.9 (36.3-58) 0.423 42.3 (32-61.3) 0.164 54.2 (38.7-70) 0.812 52.8 (40.1-70) 0.174 
Lymphocyte (%), median (IQR) 35.9 (24-49) 41 (24.5-55.6) 0.382 50.7 (39-61.6) 0.037 32.1 (19.6-49) 0.733 45.4 (31-55) 0.320 44.4 (30.7-58) 0.426 22 (13.2-35.1) 0.966 36.85 (20-50.1) 0.230 
Eosinophils (%), median (IQR) 2.3 (0.5-3.5) 1.2 (0.3-3.6) 0.631 0.9 (0.2-2.4) 0.741 1.7 (0.5-3.9) 0.812 0.7 (0.1-2) 0.160 1.1 (0.1-2.9) 0.317 2.2 (0.7-4.5) 0.771 1 (0.4-2.4) 0.795 
CRP ≥40mg/l, n(%)l 108 (22%) 68 (16%) 0.031 22 (18%) 0.242 15 (14%) 0.107 7 (14%) 0.454 10 (13%) 0.158 18 (13%) 0.068 13 (23%) 0.669 
Blood culture positive, n(%)m 18 (4%) 11 (3%) 0.158 2 (2%) 0.052 4 (4%) 0.864 0 0.392 1 (1%) 0.147 4 (3%) 0.764 2 (4%) 0.843 
LytA positive, n(%)n 23 (5%) 19 (7%) 0.584 6 (5%) 0.360 9 (9%) 0.230 4 (9%) 0.260 9 (12%) 0.090 9 (7%) 0.515 3 (6%) 0.930 
MCPP, n(%)o 6 (1%) 2 (0.5%) 0.116 0 0.141 1 (1%) 0.818 0 0.946 1 (1%) 0.709 1 (1%) 0.643 0 0.702 
HDP, n(%)p 63 (13%) 70 (16%) 0.858 14 (12%) 0.073 27 (25%) 0.012 7 (14%) 0.869 18 (24%) 0.171 23 (17%) 0.379 8 (14%) 0.877 
HRV viral load, mean (SD)q 3.8 (0.9) 3.6 (1.0) 0.121 3.3 (0.9) P<0.001 3.7 (1.0) 0.461 3.6 (1.1) 0.303 3.5 (1.1) 0.173 3.7 (0.9) 0.468 3.9 (1.1) 0.160 
Hospital stay >3 days, n(%) 247 (51%) 230 (53%) 0.654 79 (65%) 0.544 53 (49%) 0.677 23 (47%) 0.762 29 (38%) 0.062 70 (51%) 0.625 28 (50%) 0.641 
Case fatality, n(%) 44 (10%) 19 (5%) 0.002 6 (6%) 0.007 5 (5%) 0.124 1 (2%) 0.346 6 (9%) 0.768 8 (6%) 0.694 5 (10%) 0.881 
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P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable. P-values could not 
be calculated for variables where both values are 0, thus cells left blank 
a
 - P-values from logistic regression models for HRV mono-infections compared to all HRV co-infections; 
b
 - P-values from logistic regression models for HRV mono-
infections compared to each HRV co-infection individually; 
c
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference; 
d 
- HEU defined 
as undetectable viral load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative 
children < 7 months of age where documented positive maternal status was required; 
e
 - premature birth defined as <37 weeks gestational age; 
f 
- defined as radiographically 
confirmed endpoint pneumonia or any infiltrates; 
g
 - A child was considered to be hypoxic if 1) a room air pulse-oximetry reading indicated oxygen saturation <90% at the 
two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a room air oxygen saturation reading was not available and the child was on oxygen; 
h
 - 
Tachycardia defined as heart rate >160 beats per minute (bpm) if aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
i
 - 
Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if 
aged >12 months; 
j
 - Fever defined as temperature >38
o
C; 
k
 - Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 
000 cells/uL if age >12 months; 
l 
- CRP defined as levels ≥40mg/mL which are considered to potentially indicate bacterial infection; m - blood culture positive for any 
significant bacteria (non-contaminant); 
n
 - Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
o
 - MCPP defined as S. pneumoniae was cultured from a 
normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or lung aspirate was PCR LytA positive; 
p
 - HDP defined as S. pneumoniae density in 
nasopharynx>6.9 and/or density in whole blood sample>2.2 log10 copies/mL; 
q
 - HRV viral loads in the nasopharynx and expressed in log10 copies/mL. 
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Figure 3.4: Reverse cumulative plot of HRV viral load in the nasopharynx among cases with 
HRV mono-infections and HRV co-infections with other common respiratory viruses. The 
viral loads of HRV mono-infected cases are shown in red. Panel A.) the HRV viral load in 
HRV mono-infected cases and all HRV co-infections combined; Panel B.) the HRV viral load 
in HRV mono-infected cases and HRV co-infections with common respiratory viruses 
separately. 
 
3.1.3.1  HRV in radiographically confirmed cases 
Based on HRV-associated cases being more likely to have a normal chest X-ray (CXR) (60% 
vs. 54%, aOR 1.28, 95% CI: 1.10-1.50, P=0.001); Table 3.7, further analyses were 
undertaken which was limited to pneumonia cases in whom the CXR showed evidence of any 
infiltrate; Table 3.11 and 3.12. Similar trends were observed as for the all pneumonia case 
comparison; however, among children with radiographically confirmed pneumonia, HRV-
associated cases were of similar age (12.3 months) as those without HRV infection (11.2 
months, P=0.260) and did not differ in any other characteristics including presence of 
tachypnea (88% vs. 84%, P=0.362) or convulsions (2% vs. 3%, P=0.544). Additionally, the 
radiographically confirmed HRV-associated cases were still associated with more wheeze 
(46% vs. 28%, P<0.001) and head nodding (21% vs. 16%, P=0.003) than cases without HRV 
infection. Moreover, among the radiologically confirmed cases, HRV-associated cases were 
1.51-fold (aOR 95% CI: 1.16-1.97) more likely to have very severe pneumonia (34%) 
compared to the HRV negative case (28%, P=0.002). The radiologically confirmed cases 
with HRV infections, however, showed no associations with hospital stay of >3 days (58% vs. 
68%, P=0.069), requirement of supplementary oxygen therapy (33% vs. 38%, P=0.317), 
mechanical ventilation (3% vs. 4%, P=0.810) or case fatality ratio (8% vs. 7%, P=0.087) 
compared to cases without HRV infections; Table 3.11.  
 
A B 
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Among the markers for bacterial co-infection, the radiographically confirmed HRV-
associated cases were associated with leucocytosis (58% vs. 45%, P=0.001) and higher 
neutrophil percentages (50.9% vs. 47.1%, P<0.001), but lower lymphocyte percentages 
(37.5% vs. 41.3%, P=0.002) compared to the HRV negative radiographically confirmed 
cases. There were no other differences in markers for bacterial co-infections, including 
CRP≥40mg/mL (27% vs. 30%, P=0.698), blood culture positivity (4% vs. 9%, P=0.801) and 
microbiologically confirmed pneumonia (1% vs. 2%, P=0.378) between the radiographically 
confirmed cases associated with HRV and those without HRV. 
 
 Additionally, similarly to the overall study findings, among other commonly detected 
respiratory viruses the HRV-associated cases were less likely to be co-detected together with 
RSV (14% vs. 30%, P<0.001), Influenza virus (0 vs. 7%, P=0.006), HMPV (6% vs. 12%, 
P=0.001) and PIV (10% vs. 16%, P=0.002) compared to the cases without HRV infections; 
Table 3.11. 
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Table 3.11: The demographical and clinical characteristics of HRV-associated and non-HRV 
cases among children with infiltrates observed on chest X-rays 
  HRV+ HRV-  Unadjusted Adjusted 
 (n=365) (n=1355) P-value OR (95%CI) P-value aOR (95% CI) 
Age in months, mean (SD) 12.3 (11.0) 11.2 (12.3) 0.072  0.260  
Female, n(%) 157 (43%) 593 (44%) 0.798 0.97 (0.77-1.22) 0.795 0.96 (0.76-1.23) 
Never breast fed, n(%) 28 (8%) 161 (12%) 0.024 0.62 (0.41-0.94) 0.121 0.70 (0.44-1.10) 
Under weight, n (%)
a
 127 (35%) 481 (36%) 0.803 0.97 (0.76-1.24) 0.487 0.92 (0.71-1.17) 
HEU, n(%)
b
 43 (12%) 175 (13%) 0.563 0.90 (0.63-1.29) 0.737 1.07 (0.71-1.63) 
Day Care attendance, n(%) 37 (10%) 226 (17%) 0.002 0.56 (0.39-0.81) 0.144 0.70 (0.45-1.13) 
Smoker in household, n(%) 140 (38%) 470 (34%) 0.194  1.17 (0.92-1.49) 0.562 1.08 (0.82-1.41) 
Premature birth, n(%)
c
 41 (11%) 175 (13%) 0.402 0.86 (0.60-1.23) 0.555 0.89 (0.61-1.30) 
Birth weight, mean (SD) 2.8 (0.7) 2.9 (0.7) 0.819  0.825  
Clinical Features       
Very severe pneumonia, n(%) 123 (34%) 381 (28%) 0.038 1.30 (1.01-1.66) 0.002 1.51 (1.16-1.97) 
Supplementary 02 therapy, n(%) 120 (33%) 516 (38%) 0.070 0.80 (0.62-1.02) 0.317 0.83 (0.58-1.19) 
Mechanical ventilation, n(%) 12 (3%) 59 (4%) 0.363 0.75 (0.40-1.40) 0.810 0.92 (0.48-1.79) 
Hypoxic, n(%)
d
 140 (38%) 589 (44%) 0.084 0.82 (0.65-1.03) 0.992 1.00 (0.75-1.32) 
Tachycardia, n(%)
e
 178 (49%) 703 (52%) 0.285 0.88 (0.70-1.11) 0.985 1.00 (0.78-1.28) 
Tachypnea, n(%)
f
 320 (88%) 1130 (84%) 0.101 1.34 (0.95-1.90) 0.362 1.18 (0.82-1.69) 
Wheezing, n(%) 168 (46%) 377 (28%) P<0.001 1.20 (1.73-2.80) P<0.001 1.92 (1.43-2.57) 
Cough, n(%) 268 (73%) 999 (74%) 0.948 0.99 (0.76-1.29) 0.486 0.90 (0.68-1.20) 
Lethargic, n(%) 33 (9%) 119 (9%) 0.842  1.05 (0.70-1.56) 0.778 1.06 (0.70-1.62) 
Fever, n(%)
g
 285 (78%) 1151 (85%) 0.002 0.63 (0.47-0.84) 0.013 0.67 (0.49-0.92) 
Convulsions, n(%) 9 (2%) 45 (3%) 0.416 0.74 (0.36-1.53) 0.544 0.80 (0.38-1.67) 
Diarrhoea, n(%) 46 (13%) 194 (14%) 0.401 0.86 (0.61-1.22) 0.472 1.14 (0.79-1.64) 
Head nodding, n(%) 76 (21%) 217 (16%) 0.031 1.38 (1.03-1.85) 0.003 1.60 (1.17-2.18) 
Central cyanosis, n(%) 11 (3%) 29 (2%) 0.303 1.42 (0.70-2.87) 0.051 2.07 (0.99-4.28) 
Unable to Feed, n(%) 19 (5%) 100 (7%) 0.147 0.69 (0.42-1.14) 0.266 0.75 (0.44-1.25) 
Vomiting everything, n(%) 4 (1%) 30 (2%) 0.182 0.49 (0.17-1.40) 0.219 0.51 (0.18-1.49) 
Lower chest wall indrawing, n(%) 351 (96%) 1291 (95%) 0.470 1.24 (0.69-1.24) 0.512 1.22 (0.67-2.23) 
Stridor, n(%) 4 (1%) 29 (2%) 0.205 0.50 (0.18-1.45) 0.251 0.53 (0.18-1.55) 
Grunting, n(%) 42 (12%) 240 (18%) 0.005 0.61 (0.43-0.86) 0.266 0.79 (0.53-1.19) 
Nasal flaring, n (%) 211 (58%) 832 (61%) 0.190 0.85 (0.68-1.09) 0.123 1.25 (0.95-1.67) 
Markers for bacterial co-infection:     
Leucocytosis, n(%)
h
 198 (58%) 573 (45%) P<0.001 1.66 (1.30-2.10) 0.001 1.51 (1.18-1.94) 
Neutrophils (%), median (IQR) 50.9 (36-68.4) 47.1 (33-60.1) 0.001  P<0.001  
Lymphocytes (%), median (IQR) 37.5 (24-51.3) 41.3 (28.5-55) 0.002  0.002  
Eosinophils (%), median (IQR) 1.1 (0.4-3.4) 0.6 (0.1-2) 0.050  0.113  
CRP ≥40mg/l, n(%)i 99 (27%) 409 (30%) 0.255 0.86 (0.66-1.11) 0.698 0.94 (0.73-1.24) 
Blood culture positive, n(%)
j
 13 (4%) 52 (9%) 0.801 0.92 (0.50-1.72) 0.920 1.03 (0.55-1.93) 
LytA positive, n(%)
k
 20 (6%) 103 (8%) 0.149 0.69 (0.42-1.14) 0.329 0.78 (0.47-1.29) 
MCPP, n(%)
l
 4 (1%) 25 (2%) 0.327 0.59 (0.20-1.70) 0.378 0.62 (0.21-1.81) 
HDP, n(%)
m
       
-Blood 14 (4%) 71 (6%) 0.255 0.71 (0.40-1.28) 0.477 0.80 (0.45-1.46) 
-NP 46 (13%) 189 (14%) 0.504 0.88 (0.68-1.21) 0.525 0.89 (0.62-1.27) 
Viral co-infections in the nasopharynx with:     
-RSV, n(%) 51 (14%) 410 (30%) P<0.001 0.37 (0.27-0.51) P<0.001 0.36 (0.26-0.50) 
-AdV, n(%) 40 (11%) 124 (9%) 0.297 1.22 (0.84-1.78) 0.234 1.27 (0.86-1.87) 
-InFV A-C, n(%)  0 89 (7%) 0.005  0.006  
-HBoV, n(%)  58 (16%) 173 (13%) 0.122 1.29 (0.93-1.78) 0.187 1.25 (0.89-1.75) 
-HMPV, n (%) 22 (6%) 163 (12%) 0.001 0.47 (0.30-0.75) 0.001 0.46 (0.29-0.74) 
-PIV, n(%) 35 (10%) 215 (16%) 0.003 0.56 (0.39-0.82) 0.002 0.54 (0.36-0.79) 
-HCoV, n(%) 25 (7%) 99 (7%) 0.765 0.93 (0.59-1.47) 0.792 0.94 (0.59-1.49) 
Hospital stay >3 days, n(%) 212 (58%) 915 (68%) 0.001 0.66 (0.53-0.84) 0.069 0.77 (0.59-1.05) 
Case fatality ratio, n(%) 27 (8%) 86 (7%) 0.490 1.17 (0.75-1.83) 0.087 1.50 (0.94-2.40) 
Abbreviations - HRV: Human rhinovirus; OR: Odds ratios; aOR: Adjusted odds ratio; CI: Confidence interval; 
SD: Standard deviation; IQR: Inter quartile range; CXR: Chest X-ray; HIV: Human immunodeficiency virus; 
HEU: HIV-uninfected but HIV exposed; CRP: C-reactive protein; MCPP: Microbiologically confirmed 
pneumococcal pneumonia; HDP: High Density pneumococcus; NP: Nasopharyngeal; RSV: Respiratory 
Syncytial Virus, HMPV: human metapneumovirus; AdV: adenovirus; PIV: parainfluenza type 1-4; HBoV: 
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Human Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, 
B and C) ; S. pneumoniae: Streptococcus pneumoniae.
 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - HEU 
defined as HIV-uninfected but HIV-exposed. Undetectable viral load, HIV seronegative in the child with a 
positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative 
children < 7 months of age where documented positive maternal status was required; 
c
 - Premature birth defined 
as gestational age <37 weeks; 
d
 - A child was considered to be hypoxic if 1) a room air pulse-oximetry reading 
indicated oxygen saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other 
sites, or 2) a room air oxygen saturation; 
e
 - Tachycardia defined as heart rate >160 beats per minute (bpm) if 
aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
f 
- 
Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute 
if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 month; 
g 
- Fever defined as temperature 
>38
o
C; 
h
 - Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell 
count >13 000 cells/uL if age >12 months; 
i
 - CRP defined as levels ≥40mg/mL which are considered to 
potentially indicate bacterial infection; 
j
 - Blood culture positive for any significant non contaminate bacteria; 
k
 - 
Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
l
 - MCPP defined when S. pneumoniae was 
cultured from a normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or lung 
aspirate was PCR LytA positive; 
m
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density 
in whole blood sample >2.2 log10 copies/mL. 
 
The same analysis as described in detail in Table 3.10 was undertaken but limited to cases 
with radiographically confirmed cases (any evidence of infiltrates on the CXR); Table 3.12, 
which yielded similar trends to the comparison of overall HRV case analysis of HRV mono-
infected cases and those with other respiratory virus co-infections. 
 
 Overall among the radiological confirmed cases, episodes associated with HRV mono-
infections were also older (mean 13.8) than cases with other co-infecting viruses (10.8, 
P=0.013); including compared to coinfections specifically to RSV (5.4 months, P<0.001), 
HMPV (7.5 months, P=0.003) and PIV (7.5 months, P<0.001). Additionally, the HRV-
associated mono-infected cases were associated with lower birth weight (2.8kg) compared to 
HRV co-infected cases (3.0kgs, P=0.038). Among the radiologically confirmed HRV-
associated cases, HRV mono-infections were no longer associated with higher case fatality 
ratio (9%) than cases with co-infecting viruses (7%, P=0.342); although there remained a 
trend for a higher case fatality ratio among cases with mono-infections than those with RSV 
co-infection (9% vs. 6%, P=0.075); Table 3.9. 
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Table 3.12: The demographics and clinical characteristics of radiologically confirmed cases with HRV mono-infections compared to those with coinfections 
by other respiratory viruses 
  HRV mono-
infections 
(n=188) 
HRV co-
infections 
(n=177) 
P-valuea HRV-RSV 
(n=51) 
P-valueb HRV-AdV 
(n=40) 
P-valueb HRV-HMPV 
(n=22) 
P-valueb HRV-PIV 
(n=35) 
P-valueb HRV-HBoV 
(n=58) 
P-valueb HRV-HCoVs 
(n=25) 
P- 
valueb 
Age in months, mean (SD) 13.8 (11.5) 10.8 (10.5) 0.013 5.4 (6.5) P<0.001 16.4 (10.4) 0.193 7.5 (6.6) 0.003 7.5 (7.8) P<0.001 14.3 (11.3) 0.940 14.44(15.1) 0.878 
Female, n(%) 88 (47%) 69 (39%) 0.316 22 (43%) 0.765 16 (40%) 0.374 7 (32%) 0.771 10 (29%) 0.438 22 (38%) 0.508 9 (36%) 0.452 
Never breast fed, n(%) 10 (5%) 18 (10%) 0.060 6 (12%) 0.459 8 (20%) 0.017 1 (5%) 0.446 1 (3%) 0.670 4 (7%) 0.609 6 (24%) 0.011 
Under weight, n (%)c 73 (39%) 54 (31%) 0.295 11 (22%) 0.085 15 (38%) 0.982 7 (32%) 0.649 12 (34%) 0.656 13 (22%) 0.075 7 (28%) 0.612 
HEU, n(%)d 19 (10%) 24 (14%) 0.498 9 (18%) 0.733 8 (20%) 0.243 2 (9%) 0.567 3 (9%) 0.954 5 (9%) 0.627 4 (16%) 0.760 
Day Care attendance, n(%) 18 (10%) 19 (11%) 0.714 10 (20%) 0.099 4 (10%) 0.935 0  0.129 3 (9%) 0.852 3 (5%) 0.294 3 (12%) 0.702 
Smoker in household, n(%) 65 (35%) 75 (42%) 0.136 20 (40%) 0.556 13 (33%) 0.785 9 (41%) 0.568 19 (55%) 0.348 28 (48%) 0264 12 (48%) 0.196 
Premature birth, n(%)e 24 (13%) 17 (10%) 0.633 5 (10%) 0.408 1 (3%) 0.135 1 (5%) 0.483 1 (3%) 0.163 8 (14%) 0.907 2 (8%) 0.748 
Birth weight, mean (SD) 2.8 (0.7) 3.0 (0.7) 0.038 2.8 (0.7) 0.519 3.0 (0.5) 0.117 3.2 (0.5) 0.159 2.9 (0.4) 0.301 3.1 (0.7) 0.087 3.0 (0.8) 0.207 
Clinical Features:                
Very severe pneumonia, n(%) 64 (34%) 59 (33%) 0.648 19 (37%) 0.903 14 (35%) 0.456 7 (32%) 0.365 6 (34%) 0.080 19 (33%) 0.229 11 (44%) 0.150 
Supplementary 02 therapy, n(%) 61 (32%) 59 (33%) 0.415 22 (43%) 0.602 13 (33%) 0.892 4 (18%) 0.950 7 (20%) 0.273 16 (28%) 0.788 11 (44%) 0.117 
Mechanical ventilation, n(%) 6 (3%) 6 (3%) 0.915 2 (4%) 0.797 1 (3%) 0.818 0 0.395 1 (3%) 0.917 1 (2%) 0.557 3 (12%) 0.040 
Hypoxic, n(%)f 68 (36%) 72 (41%) 0.096 30 (59%) 0.399 16 (40%) 0.173 4 (18%) 0.978 8 (23%) 0.653 18 (31%) 0.589 12 (48%) 0.144 
Tachycardia, n(%)g 91 (48%) 87 (49%) 0.445 22 (43%) 0.706 20 (50%) 0.721 15 (68%) 0.104 20 (57%) 0.273 27 (47%) 0.840 9 (36%) 0.280 
Tachypnea, n(%)h 258 (84%) 162 (92%) 0.023 45 (88%) 0.112 36 (90%) 0.369 22 (100%) 0.146 33 (94%) 0.123 53 (93%) 0.188 23 (92%) 0.166 
Wheezing, n(%) 87 (47%) 81 (46%) 0.958 22 (43%) 0.212 24 (60%) 0.347 8 (36%) 0.828 14 (41%) 0.695 29 (51%) 0.599 9 (36%) 0.262 
Cough, n(%) 133 (71%) 135 (76%) 0.280 41 (80%) 0.181 31 (78%) 0.951 14 (64%) 0.531 20 (57%) 0.683 46 (79%) 0.586 20 (80%) 0.477 
Lethargic, n(%) 18 (10%) 15 (8%) 0.497 5 (10%) 0.435 3 (8%) 0.943 2 (9%) 0.506 2 (6%) 0.425 6 (10%) 0.195 2 (8%) 0.806 
Fever, n(%)i 145 (77%) 140 (79%) 0.772 39 (76%) 0.861 33 (83%) 0.218 18 (82%) 0.556 29 (83%) 0.501 48 (83%) 0.345 17 (68%) 0.269 
Convulsions, n(%) 6 (3%) 3 (2%) 0.637 2 (4%) 0.771 0 0.755 0 0.394 0 0.283 3 (5%) 0.176 0 0.373 
Diarrhoea, n(%) 22 (12%) 24 (14%) 0.845 9 (18%) 0.904 3 (8%) 0.538 3 (14%) 0.805 6 (17%) 0.374 5 (9%) 0.699 4 (16%) 0.717 
Head nodding, n(%) 36 (19%) 40 (23%) 0.551 14 (27%) 0.797 10 (25%) 0.279 4 (18%) 0.415 4 (11%) 0.254 12 (21%) 0.360 7 (28%) 0.401 
Central cyanosis, n(%) 8 (4%) 3 (2%) 0.166 0 0.169 0 0.345 1 (5%) 0.803 0 0.214 1 (2%) 0.545 1 (4%) 0.974 
Unable to Feed, n(%) 11 (6%) 8 (5%) 0.794 5 (10%) 0.657 2 (5%) 0.421 0 0.244 0 0.142 2 (3%) 0.578 2 (8%) 0.209 
Vomiting everything, n(%) 4 (2%) 0 0.205 0 0.813 0 0.503 0 0.490 0 0.384 0 0.263 0 0.462 
Lower chest wall indrawing, n(%) 179 (95%) 172 (97%) 0.437 51 (100%) 0.749 39 (98%) 0.388 22 (100%) 0.294 35 (100%) 0.186 54 (93%) 0.631 24 (96%) 0.733 
Stridor, n(%) 2 (1%) 2 (1%) 0.791 0 0.450 1 (3%) 0.677 0 0.627 1 (3%) 0.625 1 (2%) 0.853 0 0.604 
Grunting, n(%) 17 (9%) 25 (14%) 0.188 9 (18%) 0.547 4 (10%) 0.789 1 (5%) 0.514 1 (3%) 0.058 7 (12%) 0.399 6 (24%) 0.056 
Nasal Flaring, n(%) 106 (56%) 105 (59%) 0.963 34 (67%) 0.722 23 (58%) 0.515 14 (64%) 0.632 20 (57%) 0.689 29 (50%) 0.677 19 (76%) 0.120 
Laboratory markers:                
Leucocytosis, n(%)j 113 (62%) 85 (53%) 0.533 16 (32%) 0.081 24 (65%) 0.796 8 (47%) 0.965 11 (41%) 0.388 34 (64%) 0.954 15 (65%) 0.565 
Neutrophils (%), median (IQR) 53.4 (38-68.3) 47.3 (32.8-66.0) 0.332 41.2 (26.3-53.8) 0.071 60.5 (43.1-73) 0.867 41.5 (38.7-53) 0.497 38.8 (31-55) 0.077 52.4 (41-71) 0.892 58.1 (41-71) 0.783 
Lymphocytes (%), median (IQR) 34.2 (22.5-48) 41.8 (26.1-55.7) 0.205 49.2 (33.5-59.4) 0.126 31.7 (20.5-46) 0.846 47.8 (35.6-53) 0.407 48.4 (34-58) 0.196 35.7 (21-45.5) 0.775 33.1 (20-51.4) 0.981 
Eosinophils (%), median (IQR) 1.1 (0.6-3.9) 1.1 (0.3-3) 0.542 0.75 (0.2-2.4) 0.805 1.85 (0.9-3.7) 0.902 0.2 (0.1-0.9) 0.101 1.2 (0.4-2.6) 0.430 1.3 (0.4-5) 0.435 1 (0.1-2.4) 0.335 
CRP >40mg/l, n(%)k 51 (27%) 48 (27%) 0.914 17 (33%) 0.328 8 (20%) 0.439 7 (32%) 0.925 8 (23%) 0.363 14 (24%) 0.388 9 (36%) 0.512 
Blood culture positive, n(%)l 8 (4%) 5 (3%) 0.391 1 (2%) 0.322 2 (5%) 0.876 0 0.324 0 0.214 2 (4%) 0.388 1 (4%) 0.794 
LytA positive, n(%)m 11 (6%) 9 (5%) 0.345 0 0.130 2 (5%) 0.885 1 (6%) 0.184 4 (11%) 0.845 5 (9%) 0.723 1 (5%) 0.434 
MCPP, n(%)n 3 (2%) 1 (1%) 0.247 0 0.387 0 0.817 0 0.551 0 0.452 1 (2%) 0.933 0 0.533 
HDP, n(%)o                
-Blood 6 (3%) 8 (5%) 0.471 0 0.208 1 (3%) 0.856 1 (6%) 0.615 4 (11%) 0.783 5 (9%) 0.409 1 (5%) 0.757 
-NP 24 (13%) 22 (12%) 0.923 4 (8%) 0.332 9 (23%) 0.112 1 (5%) 0.486 9 (16%) 0.591 9 (16%) 0.591 3 (12%) 0.914 
HRV viral load, Mean (SD)p 3.77 (0.92) 3.68 (1.04) 0.977 3.45 (0.96) 0.068 3.91 (1.05) 0.535 3.35 (1.14) 0.941 3.77 (0.92) 0.935 3.77 (0.84) 0.767 4.03 (1.22) 0.071 
Hospital stay >3 days, n(%) 111 (59%) 101 (57%) 0.996 39 (76%) 0.681 19 (48%) 0.247 8 (36%) 0.794 15 (43%) 0.524 30 (52%) 0.743 13 (52%) 0.538 
 80 
 
Case fatality ratio, n(%) 16 (9%) 11 (7%) 0.342 3 (6%) 0.075 3 (8%) 0.870 1 (6%) 0.817 3 (9%) 0.786 6 (12%) 0.257 3 (13%) 0.771 
Abbreviations - HRV: Human rhinovirus; SD: Standard deviation; IQR: Inter quartile range; CXR: Chest X-ray; HIV: Human immunodeficiency virus; HEU: HIV-uninfected 
but HIV exposed; CRP: C-reactive protein; MCPP: Microbiologically confirmed pneumococcal pneumonia; HDP: High Density pneumococcus; NP: Nasopharyngeal.
 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable. P-values could not 
be calculated for variables where both values are 0, thus cells left blank. 
a
 - P-values from logistic regression models for HRV mono-infections compared to all HRV co-infections; 
b
 - P-values from logistic regression models for HRV mono-
infections compared to each HRV co-infection individually; 
c
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference; 
d 
- HEU defined 
as undetectable viral load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative 
children < 7 months of age where documented positive maternal status was required; 
e
 - premature birth defined as <37 weeks gestational age; 
f 
- A child was considered to be 
hypoxic if 1) a room air pulse-oximetry reading indicated oxygen saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a 
room air oxygen saturation reading was not available and the child was on oxygen; 
g
 - Tachycardia defined as heart rate >160 beats per minute (bpm) if aged <11 months, 
heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
h
 - Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, 
respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
i
 - Fever defined as temperature >38
o
C; 
j
 - Leucocytosis 
defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 000 cells/uL if age >12 months; 
k 
- CRP defined as levels ≥40mg/mL which 
are considered to potentially indicate bacterial infection; 
l
 - blood culture positive for any significant bacteria (non-contaminant); 
m
 - Blood sample positive for S. pneumoniae 
colonisation by LytA PCR; 
n
 - MCPP defined as S. pneumoniae was cultured from a normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or lung 
aspirate was PCR LytA positive; 
o
 - HDP defined as S. pneumoniae density in nasopharynx>6.9 and/or density in whole blood sample>2.2 log10 copies/mL; 
p
 - HRV viral loads 
in the nasopharynx and expressed in log10 copies/mL. 
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3.1.4.2  HRV-associated mortality in the cases 
The case fatality ratio and requirement for mechanical ventilation of HRV-associated cases 
(8%, n=63/826 and 1%, n=3/912 respectively) was not different compared to HRV-negative 
cases (8%, n=215/2659, P=0.300 and 1%, n=23/2 964, P=0.172 respectively). Similarly, 
among the radiologically confirmed cases, the case fatality ratio among HRV-associated cases 
(8%, n=27/330) was similar to those in whom HRV was not identified (7%, n=86/1 217, 
P=0.096), as was the requirement for mechanical ventilation (1%, n=3/365 vs. 1%, n=16/1 
355, P=0.810).  
 
Of the 63 HRV-associated fatalities, 75% (n=47) occurred during hospitalisation. In addition, 
the remainder occurred within 30 days of discharge, including 19% (n=12) who were well 
when discharged, 5% (n=3) who were discharged moribund or against medical advice and 2% 
(n=1) who had been transferred to another care facility. Case fatalities with HRV infections 
were seen at all sites except Thailand and in all age groups, ranging from 5% in South Africa 
to 26% in Zambia. The most deaths occurred in the infants less than 5 months of age (54%, 
n=34/63) and the least deaths in the children older than 1 year of age (22%, n=14/63).  
 
A case-case comparison at all sites to ascertain factors that might help distinguish between 
HRV positive cases that resulted in death compared to HRV positive cases that survived as 
well as distinguish between mortalities in HRV-associated cases compared to mortalities in 
cases without HRV infections was performed; Table 3.13. The HRV-associated deaths were 
younger than the HRV-associated cases that survived (mean 7.9 vs. 13.9 months, P=0.002) 
and they were 5.75-fold (aOR 95% CI: 3.17-10.42) more likely to be underweight (63% vs. 
27%, P<0.001). There were no other differences between the HRV-associated deaths and 
survivors such as attending day-care facilities (30% vs. 13%, P=0.101), having a smoker 
leaving in the household (32% vs. 38%, P=0.487) or premature birth (13% vs. 9%, P=0.556). 
There was, however, an association for the HRV-associated cases that died to have been born 
at lower birth weight than cases that survived (2.7Kgs vs. 2.9Kgs, P=0.028). 
 
The HRV-associated deaths were also 4.75-fold (aOR 95% CI: 2.75-8.20) more likely to 
present with very severe pneumonia (67% vs. 30%, P<0.001) and 4.06-fold (aOR 95% CI: 
2.38-6.91) more likely to be hypoxic (62% vs. 29%, P<0.001) compared to the cases that 
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survived. There were, however, no differences between the requirement of oxygen therapy 
(33% vs. 25%, P=0.146) or mechanical ventilation (2% vs. 1%, P=0.989). Additionally, the 
HRV-associated deaths were not associated with more abnormal chest X-rays which was 
defined as primary end point consolidation or any infiltrates (43% vs. 40%, P=0.216). The 
HRV positive case deaths were however more likely to present with lethargy (35% vs. 8%, 
P<0.001), concurrent diarrhoea (38% vs. 10%, P<0.001), central cyanosis (11% vs. 1%, 
P=0.002) and were unable to feed (30% vs. 5%, P<0.001) compared to the HRV positive 
cases that recovered. Conversely, the HRV positive case survivors were more likely to be 
associated with wheezing (51% vs. 8%, P=0.001), coughing (72% vs. 51%, P=0.044) and 
lower chest wall indrawing (93% vs. 79%, P=0.001) compared to the HRV-associated deaths. 
 
For markers of potential bacterial co-infections, the HRV-associated deaths were 6.59-fold 
(aOR 95% CI: 2.69-16.10) more likely to have positive blood cultures (19% vs. 2%, P<0.001) 
and 8.67-fold (aOR 95% CI: 1.80-41.73) more likely to have microbiologically confirmed 
pneumococcal pneumonia (6% vs. 0.5%, P=0.007) compared to the HRV-associated case 
survivors. Additionally, the HRV-associated deaths were more likely to present with fever 
(90% vs. 78%, P=0.033), CRP levels ≥40mg/mL (35% vs. 17%, P=0.022) and high 
colonisation densities of S. pneumoniae in the nasopharynx (>6.9 log10 copies/mL) which was 
shown to be a predictor of pneumococcal pneumonia in the PERCH study [117] (27% vs. 
23%, P=0.021) compared to the HRV-associated survivors. The HRV-associated deaths were 
also 2.75-fold (aOR 95% CI: 1.42-4.92) more likely to have HRV as the only respiratory virus 
detected in the nasopharynx compared to survivors (70% vs. 51%, P=0.002). Upon 
comparison of the other common respiratory viruses there were no specific associations 
observed between HRV co-infections and mortality; Table 3.13. 
 
The HRV-associated deaths fatalities were indistinguishable from the HRV negative case 
fatalities for all demographics, risk factors for infection, clinical signs and symptoms as well 
as markers for bacterial and viral co-infections. The only trend that was evident was that the 
HRV-associated deaths were less likely to be HIV-exposed but uninfected (8% vs. 16%, 
P=0.050), but more likely to have high colonisation densities of S. pneumoniae in the 
nasopharynx (>6.9 log10 copies/mL) (27% vs. 15%, P=0.035) compared to the HRV negative 
deaths; Table 3.13. 
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Table 3.13: The demographical and clinical characteristics of the pneumonia cases by mortality and HRV infection status 
  HRV Case 
fatalities 
(n=63) 
HRV Case 
recovery 
(n=763) 
Unadjusted 
P-value
a
    OR (95%CI) 
Adjusted  
P-value
a     
aOR
 
(95% CI) 
All other 
fatalities 
(n=215) 
Unadjusted 
P-value
b
  OR (95%CI) 
Adjusted 
P-value
b
 aOR(95%CI) 
Age in months, mean (SD) 7.9 (7.80) 13.9 (12.36) 0.0002  0.001  9.25 (9.81) 0.332  0.228  
Female, n(%) 35 (56%) 301 (39%) 0.014 1.91 (1.14-3.22) 0.034  1.83 (1.05-3.19) 114 (53%) 0.723 1.10 (0.63-1.95) 0.798 1.08 (0.61-1.91) 
Never breast fed, n(%) 8 (13%) 63 (8%) 0.231 1.62 (0.74-3.54) 0.065 2.41 (0.95-6.15) 20 (9%) 0.433 1.42 (0.59-3.39) 0.361 1.54 (0.61-3.93) 
Under weight, n (%)
c
 40 (63%) 207 (27%) P<0.001 4.67 (2.73-7.99) P<0.001 5.75 (3.17-10.42) 135 (63%) 0.919 1.04 (0.58-1.85) 0.955 1.01 (0.56-1.85) 
HEU, n (%)
d
 5 (8%) 62 (8%) 0.958 0.97 (0.38-2.52) 0.561 0.73 (0.25-2.13) 35 (16%) 0.105 0.44 (0.17-1.18) 0.050 0.34 (0.11-0.99) 
Day Care attendance, n(%) 19 (30%) 102 (13%) 0.036 1.59 (1.03-2.45) 0.101 0.85 (0.36-2.00) 55 (26%) 0.790 0.95 (0.65-1.40) 0.885 0.97 (0.64-1.47) 
Smoker in household, n(%) 20 (32%) 286 (38%) 0.377 0.78 (0.45-1.34) 0.487  1.19 (0.72-1.97) 48 (23%) 0.120 1.64 (0.88-3.04) 0.093 1.79 (0.90-3.53) 
Premature birth, n(%)
e
 8 (13%) 71 (9%) 0.326 083 (0.56-1.21) 0.556 0.90 (0.64-1.27) 23 (11%) 0.245 0.77 (0.49-1.20) 0.204 0.74 (0.46-1.18) 
Birth weight, mean (SD) 2.7 (0.7) 2.9 (0.6) 0.097  0.028  2. 8 (0.6) 0.219  0.195  
Clinical Features:            
Very severe pneumonia, n(%) 42 (67%) 226 (30%) P<0.001 4.75 (2.75-8.20) P<0.001 3.21 (1.76-5.84) 139 (65%) 0.768 1.10 (0.60-1.98) 0.766 1.09 (0.59-2.03) 
Chest X-ray abnormal, n(%)
f 
27 (43%) 303 (40%) 0.624 1.14 (0.68-1.92) 0.216  1.43 (0.81-2.49) 86 (40%) 0.685 1.13 (0.64-1.99) 0.872 1.05 (0.57-1.92) 
Alveolar consolidation, n(%) 21 (33%) 116 (15%) P<0.001 2.78 (1.59-4.88) 0.001 2.77 (1.49-5.16) 59 (27%) 0.365 1.32 (0.72-2.42) 0.421 1.29 (0.69-2.42) 
Supplementary 02 therapy, n(%) 21 (33%) 193 (25%) 0.340 1.20 (0.83-1.74) 0.146 2.81 (1.22-6.50) 94 (44%) 0.143 0.64 (0.36-1.16) 0.101 0.51 (0.22-1.14) 
Mechanical ventilation, n(%) 1 (2%) 11 (1%) 0.926 1.10 (0.14-8.68) 0.989 1.01 (0.10-9.38) 16 (7%) 0.123 0.20 (0.03-1.55) 0.103 0.15 (0.02-1.46) 
Hypoxic, n(%)
g
 39 (62%) 217 (29%) P<0.001 4.06 (2.38-6.91) P<0.001 3.92 (2.06-7.44) 121 (56%) 0.427 1.26 (0.71-2.24) 0.338 1.36 (0.72-2.56) 
Tachycardia, n(%)
h
 33 (52%) 353 (46%) 0.351  1.28 (0.76-2.14) 0.563 0.85 (0.49-1.48) 109 (51%) 0.840 1.06 (0.60-1.86) 0.808 1.07 (0.6-1.90) 
Tachypnea, n(%)
i
 53 (84%) 655 (86%) 0.651 0.85 (0.42-1.72) 0.923 0.96 (0.45-2.06) 171 (81%) 0.625 1.21 (0.57-2.58) 0.339 1.47 (0.67-3.26) 
Wheezing, n(%) 5 (8%) 390 (51%) P<0.001 0.08 (0.03-0.21) 0.001 0.17 (0.06-0.46) 21 (10%) 0.664 0.80 (0.29-2.21) 0.612 0.73 (0.22-2.42) 
Cough, n(%) 32 (51%) 552 (72%) P<0.001 0.39 (0.23-0.65) 0.049 0.56 (0.32-0.98) 94 (44%) 0.778 1.06 (0.73-1.53) 0.335 1.33 (0.74-2.41) 
Lethargic, n(%) 22 (35%) 62 (8%) P<0.001 6.07 (3.40-10.83) P<0.001 5.91 (2.99-11.69) 75 (35%) 0.996 1.00 (0.56-1.81) 0.895 1.04 (0.55-1.95) 
Fever, n(%)
j
 57 (90%) 592 (78%) 0.021 2.75 (1.16-6.50) 0.033 2.65 (1.08-6.50) 184 (86%) 0.318 1.60 (0.64-4.03) 0.200 1.91 (0.71-5.13) 
Convulsions, n(%) 9 (14%) 33 (4%) 0.001 3.67 (1.67-8.08) 0.014 2.98 (1.24-7.10) 29 (13%) 0.871 1.07 (0.48-2.40) 0.716 1.17 (0.49-2.80) 
Diarrhoea, n(%) 24 (38%) 78 (10%) P<0.001 5.40 (3.08-9.45) P<0.001 3.35 (1.80-6.23) 64 (30%) 0.213 1.45 (0.81-2.61) 0.105 1.66 (0.89-3.08) 
Head nodding, n(%) 12 (19%) 136 (18%) 0.815 1.08 (0.56-2.08) 0.296 0.68 (0.34-1.39) 52 (24%) 0.395  0.74 (0.37-1.49) 0.234 0.64 (0.31-1.33) 
Central cyanosis, n(%) 7 (11%) 6 (1%) P<0.001 15.77 (5.13-48.5) 0.002 7.48 (2.09-26.80) 26 (12%) 0.823 0.90 (0.37-2.19) 0.848 0.91 (0.36-2.29) 
Unable to Feed, n(%) 19 (30%) 36 (5%) P<0.001 8.70 (4.62-16.38) P<0.001 4.27 (2.10-8.66) 60 (28%) 0.743 1.11 (0.60-2.05) 0.851 1.06 (0.57-1.99) 
Vomiting everything, n(%) 4 (6%) 18 (2%) 0.070 2.80 (0.92-8.56) 0.061 3.32 (0.95-11.70) 9 (4%) 0.478 1.55 (0.46-5.21) 0.349 1.85 (0.51-6.72) 
Lower chest wall indrawing, n(%) 50 (79%) 713 (93%) P<0.001 0.27 (0.14-0.53) 0.001 9.27 (0.12-0.58) 187 (87%) 0.137 0.58 (0.28-1.19) 0.099 0.51 (0.23-1.13) 
Stridor, n(%) 1 (2%) 12 (2%) 0.801 0.84 (0.21-3.34) 0.610 0.57 (0.06-4.93) 2 (1%) 0.687 0.81 (0.31-2.17) 0.640 1.80 (0.15-21.44) 
Grunting, n(%) 21 (33%) 85 (11%) 0.102 1.21 (0.96-1.51) 0.581 1.23 (0.59-2.54) 88 (41%) 0.230 0.71 (0.40-1.24) 0.227 0.67 (0.35-1.28) 
Nasal flaring, n (%) 42 (67%) 401 (53%) 0.033 1.80 (1.05-3.11) 0.839 0.94 (0.51-1.74) 146 (68%) 0.435 0.83 (0.53-1.32) 0.863 0.94 (0.49-1.82) 
Laboratory markers:            
Leucocytosis, n(%)
k
 27 (46%) 371 (52%) 0.384 0.79 (0.46-1.34) 0.097 1.66 (0.91-3.03) 84 (40%) 0.460 1.25 (0.70-2.23) 0.217 1.47 (0.79-2.72) 
Neutrophils (%), median (IQR) 48 (30.4-65) 51.3 (36.1-69) 0.138  0.950  47.9 (32.4-64) 0.826  0.945  
Lymphocytes (%), median (IQR) 40 (28-58.3) 37 (23.4-51.4) 0.096  0.618  40 (26.3-55) 0.449  0.539  
Eosinophils (%), median (IQR) 0.9 (0-2) 1.5 (0.5-3.9) 0.021  0.329  0.8 (0.1-3.15) 0.066  0.059  
CRP >40mg/l, n(%)
l
 22 (35%) 131 (17%) 0.001 2.58 (1.49-4.49) 0.022 1.99 (1.10-3.59) 65 (30%) 0.481 1.24 (0.68-2.24) 0.379 1.33 (0.71-2.48) 
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Blood culture positive, n(%)
m
 12 (19%) 15 (2%) P<0.001 11.58 (5.15-26.0) P<0.001 6.59 (2.69-16.10) 32 (15%) 0.453 1.33 (0.64-2.75) 0.481 1.31 (0.61-2.81) 
LytA positive, n(%)
n
 8 (14%) 39 (5%) 0.013 2.80 (1.24-6.30) 0.183 1.83 (0.75-4.45) 20 (10%) 0.471 1.38 (0.57-3.32) 0.520 1.35 (0.55-3.33) 
MCPP, n(%)
o
 4 (6%) 4 (0.5%) P<0.001 12.69 (3.09-52.1) 0.007 8.67 (1.80-41.73) 7 (3%) 0.287 1.99 (0.56-7.01) 0.342 1.77 (0.48-6.50) 
HDP, n(%)
p
            
-Blood 7 (12%) 22 (3%) 0.001 4.36 (1.78-10.7) 0.056 2.65 (0.98-7.22) 15 (8%) 0.316 1.62 (0.63-4.19) 0.356 1.59 (0.59-4.28) 
-NP 17 (27%) 88 (23%) 0.001 2.83 (1.56-5.16) 0.021 2.21 (1.12-4.32) 33 (15%) 0.037 2.04 (1.05-3.97) 0.035 2.17 (0.16-4.47) 
HRV viral load, mean (SD)
q
 3.52 (0.93) 3.71 (0.94) 0.122  0.889          
HRV mono-infection, n(%) 44 (70%) 391 (51%) 0.004 2.75 (1.37-5.52) 0.002 2.64 (1.42-4.92)      
Viral co-infections in the nasopharynx with:           
-RSV, n(%) 6 (10%) 102 (14%) 0.387 0.68 (0.29-1.62) 0.017 0.31 (0.12-0.81) 16 (7%) 0.591 1.31 (0.49-3.50) 0.772 1.16 (0.42-3.20) 
-AdV, n(%) 5 (8%) 97 (13%) 0.273 0.59 (0.23-1.51) 0.401 0.65 (0.23-1.79) 26 (12%) 0.360 0.63 (0.23-1.71) 0.433 0.66 (0.23-1.86) 
-InFV A-C, n(%) 0 4 (1%) 0.849  0.668  13 (6%) 0.140  0.185  
-HBoV, n(%)  8 (13%) 117 (15%) 0.575 0.80 (0.37-1.71) 0.730 1.16 (0.49-2.72) 23 (11%) 0.658 1.21 (0.51-2.87) 0.680 1.20 (0.50-2.90) 
-HMPV, n(%) 1 (2%) 41 (5%) 0.218 0.28 (0.04-2.10) 0.309 0.34 (0.04-2.70) 11 (5%) 0.252 0.30 (0.04-2.36) 0.187 0.24 (0.03-1.99) 
-PIV, n(%) 6 (10%) 61 (8%) 0.670 1.21 (0.50-2.92) 0.682 1.22 (0.46-3.21) 19 (9%) 0.867 1.09 (0.41-2.85) 0.836 1.11 (0.40-3.02) 
-HCoV, n(%) 5 (8%) 47 (6%) 0.578  1.31 (0.50-3.42) 0.216 1.94 (0.70-5.54) 22 (10%) 0.589 0.75 (0.27-2.08) 0.554 0.73 (0.26-2.06) 
Abbreviations - HRV: Human rhinovirus; SD: Standard deviation; IQR: Inter quartile range; CXR: Chest X-ray; HIV: Human immunodeficiency virus; HEU: HIV-uninfected 
but HIV exposed; CRP: C-reactive protein; MCPP: Microbiologically confirmed pneumococcal pneumonia; HDP: High Density pneumococcus; NP: Nasopharyngeal.
 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable. Odds ratio could 
not be calculated for continuous variables or variables with 0 values, thus cells left blank. 
a
 - P-values from logistic regression models for HRV-associated mortalities compared to all HRV associated cases that survived; 
b
 - P-values from logistic regression models 
for HRV-associated case mortalities compared to all other case fatalities; 
c
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;            
d 
- HEU defined as undetectable viral load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except 
for seronegative children < 7 months of age where documented positive maternal status was required; 
e
 - premature birth defined as <37 weeks gestational age; 
f 
- Defined as 
primary end point pneumonia or any infiltrates observed on the chest X-rays; 
g
 - A child was considered to be hypoxic if 1) a room air pulse-oximetry reading indicated 
oxygen saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a room air oxygen saturation reading was not available and the 
child was on oxygen; 
h
 - Tachycardia defined as heart rate >160 beats per minute (bpm) if aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if 
aged 36-59 months; 
i
 - Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate 
>40 breaths/minute if aged >12 months; 
j
 - Fever defined as temperature >38
o
C; 
k
 - Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white 
blood cell count >13 000 cells/uL if age >12 months; 
l 
- CRP defined as levels ≥40mg/mL which are considered to potentially indicate bacterial infection; m - blood culture 
positive for any significant bacteria (non-contaminant); 
n
 - Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
o
 - MCPP defined as S. pneumoniae was 
cultured from a normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or lung aspirate was PCR LytA positive; 
p
 - HDP defined as S. pneumoniae 
density in nasopharynx>6.9 and/or density in whole blood sample>2.2 log10 copies/mL; 
q
 - HRV viral loads in the nasopharynx and expressed in log10 copies/mL. 
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3.2 DISCUSSION 
In children 1-59 months of age hospitalised with severe (n=2 630) and very severe (n=1 246) 
pneumonia, significantly higher rates of HRV detection (24%) were noted when compared to 
rates (21%, P<0.001) among community control children (n=4 977). However, in terms of 
clinical severity - such as hypoxia, requiring mechanical ventilation and very severe 
pneumonia diagnosis - there were no significant differences among HRV-associated cases and 
cases without HRV infections suggesting that there were no obvious differences in clinical 
presentation of respiratory viruses causing severe LRTI. There was however evidence that 
HRV-bacterial co-infections resulted in higher case fatality ratios. To date, this is the largest 
multi-country, case-control surveillance study providing a detailed clinical analysis of HRV 
epidemiology in the developing world.  
 
Among the community control population over the full two-year period, HRV detection 
(21%) was ubiquitous which is consistent with other African and Southeast Asian studies 
which have reported HRV prevalence of between 12-50% in children without severe 
respiratory illness [54, 83, 92, 93, 95, 99, 106]. These studies reporting on HRV detection 
among a control population often only enrolled very limited numbers of controls with all of 
the studies enrolling less than half of the number of controls compared to the number of cases, 
the highest number of controls (n=369 compared to 810 cases) were enrolled during a study 
conducted in Kenya [95]. Furthermore, in the majority of these studies the controls were a 
convenient sample of children presenting for routine immunisation at local clinics [54, 83, 92, 
93, 106] thus they might not provide a true representation of the actual community.  
 
Additionally, our study also analysed the prevalence of HRV between asymptomatic controls 
at the time of sampling and controls with RTI that did not warrant hospitalisation; and found 
that controls with RTI symptoms were 1.55-fold more likely to have HRV detected in the 
nasopharynx. The high prevalence of HRV detection in asymptomatic controls (20%) was in 
concordance with other studies (10-24%); [31, 47, 50, 51, 53, 122, 123] and could potentially 
be linked to the highly sensitive detection capabilities of PCR and the prolonged shedding 
periods of HRV. In a longitudinal study of infants, following HRV RTI, shedding of virus 
was evident for more than 30 days in 4.5% of the cases; although the majority of the episodes 
were negative within 7 days of infection [124]. In our study only a single sample was taken on 
enrolment, and controls were not interviewed about disease episodes more than three days 
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prior to enrolment, thus we were unable to determine the temporal association of detection of 
HRV in relation to the onset of current or previous RTI symptoms. Additionally, controls 
were not followed up to determine whether they became ill post sampling, thus we could not 
rule out the possibility they were in the incubation period of disease at the time of sampling. 
This was seen in a Finnish study which enrolled children under the age of 15 years with acute 
wheezing (n=161) as well as surgical controls (n=79). They found that HRV prevalence was 
16% and 8% in the cases and controls respectively. Although the controls were asymptomatic 
at the time of sampling; 5 of the 13 HRV-positive controls went on to develop respiratory 
symptoms in the following week [51]. 
 
Thus, although the detection of HRV in respiratory samples does not necessarily infer 
causality with any concurrent illness/symptom, the higher detection prevalence of HRV in 
controls with RTI than those who are asymptomatic infers a causal association between HRV 
and respiratory illness. Furthermore, in the case-control comparison of HRV in this study, 
HRV detection was more prevalent among cases (24%) compared to controls (21%); and after 
adjustment for multiple potentially confounding variables, including presence of other 
respiratory viruses, the cases were 1.45-fold (95% CI: 1.29-1.62, P<0.001) more likely to 
have HRV detected compared to community controls. Moreover, in the 12-59 month age 
group, the odds were even higher with the hospitalised cases having a 2.08-fold (95% 1.75-
2.47, P<0.001) increased odds of HRV detection compared to controls. Conversely, among 
infants the HRV prevalence was 1.29-fold (95% 1.09-1.53, P=0.004) greater among controls 
compared to cases. Viral infections, particularly RSV, are extremely common during infancy 
[112] with approximately 63% of all PERCH cases falling in the 1-12 month age group, thus 
the lower HRV prevalence among infants could be proportion to the higher prevalence’s of 
the other common respiratory viruses. Population based attack rates are required to study the 
differences in HRV prevalence among cases and controls between the different age groups 
further; however, our study was not set up to do these kind of analyses.  
 
When comparing controls to the HRV-associated cases, several differences were observed 
that might help to discriminate for more severe clinical outcomes. Firstly, more cases were 
males compared to controls and cases were more likely to be malnourished and HIV-exposed 
but uninfected than controls. In addition, cases were associated with significantly higher HRV 
nasopharyngeal viral load than controls, suggesting higher viral load could lead to more 
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severe disease. This association between increased viral load and more severe disease was 
also seen in the hospitalised children, with very severe pneumonia cases having higher viral 
loads than the severe pneumonia case. However, we were unable to calculate an optimal HRV 
nasopharyngeal density threshold capable of discriminating between cases and controls or 
between more severe disease among the cases. The association between higher HRV viral 
loads and more severe disease has also been described in other studies [59, 64, 125, 126], 
where viral load correlated with illness severity scores.  
 
Another important factor for the development of severe disease could be co-infection with 
other respiratory pathogens, with several studies reporting on HRV co-infections with other 
respiratory viruses [85, 107, 127] and bacteria [72-75, 110] to be associated with more severe 
disease. On comparison of the HRV-associated cases and controls, we however, did not find 
any compelling evidence of a significant relationship between HRV and co-infection with 
either bacteria or common respiratory viruses resulting in increased disease severity. In fact, 
on comparison of the HRV-associated cases and controls, Moraxella catarrahalis and 
Streptococcus pneumoniae were more commonly detection in the nasopharynx of controls 
rather than cases and there were no associations between HRV and S. pneumoniae (LytA) 
detection in whole blood of cases and controls. These analyses of HRV-bacterial co-infections 
were, however, limited as the majority of the data on bacterial co-infection was based on 
identification from nasopharyngeal swabs and it is well known that young children have a 
high prevalence of colonisation of different bacteria during the first years of life.  
 
HRV detection was also very ubiquitous among children hospitalised with severe (24%) and 
very severe pneumonia (23%), and was the second most common respiratory virus detected 
after RSV (25%). HRV and RSV being detected in similar proportions among children with 
LRTI have been reported in other studies, and the HRV prevalence in this study (24%) was in 
concordance with other studies conducted in similar socioeconomic settings where HRV 
detection ranged between 17% to 53% [80, 81, 94, 96, 101, 102].  
 
Overall 53% of HRV-associated cases had mono-infections, which concurs with previous 
studies conducted in Africa and Southeast Asia which also investigated for similar respiratory 
viruses as done in our study and reported mono-infection prevalence between 50-80% [52, 54, 
83, 85-87, 127, 128]. We found no differences in clinical severity - including markers such as 
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hypoxia, requiring mechanical ventilation and hospital stays longer than 3 days - between 
cases with HRV mono and mixed viral co-infections. However, cases with HRV mono-viral 
infections had fatality ratio 2.83-fold higher than cases with HRV viral co-infections and on 
closer inspection of the HRV-associated fatalities, the case fatalities were 2.2-fold more likely 
to have HRV mono-infections compared to the HRV-associated cases that survived. 
Conversely, the HRV-associated deaths had greater evidence of bacterial co-infection 
including alveolar consolidation, MCPP, positive blood culture, greater prevalence of fever, 
CRP levels ≥40mg/mL and high colonisation densities of S. pneumoniae in the nasopharynx 
and blood, compared to HRV-associated cases who survived. It has been shown in vivo, that 
epithelial cells infected with HRV enhance the adherence of Staphylococcus and 
Streptococcus bacteria to the cells, potentially increasing the potential for bacterial co-
infection [109]. Additionally, HRV have been shown to impair the immune response of 
macrophages to bacterial products [110]. Furthermore, a Finnish ecology study has found a 
link between HRV infections in the community and an increased incidence of invasive 
pneumococcal disease [73, 74]. Therefore, the HRV infection could have predisposed these 
cases to bacterial super-infections which subsequently lead to the fatal outcomes.  
 
Several previous studies have looked at the effects of HRV co-infections including a South 
African study [54] which enrolled children less than 5 years of age and which similarly to our 
study also found that HRV detection was more prevalent among cases requiring 
hospitalisation (35.8%) compared to community controls (18.8%, P=0.047). Furthermore, in 
that study 80% of the HRV-associated hospitalised cases had mono-infections, and 
significantly more of the cases with HRV mono-infections required hospitalisation (88%) 
than cases with HRV and other respiratory virus co-infections (58%), suggesting that HRV 
mono-infection caused more severe disease [54]. Conversely, a Vietnamese study [85] in 
children <15 years of age hospitalised with respiratory infection, reported that HRV co-
infections were associated with more severe disease (more chest refraction, fever and trend of 
longer hospital stays) than HRV mono-infections, and likewise a study in the USA also 
reported that HRV co-infections resulted in longer hospital stay (their indicator of more 
severe disease) than cases with mono-infections in children <2 years hospitalised with 
bronchiolitis [127]. Other studies such is from Thailand [52], United States [53, 129, 130] and 
Greece [128] did not identify significant differences in disease severity between HRV mono-
infections and co-infections in patients hospitalised with respiratory tract infections. None of 
these studies, however, investigated for bacterial co-infections as undertaken in our study and 
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they were not powered to study case fatalities; furthermore, the majority of them focused on 
bronchiolitis which we attempted to exclude from our study. 
 
There were however several limitations in our co-infection analysis - the bacterial co-
infections were for the most part based on hypothesised markers for bacterial co-infections 
including fever, alveolar consolidation, whole blood cell counts, raised CRP levels 
(≥40mg/mL), high S. pneumoniae colonisation densities in the blood and nasopharynx as well 
as physical evidence of bacterial co-infections such as positive blood cultures and detection of 
bacteria at the site of infection. This is because blood culture are very insensitive (15-30%) 
and collecting samples from the site of infection remains challenging with direct lung 
aspiration rarely being performed [95, 111] thus greatly limiting the detection of invasive 
bacterial disease. Additionally, we only analysed for the most common respiratory viruses 
which are well documented to cause the majority of respiratory infections there are however 
other respiratory viruses which we could have overlooked, although the clinical relevance of 
these other respiratory viruses (e.g Polyomaviruses) remains to be fully elucidated during 
severe disease episodes [89].  
 
In the PERCH study we found that children with HRV-associated pneumonia were more 
likely to present with wheezing, even though children were given a bronchodilator challenge 
in an attempt to exclude cases with bronchiolitis, prior to enrolment into this study. If the 
lower chest wall indrawing resolved itself post challenge, irrespective of its effects on 
wheeze, then the child was considered to have bronchiolitis and was excluded from the study. 
Thus the estimates of wheezing in children with HRV-associated severe and very severe 
pneumonia in this study are likely underestimated. Nevertheless, even after adjustment for 
potentially confounding variables including age, gender, site of enrolment, HIV exposure, 
malnutrition, other co-infecting respiratory viruses and markers for bacterial co-infections, 
HRV were almost 2-fold more likely to be detected in children presenting with wheeze. 
Additionally, the HRV-associated cases were more likely to have leucocytosis and higher 
neutrophil levels than cases without HRV infections. High white blood cell counts and 
neutrophil levels are also a predictor of reactive airway disease and chronic obstructive 
pulmonary disease [87] whereby the accumulation of excessive neutrophils at the site of 
inflammation can actually damage the host tissues [131] and this destructive process is linked 
to both asthma development and increased wheezing which was well documented to be 
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associated with HRV in this study. The association between HRV infection and increased 
wheezing has been recorded in several other studies in similar socio-economic settings in 
children with bronchiolitis and LRTI [35, 85-87, 132] and has long term implication as 
wheezing in some children has been shown to be the first clinical manifestation of asthma 
development [132, 133].  
 
In conclusion, this is the first study to our knowledge which reports on HRV-associated 
deaths and the interactions of HRV with other respiratory pathogens during fatal infections. 
This study is also strengthened by drawing on a large samples size and data from a diversity 
of settings over a two-year period. The large study size allowed us to analyses many different 
variables, relevance of HRV co-infections, and included control to account for potential 
confounders for HRV-associated disease severity and death. The study findings suggest that 
HRV clinical outcomes are influenced by multiple host-specific factors, including age, 
malnutrition, HIV-exposure as well as HRV viral loads and the presence of viral and bacterial 
co-infections. It also highlights the need to test for both viral and bacterial pathogens. These 
risk factors for infection that we have identified point the way to interventions but they are 
long-term development challenges and are not easy to correct. New treatment and prevention 
strategies are necessary to reduce what appears to be a substantial morbidity associated with 
HRV disease. 
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4.0 A case-control study of the impact of HIV-1 on the clinical and 
molecular subtyping of Human rhinovirus (HRV) in South African and 
Zambian children 
 
HIV-1 infection in children is an established risk factor for respiratory viral associated LRTI 
morbidity and mortality probably due to impaired humoral and cell-mediated immunity [5]. 
This has been described for RSV, HMPV and Influenza viruses [134-136]; however, not 
much is known on the role of HRV in the pathogenesis of severe LRTI disease in HIV-1-
infected children.  
 
In this chapter, we analyse the clinical epidemiology of HRV in children hospitalised with 
pneumonia and age-frequency matched community controls in settings with a high burden of 
HIV-1 infection.  
 
4.1 RESULTS 
4.1.1 Study populations 
A total of 1 449 children hospitalised with WHO-defined pneumonia in South Africa (n=911, 
63%) and Zambia (n=538, 37%) between August 2011 and August 2013 were enrolled into 
the PERCH project, of whom 14% (n=204) were HIV-1-infected children. HRV prevalence 
was 22% (n=323/1 449) overall and 23% (n=46/204) compared to 22% (n=277/1 245) in 
HIV-1-infected and -uninfected cases, respectively, P=0.934.  
 
Furthermore, 1 566 community controls were enrolled into the PERCH project in South 
Africa (n=959, 61%) and Zambia (n=607, 39%) of whom 13% (n=210/1 566) were HIV-1-
infected. Additionally, of the 1 566 controls enrolled into the study, 1 424 (91%) were 
asymptomatic at the time of sampling and 142 (9%) had signs of respiratory tract infections 
(RTI); and of the 210 HIV-1-infected controls, 166 (79%) were asymptomatic and 44 (21%) 
had signs of RTI (P<0.001). HRV was detected in 20% (n=319/1 556) of controls overall, but 
less commonly so among HIV-1-infected (15%, n=32/210) than HIV-uninfected controls 
(21%, n=287/1 356, P=0.045). 
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4.1.2 HRV in the community controls 
A total of 319 HRV-associated controls were enrolled into the study, of these 10% (n=32) 
were HIV-1-infected controls and 287 (90%) were HIV-uninfected. After multivariate 
regression analysis controlling for potential confounding variables, as well presence of other 
respiratory viruses and markers for bacterial co-infection, HRV was found to be 1.56-fold 
(aOR 95% CI: 1.05-2.40) more prevalent among HIV-uninfected controls (21%) compared to 
HIV-1-infected controls (15%, P=0.045); Table 4.1. Conversely, among the HRV-associated 
controls, HRV was 3.45-fold (aOR 95% CI: 1.22-9.80) more likely to be present in HIV-1-
infected children with RTI (31%) than HIV-uninfected children with RTI (7%, P=0.02). 
Subsequently, HRV was less likely to be detected in HIV-1-infected asymptomatic controls 
(69%) than HIV-uninfected asymptomatic controls (93%, aOR 0.29, 95% CI: 0.11-0.83, 
P=0.020).  
 
Among the HIV-uninfected controls, 29% were HIV-exposed uninfected (HEU) (22% were 
HRV positive, n=83/287), 51% were HIV-unexposed (HUU) (24% were HRV positive, 
n=147/287) and 20% were HIV-uninfected with an unknown HIV exposure status (HU-UE) 
(16% were HRV positive, n=57/287). There were no differences in the demographics and 
clinical epidemiology observed between these three HIV-uninfected strata, except that the 
HEU group were more likely to have never been breastfed, as such, further analysis focussed 
on comparing HRV-associated controls between the HIV-1-infected compared to the overall 
group of HIV-uninfected controls.  
 
The demographics of HIV-1-infected and HIV-uninfected community controls with HRV 
infections are shown in Table 4.1. HIV-1-infected controls infected with HRV were older 
(mean 14.4 vs. 9.9 months, P=0.010) and 6.52-fold (aOR 95% CI: 2.64-16.1) more likely to 
be underweight (34% vs. 7%, P<0.001) than HIV-uninfected controls. Additionally, the HIV-
1-infected controls were 4.23-fold (aOR 95% CI: 1.39-12.09) more likely to have a cough 
(19% vs. 4%, P=0.011) compared to HIV-uninfected controls. There were, however, no other 
associations between the HIV-1-infected compared to HIV-uninfected children with HRV 
infection among the controls including for markers of bacterial infections such as blood 
samples positive for LytA, or high densities of S. pneumoniae in colonisation the blood or 
nasopharyngeal samples. Additionally, there were no overall differences in the prevalence of 
 93 
 
HRV mono- and co-viral infections between the HIV-1-infected and -uninfected controls, 
including for any individual respiratory virus co-infections. 
 
Table 4.1: Demographical and clinical characteristics of HRV associated HIV-1-infected and 
HIV-uninfected control children living in the community 
  HIV+ 
(n=32) 
HIV- 
(n=287) 
Unadjusted  
P-value  OR (95% CI) 
Adjusted 
P-value aOR (95% CI) 
Age in months, mean (SD) 14.4 (12.9) 9.9 (10.1) 0.019  0.010  
Female, n(%) 17 (53%) 142 (49%) 0.780 0.90 (0.43-1.87) 0.895 1.05 (0.50-2.24) 
Never breast fed, n(%) 11 (34%) 68 (24%) 0.188 1.68 (0.77-3.67) 0.082 2.27 (0.90-5.73) 
Under weight, n(%)
a
 11 (34%) 19 (7%) P<0.001 7.3 (3.11-17.55) P<0.001 6.52 (2.64-16.1) 
Day care attendance, n(%) 3 (9%) 28 (10%) 0.849 0.88 (0.25-3.09) 0.921 0.94 (0.2203.87) 
Smoker in household, n(%) 11 (34%) 86 (30%) 0.607 1.22 (0.56-2.64) 0.641 1.21 (0.55-2.64) 
Premature birth, n(%)
b
 4 (13%) 69 (24%) 0.660 0.82 (0.34-1.98) 0.962 0.98 (0.37-2.54) 
Birth weight, mean (SD) 2.9 (0.7) 2.9 (0.5) 0.928  0.831  
Symptoms features:       
Cough, n(%) 6 (19%) 12 (4%) 0.003 4.87 (1.71-13.87) 0.011 4.23 (1.39-12.09) 
Fever, n(%)
c
 2 (6%) 0 0.014  0.055  
Diarrhoea, n(%) 0 1 (0%) 0.718  0.959  
Rhinorrhoea, n(%) 2 (6%) 5 (2%) 0.175 3.12 (0.60-16.16) 0.282 2.61 (0.45-15.14) 
Laboratory markers:       
LytA positive, n(%)
d
 1 (3%) 21 (7%) 0.400 0.42 (0.05-3.20) 0.418 0.42 (0.05-3.37) 
HDP, n(%)
e
       
-Blood 1 (8%) 30 (10%) 0.856 0.82 (0.10-6.60) 0.837 0.80 (0.10-6.66) 
-NP 5 (12%) 27 (10%) 0.622  1.29 (0.47-3.57) 0.464 1.48 (0.52-4.18) 
HRV load, mean (SD)
f
 3.83 (1.81) 3.63 (0.89) 0.288  0.289  
Single HRV infection, n(%)
g
 21 (66%) 205 (71%) 0.494 0.76 (0.35-1.65) 0.555 0.78 (0.36-1.74) 
Mixed HRV infection, n(%)
h
 11 (34%) 82 (29%) 0.494 1.30 (0.60-2.84) 0.555 1.27 (0.57-2.81) 
HRV co-infections in the nasopharynx with:     
-RSV, n(%) 0 8 (3%) 0.642  0.600  
-HBoV, n(%) 6 (19%) 24 (8%) 0.064 2.53 (0.95-6.75) 0.089 2.54 (0.55-6.58) 
-HMPV, n(%) 0 6 (2%) 0.784  0.696  
-AdV, n(%) 2 (6%) 26 (9%) 0.597 0.67 (0.15-2.96) 0.453 0.56 (0.13-2.53) 
-PIV, n(%) 2 (6%) 6 (2%) 0.175 3.12 (0.60-16.16) 0.158 3.42 (0.62-18.79) 
-HCoV, n(%) 3 (9%) 27 (9%) 0.995 0.99 (0.28-3.49) 0.921 1.07 (0.30-3.81) 
-InFV A-C, n(%) 1 (3%) 3 (1%) 0.340 3.05 (0.31-30.26) 0.254 4.15 (0.36-48.0) 
Fungal co-infections:       
-P. jiroveci, n(%) 3 (9%) 35 (12%) 0.642 0.75 (0.22-2.58) 0.651 1.36 (0.36-5.25) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; n: 
Number; NP: Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; HDP: High 
density pneumococcus; RSV: Respiratory Syncytial Virus, HMPV: human metapneumovirus; AdV: adenovirus; 
PIV: parainfluenza type 1-4; HBoV: Human Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and 
HKU1) and InFV: Influenza Virus (A, B and C); P. jiroveci: Pneumocystis jiroveci. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - Premature 
birth defined as gestational age <37 weeks; 
c
 - Fever defined as temperature ≥38oC; d - Blood sample positive for 
S. pneumoniae colonisation by LytA PCR;
 e
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or 
density in whole blood sample >2.2 log10 copies/mL;
 f
 - HRV viral load in the nasopharynx, expressed as log 
copies/mL; 
g 
- HRV was the only respiratory virus detected in the nasopharynx; 
h 
- HRV was detected in the 
nasopharynx together with other respiratory viruses. 
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4.1.3 Case-control comparison of HRV associated HIV-1-infected children 
Overall, there were no differences in the HRV prevalence between cases (22%) and controls 
(20%, P=0.198); however, in the children 12-59 months, HRV detection was significantly 
more prevalent among cases (25%) compared to controls (16%, P=0.003). In the HIV-1-
infected participants, there was a trend for higher prevalence of HRV among cases (23%) 
compared to controls (15%, P=0.056), which was mainly evident in South Africa (24% vs. 
13% among cases vs. controls, P=0.025); Table 4.2. However, after multivariate regression 
analysis - adjusting for multiple potentially confounding risk factors for hospitalisation 
including malnutrition, age categories and markers for bacterial, fungal and virus co-
infections - HIV-1 infection was not an independent risk factor for HRV-associated 
hospitalisation (aOR 1.49, 95% CI: 0.92-2.42, P=0.104). 
  
Table 4.2: Number of study subjects enrolled and tested for HRV - percent positive by age 
and HIV-1 infection status 
Age groups     Zambia South Africa Total   
      HIV+ HIV+ HIV+ Overall 
All Enrolled Cases 89 115 204 1449 
Controls 74 136 210 1566 
HRV positive, n (%) Cases 18 (20%) 28 (24%) 46 (23%) 323 (22%) 
Controls 14 (19%) 18 (13%) 32 (15%) 319 (20%) 
 P=0.808 P=0.025 P=0.056 P=0.198 
1-5 months Enrolled Cases 45 49 94 743 
Controls 20 45 65 636 
HRV positive, n (%) Cases 8 (18%) 13 (27%) 21 (22%) 145 (20%) 
Controls 4 (20%) 3 (7%) 7 (11%) 136 (21%) 
 P=0.831 P=0.017 P=0.061 P=0.374 
6-11 months Enrolled Cases 23 34 57 357 
Controls 18 40 58 420 
HRV positive, n (%) Cases 6 (26%) 10 (29%) 16 (28%) 92 (26%) 
Controls 3 (17%) 9 (23%) 12 (21%) 99 (24%) 
 P=0.473 P=0.499 P=0.333 P=0.478 
12-59 
months 
Enrolled Cases 21 32 53 349 
Controls 36 51 87 510 
HRV positive, n (%) Cases 4 (19%) 5 (16%) 9 (19%) 86 (25%) 
Controls 7 (19%) 6 (12%) 13 (15%) 84 (16%) 
  P=0.971 P=0.615 P=0.734 P=0.003 
Multivariate analysis of HRV prevalence between cases and controls by adjusting for confounding variates 
(<0.2 in univariate analysis) where applicable.  
 
We examined for risk factors and associations for hospitalisation by comparing HRV positive 
case to all HIV-1-infected community controls irrespective of HRV status; Table 4.3. Among 
the HIV-1-infected population, HRV associated cases were younger (median 8.9 months) than 
HIV-1-infected control population (16 months, P=0.005). Furthermore, the HRV-associated 
HIV-1-infected cases were 0.39-fold (aOR 95% CI: 0.2-0.9) less likely to have been breastfed 
(24% vs. 39%, P=0.026) and 2-fold (aOR 95% CI: 1.1-3.9) more likely to be malnourished 
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(50% vs. 31%, P=0.035) compared to HIV-1-infected controls. The HRV positive cases were 
also more likely to have higher densities of S. pneumoniae colonisation in the nasopharynx 
(i.e. >6.9 log10 copies/mL; 28% vs 11%, P=0.001) compared to the HIV-1-infected control 
population, which in PERCH was a relative measure for microbiologically confirmed 
pneumococcal pneumonia [117]. There were no significant differences in the CD4+ counts 
(%) between the HRV associated HIV-1-infected cases compared to HIV-1-infected controls 
(mean 18.2 vs. 24.5%, P=0.294); although, CD4+ counts were only available for 12 of the 
HRV associated participants, 4 cases and 8 controls. There were no associations between 
hospitalisation and co-infection with other common respiratory viruses; however, the HIV-1-
infected HRV associated cases were 5.72-fold (aOR 95% CI: 2.27-14.39) more likely to be 
co-infected with Pneumocystis jiroveci compared to the HIV-1-infected controls (30% vs 6%, 
P<0.001).  
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Table 4.3: Associations of demographic, clinical and laboratory findings of HIV-1-infected cases and controls by HRV status 
  HIV+ Cases 
(n=204) 
HIV+ HRV+ 
Cases (n=46) 
HIV+ controls 
(n=210) 
Unadjusted 
P-value*        OR (95%CI) 
Adjusted 
P-value*     aOR (95% CI) 
Age in months, mean (SD) 10.8 (12.3) 8.9 (9.7) 16.0 (15.3) 0.003  0.005   
Female, n(%) 104 (51%) 26 (57%) 111 (53%) 0.654 1.15 (0.61-2.21) 0.910 1.03 (0.5-2.0) 
Never breast fed, n(%) 50 (25%) 11 (24%) 82 (39%) 0.057 0.49 (0.24-1.02) 0.026 0.39 (0.2-0.9) 
Under weight, n(%)
a
 115 (56%) 23 (50%) 66 (31%) 0.018 2.18 (1.14-4.17) 0.035 2.04 (1.1-3.9) 
Day care attendance, n(%) 11 (5%) 4 (9%) 18 (8%) 0.629 1.29 (0.46-3.67) 0.110 2.70 (.80-9.14) 
Smoker in household, n(%) 55 (27%) 11 (24%) 76 (36%) 0.098 0.54 (0.26-1.12) 0.226 0.63 (0.30-1.33) 
Premature birth, n(%)
b
 21 (10%) 6 (13%) 32 (15%) 0.105 0.49 (0.21-1.16) 0.72 0.44 (0.19-1.08) 
Birth weight, mean (SD) 2.9 (0.6) 3.0 (0.8) 2.8 (0.6) 0.224  0.114  
Clinical features:        
Tachypnea, n(%)
c
 169 (84%) 39 (87%) 3 (27%) P<0.001 17.3 (3.57-84.2) 0.003 13.2 (2.97-84.01) 
Cough, n(%) 149 (73%) 32 (70%) 18 (9%) P<0.001 22.9 (10.5-50.4) P<0.001 36.96 (14.12-96.3) 
Fever, n(%)
d
 166 (81%) 43 (93%) 9 (4%) P<0.001 320 (83.2-1231) P<0.001 651.0 (120-3516) 
Diarrhoea, n(%) 44 (22%) 9 (20%) 4 (2%) P<0.001 12.5 (3.65-42.6) P<0.001 14.25 (3.92-51.89) 
Rhinorrhoea, n(%) 59 (29%) 15 (33%) 16 (8%) P<0.001 5.49 (2.5-12.12) P<0.001 5.91 (2.50-13.95) 
Markers for Bacterial co-infection:     
LytA positive, n (%)
e
 26 (13%) 5 (12%) 18 (9%) 0.521 1.41 (0.49-4.05) 0.283 1.8 (0.6-5.5) 
S. pneu load, mean (SD)
f
 4.6 (2.5) 4.7 (2.7) 4.0 (2.5) 0.089  0.033  
HDP, n(%)
g
        
-Blood 18 (9%) 4 (10%) 9 (5%) 0.183 2.31 (0.67-7.88) 0.105 2.89 (0.80-10.42) 
-NP 46 (23%) 13 (28%) 24 (11%) 0.005 3.04 (1.41-6.56) 0.001 3.96 (1.73-9.10) 
CD4 counts(%), mean (SD)  12.3 (9.0) 18.2 (5.34) 24.5 (1.20) 0.292  0.294 0.95 (0.86-1.07) 
Viral infections in the nasopharynx:      
-RSV, n(%) 19 (9%) 3 (7%) 5 (2%) 0.161 2.86 (0.66-12.4) 0.196 2.70 (0.60-12.18) 
-AdV, n(%) 30 (15%) 4 (9%) 15 (7%) 0.716 1.24 (0.39-3.92) 0.603 1.39 (0.41-4.72) 
-HMPV, n(%) 7 (3%) 2 (4%) 2 (3%) 0.601 1.55 (0.30-7.91) 0.703 1.38 (0.26-7.30) 
-HBoV, n(%) 29 (14%) 9 (20%) 24 (11%) 0.141 1.89 (0.81-4.38) 0.217 1.74 (0.72-4.20) 
-InFV A-C, n(%) 6 (3%) 1 (2%) 4 (2%) 0.905 1.14 (0.12-10.5) 0.972 0.96 (0.09-9.72) 
-PIV, n(%) 25 (12%) 6 (13%) 13 (6%) 0.116 2.27 (0.82-6.33) 0.139 2.24 (0.77-6.49) 
-HCoV, n(%) 16 (8%) 3 (7%) 21 (10%) 0.467 0.62 (0.18-2.20) 0.659 0.75 (0.21-2.69) 
Fungal infections:        
-P. jiroveci, n(%) 66 (32%) 14 (30%) 13 (6%) P<0.001 6.6 (2.84-15.31) P<0.001 5.72 (2.27-14.39) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: Nasopharyngeal; HRV: Human rhinovirus; HIV: Human 
immunodeficiency virus; HDP: High density pneumococcus; RSV: Respiratory Syncytial Virus, HMPV: human metapneumovirus; AdV: adenovirus; PIV: parainfluenza type 
1-4; HBoV: Human Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, B and C); P. jiroveci: Pneumocystis jiroveci. 
*P-values from Chi-squared and Wilcoxon tests by comparing HIV-1-infected HRV associated cases to all controls (regardless of HRV status), logistic regression models 
adjusted for confounding variates (<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or variables with 0 values, thus 
cells left blank. 
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a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - Premature birth defined as gestational age <37 weeks; 
c
 - Tachypnea 
defined as respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 
months; 
d
 - Fever defined as temperature ≥38oC; e - Blood sample positive for S. pneumoniae colonisation by LytA PCR; f - S. pneumoniae bacterial load in the Nasopharynx 
and expressed as log10 copies/mL; 
g
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL. 
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On comparison of HIV-1-infected HRV associated cases compared to HIV-1-infected HRV 
associated controls, there were no obvious associations between case status and HRV viral 
load or the presence of other respiratory or bacterial co-infections; except that the HIV-1-
infected HRV associated cases (30%) were more than 9.11-fold (aOR 95% CI: 2.15-38.7) 
likely to have P. jiroveci co-infections than controls (9%, P=0.003); Table 4.4.  
 
Table 4.4: Multivariate analysis for associations of HRV viral loads and co-infections 
between HIV-1-infected HRV associated cases and controls 
  HIV+ 
Cases 
(n=46) 
HIV+ 
Controls 
(n=32) 
Unadjusted  
P-value  OR (95%CI) 
Adjusted 
P-value aOR (95%CI) 
HRV Viral load, Mean (SD)
a
 3.5 (0.8) 3.8 (1.8) 0.330  0.472  
Single viral infection, n(%)
b
 27 (59%) 21 (66%) 0.537 0.74 (0.29-1.90) 0.459 0.68 (0.25-1.87) 
-HRV Viral load, mean (SD)
c
 3.5 (0.6) 36 (0.9) 0.824  0.245  
HRV Co-infections, n(%)
d
 19 (41%) 11 (34%) 0.539 1.52 (0.10-5.75) 0.459 1.46 (0.53-3.99) 
-HRV Viral load, mean (SD)
e
 3.5 (1.0) 4.3 (2.8) 0.297  0.405  
Viral infections in the nasopharynx:      
-HBoV, n(%) 9 (20%) 6 (19%) 0.928 1.05 (0.33-3.23) 0.804  0.86 (0.24-2.98) 
-RSV, n(%) 3 (7%) 0 0.279  0.141  
-AdV, n(%) 4 (9%) 2 (6%) 0.691 1.43 (0.25-8.31) 0.970 0.96 (0.13-6.96) 
-HMPV, n(%) 2 (4%) 0 0408  0.846  
-PIV, n(%) 6 (13%) 2 (6%) 0.341 2.25 (0.42-11.9) 0.179 3.3 (0.58-18.37) 
-InFV A-C, n(%) 1 (2%) 1 (3%) 0.795 0.69 (0.04-11.4) 0.816 1.4 (0.08-24.43) 
-HCoV, n(%) 3 (7%) 3 (9%) 0.644 0.67 (0.13-3.57) 0.305 0.4 (0.05-2.59) 
HRV Fungal Co-infections with:      
 -P. jiroveci, n(%) 14 (30%) 3 (9%) 0.036 4.23 (1.10-16.2) 0.003 9.11 (2.15-38.7) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: 
Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; RSV: Respiratory Syncytial 
Virus, HMPV: human metapneumovirus; AdV: adenovirus; PIV: parainfluenza type 1-4; HBoV: Human 
Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, B and C); 
P. jiroveci: Pneumocystis jiroveci. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 
in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or variables 
with 0 values, thus cells left blank. 
a 
- HRV viral load in the nasopharynx, expressed as log10copies/mL; 
b
 - HRV was the only Respiratory virus 
detected in the nasopharynx; 
c 
- The HRV viral load in participants were HRV was the only respiratory virus 
detected in the nasopharynx, expressed as log10copies/mL; 
d 
- HRV was detected together with other common 
respiratory viruses in the nasopharynx; 
e 
- The HRV viral load in participants were HRV was detected together 
with other common respiratory viruses in the nasopharynx, expressed as log10 copies/mL. 
 
4.1.4 HRV infection in the cases by HIV-1 infection status 
A total of 323 HRV associated cases were enrolled into the study, of whom 14% (n=46) were 
HIV-1-infected and 86% (n=277) HIV-uninfected. Additionally, among the 1 245 HIV-
uninfected cases, 413 (33%) were HEU and 509 (41%) were HIV- unexposed, with the 
remaining 26% (n=323) being HIV-uninfected albeit the maternal HIV status being unknown 
(HU-UE). Twenty-two percent (n=91/413) of HEU, 21% (n=108/509) of HIV-unexposed and 
24% (n=78/323) of the HU-UE were positive for HRV infection (P=0.711). There were no 
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differences in the demographics and clinical characteristics of HRV associated cases between 
these three HIV-uninfected groups (data no shown), as such, further analysis focussed on 
comparing HRV-associated cases between the HIV-1-infected compared to the overall group 
of HIV-uninfected cases. The demographics of children with HRV associated pneumonia is 
shown in Table 4.5. 
 
There were no differences in age, gender and being breastfed between the HIV-1-infected and 
HIV-uninfected HRV associated case; however, the HIV-1-infected cases were 2.87-fold 
(aOR 95% CI: 1.49-5.54) more likely to be clinically underweight (50% vs. 26%, P=0.002). 
In addition, the HRV associated HIV-1-infected cases were 2.85-fold (aOR 95% CI: 1.02-
7.75) more likely to require supplementary oxygen therapy (87% vs. 77%, P=0.045) than the 
HRV associated HIV-uninfected cases. Furthermore, they were 2.42-fold (aOR 95% CI: 1.26-
4.66) more likely to have abnormal chest X-rays, defined as primary endpoint pneumonia or 
any infiltrates, than the HIV-uninfected cases (63% vs. 42%, P=0.008). A sub-analysis which 
excluded cases with a normal CXR (HIV-1-infected and HIV-uninfected HRV associated 
cases), showed similar trend as the overall case analysis (Data not shown). The HIV-1-
infected HRV associated case were also 2.99-fold (aOR 95% CI: 1.24-7.21) more likely to be 
associated with lethargy (20% vs. 7%, P=0.010); whereas, the HIV-1-infected HRV 
associated cases presented 0.08-fold (aOR 95% CI: 0.02-0.33) less commonly with wheeze 
(4% vs. 36%, P=0.001) than the HIV-uninfected HRV-associated cases. Moreover, after 
multivariate analysis with adjustments for potentially confounding variables including other 
co-infecting respiratory viruses, P. jiroveci and markers for bacterial co-infections, the HRV 
associated HIV-1-infected cases were 2.38-fold (aOR 95% CI: 1.10-5.17) more likely to 
present with hypoxia (74% vs. 60%, P=0.028) and were associated with a 4.89-fold (aOR 
95% CI: 1.84-15.54) greater case fatality ratios (42%) compared to the HIV-uninfected cases 
(10%, P=0.001). There were no other associations between HIV-1 infection status among the 
HRV-association cases and the other markers for severe disease including prolonged hospital 
stays (>3 days), requiring mechanical ventilation and a diagnosis of very severe pneumonia.  
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Table 4.5: Demographical and clinical characteristics of HIV-1-infected and HIV-uninfected 
children hospitalised with HRV associated pneumonia 
  HIV+ 
(n=46) 
HIV- 
(n=277) 
Unadjusted 
P-value  OR (95%CI) 
Adjusted 
P-value aOR (95% CI) 
Age, months (SD) 8.9 (1.4) 9.9 (10.1) 0.564  0.561  
Gender, female, n(%) 26 (57%) 127 (46%) 0.182  1.54 (0.82-2.88) 0.204 1.50 (0.80-2.84) 
Never breastfed, n(%) 11 (24%) 56 (20%) 0.567 1.24 (0.59-2.59) 0.384 1.43 (0.65-3.16) 
Underweight, n(%)
a
 23 (50%) 71 (26%) 0.001 2.90 (1.53-5.49) 0.002 2.87 (1.49-5.54) 
Day care attendance, n(%) 4 (9%) 25 (9%) 0.232 1.23 (0.88-1.72) 0.151 1.29 (0.91-1.83) 
Smoker in household, n(%) 11 (24%) 100 (36%) 0.104 0.55 (0.27-1.13) 0.164 0.59 (0.29-1.24) 
Premature birth, n(%)
b
 6 (13%) 35 (13%) 0.637 0.94 (0.73-1.21) 0.835 0.97 (0.75-1.26) 
Birth weight, mean (SD) 3.0 (0.8) 2.9 (0.7) 0.751  0.624  
Clinical features:       
Very severe pneumonia, n(%) 16 (35%) 97 (35%) 0.975 0.99 (0.51-1.91) 0.961 0.97 (0.50-1.88) 
Chest X-ray abnormal, n(%)
c
 29 (63%) 117 (42%) 0.010 2.33 (1.22-4.44) 0.008 2.42 (1.26-4.66) 
Supplementary 02 therapy, n(%) 40 (87%) 213 (77%) 0.051 2.0 (0.94-4.94) 0.045 2.85 (1.02-7.75) 
Mechanical ventilation, n(%) 3 (7%) 10 (4%) 0.359 1.86 (0.49-7.04) 0.434 1.72 (0.44-6.76) 
Hypoxic, n(%)
d
 34 (74%) 164 (60%) 0.049 1.90 (1.0-3.87) 0.028 2.38 (1.10-5.17) 
Tachycardia, n(%)
e
 28 (62%) 151 (55%) 0.336 1.37 (0.72-2.63) 0.401 1.33 (0.68-2.60) 
Tachypnea, n(%)
f
 39 (87%) 234 (85%) 0.782 1.14 (0.45-2.86) 0.747 1.17 (0.46-2.97) 
Wheezing, n(%) 2 (4%) 100 (36%) 0.001 0.10 (0.02-0.35) 0.001 0.08 (0.02-0.33) 
Cough, n(%) 32 (70%) 221 (79%) 0.106 0.57 (0.29-1.13) 0.151 0.60 (0.29-1.22) 
Lethargic, n(%) 9 (20%) 20 (7%) 0.009 3.13 (1.32-7.38) 0.010 2.99 (1.24-7.21) 
Convulsions, n(%) 0 9 (3%) 0.213  0.391  
Diarrhoea, n(%) 9 (20%) 52 (19%) 0.899 1.05 (0.48-2.32) 0.944 0.98 (0.44-2.16) 
Head nodding, n(%) 7 (15%) 70 (25%) 0.144 0.53 (0.27-1.24) 0.160 0.54 (0.22-1.28) 
Central cyanosis, n(%) 2 (4%) 5 (2%) 0.288 2.47 (0.47-13.14) 0.315 2.42 (0.44-13.69) 
Unable to Feed, n(%) 1 (2%) 9 (3%) 0.699 0.66 (0.08-5.34) 0.590 0.56 (0.07-4.66) 
Vomiting everything, n(%) 1 (2%) 4 (1%) 0.712 1.52 (0.17-13.88) 0.793 1.34 (0.15-12.46) 
Lower chest wall indrawing, n(%) 44 (96%) 261 (94%) 0.697 1.34 (0.30-6.07) 0.586 1.53 (0.33-7.03) 
Stridor, n(%) 0 9 (3%) 0.312   0.443  
Grunting, n(%) 20 (22%) 28 (10%) 0.017 1.49 (1.08-2.06) 0.028 2.64 (1.11-6.31) 
Nasal flaring, n(%) 34 (74%) 216 (78%) 0.542 0.80 (0.39-1.64) 0.694 0.86 (0.40-1.84) 
Hospital stay>3 days, n(%) 35 (76%) 195 (70%) 0.431 1.34 (0.65-2.76) 0.398 1.38 (0.65-2.93) 
Case fatality ratio, n(%) 14 (42%) 21 (10%) P<0.001 6.45 (2.83-14.73) 0.007 4.89 (1.84-15.54) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: 
Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus  
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - Premature 
birth defined as gestational age <37 weeks; 
c
 - Abnormal chest X-rays defined as defined as primary end point 
pneumonia or infiltrates; 
d
 - Hypoxic defined as 1) a room air pulse-oximetry reading indicated oxygen 
saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a room 
air oxygen saturation; 
e
 - Tachycardia defined as heart rate >160 beats per minute (bpm) if aged <11 months, 
heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
f 
- Tachypnea defined as 
respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, 
respiration rate >40 breaths/minute if aged >12 months. 
 
Among markers for possible bacterial co-infection; Table 4.6, after multivariate analysis, the 
HRV associated HIV-1-infected cases had a 6.55-fold (aOR 95% CI: 1.97-21.76) higher 
prevalence of fever (93% vs. 68%, P=0.002), alveolar consolidation on CXR (52% vs. 26%, 
P=0.002), as well as high colonisation densities (>6.9 copies/ml) of S. pneumoniae in their 
nasopharynx (28% vs. 8%, P<0.001) compared to HRV associated HIV-uninfected cases. 
Additionally, the HRV associated HIV-1-infected cases were 2.19-fold (aOR 95% CI: 1.13-
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4.20) more likely to have CRP ≥40mg/mL (41% vs. 25%, P=0.020), microbiologically 
confirmed pneumococcal pneumonia (4% versus 0%, P=0.027) and 3.42-fold (aOR 95% CI: 
1.06-10.99) more likely to have positive blood culture for non-contaminate bacteria (11% vs. 
3%, P=0.038) compared to the HIV-uninfected HRV-associated cases. After regression 
analysis, there were no association between HRV associated HIV-1-infected cases and whole 
blood counts - elevated white blood cells, neutrophils, eosinophils or lymphocytes.  
 
Table 4.6: Markers for possible bacterial co-infections of HIV-1-infected and HIV-uninfected 
children hospitalised with HRV associated pneumonia 
  HIV+ 
(n=46) 
HIV- (n=277) Unadjusted 
P-value OR(95%CI) 
Adjusted  
P-value  aOR (95% CI) 
Fever, n(%)
a
 43 (93%) 189 (68%) 0.002 6.68 (2.01-22.10) 0.002 6.55 (1.97-21.76) 
Alveolar consolidation, n(%) 22 (52%) 67 (26%) 0.001 3.05 (1.56-5.94) 0.001 3.02 (1.54-5.93) 
Leucocytosis, n(%)
b
 20 (45%) 136 (49%) 0.638  0.86 (0.45-1.63) 0.767 0.91 (0.47-1.74) 
Neutrophils (%), median (IQR) 43.4 (19.1) 50 (36.6-64.3) 0.042  0.062  
Lymphocyte (%), median (IQR) 44.1 (17.6) 37.5 (25.4-50) 0.048  0.074  
Eosinophil (%), median (IQR) 0.2 (0.1-0.9) 0.7 (0.1-1.8) 0.202  0.206  
CRP ≥40mg/l, n(%)c 19 (41%) 69 (25%) 0.023 2.12 (1.11-4.05) 0.020 2.19 (1.13-4.20) 
Blood culture positive, n(%) 5 (11%) 9 (3%) 0.027 3.63 (1.16-11.37) 0.038 3.42 (1.06-10.99) 
LytA positive, n(%)
d
 5 (12%) 15 (6%) 0.123 2.32 (0.80-6.78) 0.159 2.17 (0.74-6.42) 
MCPP, n(%)
e
 2 (4%) 0 0.027  0.036  
HDP, n(%)
f
       
-Blood 4 (10%) 8 (3%) 0.050 3.48 (1.0-12.15) 0.063 3.30 (0.94-11.62) 
-NP 13 (28%) 22 (8%) P<0.001 4.57 (2.10-9.92) P<0.001 4.75 (2.13-10.52) 
Abbreviations - HIV: Human Immunodeficiency virus; OR: Odds ratio; aOR: Adjusted odds ratio; CI: 
Confidence interval; IQR: Inter quartile range; CRP: C-reactive protein; MCPP: Microbiologically confirmed 
pneumococcus pneumonia; HDP: High density pneumococcus; NP: Nasopharyngeal; HRV: Human rhinovirus. 
P-values from chi-square and Wilcoxon tests - logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable; odds ratios could not be calculated for variables with zero 
variables. 
a
 - Fever was defined as body temperate ≥38oC; b - Leucocytosis defined as white blood cell count >15 000 
cells/uL if age <12 months, white blood cell count >13 000 cells/uL if age >12 months; 
c 
- CRP defined as levels 
≥40mg/mL are considered to be medically significant of indirect evidence of bacterial co-infection; d - Blood 
sample positive for S. pneumoniae colonisation by LytA PCR; 
e
 - MCPP defined when S. pneumoniae was 
cultured from a normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or lung 
aspirate was PCR LytA positive;   
f
 - HDP defined as S. pneumoniae density in nasopharynx>6.9 and density in 
whole blood sample>2.2 log10 copies/mL. 
  
Additional analysis was conducted in order to determine whether HRV viral loads and co-
infection were associated with HIV-1 infection status in the HRV-associated cases; Table 4.7. 
We found that the prevalence of HRV mono-infections were similar between HIV-1-infected 
(59%) compared to HIV-uninfected cases (57%, P=0.798) in whom HRV was identified, and 
similarly the prevalence of other respiratory virus co-infections did not differ by HIV-status, 
except for a trend for the HIV-1-infected cases to have more HRV-PIV co-infections (13% vs. 
5%, aOR 2.87, 95% CI: 1.02-8.06, P=0.045) compared to the HIV-uninfected cases. 
Additionally, the HRV associated HIV-1-infected cases were 3.23-fold (aOR 95% CI: 1.47-
7.11) more likely to have co-infections with P. jiroveci: (30% vs. 12%, P=0.003) and 4.09-
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fold (aOR 95% CI: 1.75-9.59) more likely to have pulmonary Tuberculosis (14%) than HIV-
uninfected HRV associated cases (4%, P=0.001). 
 
Table 4.7: Multivariate analysis for associations between HRV viral loads and co-infections 
among HRV-associated HIV-1-infected and HIV-uninfected cases 
  HIV+ 
(n=46) 
HIV- 
(n=277) 
Unadjusted 
P-value OR (95%CI) 
Adjusted 
P-value
 
aOR (95% CI) 
HRV Viral load, Mean (SD)
a
 3.5 (0.8) 3.7 (3.6) 0.158  0.197  
Single viral infection, n(%)
b
 27 (59%) 159 (57%) 0.869 1.05 (0.56-1.99) 0.798 1.09 (0.57-2.08) 
-HRV Viral load, Mean (SD)
c
 3.5 (0.6) 3.7 (0.9) 0.254  0.264  
HRV Co-infections, n(%)
d
 19 (41%) 118 (43%) 0.869 0.95 (0.50-1.79) 0.798 0.92 (0.48-1.75) 
-HRV Viral load, Mean (SD)
e
 3.5 (0.9) 3.7 (0.9) 0.399  0.537  
Viral co-infections in the nasopharynx
g
:      
-HBoV, n(%) 9 (20%) 36 (13%) 0.237 1.62 (0.73-3.65) 0.258 1.61 (0.70-3.70) 
-RSV, n(%) 3 (7%) 41 (15%) 0.142 0.40 (0.12-1.36) 0.118 0.37 (0.11-1.28) 
-AdV, n(%) 4 (9%) 27 (10%) 0.823 0.823 (0.29-2.65) 0.824 0.87 (0.28-2.74) 
-HMPV, n(%) 2 (4%) 9 (3%) 0.705 1.35 (0.28-6.47) 0.771 1.26 (0.26-6.07) 
-PIV, n(%) 6 (13%) 13 (5%) 0.033 3.05 (1.10-8.47) 0.045 2.87 (1.02-8.06) 
-InFV A-C, n(%) 1 (2%) 3 (1%) 0.544 2.03 (0.21-19.49) 0.593 1.88 (0.19-18.83) 
-HCoV, n(%) 3 (7%) 17 (6%) 0.920 1.07 (0.30-3.80) 0.905 1.08 (0.30-8.87) 
Fungal Co-infections with:       
-P. jiroveci, n(%) 14 (30%) 34 (12%) 0.002 3.12 (1.52-6.45) 0.003 3.23 (1.47-7.11) 
Co-infection with TB, n(%) 11 (14%) 24 (4%) 0.003 3.13 (1.49-7.35) 0.001 4.09 (1.75-9.59) 
Abbreviations - OR: Odds ratio; aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: 
Nasopharyngeal; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; RSV: Respiratory Syncytial 
Virus, HMPV: human metapneumovirus; AdV: adenovirus; PIV: parainfluenza type 1-4; HBoV: Human 
Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, B and 
C); P. jiroveci: Pneumocystis jiroveci: TB: Tuberculosis. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank. 
a 
- HRV viral load in the nasopharynx, expressed as log10copies/mL; 
b
 - HRV was the only Respiratory virus 
detected in the nasopharynx; 
c 
- The HRV viral load in participants were HRV was the only respiratory virus 
detected in the nasopharynx, expressed as log10copies/mL; 
d 
- HRV was detected together with other common 
respiratory viruses in the nasopharynx; 
e 
- The HRV viral load in participants were HRV was detected together 
with other common respiratory viruses in the nasopharynx, expressed as log10 copies/mL. 
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4.2  DISCUSSION 
In this study, it was found that HIV-1 infection was not an independent risk factor for 
hospitalisation with HRV-associated pneumonia; however, HIV-1 infection was associated 
with a 4.89-fold higher case fatality ratio among children hospitalised with HRV-associated 
severe and very severe pneumonia. This study provides evidence that HRV is ubiquitous 
during severe childhood disease in both HIV-1-infected (23%) and HIV-uninfected children 
(22%). Although HRV was one of the most prevalent respiratory viruses detected in the 
hospitalised children with pneumonia (22%), irrespective of HIV-1 infection status, it was 
also detected at similar prevalence in the age-group matched control population (20% overall, 
15% and 21% among HIV-1-infected and -uninfected controls). The detection rates reported 
in this study are similar to those reported in other studies conducted in Africa (24%-32%) 
which have looked at HIV-infection and HRV co-infections in children with LRTI [54, 80, 
89, 132].  
 
To the best of our knowledge, this is one of the first studies reporting on HRV prevalence in 
HIV-1-infected community control children living in Africa. There was however a study 
conducted in South African in all age groups which looked at the attributable role of 
rhinovirus and reported on the HIV prevalence (29% among cases and 43% among controls 
which was reflective of the control enrolment criteria); however, this study did not report on 
HIV-1 incidences in children <5 years of age and did not report on HRV prevalence among 
the HIV positive cases and controls. They did however determine that HRV was mildly 
associated with severe disease with an attributable fraction of 46.9% among the entire 
population and 45.7% among children under the age of 5 years [137]. Another study 
conducted in South Africa [54] was the only other study which reported on HRV prevalence 
and HIV-infection status among sick children; and although they enrolled 46 asymptomatic 
controls, their HIV status was unknown. The prevalence of HRV was reported to be 18.8% 
among the control population in that study which is similar to other studies reporting on HRV 
prevalence in control populations (18.8-50%) [99]. This is comparable to the overall control 
population prevalence of HRV reported in our study (20%). Furthermore, in our study we 
found that the prevalence of HRV was 1.56-fold higher in HIV-uninfected controls (21%) 
compared to HIV-1-infected controls (15%, P=0.045). The HRV associated HIV-1-infected 
controls were, however, 3.45-fold more likely to have respiratory tract infection symptoms 
compared to HRV associated HIV-uninfected controls thus among the controls HIV-1-
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infection was an independent risk factor for HRV-associated RTI not requiring 
hospitalisation. Nonetheless, the detection of HRV does not necessarily imply causality of 
disease as HRV have been shown to shed for several days post infection [124] and it has been 
shown for other respiratory viruses (namely RSV) that virus shedding can be considerably 
longer in HIV-1-infected individuals [138]. Our study was not designed to distinguish 
between HRV detection in relation to shedding from previous infections, incubation period of 
current infections and controls which have asymptomatic infections thus additional 
longitudinal studies are needed to fully clarify the role of HIV-1-infections during HRV-
associated disease episodes as well as the effects and length of HRV shedding in HIV-1-
infected individuals.  
 
Nevertheless, the association between HRV detection and RTI in the HIV-1-infected controls 
infers a pathogenic role of HRV causing RTI in the HIV-1-infected population not requiring 
hospitalisation. Moreover, there was a trend for HRV detection to be associated with case 
status in the HIV-1-infected participants (23% vs. 15% for the cases vs. controls, P=0.059) 
which was mainly driven by 1-5 month age group (22% vs. 11% for the cases vs. controls, 
P=0.061). Thus suggesting that immunosuppression and young age group might be risk 
factors for development of HRV associated severe pneumonia. Future studies designed to 
analyse population based attack rates are required to study the associations between 
immunosuppression and HRV-infection among different age groups further; however, the 
association between HIV and HRV was also seen in a study conducted in Mozambique, 
which determined that HIV was associated with an increased risk of HRV-associated LRTI 
[80].  
 
Additional risk factors for HRV-associated disease were seen in the case-control comparison 
of HIV-1-infected participants, with the cases being younger and clinically malnourished 
compared to the controls. Conversely, on comparison of viral co-infections in HIV-1-infected 
participants there were no observed relationships between HRV-associated cases compared to 
the controls thus viral co-infections do not appear to be a risk factor for hospitalisation. The 
relationship between bacterial co-infection is more difficult to fully clarify as current methods 
for detecting bacterial infections are insensitive i.e. blood culture has a sensitivity of only 15-
30% and direct sampling from site of infection remains challenging and highly invasive [95, 
111]. Thus the majority of bacterial data are from nasopharynx sampling which is unreliable 
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as children are well known to be colonised with large numbers of different bacteria during the 
first years of life. Consequently, markers for potential bacterial co-infections were utilised to 
study bacterial co-infections, these include fever, alveolar consolidation, CRP levels 
≥40mg/mL and elevated white blood cell, lymphocyte and neutrophil counts are generally 
indicative of bacterial infections. Additionally, in PERCH it was found that S. pneumoniae 
colonisation densities above a threshold (>6.9 log10copies/mL in the nasopharynx and >2.2 
log10copies/mL in the blood) were strongly correlated with pneumococcal pneumonia [117]. 
Blood counts, CRP levels and chest X-rays were not performed on the controls so of the 
remaining potential bacterial markers available for both the cases and controls - fever and 
high S. pnuemoniae colonisation densities - the HRV positive HIV-1-infected cases were 
more associated with both compared to the HIV-1-infected controls. Thus we can conclude 
that HRV positive HIV-1-infected cases were most likely associated with more bacterial co-
infected than the HIV-1-infected controls. This concurs with reports which have suggested 
that bacterial infections are in fact an essential part in the pathogenesis of viral infections 
progressing to severe respiratory disease [80, 139]. Additionally, the HIV-1-infected cases 
positive for HRV infections were 5.72-fold more likely to be co-infected with Pneumocystis 
jiroveci than the HIV-1-infected controls. None of the other common risk factors for 
respiratory virus associated RTI - including day care attendance, a regular smoker in the 
household, premature birth or low birth weight - appeared to be relevant in our study 
population.  
 
The large study population of children hospitalised with pneumonia (n=1 449) of which 14% 
(n=204) were HIV-1-infected allowed us to describe the epidemiology of HRV-associated 
pneumonia (n=323) in more detail than any previous study on HRV in children living in a 
high HIV burden setting. Among the HRV-associated cases, there were no differences in 
socio-economic or demographic characteristics between HIV-1-infected and HIV-uninfected 
cases, except the HIV-1-infected cases were almost 3-fold more likely to be malnourished that 
the HIV-uninfected cases. Additionally, the HRV positive HIV-1-infected cases were more 
associated with fever, alveolar consolidation, increased CRP levels, MCPP, positive blood 
cultures and high colonisation densities of S. pneumoniae in the nasopharynx and blood 
compared to the HRV positive HIV-uninfected cases. Thus providing evidence that the HRV 
positive HIV-1-infected cases were more likely to have concurrent bacterial infections 
compared to the HIV-uninfected HRV positive cases. Furthermore, in comparison the HIV-
uninfected cases, the HIV-1-infected cases associated with HRV-infections were also more 
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likely to be co-infected with tuberculosis and P. jiroveci which is a fungal parasite well 
known to cause opportunistic infections in immunocompromised patients often with fatal 
outcomes [6, 140].  
 
The associations of the HRV-associated HIV-1-infected cases with more concurrent bacterial 
and fungal infections could account for the differences in the clinical presentation of HRV-
associated disease between the HIV-1-infected and HIV-uninfected cases with the HIV-1-
infected cases being 1.90-fold more likely to present with hypoxia and subsequently 2.0-fold 
more likely to require supplementary oxygen therapy than the HRV-associated HIV-
uninfected cases. Additionally, the HRV-associated HIV-1-infected cases were 2.33-fold 
more likely to have abnormal chest X-ray findings and 3.13-fold more likely to present with 
lethargy than the HRV-associated HIV-uninfected cases. Furthermore, among the HRV-
associated cases, the HIV-1-infected cases had a 6.45 increased odds of death. However, these 
associations of HRV-associated cases with concurrent HIV-1 infections with more severe 
disease remained even after multi-logistic regression analysis adjusting for potentially 
confounding by co-infecting viruses, bacteria and P. jiroveci. After multivariate modelling, 
the HRV-associated HIV-1-infected cases were 2.38-fold more likely to present with hypoxia 
and 2.85-fold more likely to require supplementary oxygen therapy; furthermore, they were 
2.42-fold more likely to have abnormal chest X-ray findings and 2.99-fold more likely to 
present with lethargy than the HIV-uninfected cases. Moreover, even after adjusting for co-
infecting viruses, bacteria, P. jiroveci and other potentially confounding variables the HRV-
associated cases with concurrent HIV-1-infections had a 4.89-fold increased odds of death 
compared to the HRV-associated HIV-uninfected cases.  
 
A major study limitation is that due to the very sensitive detection capabilities of multiplex 
PCR the detection of several potential pathogens among the cases was highly likely but the 
extent to which each of the detected pathogens was contributing to the disease episode could 
not be determined. This is especially true for HRV which is frequently detected in the airways 
of asymptomatic individuals. Thus the burden of HRV disease reported in this study could 
potentially be over-estimating the true incidence of HRV related LRT disease. 
 
In conclusion, the present study contributes to the understanding of the prevalence of HRV 
associated disease in children with respiratory tract infections, including children hospitalised 
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with pneumonia, across different age-groups living in high HIV-1-infection setting. HIV-
infection was found to be a risk factor for RTI among the HRV-associated community 
controls not requiring hospitalisation and a risk factor for concurrent bacterial and fungal 
superinfections and death among children hospitalised with HRV-associated pneumonia.  
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5.0 The molecular subtyping of Human rhinovirus (HRV) in children 
from three Sub-Saharan African countries 
 
HRV is currently classified into three different species: HRV-A, HRV-B and HRV-C [19-22]. 
The three species are detected perennially [45] and have been associated with ARI episodes of 
varying severity in children [35-39]. In this chapter we characterise the molecular subtyping 
of HRV in children living in Zambia, Mali and South Africa. The children were 1-59 months 
of age, and included those hospitalised for severe or very severe pneumonia and age-
frequency matched community controls.  
 
5.1 RESULTS 
5.1.1 The study population 
A total of 2 120 children hospitalised for severe or very severe pneumonia were enrolled 
between the three Sub-Saharan African sites into the PERCH project. Of these children, 439 
(21%) tested positive for HRV by PCR analysis of nasopharyngeal swabs, which were 
subtyped. Among the pneumonia cases the prevalence of HRV associated pneumonia was 
highest in South Africa (23%, n=210/911), followed by Zambia (21%, n=113/538) and lowest 
in Mali (17%, n=116/671, P=0.020).  
 
In addition, 2 290 age-frequency matched community controls were enrolled, among whom 
the prevalence of HRV infection (20%, n=462) was similar to cases (23%, P=0.852). The 
HRV prevalence among controls was similar across the sites, including 22% in South Africa 
(n=212/964), 20% in Mali (n=143/725) and 18% in Zambia (n=107/686, P=0.093). There 
was no difference in the prevalence of HRV detection between cases and controls (P=0.693); 
furthermore, the prevalence of HRV identification did not differ between cases and controls at 
the individual sites (P=0.148). By age group there was however a difference in HRV 
prevalence among children 1-5 years of age with HRV detection being 1.82-fold (aOR 95% 
CI: 1.31-2.53) higher among cases (21%, n=120/563) compared to among controls (15%, 
n=126/797, P=0.001); conversely, among infants there were no differences in HRV 
prevalence among cases (20%, n=319/1 557) and controls (23%, n=336/ 1 487, P=0.503). 
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5.1.2 HRV clinical and molecular subtyping among community controls 
Of the 462 HRV positive samples identified among community controls, 97% (n=446) were 
successfully amplified, 3% (n=14) failing to amplify and 0.5% (n=2) being unavailable for 
serotyping due to insufficient volume of the archived sample. Of the 446 successfully 
amplified samples, 5% (n=24) were typed as enterovirus, one as an Echovirus, and 92% 
(n=421) successfully speciated for HRV. The dominant HRV species among controls were 
HRV-C (45%, n=191) and HRV-A (45%, n=190), whilst 10% were HRV-B (n=40). There 
were no differences in HRV species distribution by age groups with HRV-A (46%) and HRV-
C (44%) being most prevalent among infants followed by HRV-B (10%); and similarly 
among children 1-5 years of age HRV-C was most prevalent (49%) followed by HRV-A 
(44%) and HRV-B (7%, P=0.520).  
 
HRV-B, the least prevalent species (10%), was identified sporadically throughout the year, 
Figure 5.1. There were, however no statistical differences in demographics and clinical 
symptoms among controls with HRV-B compared to those with HRV-A and HRV-C 
infection; Table 5.1, albeit the low numbers limited statistical comparisons. Thus, to further 
investigate for clinical difference between HRV species, we specifically analysed HRV-A to 
HRV-C associated controls; Table 5.1 and 5.2. Except for HRV-A associated controls being 
3.25-fold (aOR 95% CI: 1.30-8.14) more likely to have S. pneumoniae detected in whole 
blood (LytA positive) than HRV-C associated controls (10% vs. 4%, P=0.012), there were no 
other differences in demographic, risk factors associated with developing respiratory 
infections (including day care attendance, regular smoker in the household, premature birth 
and low birth weight) and symptoms of RTI between controls associated with HRV-A 
compared to HRV-C infections. Additionally, there were no differences in the nasopharyngeal 
viral loads of the HRV species. Although there was no difference in the overall prevalence of 
other respiratory virus co-infections between HRV-A (32%) and HRV-C (36%, P=0.713) 
infected controls, co-infection with PIV was 3.8-fold (aOR 95% CI: 1.17-12.42) more 
common among HRV-C (6%) than HRV-A (2%, P=0.026) associated community controls. 
The individual site analysis is shown in Table 5.3. 
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Table 5.1: The demographical and clinical characteristics of the Community controls infected 
with the three HRV species 
   HRV-A  
(n=190) 
HRV-B 
(n=40) 
HRV-C 
(n=191) 
Unadjusted 
P-value OR (95% CI) 
Adjusted 
P-value aOR (95% CI) 
Age in months, mean (SD) 9.7 (9.9) 7.3 (7.6) 10.8 (10.7) 0.300  0.230  
Female, n(%) 93 (49%) 23 (58%) 89 (47%) 0.646 1.10 (0.73-1.64) 0.854 1.04 (0.69-1.57) 
HIV+, n (%) 14 (7%) 1 (3%) 13 (7%) 0.967 0.98 (0.45-2.17) 0.999 0.99 (0.47-2.24) 
HEU, n (%)
a
 32 (18%) 6 (15%) 39 (22%) 0.382 0.79 (0.47-1.34) 0.178 0.60 (0.34-1.26) 
Never breast fed, n(%) 49 (26%) 12 (30%) 49 (26%) 0.340 1.29 (0.76-2.18) 0.420 0.82 (0.50-1.34) 
Under weight, n (%)
b
 22 (12%) 7 (18%) 16 (8%) 0.299 1.43 (0.73-2.82) 0.151 1.67 (0.83-3.36) 
Day care attendance, n(%) 44 (23%) 14 (35%) 65 (34%) 0.023 0.59 (0.38-0.93) 0.323 0.74 (0.40-1.35) 
Smoker in household, n(%) 53 (28%) 6 (15%) 52 (27%) 0.884 1.04 (0.66-1.62) 0.905 0.97 (0.62-1.54) 
Premature birth, n(%)
c
 32 (17%) 6 (15%) 34 (18%) 0.795 0.98 (0.82-1.17) 0.618 0.95 (0.79-1.15) 
Birth weight, mean (SD) 2.9 (0.6) 3.0 (0.7) 3.1 (0.5) 0.196  0.328  
Clinical features:        
Tachypnea, n(%)
d
 16 (9%) 5 (13%) 13 (7%) 0.530 1.28 (0.60-2.74) 0.433 1.37 (0.62-3.0) 
Cough, n(%) 13 (7%) 2 (5%) 13 (7%) 0.993 1.00 (0.73-1.38) 0.757 1.14 (0.50-2.57) 
Fever, n(%)
e
 1 (1%) 0 3 (2%) 0.343 0.33 (0.03-3.23) 0.481 0.44 (0.04-4.39) 
Diarrhoea, n(%) 1 (1%) 1 (3%) 0 0.364  0.462  
Rhinorrhoea, n(%) 18 (9%) 4 (10%) 33 (17%) 0.605 0.91 (0.62-1.32) 0.310 0.69 (0.34-1.41) 
Laboratory markers:        
CRP≥40mg/l, n(%)
f
 2 (1%) 0 2 (1%) 0.996 1.0 (0.14-7.21) 0.847 1.22 (0.16-9.0) 
LytA positive, n(%)
g
 19 (10%) 4 (10%) 7 (4%) 0.019 2.91 (1.20-7.10) 0.012 3.25 (1.30-8.14) 
HDP, n(%)
h
        
-Blood 12 (6%) 3 (8%) 5 (3%) 0.092 2.50 (0.87-7.23) 0.058 2.88 (0.97-8.16) 
-NP 29 (15%) 3 (8%) 35 (18%) 0.425 0.80 (0.47-1.38) 0.458 0.81 (0.47-1.41) 
HRV viral load, mean (SD)
i
 3.5 (0.9) 3.3 (0.7) 3.5 (0.9) 0.542  0.138  
HRV mono-infection, n(%)
j
 130 (68%) 27 (67%) 123 (64%) 0.406 1.20 (0.78-1.83) 0.713 1.10 (0.70-1.68) 
Viral co-infections in the nasopharynx:      
-AdV, n(%) 17 (9%) 0 22 (12%) 0.409 0.75 (0.39-1.47) 0.635 0.85 (0.43-1.68) 
-RSV, n(%) 5 (3%) 4 (10%) 5 (3%) 0.993 1.00 (0.29-3.53) 0.915 0.93 (0.26-3.31) 
-HBoV, n(%) 21 (11%) 2 (5%) 25 (13%) 0.542 0.83 (0.44-1.53) 0.797 0.92 (0.49-1.76) 
-HMPV, n(%) 4 (2%) 3 (8%) 0 0.044  0.168  
-InFV A-C, n(%) 1 (1%) 2 (5%) 0 0.179  0.175  
-PIVs, n(%) 4 (2%) 3 (8%) 12 (6%) 0.050 3.15 (1.0-9.95) 0.026 3.81 (1.17-12.42) 
-HCoVs, n(%) 16 (8%) 0 29 (15%) 0.044 0.51 (0.27-0.98) 0.091 0.57 (0.29-1.10) 
Abbreviations - HIV: Human Immunodeficiency virus; HEU: HIV exposed but uninfected; OR: Odds ratio; 
aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; HDP: High density pneumococcus; 
CRP: C-reactive protein; NP: Nasopharyngeal; HRV: Human rhinovirus; RSV: Respiratory Syncytial Virus (A 
and B), HMPV: Human Metapneumovirus; AdV: Adenovirus; PIV: Parainfluenza type 1-4; HBoV: Human 
Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and HKU1) and InFV A-C: Influenza Virus (A, B 
and C). 
P-values calculated by comparing HRV-A to HRV-C using chi-square and Wilcoxon tests - logistic regression 
models adjusted for confounding variates (<0.2 in univariate analysis) where applicable; Odds ratios could not 
be calculated for variables with zero variables.  
a
 - HEU defined as HIV-uninfected but HIV-exposed. Undetectable viral load, HIV seronegative in the child 
with a positive maternal history. Positive maternal status based on self-report was accepted, except for 
seronegative children < 7 months of age where documented positive maternal status was required; 
b
 - 
Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 c
 - Premature 
birth defined as gestational age <37 weeks; 
d
 - Tachypnea defined as respiratory rate >60 breaths/minute if aged 
<2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged 
>12 months; 
e
 - Fever defined as temperature ≥38oC; f - CRP defined as levels ≥40mg/mL which are considered 
to show potential bacterial infection. Only a subset of randomly chosen controls had CRP testing conducted at 
the South African site; 
g
 - Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
h
 - HDP defined 
as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL; 
i 
- 
HRV viral load in the nasopharynx, expressed as log copies/mL; j - HRV was the only respiratory virus detected 
in the nasopharynx. 
  
Among controls with HRV infection, HRV was identified as the sole respiratory virus in the 
nasopharynx among 67% (n=280/421) of controls, including 68% (n=130/190) of HRV-A; 
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67% (n=27/40) of HRV-B and 64% (n=123/191) of HRV-C infections (P=0.70). There were 
no significant differences in demographics, clinical presentation or laboratory markers when 
comparing controls with only HRV infections to those with other respiratory virus 
coinfections, either overall or specifically for HRV-A and HRV-C; Table 5.2.  
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Table 5.2: The demographical and clinical characteristics of the Community controls by HRV species and mono vs. mixed infections 
  HRV-A  
mono (n=130) 
HRV-A  
mixed (n=60) 
P-value
a
 HRV-B  
mono (n=27) 
HRV-B 
mixed (n=13) 
P-value
b
 HRV-C  
mono (n=123) 
HRV-C  
mixed (n=47) 
P-value
c
 P-value
d
 
Age in months, mean (SD) 9.6 (10.1) 10.0 (9.3) 0.775 7.9 (8.8) 5.8 (4.1) 0.427 10.7 (11.3) 11.0 (9.5) 0.297 0.606 
Female, n(%) 70 (54%) 23 (38%) 0.053 15 (56%) 8 (62%) 0.720 59 (48%) 30 (44%) 0.582 0.437 
HIV+, n (%) 9 (7%) 5 (8%) 0.456 1 (4%) 0 0.210 9 (7%) 4 (6%) 0.444 0.931 
HEU, n (%)
e
 22 (18%) 10 (18%) 0.996 4 (15%) 2 (15%) 0.998 27 (24%) 12 (19%) 0.445 0.299 
Never breast fed, n (%) 27 (21%) 11 (18%) 0.612 3 (11%) 2 (15%) 0.702 18 (15%) 13 (19%) 0.161 0.388 
Under weight, n (%)
f
 13 (10%) 9 (15%) 0.371 3 (11%) 4 (41%) 0.125 12 (10%) 4 (6%) 0.352 0.763 
Day care attendance, n(%) 21 (16%) 23 (38%) 0.037 11 (41%) 3 (23%) 0.273 34 (28%) 31 (46%) 0.279 0.298 
Smoker in household, n(%) 39 (30%) 14 (23%) 0.430 3 (11%) 3 (23%) 0.321 38 (31%) 14 (21%) 0.193 0.769 
Premature birth, n(%)
g
 22 (17%) 12 (20%) 0.635 5 (19%) 1 (8%) 0.369 21 (17%) 11 (16%) 0.942 0.529 
Birth weight, mean (SD) 2.9 (0.6) 3.1 (0.6) 0.065 2.9 (0.7) 2.8 (0.4) 0.528 3.0 (0.5) 3.1 (0.6) 0.658 0.763 
Clinical features:           
Tachypnea, n(%)
h
 9 (8%) 7 (13%) 0.402 3 (12%) 2 (15%) 0.770 7 (6%) 6 (10%) 0263 0.607 
Cough, n(%) 7 (5%) 6 (10%) 0.178 2 (8%) 0 0.314 8 (7%) 5 (7%) 0.397 0.761 
Fever, n(%)
i
 1 (1%) 0 0.925 0 0  1 (1%) 2 (3%) 0.431 0.815 
Diarrhoea, n(%) 1 (1%) 0 0.442 0 1 (8%) 0.144 0 0  0.509 
Rhinorrhoea, n(%) 8 (6%) 10 (17%) 0.051 4 (15%) 0 0.144 19 (15%) 14 (21%) 0.488 0.101 
Laboratory markers:           
CRP≥40mg/l, n(%)
j
 2 (1%) 0 0.573 0 0  2 (1%) 0 0.762 0.409 
LytA positive, n(%)
k
 10 (8%) 9 (15%) 0.293 3 (11%) 1 (8%) 0.736 4 (3%) 3 (4%) 0.780 0.078 
HDP, n(%)
l
           
-Blood 6 (5%) 6 (10%) 0.342 2 (7%) 1 (8%) 0.974 3 (3%) 2 (3%) 0.987 0.258 
-NP 19 (15%) 10 (17%) 0.847 3 (11%) 1 (8%) 0.736 23 (19%) 12 (18%) 0.843 0.471 
Abbreviations - SD: Standard deviation; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; HEU: HIV exposed but HIV-uninfected; CRP: C-reactive protein; 
HDP: High density pneumococcus; NP: Nasopharyngeal. 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable. P-values could not 
be calculated for variables where both values are 0, thus cells left blank 
a
 - P-values for the comparison of HRV-A mono vs. mixed infections; 
b
 - P-values for the comparison of HRV-B mono vs. mixed infections; 
c
 - P-values for the comparison 
of HRV-C mono vs. mixed infections; 
d 
- P-values for the comparison of HRV-A mono vs. HRV-C mono-infections, P-values could not be calculated for variables with zero 
variables for both groups; 
e 
- HEU defined as undetectable viral load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-
report was accepted, except for seronegative children < 7 months of age where documented positive maternal status was required; 
f
 - Underweight defined as weight for age 
<2SD of the median age-sex specific WHO reference; 
g
 - Premature birth defined as gestational age <37 weeks; 
h
 - Tachypnea defined as respiratory rate >60 breaths/minute if 
aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
i
 - Fever defined as temperature ≥38oC; j - 
CRP defined as levels ≥40mg/mL which are considered to show potential bacterial infection. Only a subset of randomly chosen controls had CRP testing conducted at the 
South African site; 
k
 - Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
l
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in 
whole blood sample >2.2 log10 copies/mL. 
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Figure 5.3: The demographics and clinical characteristics of HRV-associated cases stratified by HRV species for each of the sites 
  South-African HRV+ controls (n=189 Mali HRV+ controls (n=130)   Zambia HRV+ controls (n=102) 
  HRV-A 
(n=96) 
HRV-B 
(n=14) 
HRV-C 
(n=79) 
P-value HRV-A 
(n=46) 
HRV-B 
(n=17) 
HRV-C 
(n=67) 
P-value HRV-A 
(n=48) 
HRV-B 
(n=9) 
HRV-C 
(n=45) 
P-value 
Age in months, mean (SD) 11.3 (10.7) 6.0 (6.4) 12.4 (12.7) 0.075 7.8 (7.6) 8.8 (9.1) 11.0 (10.3) 0.205 8.3 (9.7) 6.1 (6.0) 7.8 (5.7) 0.688 
Female, n(%) 53 (55%) 9 (64%) 44 (56%) 0.854 19 (41%) 9 (53%) 31 (46%) 0.720 21 (44%) 5 (56%) 14 (31%) 0.296 
HIV+, n (%) 9 (9%) 0 6 (8%) 0.395 0 0 0 - 9 (9%) 0 6 (8%) 0.658 
Never breast fed, n(%) 38 (39%) 7 (50%) 34 (43%) 0.642 5 (11%) 3 (18%) 7 (10%) 0.655 6 (13%) 2 (22%) 8 (18%) 0.401 
Under weight, n (%)
a
 7 (7%) 2 (14%) 3 (4%) 0.359 9 (20%) 4 (24%) 5 (7%) 0.034 6 (13%) 1 (11%) 8 (18%) 0.871 
Day care attendance, n(%) 14 (14%) 0 14 (18%) 0.295 30 (65%) 14 (82%) 51 (76%) 0.286 0 0 0 - 
Smoker in household, n(%) 29 (30%) 5 (36%) 25 (32%) 0.912 9 (20%) 0 14 (21%) 0.120 15 (31%) 1 (11%) 13 (29%) 0.468 
Premature birth, n(%)
b
 30 (31%) 5 (36%) 29 (37%) 0.907 2 (4%) 1 (6%) 2 (3%) 0.864 2 (4%) 0 1 (2%) 0.759 
Birth weight, mean (SD) 2.9 (0.6) 2.7 (0.7) 3.0 (0.6) 0.179 3.1 (0.6) 3.3 (0.5) 3.4 (0.6) 0.167 2.9 (0.4) 2.9 (0.4) 2.9 (0.6) 0.732 
Clinical features:             
RTI control
c
 8 (8%) 0 3 (4%) 0.199 19 (41%) 4 (24%) 35 (52%) 0.112 6 (13%) 1 (11%) 10 (22%) 0.622 
Tachypnea, n(%)
d
 5 (6%) 2 (15%) 3 (4%) 0.488 8 (17%) 3 (18%) 6 (9%) 0.467 3 (7%) 0 4 (10%) 0.493 
Cough, n(%) 4 (4%) 0 2 (3%) 0.589 6 (13%) 1 (6%) 4 (6%) 0.472 3 (6%) 1 (11%) 7 (16%) 0.415 
Fever, n(%)
e
 0 0 0  0 0 2 (3%) 0.346 1 (2%) 0 1 (2%) 0.819 
Diarrhoea, n(%) 0 0 0  0 1 (6%) 0 0.076 1 (2%) 0 0 0.442 
Rhinorrhoea, n(%) 1 (1%) 0 0 0.587 15 (33%) 4 (24%) 30 (45%) 0.254 2 (4%) 0 3 (7%) 0.748 
Laboratory markers:             
CRP≥40mg/l, n(%)f 0 0 1 (1%) 0.405 1 (2%) 0 0 0.292 1 (2%) 0 1 (2%) 0.853 
LytA positive, n(%)
g
 13 (14%) 1 (7%) 3 (4%) 0.070 6 (13%) 3 (18%) 3 (4%) 0.089 0 0 1 (2%) 0.327 
HDP, n(%)
h
             
-Blood 7 (7%) 0 10 (5%) 0.387 5 (11%) 3 (18%) 2 (3%) 0.076 0 0 0 - 
-NP 13 (14%) 0 15 (19%) 0.161 10 (22%) 2 (12%) 15 (22%) 0.616 6 (13%) 1 (11%) 5 (11%) 0.977 
Abbreviations: SD: Standard deviation; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; RTI: Respiratory tract infections; CRP: C-reactive protein; HDP: 
High density pneumococcus; NP: Nasopharyngeal.  
P-values from chi-square and Wilcoxon tests - logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable; P-values could not 
be calculated for variables with zero values for all groups.  
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 b
 - Premature birth defined as gestational age <37 weeks; 
c 
- controls with 
any signs or symptoms of respiratory tract infections; 
d 
- Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if 
aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
e
 - Fever defined as temperature ≥38oC; f - CRP defined as levels ≥40mg/mL which are considered 
to show potential bacterial infection. Only a subset of randomly chosen controls had CRP testing conducted at the South African site; 
g
 - Blood sample positive for S. 
pneumoniae colonisation by LytA PCR; 
h
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL. 
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5.1.3 Molecular subtyping of the HRV-associated cases 
Of the 439 HRV-associated cases, 428 (97%) samples were successfully amplified and 
subtyped. The remaining 3% (n=11) of samples failed to amplify, all of which were of very 
low copy numbers (Ct >37) on the real-time PCR assay. Furthermore, of the 428 successfully 
amplified samples, 3% (n=13) were typed as enterovirus which is a closely related member of 
HRV among the Picornaviridae family. Thus, samples from 91% (n=415) of the HRV-
associated cases were successfully speciated. The order of prevalence of the HRV species 
among cases were HRV-A (48%, n=199), HRV-C (45%, n=185) and least common HRV-B 
(7%, n=31). This distribution of HRV species differed significantly by age-group with HRV-
A being most prevalent among infants (52%), followed by HRV-C (38%) then HRV-B 
(10%), compared to HRV-C (60%) being most prevalent among children 1-5 years of age, 
followed by HRV-A (38%) and HRV-B (2%, P=0.002).  
 
Similar to among controls, HRV-B was the least prevalent species (7%) and appeared 
sporadically throughout the two years; Figure 5.1. This limited the ability to conduct any in-
depth statistical analysis specific to HRV-B; nonetheless, there were no significant differences 
in demographics and clinical presentation or markers of more severe disease between HRV-B 
associated cases compared to HRV-A or HRV-C associated cases, except that HRV-B (4.8 
months) cases were significantly younger than HRV-A (9.4 months, P=0.01) and HRV-C 
(12.1 months, P<0.001) associated cases; Table 5.4. Further species specific analyses were 
limited to comparing HRV-A to HRV-C associated cases; Table 5.4-5.6.  
 
In the multivariate logistic regression model which was adjusted for confounding variates 
(P<0.2 in univariate analysis) as well as HIV-1-infection status, co-infecting viruses and 
bacteria; cases with HRV-A were younger (9.4 months) than HRV-C (12.1 months, P=0.033) 
cases. Furthermore, HRV-A associated cases were 1.57-fold (aOR 95% CI: 1.02-2.41) more 
likely to have radiographically confirmed pneumonia (abnormal chest X-ray defined as 
primary end point pneumonia or any infiltrates) than HRV-C (46% vs. 36%, P=0.040), and 
2.23-fold (aOR 95% CI: 1.24-4.02) more likely to present with concurrent diarrhoea (26% vs. 
14%, P=0.007). Conversely, cases with HRV-C were 1.60-fold (aOR 95% CI: 1.02-2.67) 
more likely to present with wheeze (35%) than HRV-A cases (25%, P=0.031).  
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There were no other differences in markers for more severe disease such as hypoxia at 
admission (55% vs. 74%, P=0.206), mechanical ventilation support (3% vs. 4%, P =0.362), 
hospital stay >3 days (71% vs. 16%, P=0.234) or clinical severity of pneumonia (44% vs. 
39%, P =0.265) between HRV-A and HRV-C associated cases. Also, there were no 
differences in laboratory parameters and putative markers of bacterial co-infections such as 
CRP ≥40mg/mL (29% vs. 25%, P=0.267), leucocytosis (44% vs. 41%, P=0.209), 
microbiologically confirmed pneumococcal pneumonia (3% vs. 1%, P=0.143), blood culture 
positivity (5% vs. 6%, P=0.623) or high colonisation densities of Streptococcus pneumoniae 
(LytA) in the nasopharynx (19% vs. 13%, P=0.069) or blood (7% vs. 5%, P=0.471). 
Additionally, there were no differences in the HRV viral load between the species. For the 
viral co-infections in the univariate analysis, HRV-A was less likely to be co-detected with 
AdV (9% vs. 16%, P=0.024) and HBoV (9% vs. 17%, P=0.029) but more likely to be co-
infected with PIV (9% vs. 3%, P=0.024) compared with HRV-C. After multivariate analysis 
the only association that remained was between HRV-A and PIV (P=0.036). Also, the case 
fatality ratio was similar between HRV-A (21%) compared to HRV-C (16%, P=0.522) 
associated cases; Table 5.4.  
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Table 5.4: The demographics and clinical characteristics of cases infected with HRV-A, HRV-B and HRV-C 
  HRV-A 
(n=119) 
HRV-B 
(n=31) 
HRV-C 
(n=185) 
Unadjusted  
P-value OR (95% CI) 
Adjusted  
P-value aOR (95% CI) 
Age in months, mean (SD) 9.4 (9.5) 4.8 (4.9) 12.1 (10.2) 0.023  0.033  
Female, n(%) 82 (41%) 17 (55%) 92 (50%) 0.094 0.71 (0.47-1.08) 0.126 0.72 (0.48-1.10) 
HIV positive, n(%) 30 (15%) 2 (6%) 16 (9%) 0.044 1.56 (1.05-2.58) 0.059 1.96 (0.98-3.94) 
HEU, n (%)
a
 41 (24%) 3 (10%) 45 (27%) 0.617 1.06 (0.83-1.36) 0.786 0.93 (0.53-1.62) 
Never breast fed, n(%) 40 (20%) 4 (13%) 27 (14%) 0.157 1.47 (0.86-2.51) 0.099 1.78 (1.02-3.11) 
Under weight, n (%)
b
 71 (36%) 7 (23%) 51 (28%) 0.089 1.46 (0.95-2.25) 0.061 1.54 (0.98-2.42) 
Day care attendance, n(%) 55 (28%) 7 (23%) 43 (23%) 0.331 1.25 (0.80-1.98) 0.126 1.63 (0.87-3.05) 
Smoker in household, n(%) 69 (35%) 9 (29%) 56 (30%) 0.421 1.19 (0.78-1.83) 0.290 1.28 (0.81-2.0) 
Premature birth, n(%)
c
 26 (13%) 2 (6%) 15 (8%) 0.248 1.42 (0.79-2.53) 0.266 1.43 (0.76-2.71) 
Birth weight, mean (SD) 2.9 (0.7) 3.0 (0.7) 3.0 (0.6) 0.237  0.235  
Clinical features:        
Very severe pneumonia, n(%) 88 (44%) 12 (39%) 72 (39%) 0.293 1.24 (0.83-1.87) 0.265 1.31 (0.85-2.01) 
CXR abnormal, n(%)
d
 91 (46%) 15 (48%) 66 (36%) 0.046 1.52 (1.01-2.29) 0.040 1.57 (1.02-2.41) 
Supplementary 02 therapy, n(%) 113 (57%) 20 (65%) 110 (59%) 0.596 0.89 (0.60-1.34) 0.791 0.92 (0.49-1.70) 
Mechanical ventilation, n(%) 6 (3%) 0 7 (4%) 0.678 0.79 (0.26-2.40) 0.362 0.58 (0.18-1.86) 
Hypoxic, n(%)
e
 108 (55%) 23 (74%) 120 (60%) 0.302 0.81 (0.54-1.21) 0.206 0.76 (0.49-1.19) 
Tachycardia, n(%)
f
 113 (57%) 17 (55%) 108 (58%) 0.796 0.95 (0.63-1.42) 0.818 0.95 (0.62-1.46) 
Tachypnea, n(%)
g
 169 (86%) 24 (77%) 161 (87%) 0.818 0.93 (0.52-1.68) 0.931 1.09 (0.59-2.01) 
Wheezing, n(%) 49 (25%) 7 (23%) 65 (35%) 0.025 0.60 (.39-0.94) 0.031 0.61 (0.39-0.95) 
Cough, n(%) 142 (71%) 23 (74%) 139 (75%) 0.339 0.80 (0.51-1.26) 0.494 0.82 (0.50-1.34) 
Lethargic, n(%) 26 (13%) 3 (10%) 15 (8%) 0.119 1.70 (0.87-3.33) 0.056 1.97 (0.98-3.96) 
Fever, n(%)
h
 152 (76%) 23 (74%) 139 (75%) 0.776 1.08 (0.67-1.71) 0.901 1.04 (0.64-1.69) 
Convulsions, n(%) 14 (7%) 2 (6%) 4 (2%) 0.033 3.43 (1.11-10.60) 0.098 2.78 (0.82-9.45) 
Diarrhoea, n(%) 51 (26%) 8 (26%) 26 (14%) 0.005 2.11 (1.25-3.55) 0.007 2.23 (1.24-4.02) 
Head nodding, n(%) 54 (27%) 9 (29%) 51 (28%) 0.924 0.98 (0.62-1.53) 0.947 1.00 (0.63-1.61) 
Central cyanosis, n(%) 9 (5%) 1 (3%) 3 (2%) 0.118 2.87 (0.77-10.78) 0.199 2.50 (0.64-9.62) 
Unable to Feed, n(%) 17 (9%) 1 (3%) 17 (9%) 0.824 0.92 (0.46-1.87) 0.611 0.87 (0.41-1.86) 
Vomiting everything, n(%) 4 (2%) 0 2 (1%) 0.470 1.87 (0.34-10.37) 0.510 2.17 (0.37-12.55) 
Lower chest wall indrawing, n(%) 183 (92%) 28 (90%) 176 (95%) 0.212 0.58 (0.25-1.36) 0.078 0.46 (0.19-1.10) 
Stridor, n(%) 7 (4%) 1 (3%) 6 (3%) 0.684 0.81 (0.29-2.27) 0.875 0.76 (0.26-2.22) 
Grunting, n(%) 46 (23%) 10 (32%) 46 (25%) 0.597 0.88 (0.56-1.40) 0.333 0.75 (0.43-1.30) 
Nasal Flaring, n(%) 152 (76%) 24 (77%) 148 (80%) 0.392 0.81 (0.50-1.32) 0.575 0.83 (0.50-1.40) 
Laboratory markers:        
Leucocytosis, n(%)
i
 88 (44%) 13 (42%) 75 (41%) 0.524 1.14 (0.76-1.71) 0.209 1.27 (0.82-1.97) 
Neutrophils %, median (IQR) 49.1 (32.9-60) 34.7 (24.1-58) 51 (36.5-67) 0.049  0.716  
Lymphocyte %, median (IQR) 41.1 (30.8-54) 52.7 (30.3-65) 37 (24.3-52) 0.052  0.779  
Eosinophils %, median (IQR) 1 (0.1-2.8) 1.05 (0.2-3.3) 0.6 (0.1-2) 0.044  0.058  
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CRP≥40mg/l, n(%)j 58 (29%) 10 (32%) 47 (25%) 0.412 1.21 (0.77-1.90) 0.267 1.32 (0.83-2.10) 
Blood culture positive, n(%)
k
 10 (5%) 5 (16%) 11 (6%) 0.692 0.84 (0.34-2.02) 0.623 0.83 (0.33-2.04) 
LytA positive, n(%)
l
 19 (9%) 4 (12%) 15 (7%) 0.514 1.28 (0.61-2.73) 0.469 1.30 (0.60-2.82) 
MCPP, n(%)
m
 6 (3%) 0 2 (1%) 0.204  2.84 (0.57-14.27) 0.143 3.78 (0.70-20.50) 
HDP, n(%)
n
        
-Blood 13 (7%) 3 (10%) 9 (5%) 0.433 1.42 (0.59-3.41) 0.471 1.40 (0.57-3.43) 
-NP 38 (19%) 4 (13%) 24 (13%) 0.105 1.58 (0.91-2.76) 0.069 1.72 (0.96-3.09) 
HRV NP viral load, Mean (SD)
o
 3.5 (3.0-4.1) 3.5 (2.8-3.8) 3.5 (3.1-4.3) 0.544  0.846  
HRV mono-infections, n(%) 110 (55%) 13 (42%) 100 (54%) 0.810 1.05 (0.70-1.57) 0.742 1.07 (0.70-1.63) 
Viral co-infections in the nasopharynx:       
-AdV, n(%) 17 (9%) 3 (10%) 30 (16%) 0.024 0.58 (0.26-0.91) 0.116 0.58 (0.29-1.14) 
-RSV, n(%) 36 (18%) 8 (26%) 24 (13%) 0.169 1.48 (0.85-2.60) 0.679 1.14 (0.62-2.07) 
-HBoV, n(%) 18 (9%) 5 (16%) 31 (17%) 0.029 0.49 (0.27-0.92) 0.095 0.58 (0.30-1.10) 
-HMPV, n(%) 5 (3%) 1 (3%) 6 (3%) 0.669 0.77 (0.23-2.56) 0.592 0.71 (0.20-2.45) 
-InFV A-C, n(%) 2 (1%) 0 2 (1%) 0.942 0.93 (0.13-6.66) 0.954 1.06 (0.14-7.98) 
-PIV, n(%) 18 (9%) 2 (6%) 6 (3%) 0.024 2.97 (1.15-7.65) 0.036 2.82 (1.07-7.40) 
-HCoV, n(%) 11 (6%) 1 (3%) 14 (8%) 0.420 0.71 (0.32-1.62) 0.414 0.70 (0.30-1.63) 
Hospital stay >3 days, n(%) 141 (71%) 23 (74%) 117 (63%) 0.113 1.41 (0.92-2.17) 0.234 1.34 (0.85-2.10) 
Case fatality ratio, n(%) 32 (21%) 2 (9%) 25 (16%) 0.332 1.33 (0.75-2.37) 0.522 1.23 (0.66-2.29) 
Abbreviations - HRV: Human rhinovirus; OR: Odds ratios; aOR: Adjusted odds ratio; CI: Confidence intervals, SD: Standard deviation; IQR: Inter quartile range; HIV: 
Human immunodeficiency virus; HEU: HIV-uninfected but HIV exposed; CXR: Chest X-ray; CRP: C-reactive protein; MCPP: Microbiologically confirmed pneumococcal 
pneumonia; HDP: High Density pneumococcus; NP: Nasopharyngeal; RSV: Respiratory Syncytial Virus, HMPV: human metapneumovirus; AdV: adenovirus; PIV: 
parainfluenza type 1-4; HBoV: Human Bocavirus; HCoV: Human Coronavirus (OC43, NL63, 229E and HKU1) and InFV: Influenza Virus (A, B and C).
 
Odds ratios and P-values were calculated by comparing HRV-A to HRV-C infected cases using Chi-squared and Wilcoxon tests, logistic regression models adjusted for 
confounding variates (<0.2 in univariate analysis) where applicable; Odds ratio could not be calculated for continuous variables or variables with 0 values, thus cells left blank. 
a 
- HEU defined as undetectable viral load, HIV seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except 
for seronegative children < 7 months of age where documented positive maternal status was required; 
b
 - Underweight defined as weight for age <-2SD of the median age-sex 
specific WHO reference; 
c
 - Premature birth defined as gestational age <37 weeks; 
d 
- Abnormal Chest X-ray defined as radiographically confirmed end point pneumonia 
consolidation or any infiltrates; 
e
 - Hypoxic defined as 1) a room air pulse-oximetry reading indicated oxygen saturation <90% at the two sites at elevation (Zambia and South 
Africa) or <92% at all other sites, or 2) a room air oxygen saturation reading was not available and the child was on oxygen; 
f 
- Tachycardia defined as heart rate >160 beats 
per minute (bpm) if aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
g 
- Tachypnea defined as Respiratory rate >60 
breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
h 
- Fever defined as 
temperature >38
o
C; 
i
 - Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 000 cells/uL if age >12 months; 
j
 - CRP 
defined as levels ≥40mg/mL which are considered to potentially indicate bacterial infection; k - Blood culture positive for any significant non contaminate bacteria; l - Blood 
sample positive for S. pneumoniae colonisation by LytA PCR; 
m
 - MCPP defined when S. pneumoniae was cultured from a normally sterile body fluid - blood, pleural fluid or 
lung aspirate - or pleural fluid or lung aspirate was PCR LytA positive; 
n
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample 
>2.2 log10 copies/mL; 
o
 - HRV viral load in the nasopharynx expressed as log10 copies/mL. 
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Among HRV-associated cases, HRV was identified as the sole respiratory virus in the 
nasopharynx 54% (n=223/415) of cases, including 55% (n=110/199) of HRV-A; 42% 
(n=13/31) of HRV-B and 54% (n=100/185) of HRV-C infections (P=0.380). There were no 
differences in the nasopharyngeal viral loads of HRV between the mono and mixed viral 
infections for any of the species. The clinical presentation, including pneumonia severity 
categorisation at admission, signs and symptoms of illness and laboratory parameters did not 
differ between cases with mono HRV-A compared to those with concurrent HRV-A 
infections with other respiratory viruses, including Influenza virus (A-B), RSV, HMPV, 
HBoV, PIV (1-4), AdV and HCoV. What was notable, was the higher case fatality ratio 
among HRV-A mono-infections (28%) than those with HRV-A together with other 
concurrent respiratory infections (10%, P=0.005). This association of higher case fatality 
ratio remained in the multivariate analysis which was adjusted for confounding variates 
(P<0.2 in univariate analysis) including HIV infection status, age categories, gender, site of 
enrolment, malnutrition and potential concurrent bacterial infection (aOR 5.81, 95% CI: 1.70-
19.98, P=0.005); Table 5.5. Moreover, HRV-A mono-infected cases had 2.20-fold (aOR 95% 
CI: 1.20-4.04) higher case fatality ratio (28%) than all other cases (16%, P=0.011). 
  
Among the HRV-C associated cases, HRV-C mono viral infections compared to HRV-C 
mixed-infection cases were 5.57-fold (aOR 95% CI: 1.77-17.47) more likely to have 
concurrent diarrhoea (18% vs. 9%, P=0.003) and 2.29-fold (aOR 95% CI: 1.20-4.38) more 
likely to present with tachycardia (68% vs. 47%, P=0.012). The HRV-C associated cases with 
mixed viral infections were however 2.19-fold (aOR 95% CI: 1.08-4.69) more likely to 
present with fever (82% vs. 69%, P=0.044), 2.07-fold (aOR 95% CI: 1.04-4.27) more likely 
to be categorised as very severe pneumonia (47% vs. 32%, P=0.49) and 2.84-fold (aOR 95% 
CI: 1.37-5.87) more likely to be hospitalised for >3 days (74% vs. 54%, P=0.005) compared 
to cases with HRV-C mono-infections; Table 5.5. There was no other association between 
HRV-C associated cases with mono compared to mixed viral infections, including no 
differences in presence of hypoxia, requiring mechanical ventilation and case fatality ratio 
(20% vs. 12% P=0.190); Table 5.5. 
 
On comparison of cases with HRV-A and HRV-C mono-infections, the HRV-A mono-
infected cases were 2.80-fold (aOR 95% CI: 1.05-7.51) more likely to present with lethargy 
(17% vs. 7%, P=0.041), 15.45-fold (aOR 95% CI: 1.39-172.40) more likely to present with 
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concurrent convulsions (8% vs. 1%, P=0.026) and 1.83-fold (aOR 95% CI: 1.07-3.49) more 
likely to be hospitalised for >3 days (72% vs. 54%, P=0.039). There were, however, no 
differences in case fatality ratio between HRV-A (28%) and HRV-C mono-infected cases 
(20%, P=0.297); Table 5.5.  
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Table 5.5: The demographics and clinical characteristics of cases with HRV-A, HRV-B and -C mono-infections compared to cases with HRV 
mixed infections 
  HRV-A  
mono (n=110) 
HRV-A 
mixed (n=89) 
P-value
a
 HRV-B  
mono (n=13) 
HRV-B 
mixed (n=18) 
P-value
b
 HRV-C  
mono (n=100) 
HRV-C 
mixed (n=85) 
P-value
c
 P-value
d
 
Age in months, mean (SD) 10.0 (11.7) 7.6 (8.6) 0.089 5.6 (6.5) 4.4 (3.6) 0.503 11.5 (11.0) 11.1 (9.2) 0.918 0.364 
Female, n(%) 47 (43%) 35 (39%) 0.902 7 (54%) 10 (56%) 0.925 51 (51%) 41 (48%) 0.758 0.246 
HIV positive, n(%) 17 (15%) 13 (15%) 0.613 1 (8%) 1 (6%) 0.124 10 (10%) 6 (7%) 0.456 0.311 
HEU, n(%)
e
 24 (26%) 17 (22%) 0.604 0 3 (18%) 0.124 25 (28%) 20 (25%) 0.718 0.763 
Never breast fed, n(%) 36 (33%) 24 (27%) 0.485 2 (15%) 2 (11%) 0.726 29 (29%) 25 (29%) 0.690 0.761 
Under weight, n (%)
f 
42 (38%) 29 (33%) 0.497 4 (31%) 3 (17%) 0.352 25 (25%) 26 (31%) 0.437 0.059 
Day care attendance, n(%) 25 (23%) 30 (34%) 0.547 1 (8%) 6 (33%) 0.092 37 (34%) 32 (36%) 0.513 0.756 
Smoker in household, n(%) 37 (34%) 32 (36%) 0.400 2 (15%) 7 (39%) 0.155 26 (26%) 30 (35%) 0.150 0.194 
Premature birth, n(%)
g
 15 (14%) 11 (12%) 0.833 1 (8%) 1 (6%) 0.675 8 (8%) 7 (8%) 0.592 0.482 
Birth weight, mean (SD) 2.9 (0.7) 2.9 (0.7) 0.915 2.9 (0.8) 3.2 (0.6) 0.376 3.0 (0.6) 3.0 (0.7) 0.886 0.221 
Clinical features:            
Very severe pneumonia, n(%) 48 (44%) 40 (45%) 0.777 7 (54%) 5 (28%) 0.141 32 (32%) 40 (47%) 0.045 0.064 
CXR abnormal, n(%)
h
 46 (41%) 45 (51%) 0.103 7 (54%) 8 (44%) 0.605 32 (32%) 34 (40%) 0.230 0.156 
CXR Alveolar consolidation, n(%) 18 (19%) 9 (11%) 0.210 4 (33%) 2 (12%) 0.158 10 (11%) 8 (10%) 0.877 0.168 
Supplementary 02 therapy, n(%) 67 (61%) 46 (52%) 0.953 11 (85%) 9 (50%) 0.087 62 (62%) 48 (56%) 0.672 0.746 
Mechanical ventilation, n(%) 4 (4%) 2 (2%) 0.569 0 0  3 (3%) 4 (5%) 0.482 0.901 
Hypoxic, n(%)
i 
55 (50%) 53 (60%) 0.084 9 (70%) 14 (78$) 0.592 56 (57%) 54 (64%) 0.441 0.224 
Tachycardia, n(%)
j
 66 (60%) 47 (53%) 0.458 5 (39%) 12 (67%) 0.119 68 (68%) 40 (47%) 0.010 0.273 
Tachypnea, n(%)
k
 145 (85%) 79 (91%) 0.082 11 (85%) 13 (72%) 0.514 88 (88%) 73 (86%) 0.696 0.390 
Wheezing, n(%) 27 (25%) 22 (25%) 0.956 2 (15%) 5 (28%) 0.415 35 (35%) 30 (35%) 0.687 0.149 
Cough, n(%) 76 (69%) 66 (74%) 0.292 8 (62%) 15 (83%) 0.171 72 (72%) 67 (79%) 0.144 0.756 
Lethargic, n(%) 19 (17%) 7 (8%) 0.066 3 (23%) 0 0.092 7 (7%) 8 (9%) 0.553 0.041 
Fever, n(%)
l
 88 (80%) 64 (72%) 0.099 11 (85%) 12 (67%) 0.260 69 (69%) 70 (82%) 0.044 0.062 
Convulsions, n(%) 9 (8%) 5 (6%) 0.296 2 (15%) 0 0.185 1 (1%) 3 (4%) 0.282 0.026 
Diarrhoea, n(%) 28 (25%) 23 (26%) 0.843 4 (31%) 4 (2%) 0.592 18 (18%) 8 (9%) 0.003 0.280 
Head nodding, n(%) 23 (21%) 31 (35%) 0.223 4 (31%) 5 (28%) 0.856 21 (21%) 30 (35%) 0.088 0.975 
Central cyanosis, n(%) 7 (6%) 2 (2%) 0.189 1 (8%) 0 0.232 3 (3%) 11 (3%) 0.903 0.272 
Unable to Feed, n(%) 11 (10%) 6 (7%) 0.158 0 1 (6%) 0.388 10 (10%) 7 (8%) 0.510 0.840 
Vomiting everything, n(%) 4 (4%) 0 0.194 0 0  1 (1%) 1 (1%) 0.913 0.250 
Lower chest wall indrawing, n(%) 99 (90%) 84 (95%) 0.154 11 (85%) 17 (94%) 0.361 96 (96%) 80 (94%) 0.631 0.072 
Stridor, n(%) 2 (2%) 5 (6%) 0.286 0 1 (6%) 0.388 5 (5%) 1 (1%) 0.673 0.232 
Grunting, n(%) 19 (17%) 27 (30%) 0.123 5 (38%) 5 (28%) 0.530 21 (21%) 25 (29%) 0.651 0.297 
Nasal Flaring, n(%) 81 (74%) 71 (80%) 0.486 10 (77%) 14 (78%) 0.955 81 (81%) 67 (79%) 0.417 0.231 
 
Laboratory markers: 
          
Leucocytosis, n(%)
m
 54 (50%) 34 (38%) 0.256 6 (46%) 7 (39%) 0.686 39 (40%) 36 (43%) 0.397 0.097 
Neutrophils %, Median (IQR) 50.3 (36.9-66) 43.1 (28-55) 0.113 39.6 (31-52) 40.2 (30.9-48) 0.947 48.9 (36-64) 55.3 (37-69) 0.683 0.588 
Lymphocyte %, Median (IQR) 37.5 (25.6-49) 46.2 (36-59.4) 0.052 42.8 (33.6-49) 37.9 (28.2-51) 0.840 37.2 (26-52) 34.1 (22-52.8) 0.823 0.495 
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Eosinophils %, Median (IQR) 0.5 (0-1.8) 0.5 (0-2) 0.664 0.6 (0-2.1) 0.8 (0-2.3) 0.868 1 (0.2-2.8) 1 (0.1-2.6) 0.887 0.148 
CRP≥40mg/l, n(%)
n
 34 (31%) 24 (27%) 0.982 5 (38%) 5 (27%) 0.530 27 (27%) 20 (24%) 0.743 0.461 
Blood culture positive, n(%)
o
 6 (5%) 4 (4%) 0.768 3 (23%) 2 (11%) 0.371 7 (7%) 4 (5%) 0.353 0.621 
LytA positive, n(%)
p
 7 (7%) 10 (12%) 0.416 1 (8%) 3 (18%) 0.474 10 (10%) 3 (4%) 0.064 0.337 
MCPP, n(%)
q
 4 (4%) 2 (2%) 0.545 0 0  2 (2%) 0 0.299 0.446 
HDP, n(%)
r
           
-Blood 4 (4%) 9 (10%) 0.098 0 3 (18%) 0.124 8 (8%) 1 (1%) 0.035 0.286 
-NP 19 (21%) 19 (17%) 0.684 2 (15%) 3 (17%) 0.924 9 (9%) 15 (18%) 0.148 0.064 
HRV NP viral load, Mean (SD)
s
 3.5 (3.0-4.1) 3.4 (3.0-4.1) 0.664 3.8 (0.5) 3.2 (0.9) 0.137 3.6 (3.1-4.2) 3.6 (3.0-4.3) 0.402 0.591 
Hospital stay >3 days, n(%) 79 (72%) 62 (70%) 0.660 11 (85%) 12 (67%) 0.260 54 (54%) 63 (74%) 0.005 0.039 
Case fatality ratio, n(%) 25 (28%) 7 (10%) 0.005 2 (25%) 0 0.150 16 (20%) 9 (12%) 0.190 0.297 
Abbreviations - HRV: Human rhinovirus; OR: Odds ratios; aOR: Adjusted odds ratio; CI: Confidence intervals, CXR: Chest X-ray; HIV: Human immunodeficiency virus; 
HEU: HIV-uninfected but HIV exposed; CRP: C-reactive protein; MCPP: Microbiologically confirmed pneumococcal pneumonia; HDP: High Density pneumococcus; NP: 
Nasopharyngeal.
 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis) where applicable. P-values could not 
be calculated for variables where both groups were zero, thus left blank. 
a
 - P-values for the comparison of HRV-A mono vs. mixed infections; 
b
 - P-values for the comparison of HRV-B mono vs. mixed infections; 
c -
 P-values for the comparison of 
HRV-C mono vs. mixed infections; 
d
 - P-values for the comparison of HRV-A mono vs. HRV-C mono-infections; 
e
 - HEU defined as undetectable viral load, HIV 
seronegative in the child with a positive maternal history. Positive maternal status based on self-report was accepted, except for seronegative children < 7 months of age where 
documented positive maternal status was required; 
f
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference; 
g
 - Premature birth 
defined as gestational age <37 weeks; 
h 
- Abnormal Chest X-ray defined as radiographically confirmed end point pneumonia consolidation or any infiltrates; 
i
 - Hypoxic 
defined as 1) a room air pulse-oximetry reading indicated oxygen saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a 
room air oxygen saturation reading was not available and the child was on oxygen; 
j 
- Tachycardia defined as heart rate >160 beats per minute (bpm) if aged <11 months, heart 
rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
k 
- Tachypnea defined as Respiratory rate >60 breaths/minute if aged <2 months, respiratory 
rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 months; 
l 
- Fever defined as temperature >38
o
C; 
m
 - Leucocytosis defined as 
white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 000 cells/uL if age >12 months; 
n
 - CRP defined as levels ≥40mg/mL which are 
considered to potentially indicate bacterial infection; 
o
 - Blood culture positive for any significant non contaminate bacteria; 
p
 - Blood sample positive for S. pneumoniae 
colonisation by LytA PCR; 
q
 - MCPP defined when S. pneumoniae was cultured from a normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or 
lung aspirate was PCR LytA positive; 
r
 - HDP defined as S. pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL; 
s
 - HRV 
viral load in the nasopharynx expressed as log10 copies/mL. 
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Similar trends as observed in the overall analysis of the three sites; Table 5.4, were evident 
when analysed for the individual three sites, with HRV-C being significantly associated with 
older children in South Africa (10 months vs. 5 and 3.5 months for HRV-A and -B 
respectively, P<0.001). Additionally, even after multivariate logistic regression adjusting for 
age group, gender, HIV infection status, malnutrition, bacterial and viral co-infection, other 
site specific significant differences included HRV-C being less associated with concurrent 
diarrhoea in South Africa (7% vs. 29% and 25% for HRV-A and HRV-B respectively, 
P<0.001), and more likely to have lower chest wall indrawing in Mali (98% vs. 83% and 89% 
for HRV-A and -B respectively, P=0.009). In Zambia, HRV-A associated cases were more 
likely to be HIV-infected (24%) compared to HRV-B (0%) and HRV-C cases (6%, P=0.010); 
Table 5.6. There were no other associations in clinical presentation, markers for bacterial co-
infections, hospital stays >3 days or case fatality ratio between the three HRV species at any 
of the sites.  
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Table 5.6: The demographics and clinical characteristics of HRV-associated cases stratified by HRV species for each of the sites 
  South-African HRV+ pneumonia cases (n=198) Mali HRV+ pneumonia cases (n=108)   Zambia HRV+ pneumonia cases (n=109) 
  HRV-A 
(n=91) 
HRV-B  
(n=16) 
HRV-C  
(n=91) 
P-value HRV-A 
(n=53) 
HRV-B 
(n=9) 
HRV-C 
(n=46) 
P-value HRV-A 
(n=55) 
HRV-B  
(n=6) 
HRV-C 
(n=48) 
P-value 
Age in months, median (IQR) 5 (2-9) 3.5 (2-7) 10 (5-17) P<0.001 5 (3-11) 2 (1-6) 5.5 (3-12) 0.434 8.5 (3.5-14.5) 3 (3-7) 5 (3-11) 0.187 
Female, n(%) 35 (38%) 7 (44%) 46 (51%) 0.1720 19 (36%) 6 (67%) 23 (50%) 0.132 28 (51%) 4 (67%) 23 (48%) 0.609 
HIV positive, n(%) 15 (16%) 2 (13%) 11 (12%) 0.753 2 (4%) 0 2 (4%) 0.691 13 (24%) 0 3 (6%) 0.010 
Never breast fed, n(%) 44 (48%) 9 (56%) 40 (44%) 0.930 7 (13%) 2 (22%) 8 (17%) 0.727 9 (16%) 0 6 (13%) 0.270 
Under weight, n (%)a 26 (29%) 3 (19%) 17 (19%) 0.323 20 (38%) 3 (33%) 16 (35%) 0.903 25 (45%) 1 (17%) 18 (38%) 0.269 
Clinical features:             
Very severe pneumonia, n(%) 37 (41%) 5 (31%) 30 (33%) 0.550 32 (60%) 5 (56%) 28 (61%) 0.956 19 (35%) 2 (33%) 14 (29%) 0.809 
Chest X-ray abnormal, n(%)b 52 (57%) 9 (56%) 38 (42%) 0.152 14 (26%) 3 (33)% 16 (35%) 0.627 25 (45%) 3 (50%) 12 (25%) 0.112 
Supplementary 02 therapy, n(%) 84 (92%) 15 (94%) 84 (92%) 0.976 0 0 3 (7%) 0.081 29 (53%) 5 (83%) 23 (48%) 0.295 
Hypoxic, n(%)c 64 (71%) 14 (88%) 68 (76%) 0.256 22 (42%) 6 (67%) 28 (61%) 0.095 22 (40%) 3 (50%) 14 (29%) 0.525 
Tachycardia, n(%)d 43 (48%) 7 (44%) 46 (51%) 0.919 30 (57%) 6 (67%) 28 (61%) 0.829 40 (73%) 4 (67%) 34 (71%) 0.950 
Tachypnea, n(%)e 69 (78%) 12 (75%) 78 (86%) 0.546 49 (92%) 6 (67%) 42 (91%) 0.137 51 (93%) 6 (100%) 41 (85%) 0.102 
Wheezing, n(%) 31 (34%) 4 (25%) 40 (44%) 0.665 12 (23%) 2 (22%) 11 (24%) 0.984 6 (11%) 1 (17%) 14 (29%) 0.104 
Cough, n(%) 79 (87%) 12 (75%) 79 (87%) 0.547 29 (55%) 6 (67%) 27 (59%) 0.758 34 (62%) 5 (83%) 33 (69%) 0.478 
Lethargic, n(%) 5 (5%) 0 6 (7%) 0.243 10 (19%) 1 (11%) 5 (11%) 0.335 11 (20%) 2 (33%) 4 (8%) 0.079 
Fever, n(%)f 59 (65%) 11 (69%) 67 (74%) 0.399 46 (87%) 7 (78%) 38 (83%) 0.730 47 (85%) 5 (83%) 34 (71%) 0.405 
Convulsions, n(%) 4 (4%) 0 1 (1%) 0.273 8 (15%) 1 (11%) 2 (4%) 0.159 2 (4%) 1 (17%) 1 (2%) 0.295 
Diarrhoea, n(%) 26 (29%) 4 (25%) 6 (7%) P<0.001 11 (21%) 3 (33%) 12 (26%) 0.656 14 (25%) 1 (17%) 8 (17%) 0.157 
Head nodding, n(%) 31 (34%) 5 (31%) 25 (27%) 0.605 18 (34%) 4 (44%) 19 (41%) 0.694 5 (9%) 0 7 (15%) 0.339 
Central cyanosis, n(%) 1 (1%) 0 0 0.559 3 (6%) 1 (11%) 3 (7%) 0.864 5 (9%) 0 0 0.047 
Unable to Feed, n(%) 0 0 2 (2%) 0.201 12 (23%) 1 (11%) 12 (26%) 0.602 5 (9%) 0 3 (6%) 0.496 
Vomiting everything, n(%) 2 (2%) 0 1 (1%) 0.664 0 0 1 (2%) 0.473 2 (4%) 0 0 0.244 
Lower chest wall indrawing, n(%) 87 (96%) 15 (94%) 86 (95%) 0.930 44 (83%) 8 (89%) 45 (98%) 0.009 52 (95%) 5 (83%) 45 (94%) 0.699 
Stridor, n(%) 2 (2%) 0 4 (4%) 0.214 4 (8%) 0 1 (2%) 0.307 1 (2%) 1 (17%) 1 (2%) 0.363 
Grunting, n(%) 2 (2%) 3 (19%) 5 (5) 0.855 31 (58%) 7 (78%) 28 (61%) 0.554 13 (24%) 0 13 (27%) 0.207 
Nasal Flaring, n(%) 82 (90%) 13 (81%) 78 (86%) 0.404 41 (77%) 7 (78%) 38 (83%) 0.790 29 (53%) 4 (67%) 32 (67%) 0.308 
Laboratory markers:             
Leucocytosis, n(%)g 45 (49%) 10 (63%) 46 (51%) 0.517 15 (28%) 1 (11%) 10 (22%) 0.492 28 (52%) 2 (33%) 19 (41%) 0.464 
Neutrophils %, median (IQR) 47 (33-56.9) 41 (24.3-60.4) 55.3 (40.7-70) 0.263 51 (30-61) 26 (23-54) 45 (27-64) 0.279 47 (36.5-64.8) 41.5 (29-58) 50 (34.7-63.9) 0.937 
Lymphocytes %, median (IQR) 41.8 (34-51.4) 51.1 (28.7-65) 33.2 (22-43.9) 0.178 43 (31-61) 65 (44-75) 49 (29-69) 0.289 37 (23.3-52) 49.2 (25.6-61) 37.5 (27.7-50)  
Eosinophils %, median (IQR) 0.3 (0.1-1.2) 1.3 (0.3-3.3) 0.8 (0.1-2.1) 0.102 1 (0-3) 1 (0-5) 2 (0-4) 0.844 0.3 (0.1-0.9) 0.85 (0.2-4.4) 0.8 (0.2-1.8) 0.244 
CRP≥40mg/l, n(%)h 27 (30%) 4 (25%) 19 (21%) 0.470 11 (21%) 4 (44%) 13 (28%) 0.302 20 (36%) 2 (33%) 15 (31%) 0.642 
Blood culture positive, n(%) 1 (1%) 2 (13%) 2 (2%) 0.145 5 (9%) 2 (22%) 6 (13%) 0.563 4 (7%) 1 (17%) 3 (6%) 0.676 
LytA positive, n(%)i 5 (6%) 3 (19%) 4 (4%) 0.137 10 (19%) 1 (11%) 5 (11%) 0.483 2 (4%) 0 4 (9%) 0.582 
MCPP, n(%)j 1 (1%) 0 0 0.429 4 (8%) 0 2 (4%) 0.444 1 (2%) 0 0 0.433 
HDP, n(%)k 14 (15%) 4 (25%) 8 (9%) 0.222 21 (40%) 2 (22%) 17 (37%) 0.601 8 (15%) 0 6 (13%) 0.367 
HRV NP viral load, Mean (SD)l 3.81 (3.2-4.6) 3.45 (3.2-3.8) 3.93 (3.2-4.7) 0.320 3.3 (2.9-3.9) 2.8 (2.4-4.5) 3.4 (2.8-4.2) 0.980 3.13 (2.9-3.7) 3.50 (2.9-3.8) 3.18 (2.9-3.9) 0.831 
Hospital stay >3 days, n(%) 72 (79%) 13 (81%) 68 (75%) 0.995 33 (62%) 6 (67%) 26 (57%) 0.889 36 (66%) 4 (67%) 23 (50%) 0.247 
Case fatality ratio, n(%) 7 (10%) 0 4 (5%) 0.212 13 (25%) 1 (11%) 13 (28%) 0.487 12 (39%) 1 (100%) 8 (28%) 0.194 
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Abbreviations - SD: Standard deviation; IQR: Inter quartile range; HRV: Human rhinovirus; HIV: Human immunodeficiency virus; CRP: C-reactive protein; MCPP: 
Microbiologically confirmed pneumococcal pneumonia; HDP: High Density pneumococcus; NP: Nasopharyngeal
 
P-values from Chi-square and Wilcoxon tests, logistic regression models adjusted for confounding variates (<0.2 in univariate analysis). P-values could not be calculated for 
variables where both values are 0, thus cells left blank. 
a
 - Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference; 
b
 - defined as primary end point pneumonia and/or infiltrates; 
c
 - Hypoxic 
defined as 1) a room air pulse-oximetry reading indicated oxygen saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other sites, or 2) a 
room air oxygen saturation reading was not available and the child was on oxygen; 
d
 - Tachycardia defined as heart rate >160 beats per minute (bpm) if aged <11 months, 
heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
e
 - Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, 
respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 month; 
f
 - Fever defined as body temperature ≥38oC; g - Leucocytosis 
defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell count >13 000 cells/uL if age >12 months; 
h
 - CRP defined as levels ≥40mg/mL which 
are considered to potentially indicate bacterial infection; 
i
 - Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
j
 - MCPP defined if S. pneumoniae was 
cultured from a normally sterile body fluid - blood, pleural fluid or lung aspirate - or pleural fluid or lung aspirate was PCR LytA positive; 
k
 - HDP defined as S. pneumoniae 
density in nasopharynx>6.9 and/or density in whole blood sample>2.2 log10 copies/mL; 
l
 - HRV viral load in the nasopharynx expressed as mean log10 copies/mL. 
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5.1.4 Case-control comparison of the molecular subtyping of HRV 
Overall, the distribution of HRV species did not differ between cases and controls (P=0.496); 
Table 5.7. 
 
Table 5.7: The molecular subtyping of the human HRV population in cases and 
community controls stratified by age groups 
    Overall 
(n=836) 
HRV-A 
(n=389) 
HRV-B  
(n=71) 
HRV-C 
(n=376) 
P-value
a
 
All ages Cases 415 (50%) 199 (49%) 31 (44%) 185 (49%) 0.496 
 Community controls 421 (50%) 190 (51%) 40 (56%) 191 (51%)  
 P-value
b
 0.334 0.425 0.306 0.861  
1-5 months Cases 198 (52%) 110 (56%) 21 (47%) 67 (48%) 0.270 
 Community controls 186 (48%) 88 (44%) 24 (53%) 74 (52%)  
 P-value
b
 0.207 0.107 0.474 0.246  
6-12 months Cases 105 (46%) 46 (46%) 8 (50%) 51 (45%) 0.921 
 Community controls 125 (54%) 54 (54%) 8 (50%) 63 (55%)  
 P-value
b
 0.951 0.925 0.650 0.750  
1-5 years Cases 112 (51%) 43 (47%) 2 (20%) 67 (55%) 0.072 
 Community controls 110 (50%) 48 (53%) 8 (80%) 54 (44%)  
  P-value
b
 0.054 0.568 0.095 0.054  
Abbreviations: HRV - Human rhinovirus.  
P-values chi-square tests with logistic regression models adjusted for confounding variates (<0.2 in univariate 
analysis). 
a
 - P-value for difference between cases and controls across the three HRV species; 
b
 - P-value for comparison of 
individual HRV species between cases and controls for the different age groups. 
 
Figure 5.1 details the seasonal circulation of the three HRV species over the full two-year 
period for the cases and controls. For both cases and controls, HRV-B appeared sporadically 
throughout the year with no obvious seasonality pattern. Furthermore, circulation of HRV-A 
and HRV–C was perennial; and there was no obvious pattern in the circulation of the species 
among both cases and controls. The overall positivity for HRV ranged from 33% in August 
2013 to 4% in October 2011 among cases; and 44% in January 2014 to 2% in October 2011 
among controls during the study period.  
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Figure 5.1: The seasonal distribution of HRV species over a period of two years in children 
hospitalised with pneumonia and age matched community controls. Prevalence is the % of 
tested samples for each month. 
 
There were 60 different HRV-A strains, 17 different HRV-B strains and 28 different HRV-C 
strains circulating throughout the two year period; Figure 5.2. The most commonly detected 
HRV-A strains (n=389) were A78 (n=30, (8%); n=19 (10%) among cases and n=11 (6%) 
among controls), A101 (n=27 (7%); n=15 (8%) among cases and n=12 (6%) among controls), 
A12 (n=19 (5%); n=13 (7%) among cases and n=6 (3%) among controls), A80 (n=16 (4%); 
n=12 (6%) among cases and n=4 (2%) among controls) and A49 (n=12 (3%); n=10 (5%) 
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among cases and n=2 (1%) among controls). The most commonly detected HRV-B strains 
(n=71) were B17 (n=10 (14%); n=4 (13%) among cases and n=6 (15%) among controls), B72 
(n=8 (11%), n=3 (10%) among cases and n=5 (13%) among controls) and B14 (n=8 (11%), 
all of which occurred among cases). Lastly; the most common HRV-C strains (n=376) were 
C11 (n=41 (11%), n=21 (11%) among cases and n=20 (10%) among controls), C35 (n=32 
(8%), n=14 (8%) among cases and n=18 (9%) among controls), NAT045 (n=32 (8%), n=22 
(12%) among cases and n=10 (5%) among controls) and C54 (n=26 (7%), n=12 (6%) among 
cases and n=14 (7%) among controls). No discernible differences were obvious in the 
distribution of strains between cases and controls; moreover, there were no apparent 
differences in the distribution of strains between the three sites (Figure 5.3-5.5). Additionally, 
no obvious patterns of temporal clustering of HRV species or strains were observed with 
strain distribution varying on a month to month basis. The study was not sufficiently powered 
for statistical analysis of case-control status or clinical epidemiology among cases for the 
different strains making up each of the HRV species.  
 
 
 
Figure 5.2: Frequency of HRV strains. For each species the prevalence of detected types is 
both cases and controls are indicated.  
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The HRV sequences for each of the species formed many unique clusters, with mean 
nucleotide diversity of 81.91% for HRV-A (nucleotide diversity range: 45.03% to 100%), 
80.01% for HRV-B (nucleotide diversity range: 52.86% to 100%) and 73.54% for HRV-C 
(nucleotide diversity range 51.89% to 100%). The nucleotide diversity did not differ among 
cases and controls for the different HRV species. The HRV-A and HRV-B sequences 
clustered with statistically significant bootstrap support with the GenBank sequences of 
known HRV-A and -B strains; whereas, the HRV-C sequences tended to form numerous sub-
clusters which did not always cluster closely with the GenBank sequences of known HRV-C 
strains. The numerous clusters and range of nucleotide diversities, especially in the HRV-C 
population, suggest considerable diversity in the strains present in the population (Figure 5.3-
5.5).  
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Figure 5.3: A phylogenetic analysis of HRV-A sequences from South Africa (), Mali () 
and Zambia () alongside reference strains from GenBank (). Sequences with closed 
circles are from cases and those with open circles were detected in controls. Bootstrap values 
after 1000 replicates are shown next to the branches, values <70% have been omitted from the 
tree. The phylogenetic tree is drawn to scale and the branch length are in the same length of 
those used to infer the tree.  
 
Among the HRV-A strains, the nucleotide similarities to the closest GenBank prototype 
reference strains varied from 82.3% to 99.4% and strain identity varied from 79.8% to 100% 
with other contemporaneous HRV-A strains.  
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Figure 5.4: A phylogenetic analysis of HRV-B strains from South Africa (), Mali () and 
Zambia () alongside reference strains from GenBank (). Sequences with closed circles are 
from cases and those with open circles were detected in controls. Bootstrap values after 1000 
replicates are shown next to the branches, values <70% have been omitted from the tree. The 
phylogenetic tree is drawn to scale and the branch length are the same length of those used to 
infer the tree. 
 
Among the HRV-B strains, the nucleotide similarities to the closest GenBank prototype 
reference strains varied from 87.9% to 99.8% and strain identity varied from 91.2% to 100% 
with other contemporaneous HRV-B strains. 
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Figure 5.5: A phylogenetic analysis of HRV-C strains from South Africa (), Mali () and 
Zambia () alongside reference strains from GenBank (). Sequences with closed circles are 
from cases and those with open circles were detected in controls. Bootstrap values after 1000 
replicates are shown next to the branches, values <70% have been omitted from the tree. The 
phylogenetic tree is drawn to scale and the branch length are the same length of those used to 
infer the tree. 
 
Among the HRV-C strains, the nucleotide similarities to the closest GenBank prototype 
reference strains showed much lower relatedness than the other two species and varied from 
74.5% to 98.8%; however, there was a high degree of similarity with the other 
contemporaneous HRV-C strains with strain identity varying from 93.9% to 100%. According 
to the criteria proposed by McIntyre et al. (McIntyre et al. 2013) (pairwise distance >10.5 
with prototype strains) no novel strains were identified in this study.   
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5.2 DISCUSSION 
This study reports the strain typing of 836 HRV positive samples, including 415 samples from 
children hospitalised with severe and very severe pneumonia and 421 samples from 
community controls; making it the largest and most in-depth case-control study reporting on 
HRV molecular subtyping. HRV-A was the dominant species identified among cases (48%) 
and cases (45%), followed closely by HRV-C (45% each among cases and controls), whereas 
HRV-B was only seen intermittently and accounted for 7% and 10% of HRV strains among 
the HRV positive samples among cases and controls, respectively. Among the three Sub-
Saharan countries, the overall prevalence of HRV detection did not differ between cases 
(21%) compared to controls (20%). The HRV prevalence was, however, associated with case 
status (21% vs. 15% among controls) among children 1-5 years of age, among whom there 
was a trend for higher percentage of the HRV belonging to HRV-C species among cases 
(60%) compared to controls (49%), albeit not significant. Furthermore, there was no evidence 
that HRV viral load differed significantly between the HRV species and there was no 
evidence that any of the HRV species were more likely to be associated with either more 
bacterial or viral co-infections. The HRV species distribution among cases and controls in our 
study are similar to that reported by others in both hospitalised and control populations [53, 
92, 99, 123, 125].  
 
Studies from Africa, Asia, Europe, America and Australia [26, 37, 42, 43] have all suggested 
that HRV-C may cause more severe illness and are more prevalent in lower respiratory tract 
infections than HRV-A and HRV-B. This was not evident in our study where both HRV-A 
and HRV-C were ubiquitous throughout the study period. Additionally, among controls there 
was no association between HRV species and signs and symptoms of respiratory tract 
infections. Similarly, there was no evidence that cases associated with HRV-C infection had 
more severe disease, based on presence of hypoxia, categorisation to being very severe 
pneumonia, prolonged hospital stay (>3 days duration), mechanical ventilation support or 
case fatality ratio. Instead, among HRV-associated cases those with HRV-A were more likely 
to have radiographically confirmed pneumonia and concurrent diarrhoea compared to those 
with HRV-C. Additionally, among cases where HRV was the only respiratory virus detected 
in the nasopharynx, those with HRV-A mono-infections where associated with more 
prolonged hospital stays, lethargy and convulsions compared to the cases with HRV-C mono-
infections. Moreover, HRV-A mono-infected cases had 2.0-fold higher case fatality ratio than 
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all other cases. Thus in our study, HRV-A was associated with more severe disease than 
HRV-C.  
 
 HRV-C, rather, tended to be more frequent among older children compared to HRV-A. The 
greater proportion of HRV being HRV-C species among older children has also been reported 
by others [53, 86, 87], and they suggested this link between HRV-C and older children might 
be linked to the higher risk for asthma exacerbation and wheezing in older children. The link 
between HRV-C and wheeze is well established, with many studies reporting that HRV-C is 
more commonly associated with wheezing exacerbation than HRV-A or HRV-B [23, 35, 86, 
87]. This was also seen in our study, whereby, cases presenting with wheeze were 1.64-fold 
more likely to have a HRV-C (35%) compared to HRV-A (25%, P=0.031). Our study was 
not, however, designed to fully study the association between HRV species and wheezing as a 
bronchodilator challenge was undertaken among prospective study participants, aimed at 
excluding children with hyper reactive airway disease, i.e. exclusion of children in whom the 
lower chest wall indrawing resolved post B2-agonist nebulisation challenger regardless of its 
effect on wheezing. This association of HRV-A with more severe LRTI and HRV-C with 
more wheezing disease has also been reported from a study in Burundi, where HRV-A was 
more prevalent among pneumonia and bronchitis cases and HRV-C among cases with acute 
wheezing [16]. This association between HRV-C and wheezing disease was also seen in a 
study which identified the cell receptors for HRV-C infection in humans, namely the CDHR-3 
receptors, which allowed for HRV-C adhesion and replication and found that certain genetic 
coding mutations in the genes for these receptor proteins increased the binding and replication 
of HRV-C in vivo. This mutation (cysteine to tyrosine mutation at amino acid 529) has also 
associated with increased susceptibility to wheezing and asthma illnesses [29].  
 
HRV-A and HRV-C strains were ubiquitous throughout the study period with a highly 
heterogeneous population of over 100 strains identified. HRV-A had the most diverse genetic 
population with 60 different strains, followed by HRV-C with 28 strains and then HRV-B 
with 17 different strains identified over the two-year period in both the cases and controls. 
Furthermore, there was no discernible relationships between strains identified among cases 
and controls and no real evidence of temporal clustering of strains over time. However, we 
failed to type 3% (n=25) of the HRV positive samples, similar percentages between cases and 
controls, which was largely due to PCR failure as a consequence of very low viral loads 
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which was inferred from Ct values greater than 37 cycle thresholds; although, it cannot be 
excluded that these PCR failures may be due to variability in the primer annealing sites thus 
some genetic variants might have been missed by our typing assays. Regardless, the 
considerable genetic diversity of HRV reported in this study highlights the heterogeneity of 
the HRV strains circulating within the general populations. However, the prevalence and the 
genetic population of HRV was similar among children hospitalised with pneumonia and 
community controls, which further highlights the difficulties in attributing causality of disease 
to HRV and also negate that some strains might be more virulent. This might be compounded 
by the fact HRV has been shown to shed for prolonged periods post infection [51, 124], thus 
we cannot determine whether the HRV species detected are from active infection or shedding 
from previous infection. Other studies have also reported on the diverse nature of the HRV 
genetic population among both cases and controls including studies from South Africa [123], 
Botswana [99], Kenya [92], and other countries [53, 122, 125] as well as the lack of obvious 
seasonal patterns among cases [16, 23, 52, 85, 128]. Additional longitudinal studies are 
required to further clarify this, as well as whether there are differences in species/strain 
specific duration of shedding. 
 
A limitation of the study is that the non-coding region used to type the HRV strains is not 
involved in the immune evasion mechanisms of the virus, thus although it is ideal for 
differentiating between the >160 different HRV genotypes, the data it provides in terms of 
molecular epidemiology of disease is unclear. Future studies done in conjunction with surface 
protein epitopes such as VP1-4 sequencing are needed to study the molecular epidemiology in 
relation to clinical outcomes in greater depth.  
 
In conclusion, this study emphasises the highly divergent nature of the HRV population 
circulating in both community controls as well as children hospitalised with pneumonia, as 
well as shows that similar strains are circulating over a large geographical location and strains 
are similar year to year. Additionally, it further highlights the difficulty in attributing causality 
of LRTI disease to HRV, as no differences were observed in prevalence of HRV detection 
between cases and controls (other than in the 1-5 year age group), nor were there differences 
in HRV genetic population between cases and controls, especially among infants. 
Nevertheless, among cases, HRV-A tended to be more important among younger children and 
was associated with more severe disease and radiographically confirmed pneumonia 
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compared to HRV-C infections, whereas HRV-C was more important among older children 
with wheezing disease. Furthermore, mono-viral infections with HRV-A was associated with 
higher case fatality ratio. 
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6.0 A case-control study on association of Human rhinovirus (HRV) 
nasopharyngeal viral load and viraemia in South African children with 
WHO-defined pneumonia 
 
HRV is considered to be an important pathogen during childhood disease; however, it is 
ubiquitous in diseased and asymptomatic individuals thus obscuring the true etiological role 
in respiratory infections [47]. Previous studies conducted on children with respiratory 
illnesses have investigated the association of HRV nasopharyngeal viral load and presence of 
HRV viraemia [64, 65]; but have not simultaneously enrolled asymptomatic controls, hence, 
limiting any inferences on causality or them being markers of severity in children with 
pneumonia. 
  
In this chapter, the epidemiology, including nasopharyngeal HRV viral load and prevalence of 
viraemia is reported from South African children hospitalised with WHO-defined pneumonia 
and age-frequency matched community controls. 
 
6.1 RESULTS 
6.1.1 HRV subtyping among cases and controls 
A total of 911 children were enrolled at the South African PERCH site with WHO-defined 
severe (n=624, 68%) or very severe pneumonia (n=298, 32%), of whom 23% (n=210/911) 
had HRV identified on nasopharyngeal swab samples through diagnostic real-time PCR. 
Additionally, 959 children were enrolled as age-matched community controls, 911 of controls 
were asymptomatic for respiratory illness and 53 had signs and symptoms of ARI. The overall 
prevalence of identifying HRV on NP swab among controls was 22% (n=212/959). There was 
no difference in overall prevalence of HRV NP swab positivity among cases (23%) and 
controls (21%, P=0.66).  
 
The cases and controls with HRV infection were similar with regard to mean age, gender and 
prevalence of HIV-infection; however, the HRV-associated cases compared to controls were 
3.7-fold (aOR 95% CI: 1.33-10.40) more likely to be malnourished (8% vs. 2%, P=0.012), 
but less likely to have been born prematurely (18% vs. 33%, P=0.004); Table 6.1. 
Furthermore, cases hospitalised with HRV-associated pneumonia were 2-fold (aOR 95% CI: 
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1.22-3.38) more likely to have another respiratory virus co-infection (46% vs. 31%, 
P=0.001), which was specifically evident for RSV (16% vs. 2%, aOR 7.91, 95% CI 2.99-
20.94, P<0.001); whilst the prevalence of coinfection by other respiratory viruses did not 
differ; Table 6.1. 
 
The 5’ NCR of the HRV genome was successfully amplified in 99% (n=207/210) of case 
samples and 96% (n=203/212, P=0.262) of the community control samples. The un-typed 
samples from case (1%, n=3/210) and community controls (4%, n=9/212) failed to amplify 
and on analysis of the real-time PCR results these samples had late cycle threshold values 
above 35 cycles. In addition, from the sequencing analysis it was determined that 4% 
(n=9/207) of HRV-associated case samples and 7% (n=14/203, P=0.262) of community 
controls respectively were in fact enteroviruses, a closely related virus member from the same 
family of Picornaviridae as HRV. The distribution of the three HRV species in the 198 HRV-
associated cases and 189 HRV-associated community controls did not differ significantly 
between the cases compared to controls (P=0.618); Table 6.1 and Figure 6.1. 
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Table 6.1: Demographics of HRV-associated cases and community controls 
  HRV+ 
cases 
(n=210) 
HRV+ 
controls 
(n=212) 
Unadjusted 
P-value  OR (95% CI) 
Adjusted 
P-value   aOR (95% CI) 
Age in months, mean (SD) 9.7 (9.7) 11.4 (11.4) 0.090  0.082  
Female, n(%) 95 (45%) 114 (54%) 0.080 1.41 (0.96-2.07) 0.061 0.69 (0.47-1.02) 
HIV+, n(%) 28 (13%) 18 (8%) 0.156 1.56 (0.84-2.90) 0.112 1.66 (0.90-3.10) 
HEU, n(%)
a
 67 (32%) 52 (25%) 0.093 1.44 (0.94-2.21) 0.095 1.34 (0.90-2.23) 
Never breast fed, n(%) 63 (30%) 75 (35%) 0.239 0.78 (0.52-1.18) 0.255 0.79 (0.52-1.19) 
Under weight, n (%)
b
 17 (8%) 5 (2%) 0.013 3.64 (1.32-10.07) 0.012 3.73 (1.33-10.40) 
Day Care attendance, n(%) 28 (13%) 31 (15%) 0.712 0.90 (0.53-1.55) 0.783 0.93 (0.52-1.63) 
Smoker in household, n(%) 81 (39%) 66 (31%) 0.089 1.41 (0.95-2.12) 0.078  1.44 (0.96-2.16) 
Premature birth, n(%)
c
 37 (18%) 69 (33%) 0.005 0.54 (0.35-0.83) 0.004 0.53 (0.35-0.82 
Birth weight, mean (SD) 2.92 (0.7) 2.94 (0.6) 0.694  0.655  
Markers for Bacterial co-infection:      
LytA positive, n (%)
d
 12 (6%) 21 (10%) 0.113 0.55 (0.26-1.15) 0.147 0.58 (0.27-1.22) 
S. pneu load, mean (SD)
e
 5.73 (1.21) 5.88 (1.13) 0.274  0.176  
HDP, n(%)
f
       
-Blood 9 (4%) 12 (6%) 0.516 0.75 (0.31-1.81) 0.607 0.79 (0.32-1.93) 
-NP 23 (11%) 29 (14%) 0.327 0.74 (0.41-1.34) 0.328 0.72 (0.39-1.38) 
HRV subtyping:       
HRV Mono-infection, n(%)
g
 113 (54%) 146 (69%) 0.002 0.53 (0.34-0.78) 0.001 0.51 (0.34-0.76) 
HRV-A, n(%) 91 (44%) 96 (47%)     
HRV-B, n(%) 16 (8%) 14 (7%)     
HRV-C, n(%) 91 (44%) 79 (38%) 0.688  0.618  
Un-typeable, n(%) 3 (3%) 9 (5%)     
Enterovirus, n(%) 9 (3%) 14 (6%)     
HRV viral load, mean (SD)
h
 4.0 (0.98) 3.7 (0.94) 0.062  0.060  
Viral co-infections in the nasopharynx:     
-RSV, n(%) 33 (16%) 5 (2%) P<0.001 7.71 (2.95-20.19) P<0.001 7.91 (2.99-20.94) 
-AdV, n(%) 22 (10%) 24 (11%) 0.781 0.92-0.50-1.69) 0.985 0.99 (0.53-1.86) 
-HMPV, n(%) 7 (3%) 5 (2%) 0.549 1.43 (0.45-4.57) 0.595 1.38 (0.42-4.46) 
-HBoV, n(%) 31 (15%) 24 (11%) 0.295 1.36 (0.77-2.40) 0.177 1.50 (0.83-2.68) 
-InFV A-C, n(%) 2 (1%) 2 (1%) 0.992 1.0 (0.14-7.23) 0.983 0.98 (0.13-7.13) 
-PIV, n(%) 12 (6%) 7 (3%) 0.238 1.77 (0.68-4.60) 0.262 1.73 (0.66-4.52) 
-HCoV, n(%) 15 (7%) 16 (8%) 0.874 0.94 (0.45-1.96) 0.920 0.96 (0.46-2.02) 
Abbreviations - HIV: Human Immunodeficiency virus; HEU: HIV exposed but uninfected; OR: Odds ratio; 
aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; NP: Nasopharynx; HDP: High 
density pneumococcus; HRV: Human rhinovirus; RSV: Respiratory Syncytial Virus (A and B), HMPV: Human 
Metapneumovirus; AdV: Adenovirus; PIV: Parainfluenza type 1-4; HBoV: Human Bocavirus; HCoV: Human 
Coronavirus (OC43, NL63, 229E and HKU1) and InFV A-C: Influenza Virus (A, B and C); S. pneu: 
Streptococcus pneumoniae 
P-values from chi-square and Wilcoxon tests - logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable; odds ratios could not be calculated for variables with zero 
variables.  
a
 - HEU defined as HIV-uninfected but HIV-exposed. Undetectable viral load, HIV seronegative in the child 
with a positive maternal history. Positive maternal status based on self-report was accepted, except for 
seronegative children < 7 months of age where documented positive maternal status was required; 
b
 - 
Underweight defined as weight for age <-2SD of the median age-sex specific WHO reference;
 c
 - Premature 
birth defined as gestational age <37 weeks; 
d
 - Blood sample positive for S. pneumoniae colonisation by LytA 
PCR; 
e
 - Bacterial load of S. pneu in the nasopharynx, expressed as log10 copies/mL; 
f
 - HDP defined as S. 
pneumoniae density in nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL; 
g
- HRV 
was the only respiratory virus detected in the nasopharynx; 
h
 - HRV viral load in the nasopharynx, expressed as 
log copies/ml 
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Figure 6.1: A phylogenetic analysis of HRV sequences. Sequences with closed circles denote 
types identified in nasopharyngeal case samples () and sequences with open circles denote 
types identified in nasopharyngeal control samples (O). Red, closed circles () denote types 
identified in viraemic cases and red, open circles (O) denoted types identified in control with 
viraemia. Closed triangles () denote reference strains from GenBank. HRV-A types are 
indicated by purple branches, HRV-B types are indicated by light blue branches and HRV-C 
are indicated by pink branches. Bootstrap values after 1000 replicates are shown next to the 
branches, values <70% have been omitted from the tree. The phylogenetic tree is drawn to 
scale and the branch length are in the same length of those used to infer the tree.  
 
 
6.1.2 Seasonal Distribution of HRV species 
Case and controls with HRV infections were identified perennially during the 2-year study 
period, although the month-on-month prevalence of positivity ranged from 0 to 40%. The 
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month-on-month prevalence of HRV was similar between cases and controls, with the highest 
prevalence observed from December 2011-February 2012 (36%-39%), April 2012 (30%), 
February 2013 (32%) and July 2013-August 2013 (38%-40%); i.e. being independent of 
summer (December-February) and winter (June-August) in Johannesburg, South Africa. 
HRV-A and HRV-C co-circulated in most months, and their prevalence fluctuated 
continuously. HRV-B appeared sporadically through the study period in both cases and 
controls; Figure 6.2.  
 
Figure 6.2: The monthly distribution of HRV species over a 2-year period in children 
hospitalised with pneumonia (cases) and community controls. On the y-axis are the proportion 
of samples from cases and controls positive for HRV infections. The seasons are indicated on 
the graph - red for winter months (June-end of August), green for spring (September-end of 
November), blue for summer (December- end of March) and orange for autumn months (April-
end of May). 
 
6.1.3 Nasopharyngeal HRV viral load  
The nasopharyngeal HRV viral load (log10 copies/mL) in children hospitalised with HRV-
associated pneumonia was not associated with any difference by age, gender, HIV status, 
disease diagnosis, clinical characteristics and length of hospital stay as well as independent of 
HRV species and whether HRV was the only virus detected in the nasopharynx. The presence 
of fever was however associated with a lower nasopharyngeal HRV viral load (3.82 log10 
copies/mL) compared to HRV-associated cases without fever (4.25 log10 copies/mL, 
P=0.009); Table 6.2. 
 
  
 141 
 
Table 6.2: Nasopharyngeal HRV viral load by demographics and clinical characteristics in 
HRV-associated cases  
  n=198 Mean HRV viral  
load (log10 cp/ml) 
P-value 
Age    
<1 year 142 3.90 (0.95)  
>1year 56 4.04 (1.04) 0.368 
Gender    
Male  110 3.8 (0.95)  
Female 88 4.02 (1.01) 0.312 
HIV    
Negative 170 3.99 (0.99)  
Positive 28 3.65 (0.82) 0.071 
HEU
a
    
Negative 133 3.90  
Positive 65 4.04 (0.93) 0.413 
Diagnosis    
Severe pneumonia 126 3.86 (0.96)  
Very severe pneumonia 72 4.08 (0.99) 0.123 
Chest X-ray
b
    
Normal 88 3.88 (0.93)  
Abnormal 99 4.00 (1.01) 0.384 
Hypoxia
c
    
Yes 146 3.85 (0.95)  
No 50 3.98 0.99) 0.420 
Supplementary Oxygen therapy    
Yes 183 3.95 (0.98)  
No 15 3.81 (0.97) 0.601 
Mechanical ventilation    
Yes 10 3.90 (0.94)  
No 188 3.94 (0.98) 0.886 
Wheeze    
Yes 75 3.95 (0.98)  
No 121 3.93 (0.97) 0.938 
Fever
d
    
Yes 137 3.82 (0.85)  
No 61 4.25 (1.12) 0.009 
Tachypnea
e
    
Yes 159 3.99 (0.98)  
No 36 3.67 (0.95) 0.073 
Tachycardia
f
    
Yes 96 4.02 (1.02)  
No 101 3.86 (0.94) 0.250 
Leucocytosis
g
    
Yes 101 4.01 0.89)  
No 97 3.87 (1.06) 0.292 
Hospital stay    
>3 days 78 3.87 (0.91)  
<3 days 120 3.99 (1.02) 0.425 
Case fatalities    
Yes 11 4.15 (0.97)  
No 153 3.94 (1.11) 0.494 
HRV mono-infection 65 3.90 (0.97)  
HRV mixed infection 133 3.96 (0.98) 0.701 
Type of HRV species    
-A 91 3.96 0.97)  
-B 16 3.57 (0.70)  
-C 91 3.99 (1.01) 0.271 
HRV viraemia     
Yes 13 4.67 (0.73)  
No 185 3.90 (0.98) 0.028 
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HRV-A 
   
Viraemia present 2 3.75 (1.7)  
Viraemia absent 89 3.96 (0.9) 0.765 
HRV-C    
Viraemia present 11 4.72 (0.45)  
Viraemia absent 80 3.87 (1.04) 0.016 
Abbreviations - HIV: Human Immunodeficiency virus; HEU: HIV negative but HIV exposed; HRV: Human 
rhinovirus. 
P-values from chi-square and Wilcoxon tests - logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable. 
a 
- HEU defined as undetectable viral load, HIV seronegative in the child with a positive maternal history. 
Positive maternal status based on self-report was accepted, except for seronegative children < 7 months of age 
where documented positive maternal status was required; 
b
 - Abnormal chest X-rays defined as defined as 
primary end point pneumonia or infiltrates; 
c
 - Hypoxic defined as 1) a room air pulse-oximetry reading 
indicated oxygen saturation <90% at the two sites at elevation (Zambia and South Africa) or <92% at all other 
sites, or 2) a room air oxygen saturation; 
d
 - Fever defined as body temperature >38
o
C; 
e 
- Tachypnea defined as 
respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, 
respiration rate >40 breaths/minute if aged >12 month; 
f
 - Tachycardia defined as heart rate >160 beats per 
minute (bpm) if aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 
months; 
g
 - Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white blood cell 
count >13 000 cells/uL if age >12 months. 
 
Similarly to the HRV-associated cases, the nasopharyngeal HRV viral load among 
community controls was also not associated with any differences by age, gender, HIV-1-
infected and HIV-exposure as well as independent of HRV species and whether HRV was 
detected as a mono viral infection in the nasopharynx. The nasopharyngeal HRV viral load 
was, however, higher among controls with symptoms of RTI (4.48 log10 copies/mL) compared 
to asymptomatic controls (3.77 log10 copies/mL, P=0.041); Table 6.3. 
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Table 6.3: Nasopharyngeal HRV viral load by demographics and clinical characteristics in 
HRV-associated community controls 
  n=189 Mean NP RV load 
(log10 cp/ml) 
P-value 
Age    
<1 year 136 3.88 (0.86)  
>1year 52 3.65 (1.12) 0.141 
Gender    
Male  83 3.89 (0.96)  
Female 106 3.75 (0.92) 0.336 
HIV    
Yes 15 3.83 (0.88)  
No 173 3.82 (0.95) 0.848 
HEU
a
    
Yes 46 3.67 (1.04)  
No 143 3.86 (0.90) 0.226 
Diagnosis    
Asymptomatic control           178             3.77 (0.94)  
ARTI control 11 4.48 (0.63) 0.041 
Tachypnea
b
    
Yes 10 8.40 (8.35)  
No 159 3.83 (0.97) 0.588 
HRV mono-infection 60 3.82 (0.97)  
HRV mixed infection 129 3.81 (0.93) 0.964 
Type of HRV    
-A 96 3.75 (0.90)  
-B 14 3.43 (0.82)  
-C 79 3.95 (0.99) 0.877 
HRV viraemia     
Yes 4 4.83 (0.83)  
No 185 3.79 (0.93) 0.018 
HRV-A    
Viraemia present 1 5.83 (-)  
Viraemia absent 95 3.73 (0.88) NP 
HRV-C    
Viraemia present 3 4.50 (0.60)  
Viraemia absent 76 3.93 (0.99) 0.181 
Abbreviations - HIV: Human Immunodeficiency virus; HEU: HIV-uninfected but HIV-exposed; HRV: Human 
rhinovirus. 
P-values from chi-square and Wilcoxon tests - logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable.
 
a
 - HEU defined as undetectable viral load, HIV seronegative in the child with a positive maternal history. 
Positive maternal status based on self-report was accepted, except for seronegative children < 7 months of age 
where documented positive maternal status was required; 
b
 - Tachypnea = Respiratory rate >60 breaths/minute if 
aged <2 months, respiratory rate >50 breaths/minute if aged 2-12 months, respiration rate >40 breaths/minute if 
aged >12 month; NP - not powered to calculate P-value. 
 
Although there was a trend for higher nasopharyngeal HRV viral load among cases (4.0 log10 
copies/mL) compared to controls (3.7 log10 copies/mL, P=0.062; Table 6.1); there was no 
discernible nasopharyngeal density threshold for differentiating cases from controls as evident 
on the reverse cumulative plot; Figure 6.3. 
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Figure 6.3: Reverse cumulative plot of HRV viral load in the nasopharynx among cases and 
controls. The viral loads of cases are shown in red and the controls in blue. 
 
6.1.4 HRV viraemia 
Overall, 7% (n=13/198) of HRV-associated cases and 2% (n=4/189, aOR 7.02, 95% CI 1.70-
28.94, P=0.007) of controls were identified as having HRV viraemia using the HRV 5’NCR 
PCR analysis. For both cases and controls with viraemia, the HRV species detected on blood 
was identical to the respiratory species. The positivity rate of viraemia differed between HRV 
species among the cases, being highest for HRV-C (12%, n=11/91), lower for HRV-A (2%, 
n=2/91) and not identified for any of the HRV-B cases (0%, 0/16, P=0.014). Similar trends 
were seen in positivity rates of viraemia among controls, highest for HRV-C (4%, n=3/79), 
lower for HRV-A (1%, n=1/96) and no HRV-B viraemia cases (0%, n=0/14). 
 
HRV-C viraemia was 4.43-fold (aOR 95% CI 1.22-16.04) more prevalent among cases (12%) 
than controls (4%, P=0.023). This was, however, not significantly different for HRV-A (2% 
vs. 1%, P=0.529) or for HRV-B (0%); Table 6.4. Furthermore, among HRV-associated cases, 
HRV-C was 2.59-fold (aOR 95% CI: 1.23-5.95) more likely to be associated with viraemia 
compared to HRV-A (12% vs. 2%, P=0.025). 
 
Table 6.4: HRV molecular subtyping by sample type and viraemia status in HRV-associated 
pneumonia cases. 
  Cases (n=198) Controls  (n=189)  
 
Viraemia- 
(n=185) 
Viraemia+ 
(n=13) P-value 
Viraemia- 
(n=185)  
Viraemia+ 
(n=4) 
P-value 
HRV-A 89 (48%) 2 (15%) 
 
95 (51%) 1 (25%)  
HRV-B 16 (9%) 0 0.001 14 (8%) 0 0.384 
HRV-C 80 (43%) 11 (85%) 
 
76 (41%) 3 (75%)  
P-values calculated using Fisher’s exact test and t-test where necessary; HRV- Human rhinovirus. % refers to 
proportion of species within the column. 
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Among children with HRV-associated pneumonia, the presence of viraemia was associated 
with higher HRV nasopharyngeal load compared to non-viraemic cases (4.67 versus 3.90 
log10 copies/mL, P=0.028). This difference was mainly driven by the HRV-C species, (viral 
load 4.72 compared to 3.87 log10 copies/ mL, P=0.016), whilst not evident for HRV-A 
(P=0.765); Table 6.2. Similarly, among HRV-associated controls, the nasopharyngeal viral 
load was higher in the presence of viraemia compared to the non-viraemic controls (4.83 vs. 
3.79 log10
 
copies/mL, P=0.018), associations by individual HRV species were not significant 
due to the very small sample size of HRV viraemia positive controls; Table 6.3. There was no 
difference in the nasopharyngeal HRV viral load between viraemic cases (4.67 log10
 
copies/mL) compared to viraemic controls (4.83 log10 copies/mL, P=0.285). 
 
Among HRV-associated cases; Table 6.5, those with viraemia were older (18.6 months) than 
children without viraemia (9.2 months, P=0.001). The presence of viraemia among cases was 
not associated with any of the indices of pneumonia severity, including requiring 
supplementary oxygen therapy, having abnormal chest X-rays or presence of leucocytosis. 
However, the HRV viraemic cases had a higher whole blood neutrophil percentage (68.1%), 
and lower lymphocyte percentage (23.3%) compared to cases without viraemia (48.5%, 
P=0.023 and 39.8%, P=0.024 respectively). Additionally, viraemic cases tended to be more 
likely associated with wheezing (62% vs. 37%, P=0.069) but less likely to be hospitalised for 
>3 days (8% vs. 42%, P=0.049) compared to non-viraemic cases. None of the HRV viraemic 
cases were fatal; with no significant difference in case fatality ratio between the HRV 
viraemic and non-viraemic cases (0% vs. 7%, P=0.382); Table 6.5.   
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Table 6.5: Characteristics and outcomes of children hospitalised with HRV-associated pneumonia by 
viraemia status 
Characteristics Viraemia+ 
(n=13) 
Viraemia- 
(n=185) 
Unadjusted 
P-value  OR (95% CI) 
Adjusted 
P-value  aOR (95% CI) 
Age in months, mean (SD) 18.6 (14.1) 9.2 (9.2) 0.002  0.001  
Female, n(%) 7 (54%) 81 (44%) 0.480 1.50 (0.48-4.63) 0.370 1.70 (0.53-5.45) 
HIV positive, n(%) 0 28 (15%) 0.130  0.269  
HEU, n(%)
a
 6 (46%) 59 (31%) 0.290 1.83 (0.59-5.69) 0.368 1.72 (0.53-5.57) 
Never breast fed, n(%) 6 (46%) 54 (29%) 0.198 2.08 (0.67-6.47) 0.151 2.40 (0.73-7.84) 
Under weight, n (%)
b
 0 17 (9%) 0.253  0.505  
Day care attendance, n(%) 4 (31%) 21 (11%) 0.667 1.11 (0.68-1.82) 0.791 1.09 (0.58-2.03) 
Smoker in household, n(%) 5 (38%) 71 (38%) 0.965 0.91 (0.37-2.25) 0.652 0.81 (0.33-2.02) 
Premature birth, n(%)
c
 2 (15%) 34 (18%) 0.619 0.65 (0.22-1.96) 0.529 0.75 (0.31-1.83) 
Birth weight, mean (SD) 3.0 (0.4) 2.9 (0.7) 0.775  0.876  
Clinical Features:       
Very severe pneumonia, n(%) 7 (54%) 65 (35%) 0.175 2.15 (0.69-6.68) 0.168 2.31 (0.70-7.61) 
Chest X-ray abnormal, n(%)
d
 6 (46%) 93 (53%) 0.611 0.75 (0.24-2.31) 0.522 0.67 (0.20-2.25) 
Supplementary 02 therapy, n(%) 12 (92%) 171 (92%) 0.987 0.98 (0.12-8.11) 0.936 1.09 (0.12-9.63) 
Mechanical ventilation, n(%) 0 10 (5%) 0.390  0.703  
Hypoxic, n(%)
e
 9 (69%) 137 (75%) 0.653 0.76 (0.22-2.57) 0.812 1.17 (0.33-4.15) 
Tachycardia, n(%)
f
 9 (69%) 87 (47%) 0.126 2.51 (0.75-8.43) 0.153 2.49 (0.71-8.70) 
Tachypnea, n(%)
g
 12 (92%) 147 (81%) 0.300 2.86 (0.36-22.71) 0.369 2.65 (0.32-22.2) 
Fever, n(%) 7 (54%) 130 (70%) 0.223 0.49 (0.16-1.54) 0.192 0.46 (0.14-1.49) 
Wheezing, n(%) 8 (62%) 67 (37%) 0.064 2.77 (0.91-8.81) 0.069 1.68 (0.89-5.57) 
Cough, n(%) 13 (100%) 157 (85%) 0.552 1.21 (0.64-2.28) 0.864 1.07 (0.50-2.30) 
Lethargic, n(%) 0 11 (6%) 0.366  0.687  
Convulsions, n(%) 0 5 (3%) 0.546  0.998  
Diarrhoea, n(%) 1 (8%) 35 (19%) 0.310 0.36 (0.05-2.83) 0.565 0.53 (0.06-4.53) 
Head nodding, n(%) 7 (54%) 54 (29%) 0.063 2.83 (0.91-8.81) 0.079 2.90 (0.89-9.56) 
Central cyanosis, n(%) 0 1 (1%) 0.790  0.181  
Unable to Feed, n(%) 0 2 (1%) 0.706  0.777  
Vomiting everything, n(%) 0 3 (2%) 0.644  0.720  
Lower chest wall indrawing, n(%) 12 (92%) 176 (95%) 0.653 0.61 (0.07-5.25) 0.739 0.68 (0.07-6.42) 
Stridor, n(%) 1 (8%) 5 (3%) 0.561 0.93 (0.39-2.22) 0.704 0.84 (0.33-2.11) 
Grunting, n(%) 0 10 (5%) 0.807  0.860  
Nasal Flaring, n(%) 13 (100%) 160 (86%) 0.156  0.391  
Laboratory markers:       
Leucocytosis, n(%)
h
 9 (69%) 92 (50%) 0.174 2.27 (0.68-7.65) 0.195 2.30 (0.65-8.09) 
Neutrophils (%), median (IQR) 68.1 (15.2) 48.5 (19.1) 0.001  0.023  
Lymphocytes (%), median (IQR) 23.3 (13.3) 39.8 (16.5) 0.001  0.024  
Eosinophils (%), median (IQR) 1.3 (2.1) 1.4 (2.8) 0.788  0.089  
CRP≥40mg/l, n(%)i 3 (23%) 51 (28%) 0.803 0.76 (0.34-3.96) 0.629 0.56 (0.38-4.88) 
Blood culture positive, n(%) 0 5 (3%) 0.548  0.196  
LytA positive, n(%)
j
 1 (7%) 10 (5%) 0.145 3.18 (0.62-16.33) 0.229 2.92 (0.51-16.7) 
MCPP, n(%)
k
 0 1 (0.5%) 0.790  0.748  
HDP, n(%)
l
       
-Blood 1 (8%) 8 (4%) 0.573 1.84 (0.21-15.98) 0.539 2.07 (0.20-21.3) 
-NP 1 (8%) 21 (11%) 0.685 0.65 (0.08-5.26) 0.896 0.87 (0.10-7.54) 
HRV mono-infection, n(%)
m
 7 (54%) 99 (54%) 0.981 1.01 (0.33-3.13) 0.887 1.09 (0.33-3.61) 
Hospital stay >3 days, n(%) 1 (8%) 77 (42%) 0.016 0.12 (0.14-0.62) 0.049 0.16 (0.02-0.98) 
Case fatality ratio, n(%) 0 11 (7%) 0.382  0.756  
Abbreviations - HIV: Human Immunodeficiency virus; HEU: HIV exposed but uninfected; OR: Odds ratio; 
aOR: Adjusted odds ratio; CI: Confidence interval; SD: Standard deviation; IQR: Inter quartile range; NP: 
Nasopharynx; CRP: C-reactive protein; HDP: High density pneumococcus; MCPP: Microbiologically confirmed 
pneumococcal pneumonia; HRV: Human rhinovirus 
P-values from Chi-squared and Wilcoxon tests, logistic regression models adjusted for confounding variates 
(<0.2 in univariate analysis) where applicable, Odds ratio could not be calculated for continuous variables or 
variables with 0 values, thus cells left blank.
  
a
 - HEU defined as undetectable viral load, HIV seronegative in the child with a positive maternal history. 
Positive maternal status based on self-report was accepted, except for seronegative children < 7 months of age 
where documented positive maternal status was required; 
b 
- Underweight defined as weight for age <-2SD of the 
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median age-sex specific WHO reference; 
c
 - Defined as primary end point pneumonia and/or infiltrates; 
d
 - 
Hypoxic defined 1) a room air pulse-oximetry reading indicated oxygen saturation <90% at the two sites at 
elevation (Zambia and South Africa) or <92% at all other sites, or 2) a room air oxygen saturation reading was 
not available and the child was on oxygen; 
e
 - Tachycardia defined as heart rate >160 beats per minute (bpm) if 
aged <11 months, heart rate >150 bpm if aged 12-35 months, heart rate >140 bpm if aged 36-59 months; 
f 
- 
Tachypnea defined as respiratory rate >60 breaths/minute if aged <2 months, respiratory rate >50 breaths/minute 
if aged 2-12 months, respiration rate >40 breaths/minute if aged >12 month; 
g 
- Fever defined as body 
temperature ≥38oC; h - Leucocytosis defined as white blood cell count >15 000 cells/uL if age <12 months, white 
blood cell count >13 000 cells/uL if age >12 months; 
i
 - CRP defined as levels ≥40mg/mL are considered to 
potentially indicate bacterial infection; 
j
 - Blood sample positive for S. pneumoniae colonisation by LytA PCR; 
k 
- MCPP defined as S. pneumoniae was cultured from a normally sterile body fluid - blood, pleural fluid or lung 
aspirate - or pleural fluid or lung aspirate was PCR LytA positive; 
l 
- HDP defined as S. pneumoniae density in 
nasopharynx >6.9 and/or density in whole blood sample >2.2 log10 copies/mL;
 m 
- HRV was the only virus 
detected in the nasopharynx.   
 
 
 
 
Figure 6.4: Reverse cumulative plots of nasopharyngeal HRV viral load in Panel A.) all 
HRV-infected viraemic and non-viraemic participants, Panel B.) cases positive for viraemia 
versus non-viraemic cases, Panel C.) community controls positive for viraemia versus non-
viraemic controls, Panel D.) all HRV-C viraemic and non-viraemic participants, Panel E.) 
HRV-C viraemic cases compared to HRV-C non-viraemic cases, Panel F.) HRV-C viraemic 
community controls compared to HRV-C associated non-viraemic controls. 
 
The higher nasopharyngeal HRV viral load in cases and controls with viraemia (red lines) 
compared to their counterpart without viraemia (blue lines) are shown in the reverse 
cumulative plot; Figure 6.4. Overall among the HRV-infected children, 95% (n=16/17) of 
viraemic participants had a nasopharyngeal viral load of ≥4 log10 copies/mL compared to 38% 
(n=140/370) of non-viraemic children (P<0.001); Figure 6.4 A. A greater proportion of 
viraemic compared to non-viraemic HRV infected children having nasopharyngeal viral load 
of ≥4 log10 copies/mL was also observed independently among the HRV-associated 
A B C 
D E F 
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pneumonia cases (93%, n=12/13 vs. 37%, n=70/185, P<0.001); Figure 6.4 B, and among the 
HRV-associated controls (100%, n=4/4 vs. 38%, n=70/185, P=0.012); Figure 6.4 C.  
 
Furthermore, the same association of a higher percentage of viraemic compared to non-
viraemic cases having nasopharyngeal viral loads of ≥4 log10 copies/mL was observed for 
infection by HRV-C overall (100%, n=14/14 vs. 39%, n=62/156, P<0.001); Figure 6.4 D; as 
well as being independently evident among HRV-C associated pneumonia cases (100%, 
n=11/11 vs. 37%, n=30/80, P<0.001); Figure 2E, and among the HRV-C infected controls 
(100%, n=3/3 vs. 42%, n=32/76, P=0.048); Figure 6.4 F. 
 
The nasopharyngeal viral loads, as well as the case-control findings of HRV subtyping and 
HRV viral co-infections were similar to the all-site data presented in Chapters 3 and 5.  
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6.2 Discussion 
The nasopharyngeal HRV viral loads were significantly higher among children with HRV 
viraemia than among children without HRV viraemia. The strength of this association 
increased as the viral load increased and a threshold density of ≥4 log10 copies/mL was found 
to significantly distinguish between HRV viraemia positive and negative participants. This 
was seen among both cases and controls with HRV viraemia and was mainly driven by HRV-
C which was more likely to cause viraemic infections than both HRV-A and HRV-B. To our 
knowledge, this is the first study assessing HRV viraemia prevalence using highly sensitive 
PCR-based methods in both children hospitalised with severe respiratory disease as well as 
age-frequency matched community controls and found that HRV viraemia was 7-fold more 
prevalent among cases (7%) than controls (2%, P=0.007).  
 
Of the four controls positive for HRV viraemia one had a respiratory tract infection and the 
remaining three were asymptomatic at the time of sampling. The nasopharyngeal load of 
HRV was substantially higher among the controls with HRV viraemia, thus the viraemia 
could have been a result of RNA shedding or “leakage” from the high nasopharyngeal 
colonisation density. The only way to detect infectious virus particles would be through 
culturing of the isolates; however, currently methods for culturing HRV-C have been 
unsuccessful. Alternatively, a study found that HRV viraemia was mainly detected during the 
early stages of disease symptoms [65] thus the 3 HRV viraemia positive controls could have 
been in the incubation period of illness at the time of sampling. The controls were not 
systematically followed up post sampling thus we were unable to conclusively determine 
whether the children developed pneumonia post enrolment into the study. This was seen in a 
case-control study conducted in Finland which enrolled asymptomatic controls in addition to 
cases and found that 38% of the HRV positive control developed respiratory symptoms within 
the week following sampling [51]. Nevertheless, the detection of HRV viraemia among 
community controls even at the very low prevalence seen in this study was unexpected, and 
further highlights the challenges of defining the etiological role of HRV during childhood 
disease.  
 
This study confirms that HRV detection during disease episodes does not imply causality as 
HRV were frequently detected in the nasopharynx of both hospitalised children (23%) as well 
as age-frequency matched community controls (21%) living in South Africa. Moreover, the 
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molecular subtyping of the HRV population was similar between the cases and controls thus 
highlighting the need for additional techniques for determining the true etiological role of 
HRV in disease. In terms of clinical relevance among cases, no positive correlations were 
found between nasopharyngeal HRV viral loads and HRV species with markers for more 
severe disease - including hypoxia, requiring mechanical ventilation, hospital stays longer 
than 3 days, very severe pneumonia diagnosis and death; however, it was found that children 
with HRV viraemia had significantly higher nasopharyngeal viral loads than non-viraemic 
children. This concurs with a previous Italian study which also found an association between 
high viral loads and HRV viraemia [64]. They postulated that high viral loads were a 
prerequisite for viraemia and that viraemia was associated with more severe disease; however, 
they failed to enrol healthy controls into the study. This greater clinical severity was not 
evident in our study as there were very little clinical differences in the disease manifestation 
among cases with HRV viraemia compared to the HRV-associated without viraemia, 
including the markers for more severe disease. In fact, the HRV viraemia positive cases were 
associated with less prolonged hospital stays compared to the viraemia negative cases. 
However, the Italian study enrolled all paediatric patients younger than 14 years of age 
admitted to hospital with signs of respiratory tract infections, including both upper and lower 
respiratory tract infections and children presenting with wheezing [64] which could account 
for the difference in clinical involvement seen, as all our cases were children admitted to 
hospital with severe or very severe pneumonia. Additionally, the HRV viraemia detection 
rates reported in our study (7%) is substantially lower than reported in previous studies 
(11.4%-12.3%) [64-66]. These studies were all conducted in paediatric patients less than 14 
years of age and enrolled all children hospitalised with severe respiratory infections, 
regardless of the site of infection. Furthermore, none of these studies enrolled control children 
into their studies. In the Greek study [65] they found 11.4% of hospitalised HRV positive 
children had HRV viraemia and the majority (70%) of the HRV viraemia cases were in 
children presenting with asthma exacerbations with no HRV viraemia cases detected among 
the children hospitalised with HRV-associated pneumonia. Similarly, in a Philippino study, 
[66] the majority (73%) of the HRV viraemia positive cases were in children presenting with 
wheezing disease. Thus the low viraemia detection rates reported in our study could be related 
to the cases receiving a bronchodilator challenge in order to exclude children with 
bronchiolitis; subsequently, a large proportion of cases with wheezing disease were excluded 
from our study. Regardless of this, a trend for wheezing to be more prevalent among HRV 
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viraemia positive cases was still evident in our study which is in accordance with the other 
studies reporting on an association between HRV viraemia and increased wheezing [64-66]. 
 
Although 73% of the HRV-associated cases (mean age of 9 months) were less than 1 year of 
age (including 44% under the age of 6 months), the majority of the HRV viraemia cases were 
more than 1 year of age (mean age of 18 months) with no viraemia cases detected in cases <6 
months of age. This was also seen in the Phillipino study and they suggested that maternal 
antibodies in children less than 6 months of age might play a protective role against HRV 
infections developing into systemic viraemic infections [66]. This has been seen for other 
enteroviruses, in a Poliovirus vaccine study it was found that viraemia levels were lower in 
infants less than 6 months of age due to the presence of maternal antibodies [141] and in a 
mouse-model study it was found that pre-treating the mice with Coxsackievirus antibodies 
resulted in greatly reduced duration of viraemia due to the rapid clearance of the virus from 
infected tissues resulting in reduced fatality rates [142].  
 
A limitation to this study was the small sample size of HRV viraemia positive cases and 
controls which could have limited the studies power to calculate statistical significance, 
especially among HRV-A positive participants (2% among cases and 1% among controls). 
Regardless, our findings provide strong evidence of a relationship between nasopharyngeal 
HRV viral loads and HRV viraemia. Furthermore, HRV viraemia was significantly more 
prevalent among children hospitalised with severe respiratory tract infections suggesting that 
high nasopharyngeal HRV viral loads (≥4 log10 copies/mL) in conjunction with HRV viraemia 
could be used as a measure for attributing causality to HRV in children hospitalised for severe 
and very severe pneumonia. Additionally, the detection rates of HRV-C viraemia were higher 
than both HRV-A and HRV-B; in fact, no HRV-B viraemia cases were detected which is in 
line with other studies which have also never detected viraemia due to HRV-B [64-67]. This 
could be related to the much lower prevalence’s of HRV-B in the population (9% among 
cases and 8% among controls) and provides additional evidence to the current hypothesis that 
HRV-B might have a lower pathogenicity than HRV-A and HRV-C [87, 143, 144]. Thus, our 
findings suggest that the pathogenicity of HRV-C is significantly different to that of HRV-A 
and HRV-C; however, additional studies are required to further understand how and why 
these differences exist.   
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7.0 Integrated Discussion and Conclusions 
Through the work undertaken in this doctoral thesis, HRV was shown to be ubiquitous 
throughout childhood, and was found in similar prevalence to RSV among cases, which is 
well known to cause very severe disease and mortality in young children. Moreover, HRV 
was found to be 1.45-fold more prevalent among HIV-uninfected children hospitalised with 
WHO-defined pneumonia compared to children living in the community; with similar trends 
evident among HIV-1-infected children. Furthermore, in the 12-59 month age group, HRV 
prevalence was 2-fold greater among cases compared to controls; whereas, among infants the 
etiologic role of HRV was less clear.  
 
This association of increased HRV detection among children 12-59 month old hospitalised 
with pneumonia was seen throughout the study, with the majority of the HRV viraemic 
infections also occurring among this age group of children. On analysis of the molecular 
genotyping, HRV-C was the dominant species among cases in the 12-59 month age-group, 
with the majority of the HRV viraemia cases being due to HRV-C. Furthermore, among the 
viraemia cases, there was minimal evidence of bacterial co-infection, suggesting that HRV-C 
was the most likely cause of pneumonia at least in this age group of children. HRV detection, 
and in particular HRV-C, in the nasopharynx and blood were more likely to be associated 
with wheezing disease as opposed to radiographically confirmed pneumonia. Also, HRV was 
the most prevalent virus detected among the children presenting with wheezing. Thus among 
children 12-59 months of age, there appears to be a causal association between HRV-C and 
respiratory wheezing illness.  
 
Conversely, HRV-A among cases was associated with younger children and presence of 
radiographically confirmed pneumonia compared to HRV-C. Furthermore, among cases 
where HRV was the sole respiratory virus detected in the nasopharynx, HRV-A was 
associated with more severe disease than HRV-C. Moreover, cases with HRV-A mono-
infections had a 5.81-fold greater case fatality ratio compared to HRV-A case with mixed 
viral infections. This association between cases with HRV mono-infections and increased 
case fatality ratio was also seen among the analysis of all HIV-uninfected children 
hospitalised with HRV-associated LRTI irrespective of HRV species. Where HRV was the 
sole respiratory virus detected in the nasopharynx, we found a 2.83-fold higher case fatality 
ratio compared to cases where HRV was detected together with other respiratory viruses. 
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Thus, in our study, HRV mono viral infections, and in particular HRV-A, were associated 
with higher case fatality ratio than HRV mixed viral infections. However, the HRV-associated 
fatalities were more likely to have bacterial co-infections compared to the HRV-associated 
cases that survived. Furthermore, bacterial co-infection was also more frequent among the 
HIV-1-infected HRV-associated cases compared to HIV-uninfected cases. Also HRV 
associated HIV-1-infected children had a 4.89-fold greater case fatality ratio than HIV-
uninfected children. It has been hypothesised that infection with HRV might predispose 
individuals to bacterial super-infections [80] which could have contributed to the fatal 
outcomes observed in this study.  
 
Other common trends were the nasopharyngeal HRV viral load which was higher among 
cases compared to controls. Moreover, controls with RTI were associated with higher HRV 
nasopharyngeal viral loads than asymptomatic controls and HRV viral loads were higher 
among cases categorised as having very severe pneumonia compared to cases categorised as 
severe pneumonia. Furthermore, the nasopharyngeal viral loads were significantly greater 
among viraemia positive cases, where the disease episode was most likely caused by HRV, 
compared to cases without viraemia with HRV nasopharyngeal viral loads ≥4 log10 copies/mL 
being significantly associated with HRV viraemia. Thus, HRV nasopharyngeal viral loads 
≥4log10 copies/mL in conjunction with HRV viraemia are potential markers for HRV-
associated severe respiratory disease. 
 
A major finding of this study, which limits attributing a role of HRV in the aetiology of 
pneumonia, was the detection of HRV in 1 out of every 5 community controls. Although one-
third of the HRV detected among controls were in children with signs and symptoms of RTI, 
the rest were identified in asymptomatic children at the time of sampling. The sampling was, 
however, only done at a single time point using a highly sensitive diagnostic PCR assays 
which is able to detect very low copy numbers of HRV, thus detection could have been due to 
shedding or RNA leakage from a previous respiratory infection among the control 
participants, and more so if HIV-1-infected [124], [138]. Furthermore, controls were not 
systematically followed up post enrolment to determine whether they developed any signs of 
RTI. The only way to differentiate between infectious viral particles and RNA leakage would 
be viral cell culture, but this process is highly insensitive and laborious [30] and currently 
methods for culturing HRV-C strains have been unsuccessful [19].  
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What’s more, the molecular subtyping of the HRV population was similar between the HRV-
associated controls with RTI and asymptomatic controls; and also similar between cases and 
controls. This negates the possibility that some strains might be more virulent than others in 
causing pneumonia. Thus, host susceptibility factors, such as the availability of the necessary 
host receptors which allows for virus attachment and replication, might be more important 
factors for risk of developing severe disease rather than HRV strain virulence per se. The 
HRV-associated cases, among the HIV-1-infected and HIV-uninfected population, were 
significantly more likely to be malnourished compared to controls without HRV infections; 
and there was a stronger attributable role of HRV as a cause of the pneumonia in children >1 
year of age. Additionally, among HIV-uninfected children with HRV infections, cases were 
more likely to be HIV-exposed and male than controls.  
 
In conclusion, this is the largest case-control study to focus on both the clinical and molecular 
subtyping of HRV infection in children under the age of five living in Africa and Southeast 
Asia, where the burden of childhood morbidity and mortality due to pneumonia is greatest. 
The large sample size of the study, allowed us to analyse the epidemiology of HRV infection 
in both hospitalised and healthy children in greater detail than previously undertaken. Also, it 
allowed us to study HRV co-infections with other respiratory viruses and bacteria. 
Nevertheless, the etiologic role of HRV in causing severe childhood pneumonia remains 
tenuous especially among infants. Our study, however, identified several risk factors for HRV 
associated severe disease and highlighted some areas that require further research to get a 
better understanding of severe HRV disease. This includes addressing the issue of only 
sampling at a single time point so as to try identify HRV prevalence among truly 
asymptomatic individuals as well as the need to test for bacterial co-infections which appears 
to be of particular importance among HIV-1-infected individuals and potentially contributes 
to HRV-associated fatal outcomes. Thus longitudinal studies, with frequent nasopharyngeal 
sampling, are required in order to better understand the role HRV plays during different 
severities of LRTI episodes with intensive testing for both co-infection with respiratory virus 
and bacteria.  
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